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Background: Prescription medicines are a common healthcare intervention. Although medicines 
are often beneficial in controlling effects of disease and preventing mortality, some people have 
negative experiences with medicines use. Health professionals often prioritise actual or anticipated 
treatment benefits above any associated psychosocial or practical burdens patients may experience 
when using medicines. There is a need for generic, valid and reliable patient-reported tools to 
evaluate varying experiences of using medicines and associated burden. 
 
Aim: This thesis focusses on instrument development, revision and validation of a novel generic 
patient-reported measure of prescription medicine burden, the Living with Medicines 
Questionnaire (LMQ).  
 
Methods: A systematic literature review was conducted to confirm the suitability of the LMQ-1 as a 
relevant measure for development. This was followed by a pragmatic, iterative, mixed 
methodological approach, including qualitative interviews and surveys that were used in further 
development and validation of this instrument. Across all studies, participants were adults, using 
long-term prescription medicines, and were recruited face-to-face from community pharmacies, 
general practices, outpatient clinics and public areas in south-east England, or on-line across 
England. Principal components analysis of responses to the LMQ-1 enabled preliminary item 
reduction, and revealed gaps in the resulting 42-item version (the LMQ-2). To cover missing 
domains, new item generation and semi-structured, cognitive interviews led to an interim, 58-item, 
LMQ-2.1 ensuring that meanings of all statements were as intended. Final item reduction and 
confirmatory factor analyses of responses to the LMQ-2.1 established the 41-item LMQ-3 as the 
final agreed instrument. Criterion-related validation of the LMQ-3 ascertained relationships among 
medicine burden concepts, treatment satisfaction and health-related quality of life (HRQoL). 
/ŶƚĞƌŶĂůĐŽŶƐŝƐƚĞŶĐǇ ?ƌŽŶďĂĐŚ ?ƐĂůƉŚĂ )ĂŶĚƚĞƐƚ-retest reliability (intraclass correlation coefficients, 
ICCs) were also examined. LMQ-3 composite scores were used to define levels of burden, while 
regression analyses assessed predictors of medicine burden.  
 
Results: The systematic review identified the original 60-item LMQ-1 as a relevant measure based 
on patient-generated concepts, but which required extensive modification and testing, including 
content addition. The final 41-item LMQ-3 instrument covers eight domains, under an overarching 
construct of medicine burden: interferences with day-to-day life; patient-doctor relationships and 
communication about medicines; lack of effectiveness; general concerns; side effects; practical 
difficulties; cost-ƌĞůĂƚĞĚďƵƌĚĞŶ ?ĂŶĚůĂĐŬŽĨĂƵƚŽŶŽŵǇ ?ĐŽŶƚƌŽůŽǀĞƌŵĞĚŝĐŝŶĞƐƵƐĞ ?ƌŽŶďĂĐŚ ?Ɛ
alpha (0.61-0.90) and ICC values (0.73-0.93) were satisfactory for most subscales. Medicine burden 
was established as a distinct concept negatively associated with treatment satisfaction and HRQoL. 
Higher-level medicine burden, estimated at 10% prevalence for the English adult population, was 
associated with age < 65 years, unemployment, residence in areas with higher relative level of 
deprivation, more frequent medicine use and combinations of formulations, but was not clearly 
related to the number of medicines.  
 
Conclusion: The LMQ-3 is a relatively comprehensive, valid, reliable, and interpretable measure of 
medicines burden suitable for use among adults using long-term medicines for any 




medicines burden or in studies of healthcare interventions aimed at the prevention, and/or 
reduction of medicine burden.  
CONTENTS 
DECLARATION .......................................................................................................................................... ii 
ACKNOWLDEGEMENTS ........................................................................................................................... iii 
ABSTRACT ............................................................................................................................................... iiv 
TABLES  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?ǆŝ 
FIGURES ..................................................................................................................................................xii 
ABBREVIATIONS AND ACRONYMS ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?ǆŝŝŝ
GLOSSARY ................................................................................................................................................ xv 
PUBLICATIONS AND PRESENTATIONS ARISING FROM THIS RESEARCH PROGRAMME .......................... xvii 
Chapter 1 General Introduction ............................................................................................................ 6 
1.1 The use of medicines ................................................................................................................... 6 
1.2 Defining polypharmacy ............................................................................................................... 6 
1.3 Epidemiology of polypharmacy- the rising prevalence ............................................................... 9 
1.4 Factors associated with polypharmacy ..................................................................................... 10 
1.5 Consequences of polypharmacy ................................................................................................ 13 
1.6 Initiatives designed to address the polypharmacy problem in the UK ...................................... 14 
1.7 Patient perspectives of medicines use....................................................................................... 18 
1.8 Existing theories  of treatment burden ..................................................................................... 19 
1.9 Conceptualising medicine-related burden ................................................................................ 23 
1.10 A summary of factors associated with medicine burden .......................................................... 27 
1.11 General aim and objectives of this doctoral thesis.................................................................... 35 
1.12 Overview of study phases in this research programme ............................................................ 36 
Chapter 2 Measuring medicine-related experiences from the patient perspective - a systematic review
 .............................................................................................................................................................42 
2.1 Introduction .............................................................................................................................. 42 
2.2 Methods .................................................................................................................................... 43 
2.2.1 Database search and search strategy ....................................................................................... 43 
2.2.2 Inclusion and exclusion criteria ................................................................................................. 43 
2.2.3 Article retrieval, data extraction and analysis .......................................................................... 44 
2.3 Results ....................................................................................................................................... 46 
2.3.1 Identified generic measures of medicine use experiences......................................................... 46 
2.3.2 Patient involvement in item generation .................................................................................... 52 
2.3.3 Reliability .................................................................................................................................. 54 
2.3.4 Scale analysis and construct validity ......................................................................................... 54 
2.3.5 Criterion-related, convergence and/or discriminant validity .................................................... 54 
2.3.6 Known-groups and predictive validity ....................................................................................... 55 




2.4 Discussion ................................................................................................................................. 60 
2.5 Chapter summary ..................................................................................................................... 64
Chapter 3 Methodology, methods, and research design ......................................................................65 
3.1 Introduction ..................................................................................................................................... 65 
3.2 Methodology .................................................................................................................................... 66 
3.2.1 Pharmacy practice research ...................................................................................................... 66 
3.2.2 Traditional research paradigms ................................................................................................ 66 
3.2.3 Rationale for choosing pragmatism and mixed-methods ......................................................... 67 
3.3 Methods .................................................................................................................................... 68 
3.3.1 Ethical considerations and approvals ....................................................................................... 68 
3.3.2 General rationale of methods used in this research programme .............................................. 69 
3.3.3 Sample population inclusion/exclusion criteria ......................................................................... 73 
3.3.4 Study settings ............................................................................................................................ 73 
3.3.5 Data management .................................................................................................................... 76 
3.3.6 Qualitative data analysis .......................................................................................................... 78 
3.3.7 Choice of measurement framework  WClassical Test Theory ...................................................... 79 
3.3.8 Factor analysis .......................................................................................................................... 80 
3.3.9 Sample size across studies ........................................................................................................ 86 
Chapter 4 Adaptation and further development of the original LMQ ...................................................87 
4.1 Introduction .............................................................................................................................. 87 
4.2 Methods .................................................................................................................................... 88 
4.2.1 Study instrument- The LMQ-1 ................................................................................................... 89 
4.2.2 Study population ....................................................................................................................... 89 
4.2.3 Questionnaire distribution ........................................................................................................ 89 
4.2.4 Data preparation ...................................................................................................................... 94 
4.2.5 Principal components analysis .................................................................................................. 94 
4.2.6 Reliability analysis ..................................................................................................................... 94 
4.2.7 Analysis of responses to the open question .............................................................................. 95 
4.3 Results ....................................................................................................................................... 95 
4.3.1 Response rates .......................................................................................................................... 95 
4.3.2 Distribution of responses, assessing missing data, and floor and ceiling effects ...................... 95 
4.3.3 Participant characteristics......................................................................................................... 99 
4.3.4 Results of the principal components analysis ......................................................................... 101 
4.3.5 Item reduction ......................................................................................................................... 103 
4.3.6 The resultant LMQ-2 factor solution ....................................................................................... 104 
4.3.7 Free-text comments  W content coverage ................................................................................. 107 
4.4 Discussion ............................................................................................................................... 109 




Chapter 5 Revising the LMQ-2 and testing face/content validity ........................................................ 113 
5.1 Introduction ............................................................................................................................ 113
 
5.2 Methods .................................................................................................................................. 115 
5.2.1 New item generation .............................................................................................................. 115 
5.2.2 Revision of existing items ........................................................................................................ 117 
5.2.3 Cognitive interviews- Assessing item comprehension in the LMQ-2.1 .................................... 117 
5.2.4 Study population and recruitment .......................................................................................... 118 
5.2.5 Interview procedures .............................................................................................................. 119 
5.2.6 Data analysis ........................................................................................................................... 120 
5.3 Results ..................................................................................................................................... 121 
5.3.1 Participant characteristics....................................................................................................... 121 
5.3.2 Interview findings ................................................................................................................... 123 
5.3.3 Questionnaire instructions and use of visual analogue scales ................................................ 123 
5.3.4 Item comprehension and modifications .................................................................................. 124 
5.4 Discussion ............................................................................................................................... 139 
5.5 Chapter summary ................................................................................................................... 143 
Chapter 6 Formulating the LMQ-3 and assessing its construct validity ............................................... 144 
6.1 Introduction ............................................................................................................................ 144 
6.2 Methods .................................................................................................................................. 146 
6.2.1 Study participants ................................................................................................................... 146 
6.2.2 Instruments ............................................................................................................................. 146 
6.2.3 Study recruitment procedures ................................................................................................. 146 
6.2.4 Data preparation .................................................................................................................... 149 
6.2.5 Data analysis ........................................................................................................................... 149 
6.2.5.1 EFA procedures ........................................................................................................................ 149 
6.2.5.2 CFA procedures ....................................................................................................................... 151 
6.3 Results ..................................................................................................................................... 158 
6.3.1 Survey response rates and sample size ................................................................................... 158 
6.3.2 Participant characteristics....................................................................................................... 158 
6.3.3 Distribution of responses ........................................................................................................ 160 
6.3.4 EFA findings ............................................................................................................................. 163 
6.3.5 CFA findings ............................................................................................................................ 168 
6.3.6 Internal consistency ................................................................................................................ 176 
6.4 Discussion ............................................................................................................................... 177 
6.5 Chapter summary ................................................................................................................... 183 
Chapter 7 Criterion-related validation of the LMQ-3 .......................................................................... 184 
7.1 Introduction ............................................................................................................................ 184 




7.2.1 Study design ............................................................................................................................ 186
 
7.2.2 Study participants and inclusion criteria ................................................................................. 186 
7.2.3 Study instruments ................................................................................................................... 186 
7.2.4 Study settings and procedures ................................................................................................ 190 
7.2.5 Data analysis ........................................................................................................................... 192 
7.3 Results ..................................................................................................................................... 193 
7.3.1 Response rates ........................................................................................................................ 193 
7.3.2 Patient population .................................................................................................................. 193 
7.3.3 Distribution of scores on all instruments ................................................................................ 195 
7.3.4 Criterion-related validity of the LMQ-3 ................................................................................... 196 
7.4 Discussion ............................................................................................................................... 201 
7.5 Chapter summary ................................................................................................................... 205 
Chapter 8 Test-retest reliability of the LMQ-3 .................................................................................... 206 
8.1 Introduction ............................................................................................................................ 206 
8.2 Methods .................................................................................................................................. 207 
8.2.1 Study design ............................................................................................................................ 207 
8.2.2 Study setting & participant inclusion criteria .......................................................................... 207 
8.2.3 Study instrument ..................................................................................................................... 207 
8.2.4 Recruitment procedures .......................................................................................................... 208 
8.2.5 Data cleaning and matching of test-retest responses ............................................................. 209 
8.3 Results ..................................................................................................................................... 211 
8.3.1 Response rate .......................................................................................................................... 211 
8.3.2 Test-retest duration ................................................................................................................. 211 
8.3.3 Participant characteristics....................................................................................................... 211 
8.3.4 Item-level stability................................................................................................................... 213 
8.3.5 Stability of subscales and composite score ............................................................................. 217 
8.4 Discussion ............................................................................................................................... 219 
8.5 Chapter summary ................................................................................................................... 224 
Chapter 9 Interpretation of scores, prevalence of medicine-related difficulties, and predictors of 
medicine burden ................................................................................................................................ 225 
9.1 Introduction ............................................................................................................................ 225 
9.2 Methods .................................................................................................................................. 227 
9.2.1 Datasets, recruitment, and study instruments ........................................................................ 227 
9.2.2 Participants ............................................................................................................................. 228 
9.2.3 Data preparation .................................................................................................................... 228 
9.2.4 Analyses .................................................................................................................................. 229 
9.3 Results ..................................................................................................................................... 233 




9.3.2 Prevalence and narratives of medicine-related problems ....................................................... 234
 
9.3.3 What proportion of people experience high medicine burden? .............................................. 241 
9.3.4 Subgroup differences .............................................................................................................. 246 
9.4 Discussion ............................................................................................................................... 257 
9.5 Chapter summary ................................................................................................................... 264 
Chapter 10 General discussion ........................................................................................................... 265 
10.1 General introduction ............................................................................................................... 265 
10.2 Discussion of key findings ....................................................................................................... 267 
10.3 Summary of key contributions to knowledge .......................................................................... 271 
10.4 Implications for research ........................................................................................................ 274 
10.5 Implications for clinical practice.............................................................................................. 276 
10.6 Implications for policy ............................................................................................................. 279 
10.7 Overall strengths and limitations ............................................................................................ 281 
10.8 Thesis summary ...................................................................................................................... 284 
References ................................................................................................................................................ 286 
 
Appendices 
Appendix 1 Full search strategy for systematic review ............................................................................ 311 
Appendix 2 Cognitive interview probing guide ......................................................................................... 325 
Appendix 3 Application for amendments to the LMQ-1 and  ethics approval ......................................... 327 
Appendix 4 The Living with Medicines Questionnaire Version 1 (LMQ-1) ................................................ 329 
Appendix 5 Phase 1- Invitation letter to the community pharmacist ....................................................... 336 
Appendix 6 Phase 1- Pharmacist information .......................................................................................... 337 
Appendix 7 Phase 1 - Participant information .......................................................................................... 339 
Appendix 8 Phase 2 Ethics approval for a study to revise the original questionnaire .............................. 340 
Appendix 9 Participant invitation letter to the cognitive interview study ................................................ 342 
Appendix 10 Participant information for cognitive interviewees ............................................................. 343 
Appendix 11 Consent form for cognitive interview participants .............................................................. 345 
Appendix 12 Participant details form for arranging cognitive interviews ................................................ 346 
Appendix 13 Snowball recruitment text for cognitive interview participants .......................................... 347 
Appendix 14 The Intermixed version of the revised LMQ-2 ...................................................................... 348 
Appendix 15 Grouped/Labelled version of the revised LMQ-2 ................................................................. 355 
Appendix 16 Sample analyses of cognitive interview data ...................................................................... 362 
Appendix 17 Invitation email to website managers ................................................................................. 363 
Appendix 18 NRES Ethics approval letter for criterion validation study ................................................... 364 
Appendix 19 Research governance letters for criterion validation study ................................................. 371 
Appendix 20 Study information for criterion validation study ................................................................. 384 
Appendix 21 The final instrument (LMQ-3) .............................................................................................. 392 
Appendix 22 The Treatment Satisfaction Questionnaire for Medication ................................................. 402
Appendix 23 The EQ-5D-5L Questionnaire ............................................................................................... 409 
Appendix 24 Ethics approval and advert for test-retest study ................................................................. 412 
Appendix 25 Comments for participants with high/extremely high medicine burden ............................. 416 







Table 1-1 Summary road map for my doctoral thesis ................................................................................ 41 
Table 2-1 Characteristics of reviewed generic measures of medicine-related experiences ...................... 49 
Table 2-2 Comparison of content areas covered by items in reviewed generic measures of medicine-
related experiences .................................................................................................................................... 51 
Table 2-3 Methods employed in item generation and testing of reviewed generic measures of medicine-
related experiences .................................................................................................................................... 53 
Table 2-4 Psychometric properties of questionnaires included in the review ........................................... 58 
Table 4-1 Distribution of responses to the 60-item LMQ-1 obtained using paper-based and on-line 
survey datasets .......................................................................................................................................... 98 
Table 4-2 Characteristics of participants completing theLMQ-1 survey .................................................. 100 
Table 4-3 Comparing eigenvalues using parallel analysis (LMQ-1) .......................................................... 102 
Table 4-4 Items deleted from the LMQ-1................................................................................................. 103 
Table 4-5 The 42-item 8-factor solution of the Living with Medicines Questionnaire version 2 (LMQ-2)
.................................................................................................................................................................. 106 
Table 5-1 New items generated about cost, side effects, and social impact. .......................................... 116 
Table 5-2 Characteristics of participants completing the cognitive interviews ....................................... 122 
Table 5-3 Item-by-item analysis of potential comprehension problems in the interim instrument (LMQ-
2.1) ........................................................................................................................................................... 128 
Table 6-1 Patient organisations that participated in the LMQ-2.1 on-line survey ................................... 147 
Table 6-2 Characteristics of participants in the EFA and CFA subsamples ............................................... 159 
Table 6-3 Distribution of responses to the 58-item interim tool (LMQ-2.1) ............................................ 162 
Table 6-4 Comparison of eigenvalues using parallel analysis (LMQ-2.1) ................................................. 164 
Table 6-5 Items deleted from the 58-item interim tool (LMQ-2.1) .......................................................... 165 
Table 6-6 The final 41-item, EFA-derived, 8-factor solution of the Living with Medicines Questionnaire 
version 3 (LMQ-3) ..................................................................................................................................... 167 
Table 6-6 Comparison of fit indices for all models tested in CFA (LMQ-3) .............................................. 172 
Table 6-7 Modifications in the revised second-order model (LMQ-3) ..................................................... 176 
Table 6-8 Internal consistency (Cronbach alpha) for LMQ-3 subscales ................................................... 176 
Table 7-1 Characteristics of participants in the criterion-related validation study .................................. 194 
Table 7-2 Distribution of scores obtained using the LMQ-3, TSQM-II and EQ-5D ................................... 195 
Table 7-3 Correlations between LMQ-3 scores and TSQM-II scores ........................................................ 196 
Table 7-4 Correlations between LMQ-3 scores and EQ-5D-5L scores ...................................................... 199 
Table 8-1 Characteristics of participants in the test-retest study ............................................................ 212 
Table 8-2 Test and retest stability of the LMQ-3 at item level ................................................................. 216 
Table 8-3 Test-retest stability of LMQ-3 subscales and total scale .......................................................... 217 
Table 9-1 Percentage of participants endorsing (agreeing or disagreeing) with the 41 Likert-type 
statements common to the two datasets ................................................................................................ 240 
Table 9-2 Cross-validation of medicine burden categories derived using LMQ-3 composite scores....... 244 
Table 9- ?ŚĂƌĂĐƚĞƌŝƐƚŝĐƐŽĨƉĂƌƚŝĐŝƉĂŶƚƐǁŝƚŚ ‘ĐĞƌƚĂŝŶůǇ ?ŚŝŐŚŽƌĞǆƚƌĞŵĞůǇŚŝŐŚŵĞĚŝĐŝŶĞďƵƌĚĞŶďĂƐĞĚ
on their LMQ-3 composite scores and global VAS ratings ....................................................................... 245 
Table 9-4 Differences in medicine burden by demographic and treatment characteristics   ............... 246 
Table 9-5 Relationship between relative deprivation in area of residence and medicine burden .......... 248 
Table 9-6 Simple linear regression analyses of predictors of medicine burden ...................................... 255 











Figure 1-1  Articles citing the term 'polypharmacy' in their titles from 1966 to 2014 ................................. 6 
Figure 1-2 Comorbidity among patients in the UK Primary care ............................................................... 10 
Figure 1-3 Definition of medicines optimisation ........................................................................................ 16 
Figure 1-4  A conceptual framework of the burden of treatment ............................................................. 21 
Figure 1-5 Overview of the concept of inherent burden of medicines ...................................................... 24 
Figure 1-6 Recent conceptualisation of medicine-related burden ............................................................ 26 
Figure 1-7 A conceptual framework of medicine burden and likely consequences .................................. 28 
Figure 1-8 Overview of the present research programme ......................................................................... 37 
Figure 3-1 Location of research study sites in south-east England ............................................................ 75 
Figure 4-1 List of patient organisations participating in the LMQ-1 on-line survey ................................... 93 
Figure 4-2 Scree plot illustrating the number of components (domains) in the LMQ-1 .......................... 101 
Figure 5-1 Sample visual analogue scale and completion instructions .................................................... 123 
Figure 6-1 Social media page (Twitter) for survey recruitment ............................................................... 148 
Figure 6-2 Hypothesised first order model for the LMQ-3 (Model 1) ...................................................... 154 
Figure 6-3 Scree plot estimating the number of factors to retain in the LMQ-2.1 .................................. 163 
Figure 6-4 First-order model estimates (Model 1) ................................................................................... 169 
Figure 6-5 Second-order model estimates (Model 2) .............................................................................. 171 
Figure 6-6 Revised second-order model estimates (Model 3) ................................................................. 174 
Figure 7-1 Scoring of LMQ-3 items and subscales/domains .................................................................... 187 
Figure 7-2 Scatter plot showing a negative relationship between medicine burden and treatment 
satisfaction ............................................................................................................................................... 197 
Figure 7-3 Scatter plot showing a negative relationship between medicine burden and general health 
status ........................................................................................................................................................ 200 
Figure 8-1 Advert for test-retest study on the University website .......................................................... 208 
Figure 8-2 Bar chart showing the test-retest intervals for the LMQ-3 ..................................................... 211 
Figure 8-3 Bar chart showing relative stability of VAS ratings over the test-retest period ...................... 213 
Figure 8-4 Bland-Altman plot showing agreement between LMQ-3 composite scores over the test-retest 
period ....................................................................................................................................................... 218 
Figure 9-1 Histograms showing distribution of LMQ composite scores................................................... 241 
Figure 9-2 Prevalence of medicine burden in the sample populations.................................................... 242 
Figure 9-3 Comparison of medicine burden categories with number of medicines used across the two 
sample populations. ................................................................................................................................. 249 
Figure 9-4 Histograms and P-P plots of normally distributed residuals ................................................... 252 













ABBREVIATIONS AND ACRONYMS 
 
ADR Adverse Drug Reaction 
AMOS Analysis of Moment Structures (statistical software) 
ANOVA Analysis of Variance 
BMQ Beliefs about Medicines Questionnaire 
BoT Burden of Treatment 
CCM Cumulative Complexity Model 
CFA Confirmatory Factor Analysis 
CINAHL  Cumulative Index to Nursing and Allied Health Literature 
CPPQ Community Pharmacy Patient Questionnaire 
CTT Classical Test Theory 
DTC Drug Therapy Concerns 
EFA Exploratory Factor Analysis 
EQ-VAS EuroQol Visual Analogue Scale   
EQ-5D-  EuroQol five dimensions questionnaire  
GP General Practitioner 
HRQoL Health-related Quality of Life 
IRT Item Response Theory 
KARU Kent Adult Research Unit 
KMO Kaiser-Meyer-Olkin (measure of sampling adequacy)  
LMQ Living with Medicines Questionnaire  
MAI Medication Appropriateness Index 
MDM Minimally Disruptive Medicine 
MO Medicines Optimisation 
MRB Medicine-related Burden 
MUR Medicines Use Review 
NHS National Health Service 





ABBREVIATIONS AND ACRONYMS 
NMS New Medicine Service 
OTC Over-the-Counter  
PAF Principal Axis Factoring 
PATD WĂƚŝĞŶƚƐ ?ƚƚŝƚƵĚĞƐdŽǁĂƌĚƐĞƉƌĞƐĐƌŝďŝŶŐ 
PCA Principal Components Analysis 
PIPS Public Involvement in Pharmacy Studies 
PPCs Prepayment Certificates  
PREM Patient Reported Experience Measure 





Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life 
PSM Perceived Sensitivity to Medicines Questionnaire 
PSMM Patient Satisfaction with Medication Management  
PTRQoL Pharmaceutical Therapy-Related Quality of Life 
QOF Quality and Outcomes Framework 
QOL Quality of Life 
RPS Royal Pharmaceutical Society 
SATMED-Q Treatment Satisfaction with Medicines Questionnaire 
SF-36 Short Form (36-item) Health Survey  
SIMS Satisfaction with Information about Medicines Scale 




Screening Tool to Alert to Right Treatment/  
 
^ĐƌĞĞŶŝŶŐdŽŽůŽĨKůĚĞƌWĞŽƉůĞ ?ƐWƌĞƐĐƌŝƉƚŝŽŶƐ 
TBQ Treatment Burden Questionnaire  
TSQM Treatment Satisfaction Questionnaire for Medication 























The perceived ability to control, cope with and make personal decisions about how one 
ůŝǀĞƐŽŶĂĚĂŝůǇďĂƐŝƐ ?ĂĐĐŽƌĚŝŶŐƚŽŽŶĞ ?ƐŽǁŶƌƵůĞƐĂŶĚƉƌĞĨĞƌĞŶĐĞƐ ? ?/ŶƚŚĞĐŽŶƚĞǆƚŽĨƚŚŝƐ
thesis, autonomy/control over medicines use relates to ability to vary medicine regimes 





A qualitative research method used to determine whether concepts and items (questions) 










The extent to which an instrument measures the intended concepts and the inferences that 





Qualitative evidence demonstrating that the instrument covers the concepts of interest 
including judgements that the items are appropriate, relevant, and comprehensive relative 





The extent to which questionnaire scores correlate with scores on another (concurrently 





The extent to whŝĐŚƚŚĞƐĐŽƌĞƐŽĨĂŶŝŶƐƚƌƵŵĞŶƚĂƌĞƌĞůĂƚĞĚƚŽĂŬŶŽǁŶ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?
measure of the same concept. tŚĞŶƚŚĞƌĞŝƐŶŽ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?ĐŽŵƉĂƌŝƐŽŶ, criterion-
related validity refers to the extent to which questionnaire scores are related to scores 






The extent to which questionnaire scores do not correlate (strongly) with scores on another 
(concurrently administered) measure of a different construct. It provides evidence that an 




A judgement that an instrument and its items, on the face of it, appears to be assessing 
the intended construct. 
 
Item An individual question or statement (and its response options) that is intended to measure 




The extent to which questionnaire scores differ between groups of persons known or 




In this thesis, medicine burden refers to negative experiences associated with using long-
term prescription medicines. 
 
Multimorbidity  The existence of two or more chronic conditions in the same patient. 
 
Patient capacity Ability to manage own health, including ability to engage with prescribed healthcare 
















A measurement based on a self-report that comes directly from the patient about his/her 
ƐƚĂƚƵƐǁŝƚŚŽƵƚĂŵĞŶĚŵĞŶƚŽƌŝŶƚĞƌƉƌĞƚĂƚŝŽŶŽĨƚŚĞƉĂƚŝĞŶƚ ?ƐƌĞƐƉŽŶƐĞďǇĂĐůŝŶŝĐŝĂŶŽƌ
anyone else.  
 




Attributes relevant to the application of an instrument (questionnaire) including the 
different forms of validity (e.g. content validity, construct validity) and reliability. The term 




Evidence that an instrument yields consistent (or reproducible) estimates, producing the 
same or similar results, when used to measure a given construct. 
 
Scale The system of numbers or verbal anchors by which a value (or score) is derived for an 
item. For example, Likert-type scales may use a scale of 1 to 5 to reflect the level of 
agreement with a statement. A visual analogue scale (VAS) may have verbal anchors to 
reflect levels of an attribute. 
 




Self-care practices that patients with chronic illness must perform to respond to the 
requirements of their healthcare providers (e.g. doctor visits, blood tests) and the impact 
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Chapter 1 General Introduction 
1.1 The use of medicines 
Within modern medical practice, prescribing medicines is one of the common 
therapeutic interventions following a patient consultation.1 Both prescription 
medicines and over-the-counter (OTC) medicines contribute to the total medicine 
consumption,2 but there is a growing interest in the long-term use of prescription 
medicines by various stakeholders.3,4 Prescription medicines are those sold or supplied 
only in accordance with a valid prescription from an appropriate practitioner.5 
Medicines are not only used for alleviating symptoms, but increasingly are prescribed 
prophylactically for primary or secondary prevention of different health conditions 
(e.g. for cardiovascular disease risk protection).4  
1.2 Defining polypharmacy 
Over the years, the interest in polypharmacy has rapidly grown. Both the World Health 
Organisation (WHO)6 and the Kings Fund4, an independent organisation seeking to 
improve healthcare in England, define polypharmacy as the concurrent use of 
 ‘ŵƵůƚŝƉůĞ ?Žƌ ‘ĞǆĐĞƐƐŝǀĞ ?medicines by an individual. Numerous studies have researched 
different aspects of this subject. To illustrate this, combined literature searches for the 
ƚĞƌŵ ‘ƉŽůǇƉŚĂƌŵĂĐǇ ? ?ŝŶŵƵůƚŝƉůĞ databases (Medline, CINAHL Plus, and PsychInfo) 
revealed an estimated seven-fold increase in publications citing the term 
 ‘ƉŽůǇƉŚĂƌŵĂĐǇ ?ǁŝƚŚŝŶƚŚĞŝƌƚŝƚůĞƐ ?ŽǀĞƌƚŚĞƉĞƌŝŽĚƐ ? ? ? ?-1998 to 2010-2014 (See 
Figure 1-1). 
 





/ŶƐƉŝƚĞŽĨƚŚĞĚĞĐĂĚĂůƵƐĞŽĨƚŚĞƚĞƌŵ ‘ƉŽůǇƉŚĂƌŵĂĐǇ ?and the cumulative literature on 
polypharmacy, there are definitional problems, for researchers, with an apparent lack 
of consensus in definitions. Nevertheless, there are two major approaches to defining 
polypharmacy; use of a specific numeric threshold/cut-off value for the number of 
medicines used, or the appropriateness of medicines used according to pre-defined 
criteria.4,7,8  
 
Consensus regarding what number of medicines (or threshold) defines polypharmacy 
is also lacking. Using at least five medicines appears the most cited threshold for 
defining polypharmacy,4,7,9 but Bjerrum et al (1997)10 justified subdivisions (e.g. minor 
polypharmacy for 2-4 medicines and major polypharmacy for A? 5 medicines) or higher 
thresholds. In a recent Cochrane review, Cooper et al (2015)11 used A? 4 regular 
medicines as their cut-off for polypharmacy. Bushardt et al (2008)12 considers a 
threshold of six medicines or over, while Steinman et al (2006)13 proposed eight or 
more medicines as a potential threshold for polypharmacy.  
 
Owing to the shifting population demographics over the years, patients continue to 
receive a rising number of medicines, and polypharmacy thresholds may change.14 
Current propositions suggest 10 or more medicines as a more suitable threshold for 
defining polypharmacy (hyperpolypharmacy),4,15 while 20 or more is currently 
ĐŽŶƐŝĚĞƌĞĚ ‘ĞǆĐĞƐƐŝǀĞ ?.9  Although often arbitrary, using numeric cut-off values to 
define polypharmacy is a simple way, which is commonly used.  As the number of 
prescription medicines increases, the number of medicine-related problems and 
adverse effects (e.g. falls, hospitalisation) also increases.4,7 Nonetheless, a recent 
ŽĐŚƌĂŶĞ ?ƐƌĞǀŝĞǁ indicated ƚŚĂƚ ‘ QƉŽůǇƉŚĂƌŵĂĐǇŝƐŶŽƚũƵƐƚĂďŽƵƚƚŚĞ QŶƵŵďĞƌƐŽĨ
drugs but rather thĞƉƌĞƐĐƌŝƉƚŝŽŶŽĨŵĞĚŝĐĂƚŝŽŶĂƉƉƌŽƉƌŝĂƚĞƚŽƚŚĞŶĞĞĚƐŽĨƉĂƚŝĞŶƚƐ ? ?16  
 
While there has been much research about the appropriateness of medicines, there 
are definition problems here too. Recent definitions by the Kings Fund4 describe 
polypharmacy as either  ‘aƉƉƌŽƉƌŝĂƚĞ ?Žƌ ‘inappropriate ? (problematic). 
Problematic polypharmacy includes the use of a potentially inappropriate medicine or 
the prescription of more medicines than are warranted clinically.4,8 From the 




ƚŚĂŶĂƌĞŶĞĞĚĞĚĨŽƌĂŶŝŶĚŝǀŝĚƵĂů ?s clinical condition or where the anticipated 
therapeutic benefits are not attained.4 However, multiple medicines may be 
appropriate if they are beneficial to the patient, especially in cases of multiple complex 
illnesses (multimorbidity).4,16  
 
,ŽǁĞǀĞƌ ?ƚŚĞĐŽŶĐĞƉƚŽĨ ‘ĂƉƉƌŽƉƌŝĂƚĞŶĞƐƐ ?ŽĨŵĞĚŝĐŝŶĞƐŚĂƐĚŝĨĨĞƌĞŶƚŵĞĂŶŝŶŐs for 
prescribers and patients. WƌĞƐĐƌŝďĞƌƐ ?ǀŝĞǁƐŽĨwhat constitutes an appropriate 
ŵĞĚŝĐŝŶĞĚŝĨĨĞƌĨƌŽŵƉĂƚŝĞŶƚƐ ?ǀŝĞǁƐ.17,18 &ƌŽŵƚŚĞƉƌĞƐĐƌŝďĞƌ ?ƐƉĞƌƐƉĞĐƚŝǀĞ ?ŵĞĚŝĐŝŶĞƐ
ĂƌĞĚĞĞŵĞĚ ‘ĂƉƉƌŽƉƌŝĂƚĞ ?ŝĨƚŚey have evidence of efficacy and safety, and are of 
minimal cost to the health system, according to some predefined  ‘ƐĐŝĞŶƚŝĨŝĐ ?criteria.19  
For a patient, medication appropriateness relates to broader issues including 
psychosocial aspects, day-to-day experiences of managing medicines, effectiveness (if 
medicines are working), side effects, choice, anxieties and concerns about medicines, 
relationships with health providers, and consequences of treatment, among many 
other factors.17,20,21 Some patients look to general practitioners (GPs) to decide/assess 
ŝĨƚŚĞŝƌŵĞĚŝĐĂƚŝŽŶŝƐ ‘ĐŽƌƌĞĐƚ ?ĂŶĚĞĨĨĞĐƚŝǀĞ,17 and feel they lack sufficient medical 
knowledge and expertise to evaluate the appropriateness of their medication. Many 
others seek clear and simplified information to enable themselves to assess their 
ŵĞĚŝĐĂƚŝŽŶ ?ƐĂƉƉƌŽƉƌŝĂƚĞŶĞƐƐ ?22,23 More recently, a person-centred perspective of 
defining and understanding inappropriate/problematic polypharmacy is recommended 
by Heaton and colleagues (2016).24   
 
In this research programme, participants were included in the different studies if they 
used at least one long-ƚĞƌŵƉƌĞƐĐƌŝƉƚŝŽŶŵĞĚŝĐŝŶĞĂŶĚŝŶǀĞƐƚŝŐĂƚŝŽŶƐŽĨƉĂƚŝĞŶƚƐ ?
experiences were not restricted to multiple medicine users. This is in recognition of the 
fact that some patients may feel burdened by just one medicine while others cope 
with many perceiving no burden. /ŶĨĂĐƚ ?ĂƌŽǁŝƚǌƐƵŐŐĞƐƚƐƚŚĂƚ ‘ĨŽƌƐŽŵĞƉĂƚŝĞŶƚƐ ?ŽŶe 
ŵĞĚŝĐĂƚŝŽŶŵĂǇďĞƚŽŽŵƵĐŚ ?ĂŶĚĨŽƌŽƚŚĞƌƐ ? ? ?ŵĞĚŝĐĂƚ ŽŶƐŵĂǇďĞƚŽŽĨĞǁ ? ?8  Thus 
ƚŚĞƉƌŽŐƌĂŵŵĞĐŽŶĐĞƌŶƐƉĂƚŝĞŶƚƐ ?ƉĞƌĐĞŝǀĞĚďƵƌĚĞŶŽĨŵĞĚŝĐŝŶĞƐƵƐĞ ?ƌĞŐĂƌĚůĞƐƐŽĨ
the number of medicines used, and does not only focus on those using multiple 
medicines. Nonetheless, the association between the number of medicines used and 





1.3 Epidemiology of polypharmacy- the rising prevalence 
Globally, there is an increasing prevalence of polypharmacy, with more and more 
individuals taking multiple medicines.14,25 W27 There are international variations in 
medicines use. In a 2008/2009 comparative study (updated to 2012/2013) into 
variations in medicines usage across high income countries, the UK ranked 8th/9th out 
of the 13-14 countries studied; usage per head of population rose in 11 of 16 medicine 
categories used for managing or preventing different long-term conditions, including 
cancer, heart disease, stroke, dementia.28,29  
 
The increasing consumption of medicines in the UK is even more vivid, and reportedly 
reflects  ‘Ă nation of pill ƉŽƉƉĞƌƐ ? ?30 This follows the findings of the 2013 Health Survey 
for England on prescription medicines use, which revealed that about 50% of all adults 
used one or more prescribed medicines in the week prior to the survey.31 In England 
alone, the average number of prescription items dispensed (including medicines) is 
estimated to have risen by 55.2% over the last decade (the period 2004 to 2014)32 and 
prescribing data indicates yearly increments in the number of medicines dispensed in 
primary care.32 One large Scottish study indicates that the proportion of patients 
receiving five or more dispensed medicines rose from 12% in 1995 to 22% in 2010.14 
This study further indicates that the number of patients receiving 10 or more 
dispensed medicines tripled (from 1.9% to 5.8%) over the same period,  highlighting 
the substantial risĞŝŶƉƌĞǀĂůĞŶĐĞŽĨ ‘ŚǇƉĞƌƉŽůǇƉŚĂƌŵĂĐǇ ?.14 Comparative data for 
polypharmacy trends in England is limited, but similar patterns are likely. The 
polypharmacy problem is not just confined to primary care, as some studies indicate 












1.4 Factors associated with polypharmacy  
Several factors are associated with the rising prevalence of polypharmacy in the UK, 
encompassing changing demographics, the impact of health technology assessments 
and evidence-based medicine, clinical guidelines and health policies and systems, and 
changing societal attitudes and expectations towards treatments.   
 
Changing demographics ʹ aging and multimorbidity 
The prevalence of polypharmacy increases with both age and multi-morbidity.4,9,14 The 
h< ?ƐƉŽƉƵůĂƚŝŽŶŝs increasingly aging and more people are living longer with at least 
two or more chronic conditions (termed multimorbidity) for which multiple medicines 
are prescribed.34 With the population aged 85 years and over projected to more than 
double by 2035, polypharmacy is projected to continue growing.4 Multimorbidity is 
more common among the elderly (age 65 years or over).34,35 For instance, most elderly 
patients with diabetes have, on average, six or more co-existing long-term conditions 
when compared those under 65 years of age with approximately three conditions (See 




Figure 1-2 Comorbidity among patients in the UK Primary care 
 




The impact of health technology assessments, clinical guidelines and health policies 
There has been a trend towards greater use of evidence-based practice both in the UK 
and internationally, with more prescribers feeling compelled to adhere to clinical 
guidelines, such as those developed by the National Institute for Healthcare Excellence 
(NICE). NICE is responsible for appraising new and existing medicines and 
recommending their use within the National Health Service (NHS) in England. Existing 
clinical guidelines are largely criticised for having a single-disease focus, and less 
consideration of medicines use in the context of multimorbidity.35,36 For patients with 
multiple disease conditions, prescribing based on disease-specific clinical guidelines, if 
used in isolation for each condition, contributes to polypharmacy.36 Moreover, most 
evidence-based guidance is derived from studies conducted in atypical patient 
populations that lack complex multimorbidities encountered in real-life settings. 
Guidelines are also described as limiting to professional judgment and person-centred 
practice, and impact on patient preferences.36,37 Some professionals may have more 
difficulties than others in considering patient wishes, concerns or obtaining detailed 
accounts, and enacting patient preferences may be viewed as out-of-protocol and 
against evidence-based guidelines.37 Another significant consequence of adhering to 
clinical guidelines is a rise in the use of prophylactic medicines for disease- and 
mortality-prevention, especially among asymptomatic patients. This results in many 
 ‘ǁĞůů ? individuals increasingly prescribed medicines, particularly for the prevention of 
cardiovascular disease and stroke, and contributes to the growing levels of 
polypharmacy.4 
 
Furthermore, prescribing targets set out by incentivised initiatives, particularly the 
Quality and Outcomes Framework (QOF) for general practice in the UK, may contribute 
to polypharmacy.37 The QOF ŝŶŝƚŝĂƚŝǀĞ ?ĂƐĂ ‘ŶĂƚŝonal primary care pay-for-performance 
(P4P) scheme Q designed to improve evidence-based quality targets ? ?awards practices 
for managing and preventing common chronic conditions.38 For instance, one QOF 
indicator is the percentage of patients treated with statins of those with cardiovascular 
risk assessment scores A? 20% in the previous one-year, and practices prescribing more 
of these lipid-lowering medicines would be rewarded for primary prevention of 
cardiovascular disease.39 A recent systematic review into the impact of the QOF 




and on continuity of care, all of which may cause inappropriate polypharmacy and 
dissatisfaction with care.38 
 
Health systems 
The rise in polypharmacy may also be related to prescribing systems. In England, the 
use of repeat prescriptions, among patients with chronic conditions, has gradually 
increased over the years.40 It is estimated that repeat prescriptions contribute 80% of 
all dispensed prescription items in primary care.4 Patients (or their representatives) 
can request repeat prescriptions through wide-ranging methods depending on the 
practice: in person, telephone, on-line, by post  or fax.41 This enables patients with 
long-term conditions to have easier access to medicines, but systems may not provide 
adequate control over the extent of repeat prescribing,42 which could contribute to 
polypharmacy. More recently, electronic prescribing, which enables prescriptions to be 
sent electronically to a patient-chosen community pharmacy,43 is further easing access 
to repeat medicines, but with even greater possibility of minimal communication 
between the patient and the prescriber. 
 
With about a third of patients in England paying for their prescriptions, the cost of 
prescription medicines is another health-system-related challenge for some users of 
long-term prescription medicines. Within the English NHS, regulations set out 
prescription charges and arrangements for exemptions among specific groups of 
people (e.g. based on age, disease/condition state, and income brackets) or for specific 
medicines.44 Different cost-sharing mechanisms, including a fixed co-payment (a 
prescription charge of £8.40 per item as of April 201645), are applicable in England. 
Also in use are quarterly (£29.10) or annual (£104) prepayment certificates (PPCs) that 
are intended to put a ceiling on patient charges, among those in need of regular 
medicines.45 However, previous studies have indicated low levels of awareness of the 
existence of PPCs as cost-saving strategies.46 All these cost-related issues may affect 
access to prescription medicines. In their 2014 report, a coalition of patient 
organisations against prescription charges for patients in need of long-term 
prescriptions in England, revealed that cost-related non-adherence affects about a 




1.5 Consequences of polypharmacy 
Whereas polypharmacy may be beneficial, it also poses several challenges and has 
wide-ranging impacts on the healthcare system, society, and patients. For health 
systems, including the NHS, polypharmacy has financial implications associated with 
costs of medicines (over £14.4bn per annum) and related pharmaceutical services, and 
expenditure and wastage resulting from patient non-adherence and medicine-related 
problems (e.g. medication errors).4 For society, polypharmacy may influence caregiver 
burden or strain/family relationships among those needing to care for patients unable 
to manage their own medicines.48,49 For patients using multiple or inappropriate 
medicines, the consequences are well documented. Non-adherence, one of the most 
common implications for the patient, is very common; up to 50% of medicines are not 
taken as prescribed.3 Other polypharmacy-related problems include pill burden, time 
and effort related to organising multiple regimens, self-monitoring demands,48 W50 
adverse drug reactions (ADRs), drug-drug or drug-food interactions.7,14,15 All these may 
contribute to poor clinical outcomes, including symptom occurrence, relapse, and 
exacerbation of disease/condition or hospitalization. For patients without an 
exemption from prescription fees, polypharmacy can lead to direct financial burden 
associated with out-of-pocket payments for their medicines.44,51,52 Overall, the use of 
multiple or inappropriate medicines may impact ŽŶƉĂƚŝĞŶƚƐ ?ƋƵĂůŝƚǇŽĨůŝĨĞ ?physical 














1.6 Initiatives designed to address the polypharmacy problem in the UK  
Over the years, there have been several national recommendations for supporting 
medicines management schemes within primary and secondary care in the UK.53,54 
These promote improved access to medicines, rational prescribing, and reduction of 
costs and medicine wastage within the NHS. Several researchers have devised 
interventions/methods to promote identification and reduction of polypharmacy, 
which are discussed in this section.  
1.6.1 Prescribing guidelines, indicators, and tools 
As part of interventions to solve the global problem of polypharmacy, a number of 
guidelines, prescribing indicators, and risk assessment/screening tools to identify 
medicine-related-problems and inappropriate prescriptions have been developed. 
In the UK, key guidelines targeting polypharmacy include:   
a) the 2014  ‘Polypharmacy: Guidance for Prescribing ? for Scotland and Wales that 
targets the frail and elderly, those using multiple medicines, high-risk medicines 
and those with shortened life expectancy;55   
b) the 2015  ‘Polypharmacy Guidance ?published by the Scottish Government, 
which describes a 7-step approach to reviewing medicine use among adult 
patients encompassing aims, need, effectiveness, safety, cost-effectiveness, 
adherence or patient-centredness;56  
c)  the 2015 E/ŐƵŝĚĞůŝŶĞŽŶ ‘DĞĚŝĐŝŶĞƐKptimisation: the safe and effective use 
of medicines to enable the best possible outcomes ?, whose key priorities relate 
to medicine-related communication and methods to identify patient safety 
issues.57 Most of the guidance appears prescriber-focussed and centred on the 
appropriateness of medicines from the health professional perspective.  
 
Common indicators (and measures) of appropriateness of medicines use predefined 
criteria, such as the Beer ?ƐĐƌŝƚĞƌŝĂ(and its adaptations),58 and the Medication 
Appropriateness Index (MAI).59 The START/ STOPP tools (Screening Tool to Alert to 
Right Treatment and Screening Tool of Older People ?ƐWƌĞƐĐƌŝƉƚŝŽŶƐ ),60 are 
recommended by the NICE Guidelines in the identification of medicine-related 
problems among older people with polypharmacy, but neither has been routinely used 




Within the UK, other prescribing indicators include those tested in the PINCER trial, a 
pharmacist-led information technology intervention that provided feedback and 
education to GPs to minimise medication errors.61 Other prescribing indicators for UK 
general practice were developed by the Royal College of General Practitioners,62 while 
KďŽƌŶĞ ?Ɛ63 prescribing indicators were intended for elderly medical inpatients. 
Although validated for use in various settings, prescribing indicators are largely 
prescriber-led, require healthcare professional judgement, and require little or no 
input from patients. They are also medicine-centred, and applicable to specific patient 
populations with less consideration of multi-morbidity. Other recent guidance on 
strategies designed to tackle polypharmacy considers the selection of appropriate 
formulations with minimal regimen complexity.16  
 
Deprescribing algorithms, which involve tapering or cessation of undesirable 
medicines,64 W67 are also proposed to guide clinical decisions in reducing polypharmacy 
but are also clinician-driven and tend to focus on reducing medicine usage and costs.  
Deprescribing has also been criticised for general lack of effectiveness, sustainability, 
and insufficient validation.65  
 
1.6.2 Medicine use reviews 
Other interventions aimed at reducing polypharmacy, include pharmacist-led medicine 
use reviews.68 In England and Wales, the Medicine Use Reviews and Prescription 
Intervention (MUR) service was initiated in 2005, under the Community Pharmacy 
Contractual Framework, as one of the Government strategies to ŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐ ?
adherence and reduce medicine costs and waste. Provided by the vast majority of 
community pharmacies in England, MUR services are increasingly targeted to people 
using high-risk medicines (e.g. anticoagulants for stroke prevention), those recently 
discharged from secondary care and had altered regimens during admission, those in 
need of medicines with respiratory conditions (e.g. corticosteroids), diabetes, and the 
elderly. Tools to guide or document MURs vary, but comprise questions around 





The New Medicine Service (NMS), which is also provided by most community 
pharmacies in England, specifically offers support to using newly-prescribed medicines 
in the context of long-term illness, but also aims to improve adherence.70 Despite 
evidence to support MURs, particularly the achievement of prescribing process 
outcomes (and reducing polypharmacy),71 from ƚŚĞƉĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞ, these 
services have been criticised to have minimal impact regarding how patients use their 
medicines or even less with improving knowledge of medicines, and not addressing 
ƉĂƚŝĞŶƚƐ ?ŶĞĞĚƐĨƵůůǇ.72,73  
 
1.6.3 Drive towards patient-centred strategies  
Most recently, improving the quality of patient care has been placed at the heart of 
the NHS. In their 2014/15- ? ? ? ? ? ? ?ƌĞƉŽƌƚ ? ‘ǀĞƌǇŽŶĞĐŽƵŶƚƐ PƉůĂŶŶŝŶŐĨŽƌƉĂƚŝĞŶƚƐ ? ?
NHS England prioritises delivering and measuring patient-centred outcomes against 
ĨŝǀĞŵĂũŽƌĚŽŵĂŝŶƐ ?ƚǁŽŽĨƚŚĞƐĞƌĞůĂƚĞƚŽ ‘ĞŶŚĂŶĐŝŶŐƋƵĂůŝty of life for people with 
long-ƚĞƌŵĐŽŶĚŝƚŝŽŶƐ ?ĂŶĚ ‘ĞŶƐƵƌŝŶŐƚŚĂƚƉĞŽƉůĞŚĂǀĞ ĂƉŽƐŝƚŝǀĞĞǆƉĞƌŝĞŶĐĞŽĨĐĂƌĞ ? ?74  
 
Other recent developments within the UK include the concept of medicines 
optimisation, an agenda originally developed and promoted by the Royal 
Pharmaceutical Society (RPS),1 the professional body for pharmacists and pharmacy in 
Great Britain. Figure 1-3 illustrates the RPS definition of medicines optimisation.  
 
 
  ‘ Qensuring that the right patients get the right choice of medicine, at the right 
 time.. It represents a paradigm shift to a more holistic, patient-focused 
 approach to health care. By focusing on patients and their experiences, the goal 
 of medicines optimisation is to: help improve patient outcomes, encourage 
 patients to take their medicines as prescribed, avoid use of unnecessary 
 medicines, reduce wastage of ŵĞĚŝĐŝŶĞƐ ?ĂŶĚŝŵƉƌŽǀĞŵĞĚŝĐŝŶĞƐƐĂĨĞƚǇ ? ?1  
 












The medicines optimisation agenda has four guiding principles, with the foremost 
ĂŝŵŝŶŐ ‘ƚŽƵŶĚĞƌƐƚĂŶĚƚŚĞƉĂƚŝĞŶƚ ?ƐĞǆƉĞƌŝĞŶĐĞ ?ĞŶĐŽƵƌĂŐŝŶŐ ‘ŽŶŐŽŝŶŐ ?open dialogue 
ǁŝƚŚƚŚĞƉĂƚŝĞŶƚ Q ?.1 The medicines optimisation agenda is supported by other 
organisations  in the UK, such as NHS England.75 In their call for research on 
ƉŽůǇƉŚĂƌŵĂĐǇĨƌŽŵƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞ ?Heaton et al (2016)24 reviewed  five 
recent policy reports and guidelines in England, including those published by Exemplar 
organisations (e.g. NICE, The Kings Fund, RPS). The authors found minimal 
documentary guidance considering the patient experience of medicines use in the 
reviewed policy documents, and they proposed further research into the patients ?
perspectives of polypharmacy.24  
 
In an updated Cochrane review on interventions to improve the appropriate use of 
medicines ŝŶŽůĚĞƌƉĞŽƉůĞ ?A? ? ?ǇĞĂƌƐƵƐŝŶŐA? ?ƌĞŐƵůĂƌŵĞĚŝĐŝŶĞƐ ) ?Cooper et al (2015)11 
highlighted a dearth of effective interventions. These findings which were similar to 
the preceding Cochrane review, which ĐŽŶĐůƵĚĞĚƚŚĂƚ ‘ŝƚŝƐunclear if interventions... 
such as pharmaceutical care [interventions], resulted in a clinically significant 
improvement; however, they appear beneficial in terms of reducing inappropriate 
prescribing and medication-ƌĞůĂƚĞĚƉƌŽďůĞŵƐ ?.68 A range of interventions were 
described, including medication reviews, screening tools (e.g. the START/STOPP), 
computerised-decision support to prescribers, and patient consultation or education. 
Most interventions described ŝŶŽŽƉĞƌ ?ƐƌĞǀŝĞǁ11 did not consider certain patient 
outcomes in depth, particularly adherence and quality of life, and were tested in 
populations outside of the UK. This may indicate a need for UK-based interventions. 
 
Another Cochrane review included 18 randomised-controlled trials testing 
interventions for improving outcomes in patients with multimorbidity in primary care 
and community settings.76 Smith et al (2016)76 reported that most trials incorporated 
changes to the organisation of care delivery though multidisciplinary teams, while a 
few others were patient-oriented and considered education or self-management 
interventions delivered directly to participants. dŚĞƌĞǁĞƌĞ ‘no clear positive 




Despite mixed findings in terms of the effectiveness of interventions, the review 
ŝŶĚŝĐĂƚĞĚƚŚĂƚ ‘...Interventions ƚŚĂƚĨŽĐƵƐŽŶĚŝĨĮĐƵůƚŝĞƐƚŚĂƚƉĞŽƉůĞĞǆƉĞƌŝĞŶĐĞǁŝƚŚ
daily fƵŶĐƚŝŽŶŝŶŐ QŵĂǇďĞŵŽƌĞĞĨĨĞĐƚŝǀĞ ?.76    
 
Indeed, an earlier synthesis of Cochrane reviews77 exploring the consumer-
perspective, on strategies to encourage safe and effective use of medicines, found that 
patient-centred strategies (e.g. self-management programmes) were most promising, 
compared to other interventions (e.g. pharmacist-led medicine reviews).77 Other 
useful interventions were aimed at promoting medicine-related communication, 
education/information provision, and  behavioural  support (including adherence).77  
1.7 Patient perspectives of medicines use 
In their recent debate and analysis, exploring solutions to problematic polypharmacy, 
Reeve and colleagues indicated the lack of an evidence base that considers the 
ƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞŽŶƉŽůǇƉŚĂƌŵĂĐy.78 The authors emphasise that, despite the 
decision-making role by health professionals who determine what medicines to use, 
patients (or consumers of healthĐĂƌĞ )ŚĂǀĞƚŚĞƵůƚŝŵĂƚĞƌĞƐƉŽŶƐŝďŝůŝƚǇŝŶ ‘ƚƌĂŶƐůĂƚing a 
medical decision into the best decision [for ƚŚĞŵ ? ?.78 In 2012, NICE published 
guidelines, titled  ‘Ɖatient experience in adult NHS services: improving the experience 
of care for people using adult NHS services ? ?to encourage health professionals to 
deliver patient-centred care.79 dŚĞƌĞƉŽƌƚŚŝŐŚůŝŐŚƚĞĚƚŚĞŶĞĞĚƚŽ ‘recognise that 
individual patients are living with their condition  Q and how the person's 
circumstances and experiences affect their condition and treatment ?ŶĞĞĚƚŽďĞƚĂŬĞŶ
into consideration.79 dŚĞƌĞƉŽƌƚ ?ƐĞŵƉŚĂƐŝƐƌĞůĂƚĞƐƚŽƉĂƚŝĞŶƚŝŶǀŽůǀĞŵĞŶƚĂŶĚĂĐƚŝǀĞ
participation in healthcare, recognising self-management as fundamental to people 
with long-term conditions. 
 
 For people using long-term medicines, the demands of therapies (or the health 
condition) dictate that they devise ways of incorporating medicines into their day-to-
day life.80 Subsequently, decisions about using medicines (or not) often depend on 
 ‘ƌĞĂůǁŽƌůĚĐŽŶƐŝĚĞƌĂƚŝŽŶƐ ?.81 Some individuals value the ability to live a normal life 
that allows them to meet personal and social obligations over controlling symptoms or 




medicines use is increasingly reported, relatively little research has been done to 
assess the impact of medicines and how they fit into routine lives of people on long-
term medicines. Put simply, Reeve and colleagues (2015) suggest that while some 
people using long-teƌŵŵĞĚŝĐŝŶĞƐĂƌĞĂďůĞƚŽĐŽƉĞ ? ‘ ...many become overwhelmed 
and confused Q ? ?.78There is an increasing recognition that self-care activities, including 
prescription medicines use, can be burdensome for some individuals. The Oxford 
ĚŝĐƚŝŽŶĂƌǇĚĞĨŝŶĞƐƚŚĞŶŽƵŶďƵƌĚĞŶĂƐ ‘ĂĚƵƚǇƚŚĂƚĐĂƵƐĞƐǁŽƌƌǇ ?ŚĂƌĚƐŚŝƉ ?Žƌ
ĚŝƐƚƌĞƐƐ ?.82  
 
1.8 Existing theories  of treatment burden  
The burden associated with managing chronic disease has been the subject of several 
studies. Definitions of treatment burden vary but a more explicit definition by Tran et 
al (2012)83 considers  ‘ƚŚĞŝŵƉĂĐƚŽĨhealthĐĂƌĞŽŶƉĂƚŝĞŶƚƐ ?ĨƵnctioning and well-being, 
apart from specific treatment side effects. It takes into account everything patients do 
to take care of their health: visits to the doctor, medical tests, treatment management, 
and lifestyle changes. ?83 
 
For others, the concept of treatment burden relates to patient workload of healthcare 
activities and capacity to manage this. Shippee and colleagues (2012),84 in their 
literature review on patient complexity, shed more light on the concepts of patient 
workload and capacity. The authors view patient workload as a broader concept that 
ĐŽǀĞƌƐ ‘ĂůůƚŚĞĚĞŵĂŶĚƐŝŶƉĂƚŝĞŶƚƐ ?ůŝǀĞƐ ?ŝŶĐůƵĚŝŶŐĞǀĞƌǇĚĂǇƌĞƐƉŽŶƐŝďŝůŝƚŝĞƐĂůŽngside 
the demands of patient-ŚŽŽĚ ?ƚŚĂƚƌĞƋƵŝƌĞƚŝŵĞ ?ĞĨĨŽƌƚĂŶĚĂƚƚĞŶƚŝŽŶ ?ŝŶĐůƵĚŝŶŐŶŽŶ-
healthcare activities (such as jobs and family).84 It also encompasses healthcare 
activities, such as the workload associated with travel, attending clinical appointments, 
preventative care, self-education, self-care, and organising/using medicines.     
Treatment burden is imposed by investments into healthcare in the form of time, 
money and effort. Patient capacity relates to ability or readiness to handle the 
workload demands, including the physical and mental functioning.84 Other factors that 
impact on patient capacity include socioeconomic, psychological issues, literacy and 





In the UK, Gallacher et al (2013)85 have identified components of treatment burden 
after reviewing 69 qualitative studies exploring experiences of stroke management of 
adult patients: making sense of management and care plans, demands of social 
interactions with family, other patients and healthcare professionals, and 
implementing management strategies (e.g. managing the condition in the community). 
ůƚŚŽƵŐŚ'ĂůůĂĐŚĞƌƐ ?ƌĞǀŝĞǁ was disease-specific, it highlighted challenges of managing 
long-term conditions and problems relating to information provision and 
communication with health professionals.85   
 
In another review attempting to identify how trĞĂƚŵĞŶƚďƵƌĚĞŶĐĂŶďĞ ‘ŶŽƌŵĂůŝƐĞĚ ?,
Gallacher et al (2011)86 also identified specific aspects of patient workload using data 
from 47 patients managed for chronic heart failure in primary care. These were: 
adherence to treatment and lifestyle changes, which was the most prominently 
identified component of treatment burden; learning about treatments and their 
consequences; monitoring and appraisal of treatments; and engaging with others to 
seek social support. Similar findings have been reported by research into everyday 
experiences of long-term medicines, suggesting that many practical, organisational, 
logistic, and financial efforts are made by patients in order to cope with their 
treatment.23,87,88  
 
In their concept analysis, Sav et al (2013)48 indicated that treatment burden is 
multifactorial identified by five major antecedents: treatment characteristics, the 
healthcare system,  patient characteristics, the disease condition (s), and the family or 
support network.48 dŚĞƐĞĨĂĐƚŽƌƐǁĞƌĞĨƵƌƚŚĞƌĞůĂďŽƌĂƚĞĚŝŶƚŚĞŝƌƐĞŵŝŶĂůƉĂƉĞƌ ? ‘You 
say treatmenƚ ?/ƐĂǇŚĂƌĚǁŽƌŬ ? ?in which Sav and colleagues revealed inter-related 
constituents of treatment burden: medication burden, healthcare access burden, 
financial burden (including costs of medicines and consultations), time and travel 
burden.49 Many of these efforts are described as laborious, troublesome, and time- 
and energy-consuming. Eton et al (2015)89 proposed similar factors in their updated 
conceptual framework of burden of treatment (See Figure 1-4). Healthcare access 
burdens were associated with poor unhelpful relationships with individual providers or 





Figure 1-4  A conceptual framework of the burden of treatment  
 
Source: Eton et al (2015)89 
 
The Burden of Treatment Theory  
More recently, May et al (2014)90 proposed the burden of treatment theory (BoT) as a 
contemporary model ƚŚĂƚ ‘aims to facilitate a new understanding of the interaction 
between capacity for action and the work that healthcare systems pass on to patients 
ĂŶĚƚŚĞŝƌƌĞůĂƚŝŽŶĂůŶĞƚǁŽƌŬƐ ? ?90 As a structural model, the BoT model illustrates the 
ŝŵƉĂĐƚŽĨƉĂƚŝĞŶƚ ‘ǁŽƌŬůŽĂĚ ? ?ŝŶĐůƵĚŝŶŐĂůl tasks delegated by the healthcare system 
that patients and their social networks must do to manage long-term conditions. The 
BoT model attempts to explain relationships between workload and patient capacity, 
which relates to the ability to perform different healthcare tasks (e.g. cognitive and 
informational tasks relating to learning about disease or its treatments, and 
organisational demands of accessing care e.g. seeking appointments). It suggests 
redesigning of healthcare services so they are geared towards improving patients ? 
experiences, and providing better co-ordinated and more-patient-centred care that 





The work involved in learning/understanding various aspects treatments (or 
medicines), including differentiating various formulations, and understanding the 
rationale for using medicines, can be burdensome. In their BoT concept, May and 
colleagues suggest that supporting patients can help them improve capability to 
perform delegated healthcare tasks. This in turn may result in better patient 
experiences, and confidence in performing these tasks. Though this requires further 
validation and is mostly broad and theoretical, the BoT concept appears to have a 
patient-focus ĂŶĚĐĂůůƐĨŽƌŝŶƚĞƌǀĞŶƚŝŽŶƐƚŽŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨĐĂƌĞ ? 
 
The Cumulative Model of Patient Complexity 
The Cumulative Complexity Model (CCM), also known as the cumulative model of 
patient complexity, is a more elaborative model that also considers patient 
experiences of long-term care.84 The CCM iƐĂ ‘patient-centred framework that 
emphasises the workload-capacity balance and incorporates treatment and illness 
burdens ?.84 The developers of the CCM indicate that experiences of care become 
burdensome when workload demands exceed capacity.84 Eton and colleagues (2015),89 
who ŝŶĚŝĐĂƚĞƚŚĂƚ ‘ĐĂƉĂĐŝƚǇĚĞƚĞƌŵŝŶĞƐǁŚĞƚŚĞƌǁŽƌŬǁŝůůďĞƉĞƌĐĞŝǀĞĚĂƐŵĂŶĂŐĞĂďůĞ
and routine or unmanageable and excessively ďƵƌĚĞŶƐŽŵĞ ? ?support this finding. In 
the CCM framework, burden of treatment is theorized as  ‘Ă feedback loop, connecting 
poor outcomes with further erosion of patient capacity and intensified demands, such 
that patient complexity may build through cumulative cycles. ?84 The CCM encourages 
using treatments that minimise burden while avoiding workload-capacity imbalances. 
The authors recommend patient-provider partnerships and research to identify 
workload-capacity difficulties, solutions for reducing patient burden, and 
 ‘ĚĞǀĞůŽƉŵĞŶƚŽĨa decision-support tool to help ascertain problems during clinical 
encounters ?.84 Though relevant in the context of chronic illness and long-term care, 
both the BoT and CCM frameworks consider treatment burden as a broader concept 









The MDM Care Model 
The Minimally Disruptive Medicine (MDM) care model is another framework that 
covers both treatment burden and patient complexity.91 It has recently been proposed 
ĂƐ ‘ĂƚŚĞŽƌǇ-based, patient-centred, context-ƐĞŶƐŝƚŝǀĞĂƉƉƌŽĂĐŚƚŽĐĂƌĞ ?ĨŽƌŵĂŶĂŐŝŶŐ
ŵƵůƚŝƉůĞĐŚƌŽŶŝĐŝůůŶĞƐƐĞƐ ?ĂŶĚŝƐĨŽĐƵƐƐĞĚŽŶ ‘ŽŶĂĐŚŝĞǀŝŶŐƉĂƚŝĞŶƚŐŽĂůƐĨŽƌůŝĨĞĂŶĚ
health while imposing the smallest possible treaƚŵĞŶƚďƵƌĚĞŶŽŶƉĂƚŝĞŶƚƐ ?ůŝǀĞƐ ? ?91 The 
MDM framework is founded on two key strategies, including identification of the  ‘right 
care ? for patients and making the  ‘right care ? happen in the context of multimorbidity.  
By  ‘ƌŝŐŚƚĐĂƌĞ ? ?ƚŚĞĂƵƚŚŽƌƐ imply  ‘ĐĂƌĞƚŚĂƚŝƐŶĞĞĚĞĚĂŶĚǁĂŶƚĞĚďǇƉĂƚŝĞŶƚƐ and 
ĨĞĂƐŝďůĞĨŽƌƚŚĞŵƚŽĞŶĂĐƚ ? ?91 They acknowledge a need for workload-capacity 
balances, similar to other treatment burden theories, and the need to integrate 
healthcare activities into ƉĂƚŝĞŶƚƐ ?ĚĂǇ-to-day routines.91 Although the authors 
recognise the need for further validation and refinement of the MDM care model, they 
uniquely propose tools to identify and implement right care, for instance, through 
workload and capacity assessments and systematically tracking patient-reported 
outcomes.91 Nonetheless, a notable challenge across most models is the use of 
terminology that is prone to patient aversion (e.g. capacity, burden); further validation 
may involve different patient cohorts to assess the likelihood of this. 
 
1.9 Conceptualising medicine-related burden 
To inform the development of interventions or measures of medicine-related burden, 
there is a need to understand existing theoretical/conceptual frameworks, including 
potential causative factors, how they relate to each other, and consequences of 
excessive burden. 
 
Prescription medicine burden is a relatively new concept relating to medicine-only 
therapies and little research has defined or focussed on this construct. As previously 
described, there have been several attempts to conceptualise treatment burden. 
Relevant theories looking at the burden of treatment are rather broad and explore the 
general burden of healthcare activities, with less focus on prescription medicine use. 
Nonetheless, treatment burden is depicted as a broader concept that encompasses 




 A few researchers have proposed theoretical frameworks specifically looking at the 
burden of ŵĞĚŝĐŝŶĞƐŽƌƉŚĂƌŵĂĐĞƵƚŝĐĂůƉƌŽĚƵĐƚƐĨƌŽŵƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞ. The 
earliest research by Murawski and Bentley (2001)92 described ƚŚĞ ‘ŝŶŚĞƌĞŶƚďƵƌĚĞŶ of 
drug treatment ? that was conceptualised in terms of health-related quality of life 
(HRQoL). Specifically, the inherent burden of medicines (termed pharmaceutical-
therapy related quality of life) was conceptualised as the difference or gap between 
the theoretically maximum possible HRQoL obtained after drug therapy and that 
actually observed/experienced post-treatment (See Figure1-5).92   
 
 
Figure 1-5 The concept of  ‘inherent burden ? of medicines 
 
Source: Murawski & Bentley (2001),92 simplified by Renberg (2009)93  
 
Negative consequences or burden were thought to arise from biophysiological effects 
of medicines (e.g. side effects). Despite the quantitative and somewhat biomedical 
definitions ƵƐĞĚǁŝƚŚŝŶDƵƌĂǁƐŬŝĂŶĚĞŶƚůĞǇ ?ƐĨƌĂŵĞǁŽƌŬ, psychosocial factors and 
subjective experiences of medicine use were considered by the authors to relate to the 
inherent burden. Issues around practicalities and logistics of managing medicine 
regimens, including administration and scheduling difficulties, indicating that complex 
regimens are associated with greater burden on the patient, were highlighted.92 
Inconveniences that can be burdensome to patients were also considered, for instance 




Psychosocial factors were also highlighted, including social stigma around using 
medicines, and interferences to social activities or impairment of social skills as a side 
effect of certain medicines.92 Stress, fear or anxiety related to medicine use were also 
considered, as well as worries and concerns about the negative effects of medicines, 
including fears of addiction, dependence, tolerance and ineffectiveness. The negative 
impact of medicines on personal control and anxieties related to missing or changing 
doses were also superficially considered.  
 
Although the authors described factors that reflect the burden of medicines, their 
theoretical framework covered all forms of pharmaceutical agents and services and 
was not limited to prescription only medicines. Moreover, the authors deliberately 
omitted the financial burden of using medicines use, relating to the cost of prescription 
medicines, citing that it not part of conceptualisations of HRQoL; the general context 
used to define medicine burden. What is clear from the Murawski and Bentley ?Ɛ(2001) 
model92 is that the burden associated with medicine therapies, just like other 
treatment modalities, is a multidimensional concept. Despite covering relevant 
domains, further empirical work on the model, reported by Renberg et al (2008),94 
revealed conceptual problems.  
 
In a recent metasynthesis of qualitative studies,88 medicine-related burden (MRB) was 
conceptualised as one of the three ŝŶƚĞƌƌĞůĂƚĞĚĐŽŵƉŽŶĞŶƚƐŽĨƉĂƚŝĞŶƚƐ ?ůŝǀĞĚ
experience with medicines (PLEM), alongside medicine-related beliefs and medicine 





Figure 1-6 Recent conceptualisation of medicine-related burden 
 
Source: Mohammed et al (2016)88 
 
In this conceptual framework, five aspects of medicine-related burden are described: 
routines of medicines use, characteristics of medicines, adverse events relating to 
medicines, social burden, and healthcare system-related burden.88 Most of these 
aspects of medicine-related burden are similar to those described in earlier 
conceptualisations of treatment burden. Although it considers key aspects that are 
burdensome to users of prescription medicines in detail, Mohammed and colleaŐƵĞƐ ? 
conceptual framework88 seems to be rather restrictive or perhaps overly structured. 
For instance, the framework deliberately ĐŽŶƐŝĚĞƌƐƚŚĞĞǆƉĞƌŝĞŶĐĞŽĨ ‘ŵĞĚŝĐŝŶĞ-ƚĂŬŝŶŐ ?
and medicine-related beliefs, attitudes, concerns and emotions as external to the 
burden construct. The authors88 acknowledge that empirical testing of this framework 
is necessary to understand this construct further. Nonetheless, the issues covered in 
the framework are supported by Demain and colleagues (2015)95 whose view of 





Social burden, denoted as relational disruptions, considers strains to family and social 
relationships as a result of treatment; biological disruptions in the form of side effects 
are a burden; and biographical disruptions relating to restrictions to day-to-day 
activities, impact on personal identity, freedom and independence, and social stigma 
can be burdensome among those using routine treatments.95 
 
1.10 A summary of factors associated with medicine burden  
As noted in the previous sections, treatment (and medicine burden) are disruptive and 
there is a need to understand associated factors. This section summarises factors or 
issues that may affect medicine burden and likely consequeces, based on collated 
findings from the aforenamed theoretical frameworks and related literature (See 
Figure 1-7).  
 
WĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐǁŝƚŚƵƐŝŶŐprescription medicines vary.  Numerous studies in 
many countries show that most patients would prefer not to take medicines, 
particularly those with chronic conditions, that some patients are resistant towards 
using medicines,21 and that there is a desire among some patients to stop some or all 
of their medicines.96  
 
Managing medicines routines can be burdensome to some individuals whose overall 
goal is to maintain health and perform normal activities of daily living.88 Some patients 
struggle to fit medicine use routines into their day-to-day lives and may utilise 
different coping strategies, including the use of practical tools (e.g. reminders, 
dossette boxes/pill organisers). Others may fail to manage demands relating to 
accessing prescriptions and medicines. Self-administration of medicines(e.g. that which 
requires multiple steps in premixing formulations), and self-monitoring medicine use 
may also exacerbate medicine-related burden and impact on behaviours, including 
non-adherence. Some patients rely on family, friends or health providers to support 









Figure 1-7 A conceptual framework of medicine burden and likely consequences 
 
Notes: The top half of the figure (in blue) reflects factors associated with medicine burden while the 





Medicine-specific characteristics including the number of medicines, formulation (e.g. 
smell, taste, size of tablet, ease of swallowing/use), route of administration (e.g. oral 
versus injections), the dosing frequency,  may all affect medicines use experiences and 
perceived burden.83,88,97 As the complexity of medicine regimes increases, including 
the number of doses, number of dosage units per dose or dosing schedules and 
frequency of use or self- monitoring, medicine burden may increase.16,98,99 Complexity 
of regimes may be augmented by strict food requirements, for example some 
medicines need to be used a few hours before or after food, while certain foods/drinks 
may need to be avoided when using certain medicines (e.g. no grapefruit juice when 
using atorvastatin). This may subsequently impact on daily routines and having to 
adjust life to suit medicine use. Issues around generic brand switching may also cause 
worries or concerns about efficacy/tolerability of different brands,100 which may, in 
turn, exacerbate the burden of medicines. Practical difficulties (and discomfort) 
associated with opening certain medicine packaging may be burdensome to 
individuals, especially the elderly, as with the time taken in organising medicines 
use.23,89 
Medicine-related adverse events 
Concerns about potential harm from medicines (and adverse events) and experiences 
of side effects may contribute to medicine burden. Patients experiencing side effects 
may perceive more burden than those who do not.83 Patients are more likely to alter 
medicine use (or even stop) or request changes to medicines if they are dissatisfied 














Healthcare system factors 
As previously discussed, healthcare systems contribute, indirectly or directly, to 
treatment burden.48,86,89 Medicine-related burden could arise from poor access to 
prescriptions and medicines. Difficulties may be associated with arranging doctor 
appointments, asking for prescriptions, long waiting times and effort in accessing 
medicines. Patient-provider relationships and communication difficulties and/or 
information burden23,88 and lack of continuity of care (and multiplicity of providers) can 
exacerbate actual or perceived medicine burden. ^ƚƵĚŝĞƐƐƵŐŐĞƐƚƚŚĂƚƉĂƚŝĞŶƚƐ ?
experiences of medicine use may be neglected during consultations with providers, 
and thus issues influencing medicine burden are often not discussed.101 Some patients 
desire convenient, flexible regimes (dosinŐĂŶĚƚŝŵŝŶŐ )ƚŚĂƚĐĂŶ ‘ŵŝƌƌŽƌ ?their personal 
life situations.99 Interruption to medication routine may be caused by changes in 
prescriptions and could be burdensome to some patients.  
 
Cost of prescription medicines 
The financial burden of prescription medicines, for individuals that have to pay out-of-
pocket or co-pay to access their long-term medicines is well documented. Prescription 
medicine costs influence how some patients manage their condition,46 and can be 
particularly burdensome to chronically ill patients.51 Some patients may reduce or alter 
using their essential medicines due to costs (cost-related non-adherence), while others 
may forego basic needs to pay for their medicines,47,51 which may ultimately impact 
negatively on health outcomes. Cost reduction strategies employed by patients have 
encompassed: not getting items dispensed, delay in cashing prescriptions, reducing or 
spreading out the dose, or buying cheaper alternatives.46,47,102   
 
Cost-related non-adherence is not uncommon, and is associated with several patient 
factors such as income levels, age, ethnicity, attitudes and beliefs about medicines 
(including low perceived need and side-effect-related concerns), type of medicines, 
health status, or low educational level.51,103,104 A recently published measure of 
ƉĂƚŝĞŶƚƐ ?ĐŽƐƚ-related medicine burden (and non-adherence) has assessed this 





Different countries and health systems have varying mechanisms for paying for 
prescriptions105 and different policy strategies to reduce cost-related burden among 
patients using long-term prescription medicines.44 Despite the various cost-reduction 
strategies, prescription charges may pose an access barrier for some patients in need 
of long-term prescription medicines in England.46  
 
Patient-related attributes 
Certain patient-related attributes and socio-demographic characteristics may be 
associated with medication burden. The nature/type, severity, and duration of illness 
(e.g. chronic versus acute, mental health condition versus physical condition, 
multimorbidity versus single disease states) may be associated with differing 
perceptions and levels of medicine burden.48 Patients who have symptomatic illness 
(e.g. chronic/severe pain) may perceive less (or no) burden of medicines, as they are 
likely to experience immediate benefits of medicines (e.g. symptom relief) more than 
treatment-related inconveniences. On the other hand, asymptomatic patients, who 
may not perceive an immediate burden of illness, may perceive greater medicine 
burden if the need for their regimens, or their immediate benefits, is not realised.  
 
Aging, which is associated with multiple medicines use, may affect perceptions of 
medicine burden. Although elderly patients may experience greater treatment burden 
when compared to younger people,48 this may vary across different populations. 
Nonetheless, elderly people may experience practical difficulties with accessing their 
medication and with opening packages, especially those with problems relating to 
physical functioning and dexterity. However, increasing age is associated with fewer 
expectations of healthcare and greater satisfaction,106 which could manifest as less 
medicine burden.  
Gender has also been associated with treatment burden,48 with females more likely to 
experience higher burden when compared to males. Women are more likely to seek 
medical care and be more evaluative of their medicines.21 Women are also more likely 
to perceive themselves as sensitive to the negative effects of medicines, and thus 
report more medication burden. Socioeconomic factors, particularly unemployment 
may also be associated with treatment (and medication) burden,48 possibly due to 





The burden of medicines may be infůƵĞŶĐĞĚďǇƉĂƚŝĞŶƚƐ ?ďĞůŝĞĨƐ ?ĂƚƚŝƚƵĚĞƐĂŶĚ 
perceptions about medicines. Efficacy-related beliefs are a major basis for health-
related actions, including medicines use.107 Decisions which affect using medicines  ‘are 
influenced by the weighted judgment of [the] positive value of medicine, and negative 
value of medicine ? harms and inconveniences.108,109 Patients are likely to persist or 
follow prescribed medicine regimes if they believe that perceived benefits (e.g. relief 
or control of symptoms, avoidance of relapse), outweigh the negatives of potential 
harm.110 Research into adherence and persistence with medicine use has 
demonstrated the role of medicine-related beliefs.111 W114  
 
Stronger beliefs about the necessity of medicines,110 may translate into lower 
perceived medicine burden. People evaluate their medicine in terms of effectiveness 
(if the medicine is doing what it is intended to do); experiences or concerns about side 
effects (and their impact on physical health and functioning, mood or emotions, 
mental function); and convenience of medicine use, including ease of 
administration.17,108,109 Perceived effectiveness is the greatest valued attribute and 
determinant of treatment success among most, if not all, patient groups.108,109 If 
effectiveness is achieved, tolerating side effects or medicine-related 
discomforts/inconveniences becomes less weighted.108,109 Patient satisfaction and 
dissatiƐĨĂĐƚŝŽŶǁŝƚŚƚƌĞĂƚŵĞŶƚĐĂŶďĞƉƌĞĚŝĐƚĞĚďǇƉĞŽƉůĞ ?ƐĞǆƉĞĐƚĂƚŝŽŶƐǀĞƌƐƵƐƚŚĞŝƌ
actual experiences of treatment.106,115 Expectations include beliefs about the likelihood 
of achieving a successful outcome and are in the form of anticipations, wants, hopes 
and desires.106 Unmet/met expectations with healthcare services affect patient 
satisfaction,106,115 and could contribute to perceived burden. Greater satisfaction with 
medicines could be associated with lower medication burden.83 
 
Higher levels of self-efficacy, which relates to  ‘ QďĞůŝĞĨƐŝŶŽŶĞ ?ƐĐĂƉabilities to organise 
and execute the courses of action required to produce given attainments ?,107 may be 
associated with lower perceived medication burden. Beliefs of self-efficacy are cited to 
ŝŶĨůƵĞŶĐĞĂŶŝŶĚŝǀŝĚƵĂů ?ƐŬŶŽǁůĞĚŐĞĂĐƋƵŝƐŝƚŝŽŶ (necessary in learning about medicines 
or their effects), course of action, and behavior.107 Although inherent, self-efficacy also 




time, efforts, and resources. With practice and routinisation, skills become easily 
executed, and may not need higher cognitive effort.107 The latter concepts are akin to 
'ĂůůĂĐŚĞƌ ?ƐƚŚĞŽƌǇŽĨ  ‘ŶŽƌŵĂůŝƐŝŶŐ ?ƚƌĞĂƚŵĞŶƚďƵƌĚĞŶ.86 Self-efficacy also affects 
motivation, perseverance and resilience, the nature of thought patterns, and the 
amount of stress experienced in coping with challenging demands.107  All these factors 
may influence perceptions of burden. 
 
Locus of control, which is a personality belief that certain outcomes are as a result of 
self (internal), others (external), or chance,107 may also affect perceptions of medicine 
burden.  External locus of control is associated with less ability to cope with difficult 
situations.116 On the other hand, internal locus of control is associated with more 
positive experiences, such as active engagement in activities, better relationships, 
information seeking, independent decision making, and a better sense of wellbeing.116 
In terms of medicines use, patients with a high internal locus of control may report 
more positive experiences of medicines use, thus are likely to report lower burden of 
medicines. 
 
Consequences of medicine burden from the patient perspective 
Like treatment burden, medication burden may affect an individual in multiple ways.  
The consequences could be physical (e.g. poor clinical outcomes), psychological (e.g. 
dissatisfaction with medicines), social (e.g. transfer of burden to carers) or take the 
form of financial burden.  Medicine burden is associated with non-adherence, with 
some patients cited to manipulate their own regimens ? ‘particularly when intolerable 
burden was experienced ?, without consulting their healthcare providers.88 More 
recently, Demain et al95 ŚĂƐĚĞƐĐƌŝďĞĚƚŚĞůĂƚƚĞƌĂƐ ‘rationalised non-ĂĚŚĞƌĞŶĐĞ ? ?Ă
secret coping strategy, as a consequence of treatment burden.95 It is possible that 
consequences of medicine burden are likely to exacerbate the felt burden. For 
instance, the resulting non-adherence may not only contribute to sub-optimal clinical 
outcomes (e.g. poor symptom control, disease progression or relapse, deterioration of 
health and quality of life), but could also trigger another prescribing cascade to 





Besides impacting on physical health and psychosocial wellbeing, the burden of 
ŵĞĚŝĐŝŶĞƐŵĂǇĂĨĨĞĐƚĂƉĂƚŝĞŶƚ ?ƐǁŽƌŬĂŶĚƉƌŽĚƵĐƚŝǀŝƚǇ ?ŝŶĐůƵĚŝŶŐĞŵƉůŽǇŵĞŶƚ ) ?ĂƐ
well as activities of daily living. Medicine-related absenteeism from work may be 
associated with the need to seek repeat prescriptions and refills, or experience of side 
effects. Treatment-related absence from work could lead to a loss of annual leave or 
sick days per month, or feelings of guilt about lost productivity and burdening their co-
workers; .48 this can in turn worsen existing burden. Psychologically, medication 
burden may lead to dissatisfaction with medicines (including concerns), affect patient 
choice, and lead to refusal of medicines.  
 
Using certain medicines may also disrupt individual lifestyles and  social lives, including 
planning leisure or social activities, holding conversations with friends and 
family.81,92,95 All this, coupled with the demands of fitting medicine regimes into usual 
life and social stigma may worsen medicine burden and affect relationships with family 
and friends. Some individuals may face social isolation with the aim of adhering to 
discreet regimes, all of which could exacerbate perceived or actual burden.21,81 
Moreover, disruptions to medicine use routines (and non-adherence) are associated 
with changes in day-to-day schedules.88  
 
On the other hand, social networks and support may reduce medicine burden. 
The role of spouses/partners or caregivers, in supporting patients to cope with 
practicalities involved in using medicines, has been cited117 and those living alone may 
have real difficulties. However, treatment-related demands can lead to caregiver 
burden (including fatigue and distress),48,49 which in turn may affect the patient and 
his/her social or family structure. Paradoxically, loss of independence (in form of 












1.11 General aim and objectives of this doctoral thesis 
Aim 
The series of studies in this thesis aimed to identify, develop and test a generic 
ŵĞĂƐƵƌĞŽĨƉĂƚŝĞŶƚƐ ?experiences of long-term prescription medicine use and 
associated burden in the English adult population.  
Research question  
This thesis explores the specific research question:  Is the Living with Medicines 
Questionnaire (LMQ) (or its adaptations) a comprehensive, valid, reliable, and 
interpretable measure of medicines burden?  
Specific research objectives were:  
1. To identify a suitable measure of prescription medicine burden and assess its 
content coverage in relation to existing measures. 
2. To assess the original version of the measure (LMQ-1) so as to identify areas of 
improvement and revise and test its interim versions (LMQ-2 and LMQ-2.1) for 
fĂĐĞĂŶĚĐŽŶƚĞŶƚǀĂůŝĚŝƚǇ ?ďǇŽďƚĂŝŶŝŶŐƉĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞƐŽĨƚŚĞĐŽŶƚĞŶƚ
coverage, concepts measured, and item readability. 
3. To evaluate psychometric properties of the LMQ (version 3) including: 
- Construct validity, by exploring and confirming underlying domains or 
concepts measured; 
- Criterion-related validity by comparing LMQ concepts to those in relevant 
standard questionnaires; 
- Reliability (internal consistency and test-retest) of the questionnaire; 
- Interpretation of questionnaire scores. 
4. To determine the prevalence of medicine-related problems uncovered by the 















1.12 Overview of study phases in this research programme 
To help clarify the roadmap for this research programme, and show how the different 
chapters within this thesis meet the objectives defined above, I will provide an 
overview of all phases of research conducted. Figure 1-8 illustrates the iterative 
procedures involved in LMQ instrument development and validation.  The LMQ was 
developed and validated through iterative processes (See Figure 1-8), which are 
































































Figure 1-8 Overview of the present research programme 
Literature reviewed  
to identify existing measures of medicine-
related experiences and medicine burden 
 
Piloting the LMQ-1 
 
New content generation  
Face and content validity testing  
Construct validity testing 
Identification of the LMQ-1, an original 60-item 
questionnaire.  
Chapter 2, Phase 1a 
Piloting the 60-item LMQ-1 identified gaps in 
content coverage. Preliminary analyses enabled item 
reduction, leading to a 42-item LMQ-2. 
Chapter 4, Phase 1b 
 
New items were generated from the literature, 
patient comments & secondary interview data;  
Item generation led to a 58-item, interim, LMQ-2.1.  
Chapter 5, Phase 2a 
Using cognitive interviews, item readability and 
meanings of concepts in the LMQ-2.1 were assessed.  
Chapter 5, Phase 2b 
 
In a national on-line survey using the LMQ-2.1, data 
were subjected to exploratory and confirmatory 
factor analyses to ascertain construct validity. Final 
item reduction led to the LMQ-3, as a 41-item tool. 
Chapter 6, Phase 3 
 
Criterion-related validity testing 
In a regional survey (in south-east England), the 
LMQ-3 was tested against standard measures of 
treatment satisfaction (TSQM-II) & HRQoL (EQ-5D-
5L) to confirm underlying concepts 
Chapter 7, Phase 4 
Test-retest reliability  
In two cross-sectional surveys, retaken about two 
weeks apart by the same participants, stability of 
LMQ-3 scores (test-retest reliability), over the study 
duration, was to evaluated. 
Chapter 8, Phase 5 
 
Interpretation of LMQ-3 scores and 
defining levels of medicine burden 
Two survey datasets were reanalysed to aid 
interpretation of LMQ scores.  Statistical analyses 
estimated the prevalence of medicine-related 
issues & predictors of medicine burden. 




Phase 1- Instrument identification and preliminary item reduction 
Phase 1a involved a systematic literature review described in Chapter 2. A critical 
literature review is a fundamental step in instrument development.118 In this case, it 
enabled identification and comparison of existing measures of medicine-related 
experiences, while examining their relevance to this research programme. This phase 
identified a relevant questionnaire, the LMQ-1 as the original 60-item instrument, 
which was reported to measure medicine burden in the adult English population, but 
which required further development;119 preliminary analyses of the LMQ-1 did not 
identify meaningful item-groupings in the questionnaire. 
 
Phase 1b involved a large cross-sectional survey undertaken to pilot the LMQ-1 among 
people on long-term medicines recruited from community pharmacies and from public 
areas. This enabled preliminary item reduction to produce a 42-item interim version of 
the questionnaire (LMQ-2) reported in Chapter 4. However, this phase also identified 
gaps in the LMQ-2 instrument, which was found to be deficient of explicit statements 
on cost-related burden, and also had inadequate coverage of side effects and the 
social impact of medicine use. Therefore, subsequent work was needed to address 
these problems. 
 
Phase 2 ʹ Generation of new content and review of existing statements  
Phase 2a involved generation of new statements to address the gaps identified from 
the analyses of phase 1b and review of the existing statements in the LMQ-2. New 
content was based on reanalysis of patient interview data, originally used to elicit 
concepts in the LMQ-1.23 Alongside qualitative literature, free-text comments from 
survey participants in Phase 1b were also used for new item generation. Following new 
item addition and revisions, the interim instrument (a 58-item LMQ-2.1) was assessed 
qualitatively. Phase 2b comprised a qualitative study using cognitive interviews with 
the general public using long-term medicines. It was designed to evaluate face and 
content validity of the LMQ-2.1, enabling early identification and resolving potential 
questionnaire problems (such as misinterpretation of statements). The findings of 






Phase 3 - Final item reduction and construct validation 
The remaining phases constituted a series of studies designed to assess different 
aspects of questionnaire validity and reliability (altogether referred to as psychometric 
testing). In Phase 3 (described in Chapter 6), final item reduction was conducted using 
on-line survey responses to the 58-item interim version (LMQ-2.1) completed by the 
UK general public on long-term medicines. Poorly performing items were eliminated 
which resulted in the final 41-item instrument (the LMQ-3). The LMQ-3 was statistically 
tested (by factor analyses) to verify and confirm underlying concepts (domains) to 
ascertain construct validity.  Internal consistency of the LMQ-3 was also assessed in 
Phase 3.   
 
Phase 4 -Criterion-related validation 
In Phase 4 (described in Chapter 7), a criterion-related validation study was conducted 
using survey responses from patients on long-term medicines recruited via community 
pharmacies, GP practices, and outpatient clinics in south-east England. Criterion-
related validation involved comparison of LMQ-3 scores with reference measures of 
treatment satisfaction (the TSQM-II) and health-related quality of life (EQ-5D-5L) 
respectively. Although criterion-related studies are traditionally used to validate a new 
ƋƵĞƐƚŝŽŶŶĂŝƌĞĂŐĂŝŶƐƚĂ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?ŵĞĂƐƵƌĞŽĨƚŚĞƐĂŵĞĐŽŶƐƚƌƵĐƚ ?ƚŚĞůĂĐŬŽĨĂ
 ‘gold standard ? measure of prescription medicine burden explains the use of 
alternative comparisons. Streiner and colleagues (2015) support verification of a new 
ŝŶƐƚƌƵŵĞŶƚĂŐĂŝŶƐƚĞǆŝƐƚŝŶŐŽŶĞƐƚŚĂƚĂƌĞĚĞĞŵĞĚ ‘ŵĂǆŝŵĂůůǇĚŝĨĨĞƌĞŶƚ ?,118 but Chapter 
2 highlighted  possible relationships between the three constructs. This study phase 
was used to ascertain relationships between medicine burden and satisfaction with 
medicines and health-related quality of life, thus indirectly contributing to construct 
validation of the final questionnaire (LMQ-3). 
 
Additionally, data from the Phase 4 (Chapter 7) study was reanalysed, together with 
data from Phase 3 (Chapter 6), to aid interpretation of LMQ scores, determine 
prevalence of medicine-related issues, and to understand predictors of medicine 
burden (described in Chapter 9). Known-groups validity of the LMQ-3, testing its ability 
to differentiate cohorts of patients with well-known treatment characteristics 




Chapter 9. Known-groups analyses shed light on potential predictive validity of the 
LMQ-3, which relates to an ŝŶƐƚƌƵŵĞŶƚ ?ƐĂďŝůŝƚǇƚŽƌĞǀĞĂů associations or differences in 
certain variables in the hypothesised direction.   
 
Phase 5- Stability testing (test-retest reliability) 
 To examine stability of scores and whether the LMQ-3 measures underlying concepts 
ŝŶĂƌĞƉƌŽĚƵĐŝďůĞŵĂŶŶĞƌ ?WŚĂƐĞ ?ƐƚƵĚŝĞĚƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ƐƚĞƐƚ-retest reliability 
(described in Chapter 8). The same participants completed the questionnaire on two 
different occasions with an average retest interval of two weeks to minimise recall of 
ŝŶŝƚŝĂůƌĞƐƉŽŶƐĞƐĂŶĚƚŽůŝŵŝƚǀĂƌŝĂƚŝŽŶƐŝŶƉĂƌƚŝĐŝƉĂŶƚƐ ?ŵĞĚŝĐŝŶĞƵƐĞĞǆƉĞƌŝĞŶĐĞƐŽǀĞƌ
the study period.  
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Adult members of the 
general public/ on-line  
recruitment across the UK/  
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Kent  & Medway 
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Adult members of a public 
engagement group at the 
Medway School of 
Pharmacy/ face-to-face 
recruitment in Medway. 
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Adult public engagement 
group at the  University of  
Kent/  on-line recruitment 
Chapter 8 
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Chapter 2 Measuring medicine-related experiences from the patient perspective - a 
systematic review 
Acknowledgments 
The work presented in this chapter was published in Patient-Related Outcomes, and 
permission to reproduce it in this thesis was granted by the Journal on 21/11/2016. As 
the first author, I conducted all literature searches, synthesised and critically reviewed 
all primary data, and drafted early versions, compiled responses to the reviewers, and 
proofread the final published paper. The supervision team (JK and SC) and an external 
advisor (JR) reviewed and commented on early versions, and read and approved the 
final paper. 
2.1 Introduction 
In order to identify a patient-reported measure of medicine-related burden for use in 
the present research programme, a thorough, systematic, search of the literature was 
necessary. This chapter aimed to identify all potential generic measures of medicine-
related experiences and to identify the most appropriate to measure medicine-related 
burden. By assessing content domains, comparing and summarising the development 
and/or validation processes across all instruments, the original Living with Medicines 
Questionnaire (LMQ-1) was identified, in this Chapter, as the only tool reported to 
assess medicine burden in the context of chronic illness and long-term medicine-only 
therapies. This work addressed the first research objective. Standard methodology 
was used to systematically search for relevant instruments across a range of 
databases using pre-defined inclusion criteria. Data abstraction was conducted by 
myself (BK) and double-checked by the supervision team. This chapter contributed to 
understanding of the literature on measurement of prescription medicine-related 
experiences, and highlighted the LMQ-1 instrument identifying its unique application, 







2.2.1 Database search and search strategy 
Multiple electronic databases were searched: Medline, Embase, PsycINFO, 
PsycARTICLES, the Cumulative Index to Nursing and Allied Health Literature (CINHAL 
Plus), and Google Scholar.  A manual, free-text, search of the PROQOLID® 
(http://www.proqolid.org), a specific database that houses several patient-related 
measures was also conducted. Hand searching of bibliographies of relevant articles 
was undertaken to identify related articles. A 20-year search period, January 1995 to 
April 2015, was selected, based on the publication date of an early landmark measure 
of lay representations and beliefs about prescription medicines, the Beliefs about 
Medicines Questionnaire (BMQ).110 This timeframe ensured relevant measures 
developed in the five years before publication of the BMQ110 were included. A broad, 
but sensitive, key-word search strategy was employed to identify studies describing 
the development and/or validation of ŵĞĂƐƵƌĞƐƵƐĞĚƚŽĂƐƐĞƐƐĂĚƵůƚƐ ?ŵĞĚŝĐŝŶĞ-
related experiences. Categories of search terms were combined in a stepwise fashion 
and relevant search filters applied to specific publication dates. Sample categories and 
search terms used include [1]  ‘medicine ? or  ‘medication ? or  ‘drug ? or  ‘prescription ? [2] 
 ‘patient experiences ? or  ‘experienc* ? or  ‘view* ? or  ‘perception* ? or  ‘attitude* ? or 
 ‘belief ? or  ‘concern* ?. Categories [1] and [2] were crossed with search terms in 
category [3]:  ‘questionnaire ? or  ‘instrument ? or  ‘tool ? or  ‘scale ? or  ‘measure ? or 
 ‘survey* ? or  ‘self-report ? or  ‘patient reported measure ? or  ‘develop* ? or  ‘valid* ?. 
Neither disease-conditions nor medicine-types were specified. Appendix 1 provides 
the full search strategy. 
2.2.2 Inclusion and exclusion criteria 
Studies which involved adults (age 18 years and over) using prescription medicines 
were reviewed ?ĂƐĐŚŝůĚƌĞŶ ?ƐĂďŝůŝƚǇƚŽƐĞůĨ-report their own experiences differ and 
instrument development processes may also vary.121 Primary research studies using a 
generic (not disease- or treatment-specific), self-completion instrument on any aspect 
relating to medicine use experiences and describing questionnaire development 
and/or validation in a target population were included. Articles were published in 
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English. We excluded studies that: involved only children or adolescents; primarily 
reported use of over-the counter medicines or other therapies  (e.g. diet, exercise, or 
any other aspect of self-care); described disease-, product- and/or device- specific 
measures; used clinician- or pharmacist-reported tools for drug-related problems; 
ƵƐĞĚƚŽŽůƐĂƐƐĞƐƐŝŶŐƉĂƚŝĞŶƚƐ ?Ăďŝůity to manage their medicines; described screening 
tools for assessing inappropriate prescribing; used side effects and ADR rating scales; 
satisfaction with pharmaceutical services; measures primarily assessing adherence; 
secondary validation studies, except if they reported a revised version of the 
instrument; cross-cultural (and language) adaptations of  eligible questionnaires; and 
protocols for research.  
2.2.3 Article retrieval, data extraction and analysis 
All study titles and abstracts were reviewed, discarding duplicates. If eligible, the full-
text article was scrutinised to check for the questionnaire and/or its items (questions). 
Additional searches were conducted if the questionnaire was not included in the 
primary article. Potentially relevant studies were screened for inclusion suitability and 
discussed among the research team (BK, SC, JK). Data extraction (by BK) from eligible 
articles was checked and supervised (by SC, JK) and regular discussions among all 
authors were held to resolve any issues. The initial literature search was conducted in 
April 2015, first updated in November 2015, and then in March 2017. 
 
A data extraction form was used to collect the following study-specific information: 
sample size, study population and setting, country and language of origin; and 
questionnaire-specific information: name and purpose, number of items, content 
domain(s) and/or subscales, type of response scale, mode of administration and recall 
period (if specified). Questionnaire derivation (and the extent of direct patient 
involvement in item generation and testing) and validation methods were reviewed 
and psychometric properties, such as reliability and different forms of validity, 
assessed, in relation to published criteria.122 Comparison of instruments included: 
domain coverage, development history, particularly patient involvement in item 
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generation, reliability and validity. Practical properties, such as completion time, were 
also examined where available.  
 
^ƚĂŶĚĂƌĚƐĂŶĚŐƵŝĚĂŶĐĞƐƚĂƚĞƚŚĂƚĚŽĐƵŵĞŶƚĂƚŝŽŶŽĨĂŶŝŶƐƚƌƵŵĞŶƚ ?ƐĚĞǀĞůŽƉŵĞŶƚ
history is fundamental.123,124 This includes item generation and testing of how well 
patients understand questionnaire items and response options and the 
appropriateness of the measure to the patient group,125,126 helping to assess face and 
content validity, alongside researchers and expert panels.122 Records of measurement 
(or psychometric) properties, particularly reliability and validity, also provide evidence 
that an instrument measures what it claims.122 W124 Other characteristics, such as mode 
of questionnaire administration and the time period over which a participant is 
requested to reflect (recall period), content domains, the number of items and their 
response options and the population and setting used also impact on instrument 
validity.124  
Construct validation of underlying theoretical concepts and domains in a 
questionnaire can be conducted using different methods: scale analysis (through 
exploratory and/or confirmatory factor analysis, item-total correlations (adequate if > 
0.20)118,127 and floor-ceiling effects that explore lowest or highest possible scores); 
convergent- and discriminant (or divergent) validation, which explore relationships 
with conceptually similar and dissimilar reference instrument(s) respectively.118,122,127 
ŽƌƌĞůĂƚŝŽŶƐA? ? ? ?ŵĂǇƐƵƉƉŽƌƚĐŽŶǀĞƌŐĞŶƚǀĂůŝĚŝƚǇ ?ǁŚĞƌĞĂƐĂƚƌĞŶĚŽĨůŽǁ
correlations may infer discriminant validity.118,127   Both convergent and discriminant 
validations are aspects of criterion-related validation, in which scores of new 
questionnaires (or those undergoing development) are compared with established 
ŽŶĞƐ ?Žƌ ‘ŐŽůĚƐƚĂŶĚĂƌĚƐ ? ) ?ĐŽƌƌĞůĂƚŝŽŶƐŽĨĂƚůĞĂƐƚ ? ? ? ?ǁŝƚŚĂ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?ŵĞĂƐƵƌĞ
may confirm criterion-related validity.122 Other aspects of criterion-related validity, 
ƐƵĐŚĂƐƉƌĞĚŝĐƚŝǀĞǀĂůŝĚĂƚŝŽŶ ?ƚĞƐƚĂŶŝŶƐƚƌƵŵĞŶƚ ?ƐĂďŝůŝƚǇƚŽƉƌĞĚŝĐƚĂƐƐŽĐŝĂƚŝŽŶƐŽƌ






2.3.1 Identified generic measures of medicine use experiences 
Fifteen articles described the development and/or validation of generic measures 
relating to the experience of using prescription medicines among adult patients.  
Of these, nine were multi-domain (3-10 domains), five of which examined satisfaction 
with different aspects of using medicines: three versions of the Treatment Satisfaction 
Questionnaire for Medication-TSQM (TSQM version 1.4,108 TSQM II,109 and TSQM-
9129); the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q130); and 
the Patient Satisfaction with Medication Management instrument (PSMM131). Other 
multi-domain instruments were: the Drug Therapy Concerns Questionnaire (DTC132); 
the Okere-Reiner Survey;133 the Living with Medicines Questionnaire (the LMQ119);  
and the Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of 
Life (PROMPT-QOL134). 
 
Six instruments covered only one domain, although some of these were divided into 
subscales by statistical analyses: a unidimensional measure of treatment burden (the 
TBQ83 ) ?ĂƋƵĞƐƚŝŽŶŶĂŝƌĞĂƐƐĞƐƐŝŶŐƉĂƚŝĞŶƚƐ ?ĂƚƚŝƚƵĚĞƐƚŽĚĞƉƌĞƐĐƌŝďŝŶŐŽƌŵĞĚŝĐŝŶĞ
cessation (PATD64), the Beliefs about Medicines Questionnaire (BMQ110), a measure of 
perceived sensitivity to medicines (PSM135), the Satisfaction with Information about 
Medicines Scale (SIMS136) and questionnaires looking at doctor-patient 
communication about medicines.137  
 
Most of the questionnaires identified are self-administered on 3- to 10-point Likert-
type scales. All instruments were multi-item, ranging from 5 to 60 items per 
questionnaire. The majority were developed in English, originating from the UK, USA 
and Australia, with only three83,130,134 from non-English speaking countries: Spain, 




Instrument Focus Study population / 
setting 









Chronically ill patients,  
aged 45-64 years , 
ƵƐŝŶŐA䠀  ?ƌĞŐƵůĂƌ
prescription  medicine 
/  hospital clinics 
18 items in 4 subscales 
 
  
5-point Likert-type scale 





SIMS136  Patient satisfaction 
with medicine 
information 
Chronically ill patients, 
aged 46-68 years,  
using A? ?ƌĞŐƵůĂƌ
prescription medicine 
/ hospital clinics & 
wards 
17 items in  2 subscales 
 
 
5-point Likert-type scale 
(too much, about right, 










Patients  with a doctor 
consultation / 
general practice 
12-20 items for pre- and post-
consultation questionnaires. 
 






DTC132  WĂƚŝĞŶƚƐ ?ƉĞƌĐĞƉƚŝŽŶƐ
of  medicine-related 
problems  
Adults,  average age 




pharmacies  & general 
public  
25 items in 5 subscales 
 
 
5-point Likert-type scale 






(v. 1.4)108  
Patient satisfaction 
with medicines 
Chronically ill adults,  
mean age 50 years, 
using regular 
medicines / 
general public  
14 items in 4 subscales 
 
 
5- and 7-point Likert-type 
scales 
& a yes/no  response 
Self-completion 
 / 2-3 weeks, or 
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Instrument Focus Study population/ 
setting 
No. of items  and subscales Response scale Administration 
mode / 








using  new 
prescription 
medicine(s)/ 
Community pharmacy  
11 items in 4 subscales 
 
 
5- and 7-point Likert-type 
scales  (e.g. Extremely 
Dissatisfied  to Extremely 
Satisfied) 
& a yes/no response 
Self-completion 
/ 2-3 weeks, or 
since last use. 
English/ USA 




patients, average  age   
55 years,  on 
prescribed medicines/ 
general public  
9 items in 3 subscales 
 
 
7-point Likert-type scale  
(extremely dissatisfied  to 
extremely satisfied) 
Self-completion 
/2 -3 weeks, or 
















condition, in receipt  
ŽĨA䠀  ?ŵŽŶƚŚƐŽĨ
treatment/ 
hospital & general 
public  






5-point Likert-type scale 
(Not at all, 
a little bit, somewhat, 
quite a bit,  very 
much) 
Self-completion 







of  medicine 
management 
Adult inpatients/ 
hospital setting  
9 items in 3 domains 
 
 
Likert-type: poor to 
excellent, much worse to 
much better, or strongly 
disagree to strongly agree 









TBQ83 Treatment burden 
among multi-morbid 
patients.  
Adults,  of mean age 
59, using  average of 
two medicines daily/ 
hospital & general 
practitioner clinic 
14 items: 
an open question, & 13 items 
in one scale  
  
0 to 10scale (ranging  











Table 2-1 Characteristics of reviewed generic measures of medicine-related experiences 
Acronyms: BMQ, Beliefs about Medicines Questionnaire; SIMS, Satisfaction with Information about Medicines Scale; DTC, Drug Therapy Concerns Questionnaire; 
TSQM, Treatment Satisfaction Questionnaire for Medication; SATMED-Q, Treatment Satisfaction with Medicines; PSMM, Patient Satisfaction with Medication 
Management instrument; TBQ, Treatment Burden Questionnaire; Wd ?WĂƚŝĞŶƚƐ ?ƚƚŝƚƵĚĞƐdŽǁĂƌĚƐĞƉƌĞƐĐƌŝďŝŶŐ ?PSM, Perceived Sensitivity to Medicines 
questionnaire; LMQ, Living with Medicines Questionnaire; PROMPT-QoL, Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life; MCQs, 
Multiple Choice Questions
Instrument Focus Study population/ 
setting 
No. of items  and subscales Response scale Administration 
mode / 









Adults with multiple 
chronic conditions, 
ƵƐŝŶŐA䠀  ?medicine/ 
hospital   
15 items (number of 
subscales not known) 
 
 
10 items have a 5-point 
Likert-type scale ( strongly 
agree to strongly disagree 
4 MCQs & one item has 






PSM135 Perceived sensitivity 
to medicines and 
their adverse effects 
HIV & hypertension 
patients, those on 
travel vaccination & 
students /general 
practices, travel clinics 
& university  
5 items in one scale 
 
 
5-point Likert-type scale  
(strongly disagree 











confidence in using 
medicines. 
Adult inpatients,  of 
mean age 48 years, 
ƵƐŝŶŐA? ?ƉƌĞƐĐƌŝƉƚŝŽŶ
medicine / 
hospital   
7 items in 3 subscales 
 
 
5-point Likert-type scale 
















& general public 
60 items in 8 domains 
 
 
5-point Likert-type scale 













months/ hospital  
43 items in 10 domains:  
  
5- and 4-point Likert-type 
scales   









The 15 instruments covered a wide range of domains (Table 2-2), described by authors 
as: effectiveness; convenience, practicalities and/or managing medicines; information, 
knowledge and/or understanding; side effects; relationships and/or communication 
with health professionals; impact on daily living and/or social life; general satisfaction; 
attitudes; beliefs, concerns, and/or perceptions; medical follow-up and/or adherence-
related issues; treatment- and/or medicine-related burden, perceived control or 
autonomy; self-confidence about medicine use; availability and accessibility; and 
medicine-related quality of life; these may reflect most issues that affect people using 














                                                                       
Content area 
BMQ110 SIMS136 Jenkins 
et al137 















Effectiveness    3 3 3 3 3      3 3 7 
Convenience, practicalities 
and/or managing medicines 
    3 3 3 3 3     3 3 7 
Information, knowledge &/or 
understanding  
 3  3     3    3 3 3 6 
Side effects     3 3  3      3 3 5 
Relationships and/or 
communication  with HCPs 
about medicines 
  3      3     3 3 4 
Impact on daily living          3  3    3 3 4 
General satisfaction     3 3 3 3        4 
Attitudes           3   3 3 3 
Beliefs, concerns and/or 
perceptions 
3   3        3    3 
Medical follow-up, monitoring, 
or adherence issues 
   3    3  3      3 
Treatment or medicine-related 
burden 
         3    3  2 
Perceived control/autonomy               3  1 
Self-confidence               3   1 
Availability & accessibility of 
therapy 
              3 1 
Medicine-related quality of life               3 1 
Table 2-2 Comparison of content areas covered by items in reviewed generic measures of medicine-related experiences 
 
Abbreviations: BMQ, Beliefs about Medicines Questionnaire; SIMS, Satisfaction with Information about Medicines Scale; DTC, Drug Therapy Concerns Questionnaire; 
TSQM, Treatment Satisfaction Questionnaire for Medication; SATMED-Q, Treatment Satisfaction with Medicines; PSMM, Patient Satisfaction with Medication Management 
instrument; TBQ, TreatmĞŶƚƵƌĚĞŶYƵĞƐƚŝŽŶŶĂŝƌĞ ?Wd ?WĂƚŝĞŶƚƐ ?ƚƚŝƚƵĚĞƐdŽǁĂƌĚƐĞƉƌĞƐĐƌŝďŝŶŐ ? PSM, Perceived Sensitivity to Medicines questionnaire; LMQ, Living 
with Medicines Questionnaire; PROMPT-QoL, Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life;  N- No. of instruments covering domain or 
area. HCPs- healthcare providers 
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2.3.2 Patient involvement in item generation 
For the majority of instruments, item generation was based on the literature. Some 
ŝŶĐŽƌƉŽƌĂƚĞĚƉĂƚŝĞŶƚƐ ?ǀŝĞǁƐďƵƚŝŶĚŝƌĞĐƚůǇ ?KŶůǇ seven measures had evidence of 
being developed using direct patient input: five employed patient interviews as the 
primary source of questionnaire items (BMQ,110 PSMM,131 TBQ,83 LMQ119 and 
PROMPT-QOL134) and two focus groups (SATMED-Q130 and TSQM version 1.4108). 
Several were judged to emphasise the perspective/opinions of researchers or health 
professionals over those of paƚŝĞŶƚƐ ?:ĞŶŬŝŶƐ ?ŝŶƐƚƌƵŵĞŶƚ ?137 SIMS,136 and DTC132).  










Table 2-3 Methods employed in item generation and testing of reviewed generic measures of medicine-related experiences 
 
Note: 3  indicates the method was used 
Abbreviations:  BMQ, Beliefs about Medicines Questionnaire; SIMS, Satisfaction with Information about Medicines Scale; DTC, Drug Therapy Concerns 
Questionnaire; TSQM, Treatment Satisfaction Questionnaire for Medication; SATMED-Q, Treatment Satisfaction with Medicines; PSMM, Patient Satisfaction with 
Medication Management ŝŶƐƚƌƵŵĞŶƚ ?dY ?dƌĞĂƚŵĞŶƚƵƌĚĞŶYƵĞƐƚŝŽŶŶĂŝƌĞ ?Wd ?WĂƚŝĞŶƚƐ ?ƚƚŝƚƵĚĞƐdŽǁĂƌĚƐĞƉƌĞƐĐƌŝďŝŶŐ ?W^D ?WĞƌĐĞŝǀĞĚ^ĞŶƐŝƚŝǀŝƚǇto 
Medicines questionnaire; LMQ, Living with Medicines Questionnaire; PROMPT-QoL, Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of 
Life.
































Item generation                
Literature 3 3  3 3   3  3 3  3  3 
Patient involvement (via  
interviews/ focus groups/ 
feedback /comments from 
consultations) 
3   9  3 3  3      3 3 3 3  3 3  
Expert opinion, including  
health professionals or 
other care providers 
   3    3    3 3 3 3    
Developed from existing 
instrument (s). 




 3 3 3       3     
Item clarification  ?face and/or content validation 




   3 3   3   3   3  3 
Expert opinion, including 
health professionals or 
other care providers 





The vast majority of instruments were assessed for internal consistency (Table 2-4), 
ŵŽƐƚůǇƵƐŝŶŐƌŽŶďĂĐŚ ?ƐĂůƉŚĂǁŝƚŚƐŽŵĞƌĞƉŽƌƚŝŶŐƚĞƐƚ-retest reliability as intra-class 
correlation coefficient (ICC), and corƌĞůĂƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚƐ ?ƌ ) ?ǀĂůƵĞƐA? ? ? ? ?ŽďƚĂŝŶĞĚ
from a sample size of at least 50 patients, are advisable.122 One study134 employed 
Rasch analysis to estimate person and item reliabilities (acceptable values > 0.8 and 
0.9 respectively), which ĂƐƐĞƐƐĂŶŝŶƐƚƌƵŵĞŶƚ ?ƐĂďŝůŝƚǇƚŽĚŝƐƚŝŶŐƵŝƐŚďĞƚǁĞĞŶŚŝŐŚĂŶĚ
low patient scores, and the level of item difficulty respectively.138    
2.3.4 Scale analysis and construct validity 
Most instruments employed exploratory techniques for scale analysis (Table 2-4). 
However, only a few employed confirmatory methods ascertaining underlying content 
domains and/or their relationships: TSQM II, TSQM-9, SATMED-Q, BMQ, and the 
Okere-Reiner Survey.  
2.3.5 Criterion-related, convergence and/or discriminant validity 
 Criterion-related, convergence and/or discriminant validity were variably reported by 
only eight instruments: TSQM (version 1.4), TSQM II, SATMED-Q, TBQ, SIMS, BMQ, 
PSM, PATD (Table 2-4). The BMQ110 and earlier versions of the TSQM108,109 were the 
most commonly used criterion-referenced instruments. For instance, in validating the 
SIMS,136 patients with stronger concerns about medicines as measured by the BMQ, 
were more likely to be less satisfied with their medicine information. Patients with 
more medicine-related concerns, or beliefs about harm, are reported to not only be 
less trustful of their medicines but also to desire alterations to their regimes or avoid 
them.110 In the development of the PSM scale,135 ƐĐŽƌĞƐŽŶƚŚĞ ‘ĐŽŶĐĞƌŶƐ ?ƐƵďƐĐĂůĞŽf 
the BMQ indicating negative beliefs about medicines were significantly associated 
with perceived sensitivity to medicines (r=0.5, p<0.001). Negative moderate 
correlations (r=-0.56, p<0.001) were reported between scores on BMQ items relating 
ƚŽ ‘ŶĞĐĞƐƐŝƚǇ ŽĨĐƵƌƌĞŶƚŵĞĚŝĐĂƚŝŽŶƐ ?ĂŶĚƐĐŽƌĞƐŽŶƚŚĞWd ?,ŽǁĞǀ ƌ ?ƚŚĞƐĂŵƉůĞ
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size used in this study (n=51) was inadequate to validate the measure of patient 
attitudes to medicine cessation.64  
 
Ruiz et al130 examined associations between SATMED-Q scores and the Spanish 
version of the TSQM (v.1.4); significant correlations (range, 0.58-0.68, p<0.0005) were 
reported between subscales assessing similar domains: treatment effectiveness, side 
effects, convenience and global satisfaction.130 During validation of the TBQ, Tran et 
al83 established a negative relationship between treatment burden and treatment 
satisfaction assessed using  the TSQM Version II; moderate negative correlations 
between TBQ scores and TSQM global satisfaction and convenience subscales (r=-0.41 
and r=-0.53 respectively) and weak negative correlations (r=-0.26) between TBQ 
scores and TSQM efficacy subscale. Treatment burden was significantly higher among 
patients who had experienced side effects compared to those who had not. 
  
Satisfaction with medicines is positively associated with adherence.129 While validating 
the TSQM-9,129 moderate correlations (range, 0.34-0.46) were reported between 
convenience, effectiveness and global satisfaction TSQM-9-subscale scores, and the 
Modified Morisky scale,139 which measures adherence. Weak correlations (range 0.09-
0.22) were reported between SATMED-Q scores and Morisky-Green adherence 
questionnaire scores,140 several failing to reach statistical significance.  
2.3.6 Known-groups and predictive validity 
Known-groups validity was reported for six measures: BMQ, TSQM (v.1.4); TSQM II, 
TSQM-9, TBQ, and the Okere-Reiner Survey (Table 2-4). The Okere-Reiner Survey was 
ƌĞƉŽƌƚĞĚƚŽ ‘ĐůĞĂƌůǇĚŝƐƚŝŶŐƵŝƐŚďĞƚǁĞĞŶƉĂƚŝĞŶƚƐǁŝƚŚŐŽŽĚĂŶĚƉŽŽƌƉĞƌĐĞŝǀĞĚ
ŬŶŽǁůĞĚŐĞŽƌĐŽŶĨŝĚĞŶĐĞŽƌƐĂƚŝƐĨĂĐƚŝŽŶ ? ?133 Least reported was predictive validity 
(Table 2-4). The BMQ was reported to adequately distinguish patients with different 
illnesses and treatments110 and to predict adherence to therapy.112  
In validating the TSQM (v.1.4), Atkinson et al108 tested associations between medicine 
types and routes of administration and satisfaction levels on all four subscales; 
patients using parenteral medicines were least satisfied with convenience and side 
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effects, while oral medicines were rated highly on overall satisfaction and 
convenience.108 Similarly, Ruiz et al130 reported significantly lower satisfaction for 
convenience for parenteral routes of administration compared to oral and inhalation 
routes. Treatment satisfaction assessed by TSQM-9 was significantly greater among 
 ‘ŵĞĚŝƵŵĐŽŵƉůŝĞƌƐ ? ?ŵĞĂƐƵƌĞĚďǇƚŚĞŵŽĚŝĨŝĞĚDŽƌŝƐŬǇ ĐĂůĞ ?139 ĐŽŵƉĂƌĞĚƚŽ ‘ůŽǁ
ĐŽŵƉůŝĞƌƐ ? ?ƉAM ? ? ? ? ? ? ) ?dƌĂŶĞƚĂůƌĞƉŽƌƚĞĚƐŝŐŶŝĨŝĐĂŶƚůǇŚŝŐŚĞƌƐĐŽƌĞƐĂŵŽŶŐƉĂƚŝĞŶƚƐ
with high treatment burden, measured by the TBQ, compared to those with low or 
moderate treatment burden, on specific items relating to treatment workload.83 
WĂƚŝĞŶƚƐǁŝƚŚ ‘ŚŝŐŚďƵƌĚĞŶ ?ŶĞĞĚĞĚĂŶĂǀĞƌĂge of 43 minutes/week to organise their 











Instrument Internal consistency  
 ?ƌŽŶďĂĐŚ ?ƐĂůƉŚĂ ?ƌ ? 
Test-retest reliability/ ICC 
or r (sample size) 
Criterion-related, convergence 
and/or discriminant validity/ 
reference instrument (s)  






Specific-Necessity (0.55 -0.86) 
Specific-Concerns (0.63 -0.80) 
General-Overuse (0.60 -0.80) 
General-Harm (0.47-.83) 
3 
0.60- 0.78 (n=31) 
3Illness Perception Questionnaire, 
the Reported Adherence to 
Medication scale, the Sensitive 
Soma Scale, and  items on 
medication-related thoughts 
3 
EFA & CFA confirmed  































  3EFA revealed 5 subscales; 












Tested associations among 
medicine & illness characteristics 
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EFA & CFA revealed & 














3Item & person separation 
reliabilities range 0.52-0.96 
  3 Rasch analysis suggested 
10 domains 
  
Table 2-4 Psychometric properties of questionnaires included in the review 
 
Note: 3 indicates the test was conducted. EFA  W exploratory factor analysis and methods such as principal components analysis 
Abbreviations: NR-Not reported;   CFA ? confirmatory factor Analysis; SEM- Structural Equation Modeling; BMQ, Beliefs about Medicines Questionnaire; SIMS, 
Satisfaction with Information about Medicines Scale; DTC, Drug Therapy Concerns Questionnaire; TSQM, Treatment Satisfaction Questionnaire for Medication; 
SATMED-Q, Treatment Satisfaction with Medicines; PSMM, Patient Satisfaction with Medication Management instrument; TBQ, Treatment Burden Questionnaire; 
Wd ?WĂƚŝĞŶƚƐ ?ƚƚŝƚƵĚĞƐdŽwards Deprescribing; PSM, Perceived Sensitivity to Medicines questionnaire; LMQ, Living with Medicines Questionnaire; PROMPT-QoL, 
Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life. HADS-  Hospital Anxiety and Depression Scale.
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2.3.7 Summary characteristics of measures of medicine-related experiences 
Of the 15 generic measures of medicine-related experiences, six covered multiple 
domains and were developed with direct patient involvement, particularly in the item 
generation phase, tested for any forms of reliability (as internal consistency, test-test, 
and/or person/item reliability), and/or attempted to confirm construct validity by any 
means. These were: TSQM (including the 14-item, 11-item, and 9-item versions), 
SATMED-Q, PROMPT-QOL and LMQ. However, validity was reported using different 
methods and to different extents for all these measures, and most authors 
acknowledge the need for further developmental and/or validation work. None of the 
identified questionnaires covered all domains or considered potential financial burden 
of medicines in-depth.   
 
The BMQ, one of the earliest, domain-specific, measure of beliefs about medicines,110  
has been used widely to understand many aspects of medicine use, especially 
adherence-related behavior.142 The DTC questionnaire132 serves as a potentially useful  
ƚŽŽůĨŽƌĞůŝĐŝƚŝŶŐƉĂƚŝĞŶƚƐ ?ƉĞƌĐĞƉƚŝŽŶƐĂŶĚĐŽŶĐĞƌŶƐĂďŽƵƚŽĨŵĞĚŝĐŝŶĞ-related 
problems; however, it lacked patient involvement in item generation phases of its 
development. The domain-specific PSM scale135 may be useful for studies evaluating 
concerns about potential adverse effects of medicines. Measures of satisfaction with 
different aspects of medicine use,108,109,129 W131 including information needs,136 are also 
predominant.  The Okere-Reiner Survey133 ŝƐĂƐŚŽƌƚŵĞĂƐƵƌĞŽĨƉĂƚŝĞŶƚƐ ?ŬŶŽǁůĞĚŐĞ
and self-confidence with medicine use, the latter aspect not being included in other 
instruments, which play an important role in the medicine use experience; however, it 
was not derived directly from patients despite testing instrument reliability and 
validity. The PSMM,131 ĂŶŝŶƐƚƌƵŵĞŶƚƌĞƉŽƌƚĞĚƚŽŵĞĂƐƵƌĞƉĂƚŝĞŶƚƐ ?ƉĞƌĐĞƉƚŝŽŶƐŽĨ
medicine management, is prescriber-centered and focused on service evaluation, 
despite being derived directly from patient interviews and including relevant issues. 
For instance, it considers the practicalities of managing regularly-used medicines while 
in hospital, medicine information, understanding and patient-provider communication 
about medicines. The latter aspect was the subject of the scale developed by Jenkins 
and colleagues.137 The PATD questionnaire64 considers deprescribing (medicine 
cessation), and may be used to gain insight into patient preferences or dissatisfaction 
 60 
 
with medicine regimes; however, further validation of this instrument is also 
necessary, as it was developed from the perspective of health professionals and 
evaluated in only a few patients. Although domain-specific and not solely focused on 
medicine-therapeutic interventions, the TBQ83 is potentially useful in assessing 
treatment burden among multi-morbid patients. Two broad, patient-generated, multi-
domain measures, the PROMPT-QOL134 and the LMQ,119 may provide insight into 
measurement of multiple, albeit complex, issues surrounding regular medicine use; 
however, both require further psychometric testing (and/or cross-cultural adaptation) 
for potential use in research or practice.  
2.4 Discussion  
To my ŬŶŽǁůĞĚŐĞ ?ƚŚŝƐŝƐƚŚĞĨŝƌƐƚƌĞǀŝĞǁŽĨŐĞŶĞƌŝĐŵĞĂƐƵƌĞƐŽĨĂĚƵůƚƉĂƚŝĞŶƚƐ ?
experiences of using prescription medicines. Most of the 15 instruments identified 
could potentially be used in patients with multi-morbidity, using a wide range of 
medicines, allowing comparison of experiences across different patient groups. 
However, those which instruct respondents to focus only on one medicine130 would 
require modification. Only a few directly involved patients in item generation and 
further validation work is needed, particularly for those instruments covering multi-
dimensional aspects of medicine use. 
 
Collectively, the domains covered probably reflect most issues that affect people using 
regular medicines. However, none covered all domains  W an important omission if a 
whole patient-centered understanding of medicine experiences is to be quantified.  
 
Notably, none of the instruments considered the potential financial burden of using 
prescription medicines in any depth. One of the broad instruments, PROMPT-QOL, 
ŝŶĐůƵĚĞƐŽŶĞŝƚĞŵŽŶ ‘ŵĞĚŝĐĂƚŝŽŶĂŶĚƚƌĂǀĞůĞǆƉĞŶƐĞƐ ?134 which is limited as an 
assessment of cost-related burden. An item in the PATD questionnaire:  ‘ŚĂǀŝŶŐƚŽƉĂǇ
for less [fewer] medications would play a role in my willingness to stop one or more of 
ŵǇŵĞĚŝĐĂƚŝŽŶƐ ?,64 only focusses on cost-related cessation. One recently-developed, 
10-item, domain-specific measure of cost-related medicine burden in the USA 
population52 explores this issue in isolation. However, it was not included in this review 
as half the statements relate to non-adherence (e.g. cost-related delays in refilling 
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prescriptions and skipping or reducing doses).52 There remains a need for instruments 
that incorporate and assess cost-related issues alongside other dimensions of the 
medicine use experience.  
 
Overall satisfaction with medicines could be regarded as a potentially key, over-arching 
domain, which is influenced by many of the other domains covered by these 
instruments and was the main focus of several questionnaires. Of the generic 
instruments, TSQM (versions 1.4 and II)108,109 and SATMED-Q130 seem promising for 
evaluating aspects of medicine use which impact on satisfaction. However, both have 
been criticisĞĚĂƐĐŝƌĐƵŵƐĐƌŝďĞĚĂŶĚůĂĐŬŝŶŐŝŶ ‘ƉƐǇĐŚŽůŽŐŝĐĂůĚŽŵĂŝŶƐ ?ƐƵĐŚĂƐǁŽƌƌǇ ?
fear, or ĐŽŶĐĞƌŶƐ ? ?ƌĞůĂƚŝŶŐƚŽƚŚĞŵĞĚŝĐŝŶĞƵƐĞĞǆƉĞƌŝĞŶĐĞ ?134  
 
Patient satisfaction with treatment (and medicines) is positively associated with 
persistence and adherence to therapy,143 but negatively associated with treatment 
burden.83 Life-long medicine use can be burdensome to some patients,23,49,144 and may 
impact negatively on health-related quality of life. As already noted in Chapter 1 
(section 1.8), research attempting to describe the burden (or negative experience) of 
ƵƐŝŶŐŵĞĚŝĐŝŶĞƐŚĂƐĚŽŶĞƐŽƵŶĚĞƌƚŚĞ ‘ƵŵďƌĞůůĂ ?ŽĨƚƌĞĂƚŵĞŶƚďƵƌĚĞŶ ?48,85,89 which 
may represent unshared patient experiences that are not fully addressed during 
consultations.101 However, measures of treatment burden are currently limited, as 
reported in a review by Eton et al (2013).120 In contrast to the present review, Eton 
focused on the overall burden of healthcare activities particularly pĂƚŝĞŶƚƐ ?ǁŽƌŬůŽĂĚŽĨ
self-care. An instrument addressing the need for such a measure, the TBQ,83 includes 
some aspects of medicine-related burden, as well as impact or restriction of daily 
activities and social life. A potentially useful multi-domain measure of medicine burden 
is the LMQ,119 which also requires further psychometric testing.  
 
Communication and relationships with healthcare providers was an aspect of 
medicines use included in a number of the instruments, including the two broadest, 
patient-centered measures, PROMPT-QOL134 and LMQ,119 emphasising the potential 
contribution of this domain to satisfaction and treatment burden. The PSMM 
questionnaire131 also includes patient-provider communication problems, for instance 
perceived patient-burden following repetitive questioning about medicine-history, 
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often by multiple providers, and ineffective flow of medicine-related  information 
among health professionals. Most measures of patient satisfaction with consultations 
and patient-provider relationships145 W147 do not focus on medicine-related 
communication, hence the instrument developed by Jenkins et al (2003)137 is 
potentially valuable. Two other instruments, the SIMS136 and the Okere-Reiner 
Survey,133 also cover medicines information transfer. The SIMS focuses on this 
exclusively and is founded on pharmaceutical industry literature, with minimal patient 
involvement, While the Okere-Reiner Survey measures medicine-related knowledge 
and understanding, but again had ůŝƚƚůĞƉĂƚŝĞŶƚŝŶǀŽůǀĞŵĞŶƚĚƵƌŝŶŐŝƚƐ ?ĚĞǀĞůŽƉŵĞŶƚ ?
 
Many other instruments reviewed were essentially uni-dimensional, with variable 
patient involvement in development. As already noted, the BMQ, which assesses 
psychological beliefs and concerns about the necessity and safety of medicines,110 has 
been extensively used in adherence-related studies.113,142,148 The PSM scale covers only 
patient concerns about potential adverse effects of medicines,135 while the PATD was 
ĚĞǀĞůŽƉĞĚƚŽŵĞĂƐƵƌĞƉĂƚŝĞŶƚƐ ?ĂƚƚŝƚƵĚĞƐƚŽĐĞƐƐĂƚŝŽŶŽĨŵĞĚŝĐŝŶĞƐ ?64 thus seeks to 
predict behavior. Like most instruments assessing inappropriate prescribing,19 PATD 
questionnaire development seemed to emphasisĞƚŚĞĐůŝŶŝĐŝĂŶ ?ƐƉĞƌƐƉĞĐƚŝǀĞ ?ƌĂƚŚĞƌ
than the patient perspective. Moreover, deprescribing itself is criticised as a clinician-
driven agenda, which aims to reduce medicine usage and health-system costs.65,67 The 
DTC questionnaire is broader, including concerns about adverse drug reactions, as well 
as regimen complexity, overmedication and use of prescription medicines,132 but also 
based on the clinician perspective. 
 
A further instrument, developed in Taiwan and published since the literature review 
was completed, claims to measure Medication-Related Quality of Life,149 a term 
originally adopted for the LMQ.150 This instrument was developed based on subjective 
well-being scales plus patient interviews and consists of 14 items, covering only three 
domains, role limitations, self-control and vitality.149 Only the first of these relates 





Most instruments included in this review were developed and tested in a specific 
language and in specific demographic settings and, with some exceptions, have not 
been tested in other situations. Therefore cross-cultural adaptations and/or further 
testing may be required prior to use in particular clinical or research settings. Given the 
psychometric properties of the reviewed instruments, there is a need for further 
development and/or validation of the existing multi-dimensional, generic, patient-
generated, measures of experiences of using prescription medicines among adult 
patients living with chronic illness.   
 
Study strengths & limitations 
Owing to the heterogeneity of studies and reported results, data could neither be 
evaluated methodologically (as with most systematic reviews) nor collated for meta-
analysis. Although relevant guidelines were used to critique the reported 
measurement properties of questionnaires,122 I did not set out to report an overall 
quality score for the instruments and their methodological study designs, particularly 
as many of the instruments were developed long before the recently recommended 
quality-scoring criteria.151 W153 Therefore, this review employed a descriptive style to 
compare characteristics, content areas, questionnaire-derivation and validation 
processes across reviewed measures. It excluded all disease-, product- and/or device- 
specific instruments, pharmaceutical service evaluations, clinician- and pharmacist-led 
screening tools for medicine-related problems, including ADRs, tools assessing 
ƉĂƚŝĞŶƚƐ ?Ăďŝůŝƚies  to manage their medicines, adherence-focused tools, and cross-
cultural (and language) adaptations of eligible questionnaires, even though they may 
have considered key aspects of the medicine use experience. It did include measures 
of satisfaction with various aspects of medicine use, despite concerns that measuring 
ƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŝŶƚĞƌŵƐŽĨƐĂƚŝƐĨĂĐƚŝŽŶŵĂǇŝŶƚƌŽĚƵĐĞĂĐƋƵŝĞscence bias. 
Although an organised and broad literature search was conducted across multiple 
databases, it is possible that a few generic instruments reporting certain aspects of 
medicine-related experiences may have been missed. Appropriate search strategies 






2.5 Chapter summary 
This chapter identified the LMQ (relabelled as LMQ-1 to clarify subsequent versions) as 
a potential measure of medicine burden, which however required further validation.  
This chapter also revealed a scarcity of generic, patient-generated, psychometrically 
sound, comprehensive measures of the medicine use experiences of adult patients. 
Moreover, there is insufficient evidence for the routine use of existing measures in 
clinical practice. Therefore, there is a need for further development and/or validation 
of existing patient-derived, multi-domain, instruments, particularly the LMQ-1.  
 
Although the PROMPT-QOL was the broadest (10-domain), patient-generated, 
ŝŶƐƚƌƵŵĞŶƚƌĞƉŽƌƚĞĚŝŶƚŚŝƐŚĂƉƚĞƌ ?ŝƚǁĂƐĚĞƐŝŐŶĞĚĂƐĂŶ ‘,ZYK>ŵĞĂƐƵƌĞĨŽƌ
ŵĞĚŝĐĂƚŝŽŶŵĂŶĂŐĞŵĞŶƚ ?134 which is a separate concept that may overlap with 
medicine burden,92 at least on face value. Moreover, the PROMPT-QOL was developed 
and tested among adult outpatients in Thailand, where the health systems differ 
considerably from the English NHS. It would therefore require considerable cross-
cultural adaptation for it to be used in the English sample populations included in this 
research programme. The only instrument reported to measure the intended 
construct, medicines burden, the LMQ (relabelled the LMQ-1), was adapted for use in 
this research programme. As a multi-dimensional instrument, the LMQ-1 is a generic 
patient-generated measure that was reported to evaluate the negative impact of 
medicine interventions. Such a measure could facilitate the identification of patients 
who find using long-term medicines a challenging experience. There is, therefore, a 
need to develop further and fully validate the LMQ-1 as the most suitable patient-
generated instrument identified through this systematic review, to facilitate such use.  
 
As the need to develop a new instrument is evident, adding key, albeit deficient, 
content domains to the existing multidimensional measure (i.e. the LMQ) may support 
a more comprehensive assessment of medicine use experiences (and associated 
burden) among those living with chronic illness. The next chapters constitute a series 
of studies designed to assess and validate the LMQ-1. Chapter 3, in particular, 
discusses the methodological approach to further development and validation of the 




Chapter 3 Methodology, 
methods, and research design 
3.1 Introduction 
This chapter presents the research methodology (and paradigm), methods of data 
collection and analysis procedures, and their theoretical underpinning. Specific tools 
(and questionnaire versions) employed in the development and validation of the Living 
with Medicines Questionnaire (LMQ) are also clarified. Briefly, I provide a rationale for 
the relatively complex (and iterative) process of designing and evaluating a patient- 
reported measure specific to prescription medicine use experiences.   
 
According to Streiner et al (2015) 118 and other guidelines,123,124 new patient-reported 
measures intended for use in research or clinical settings should undergo rigorous 
development and validation processes. Some of these processes (including item 
generation and testing) were illustrated in the previous chapter (See Table 2-3), which 
indicated variations in pathways for questionnaire development and validation. There 
is standard guidance on patient-reported measures recommended by regulatory 
agencies, including that by the US Food and Drug Administration124 and the European 
Medicines Agency (EMEA).154 Though restricted to clinical trial contexts and drug 
development, this guidance emphasises thorough evaluation of the measurement 
properties of patient-reported tools including content and construct validation, and 
reliability assessment via qualitative and quantitative methodologies. Such evaluation 
may help avoid unintended outcomes arising from decisions based on the measure, 
e.g. where scores on the instrument may determine whether or not an individual 
receives a health intervention.118 Thus, it was vital to carefully develop and validate the 
LMQ while drawing on recommendations from standard guidance and current 
practices in psychometrics.  








3.2.1  Pharmacy practice research 
Pharmacy practice research, a speciality within the broader area of health services 
research,155 aims to understand  ‘ŚŽǁĂŶĚǁŚǇƉĞŽƉůĞĂĐĐĞƐƐpharmacy services, the 
costs of pharmacy services, and the outcomes of patients as a result of using these 
ƐĞƌǀŝĐĞƐ ? ?156 Besides clinical and economic outcomes, broader definitions encompass 
humanistic aspects of pharmacy practice research relating to patient beliefs, attitudes, 
values, experiences, and practices.157 With a gradual paradigm shift to patient-centred 
care, ƚŚĞƌĞŝƐĂŶĞĞĚƚŽƵŶĚĞƌƐƚĂŶĚƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞ ?ĂŶĚǁŝƚŚŝŶƉŚĂƌŵĂĐǇ
practice research studies increasingly seek to elicit  patient and societal perspectives of  
medicines use.21,81,158 This doctoral programme is highly relevant to pharmacy practice 
research as it aimed to investigate the patient perspective on medicine use, by 
developing (and testing) a tool to evaluate medicine use experiences. 
3.2.2 Traditional research paradigms 
This subsection briefly discusses philosophical assumptions and approaches 
(paradigms) to research, so as to clarify the methodological positioning of my own 
research. Research philosophy in the context of pharmacy practice research is not well 
demarcated.158 Nevertheless, it is surrounded by complex philosophical terminology 
rooted in social sciences, particularly epistemology that relates to knowledge theories 
(and justified beliefs) that inform research methodology and data generation.158 
Research paradigms can take on two contrasting assumptions on a continuum: 
positivism (or empiricism) on the far left, interpretivism (constructivism or 
phenomenology or anti-positivism) on the far right, and pragmatism (subtle realism) 
somewhere in the middle.155,158,159 Although these paradigms cannot be exhaustively 
discussed here, their tenets are highlighted.  
 
Positivists (empiricists) believe in objectivity and measurability of phenomena with 
ŶŽƚŝŽŶƐƚŚĂƚ ‘ƉĞŽƉůĞĂŶĚƐŽĐŝĂůƐƚƌƵĐƚƵƌĞƐĐĂŶďĞƐƚƵdied scientifically Q ?.156  Early 
pharmacy practice research assumed a positivistic perspective, in which predominant 
frameworks were used to derive  ‘ƵŶŝǀĞƌƐĂůůĂǁƐ ?,155 akin to biomedical research, 
assuming generalisability of findings, through quantitative methods of data collection 




Interpretivists (and phenomenologists) recognise subjectivity of phenomena156  and 
explore, in-ĚĞƉƚŚ ?ƉĞŽƉůĞ ?ƐǀŝĞǁƐ ?ƚŚŽƵŐŚƚƐĂŶĚůŝǀĞĚĞǆƉĞƌŝĞŶĐƐƉƌŝŵĂƌŝůǇƚŚƌŽƵŐŚ
qualitative methods (such as interviews, document analysis).157 Regardless, purely 
qualitative findings may not establish whether or not lived experiences are typical, 
possibly due to the small samples employed. Also, highly qualitative data may pose 
practical challenges for end-users other than researchers (e.g. patients or 
practitioners) in terms of presentation of data.  
  
3.2.3 Rationale for choosing pragmatism and mixed-methods  
For this research programme, pragmatism was considered the most suitable 
standpoint. Pragmatism is increasingly recognised as a valuable approach in health-
related research, and has been embraced by recent pharmacy practice researchers.158 
Pragmatism is a more flexible research paradigm uncommitted to unidimensional 
viewpoints (and single-method designs) of positivists or 
interpretivists/phenomenologists. As a philosophical framework underpinning mixed-
methods research, pragmatism employs both quantitative and qualitative methods 
(such as interviews and questionnaires) for data collection and analysis to understand 
the research problem.157 As a practical, problem-centred, and outcome-oriented 
paradigm, pragmatists adapt methods suited for addressing research questions or   
objectives.159  
 
This research programme aimed to develop and validate a tool for exploring medicine-
related experiences (and burden) in adults using long-term medicines. As described in 
Chapter 1, the concept of medicine burden is relatively new, and adapting 
methodology to evaluate the hypothesised construct and to devise a suitable measure 
was relevant. In choosing a pragmatic approach, multiple techniques were used to 
generate, revise, and test items in the LMQ.  
 
Qualitative interview data from patients using long-term medicines was used by the 
originators of the 60-item LMQ, which was reported in the previous chapter. 23,119 In 
this research programme, qualitative cognitive interviews helped to clarify meanings 
and interpretations of LMQ statements, from the pĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞ ?
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Through other forms of qualitative data (free-text comments in surveys ) ?ƚŚĞƉĂƚŝĞŶƚ ?Ɛ
voice (as views, experiences, or feelings) was captured and represented in a language 
used by and understood by people on long-term medicines.  
 
Quantitative methods, by cross-sectional surveys, were predominantly used to 
ĞǀĂůƵĂƚĞƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ƐŵĞĂƐƵƌĞŵĞŶƚ properties (such as reliability and validity). 
For instance, construct validation used quantitative data to determine which items (or 
groups of items) were measuring specific aspects of medicines use (e.g. medicine-
related interferences with day-to-day life), and to investigate whether all LMQ 
domains measured aspects of medicine burden and to what extent. A pragmatic and 
mixed-methods approach has been endorsed in the development of patient-reported 
measures, and is illustrated by Winit-Watjana158 as the approach used in the 
development of a measure of medicine-related quality of life (the PROMPT-QoL).134 
Thus, a pragmatic stance helped achieve the aims of this doctoral research by 




3.3.1 Ethical considerations and approvals   
Ethics approval was granted for each phase of study. Phases that involved the general 
public were approved by the Medway School of Pharmacy, which has its own ethics 
review committee. The National Research Ethics Service (NRES Committee South 
Central - Oxford C) approved the Phase 4 study (reported in Chapter 7) to allow access 
to patients in NHS sites in Kent and Medway areas. Relevant procedures for research 
governance at different research sites were followed, including obtaining letters of 
access. At all phases of research, explicit research protocols, compiled a priori, were 
adhered to. 
 
While undertaking all the individual research studies, participant respect, 
confidentiality, information provision, and encouraging voluntary participation was 
guided by  the International Conference on Harmonisation (ICH) guidelines for good 
clinical practice.160 For studies requiring disclosure of personal information (e.g. 
prescription medicine use and health status), assurances of anonymity and 
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confidentiality of  data may improve response rates. It is worth noting that this 
research programme encompassed non-interventional studies, and consent was 
implied for those participating in anonymous surveys; written consent was obtained 
for cognitive interviewees in Phase 2b (described in Chapter 5). 
 
In terms of potential benefits to participants, this research programme may have 
offered platforms for sharing lived experiences, views, feelings, and thoughts about 
long-term medicines some of which remain  ‘ƵŶŚĞĂƌĚ ?ŝŶŚĞĂůƚŚĐĂƌĞƐĞƚƚŝŶŐƐ ? Feedback 
reports were disseminated to all patient organisations/fora and recruitment sites that 
assisted at various phases of the research programme. 
 
3.3.2 General rationale of methods used in this research programme 
3.3.2.1 Survey methods 
Questionnaires were predominantly used in this research programme. Surveys can 
gather large-scale data from wider geographic populations in a relatively short 
time.128,161,162 They may enable generalisability of findings if response rates are 
adequate. With questionnaires, standardised data were collected on all variables  W this 
was relevant to assess measurement properties of the LMQ (such as test-retest 
reliability). 
All questionnaires were intended for self-completion, simulating real-life use of 
patient-reported tools enabling direct assessments of medicines use experiences. Self-
completion allowed participants to understand and answer questions from their own 
perspective, unlike interviewer-administered surveys that are more resource-intensive. 
Anonymous self-reports can draw sensitive information from individuals, possibly due 
to a perceived sense of privacy. LMQ statements about personal impact of medicines 
on social and sexual life may have been answered truthfully with the anonymous 
surveys conducted in this research programme. Regardless, self-completed 
questionnaires impose cognitive demands on the participant, and necessitate a certain 
level of literacy (reading and language skills) present in the respondent sample. Also, 
participants with visual impairment or inadequate dexterity (of wrist and figures) may 
be unable to complete questionnaires.161 Readability of the questionnaire had been 
assessed previously during development of the LMQ-1,119 and was reassessed for the 
LMQ-2.1 in a study described in Chapter 5.  
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3.3.2.2 Modes of survey distribution  
Two survey distribution methods were used at various phases of this research 
programme: face-to-face and on-line distribution. Mixed-mode surveys are 
advantageous in improving response rates, as well as attaining representative samples 
of participants.162  
a) Face-to-face distribution 
Face-to-face recruitment using paper questionnaires, as a traditional mode of data 
collection, was employed in two study phases (Phases 1b and 4 as shown in Figure 1-
8). Participants who can read and write, regardless of computer literacy or access to 
the Internet, can use paper-based questionnaires. Postal mail was mostly used to 
return paper questionnaires with only a few participants completing and returning 
questionnaires directly, by hand, to researchers. Returning questionnaires by mail may 
offer ample time to participants to respond and submit their responses at leisure. It 
also requires minimal co-ordination by the researcher who picks up completed 
questionnaires from one address.118 To increase the likelihood of returning mailed 
questionnaires, all paper questionnaires were supplemented by a cover letter, 
participant information sheet, and a pre-paid postage, self-addressed envelope. A 
cover letter impacts on attitudes and practices of questionnaire completion.118 Using 
cover letters and information sheets ?ŽŶƚŚĞ^ĐŚŽŽů ?ƐůĞƚƚĞƌŚĞĂĚ ?ŝŶĨŽƌŵĞĚƉŽƚĞŶƚŝĂů
participants about specific aspects of each study, including rationale, inclusion criteria, 
and ethical issues (See Appendices).  
 
b) On-line distribution 
With recent technological advances and increased access to computer devices, smart 
phones and the Internet, web-based questionnaires provide an alternative, faster and 
easier, means of collecting data. Software (such as Qualtrics© provided by Qualtrics 
LLC  via https://www.qualtrics.com/ ) can be used to host a questionnaire on a web-
site and provide a unique link (url), which can then be used to promote the 
questionnaire via health websites, social media sites of selected patient organisations, 
and by email invitation. Qualtrics© automatically records survey responses into a 
database, thus minimising data entry errors associated with transcribing paper-based 
data into a database.118 Web-based surveys were used because they reach people 
from wider geographical locations and in hard-to-reach areas that may otherwise not 
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have been encountered during face-to-face recruitment. Besides simplifying 
questionnaire layout, formatting replicated the paper questionnaire into an electronic 
form with the same statements. A cover page, participant information, and screening 
questions on inclusion criteria were also embedded in the electronic format, which 
also had aŶ ‘ĂůĞƌƚ ? to remind participants of incomplete responses- this may have 
minimised missing data. A disadvantage of on-line surveys, besides excluding those 
without computers/internet or with lower levels of education, relates to accurately 
estimating response rates.118 For instance, it is difficult to determine how many people 
receive an anonymous web-based survey ƉƌŽŵŽƚĞĚƚŽĂŶ ‘ŽƉĞŶ ?patient organisation, 
although using an email list may solve this problem. Email recruitment has its unique 
limitations, although it was used in the Phase 5 study (described in Chapter 8). It 
requires access to valid email addresses of potential participants, and their ability and 
willingness to regularly read and respond to emails.118  
 
3.3.2.3 Cognitive interviews 
Cognitive  interviews were used in Phase 2b (See Figure 1-8) to gain patient feedback 
on questionnaire content, and to check interpretability of all items. This subsection 
provides a general rationale for using cognitive interview procedures reported in 
Chapter 5. 
Derived from the field of social and cognitive psychology,163,164 cognitive interviews 
ĞǆƉůŽƌĞƌĞƐƉŽŶĚĞŶƚƐ ?ĂƉƉƌŽĂĐŚƚŽƚŚĞƚĂƐŬŽf answering questionnaire items.127 There 
is no consensus about how to conduct cognitive interviews, but the most commonly 
used cognitive-interview methods are think-aloud and verbal probing.127,165,166 The 
think-aloud technique involves respondents verbalizing their thoughts as they respond 
to questionnaire items.127,166 It is appropriate for questions involving recall,127 is open-
ended and may elicit unexpected information from respondents.167 Conversely, 
thinking aloud is respondent-controlled and ŝŵƉŽƐĞƐĂ ‘ƚŚŝŶŬŝŶŐďƵƌĚĞŶ ?ŽŶƚŚĞ 
participant, who may stray from the main task of questionnaire evaluation.127,167,168 
Moreover, think-aloud interviewing is somewhat dependent on how outspoken or 
articulate a respondent is; some respondents may simply answer the questions 
without much elaboration, while others may spend more time talking about one 





Verbal probing, an altetrnative technique, is interviewer-led by asking follow-up 
questions (probes) during or after item completion to facilitate relevant discussions 
about the questionnaire.168 Concurrent probing is preferable for using  ‘ĨƌĞƐŚ ?
information (ŝŶƚŚĞƉĂƌƚŝĐŝƉĂŶƚ ?ƐŵŝŶĚ )during item completion, unlike retrospective 
probing where participants may not remember what they were thinking in relation to a 
particular item when interviewed at the end of questionnaire completion.168 Probing is 
an increasingly preferred technique,166 as it helps to gather more information on 
questionnaire items (e.g. clarity and relevance), appropriateness of response options, 
and general comments about questionnaire length, item order, formatting and layout. 
Probing enabled ĂĐůĞĂƌĂŶĚƉƌĞĐŝƐĞƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƉĂƌƚŝĐŝƉĂŶƚƐ ?ŝŶƚĞƌƉƌĞƚĂƚŝŽŶŽĨ
each question they answered.166 During verbal probing, the interviewer asks for more 
specific information about questionnaire items, and seeks explanation of the answers 
given by participants; thus assessing questionnaire interpretation even further.168 The 
same probes may be used for all survey items (standardised), or may vary depending 
on a participĂŶƚ ?ƐĂŶƐǁĞƌƚŽĂƐƉĞĐŝĨŝĐŝƚĞŵ.127 Spontaneous probes may assess what a 
participant thinks of an unanticipated questionnaire problem, while targeted probing 
majorly focuses on potentially problematic items (e.g. newly generated or revised 
items). For a relatively lengthy questionnaire, such as the LMQ-1, targeted-probing can 
minimise respondent burden while allowing quick evaluation of the questionnaire.  
 
Nevertheless, adapting a method that elicits adequate and relevant information 
(pragmatism) is preferable to maintaining consistency during cognitive interviews.127  
In the Phase 2 study (described in Chapter 5), a triangulation of think-aloud and verbal 
probing techniques achieved relevant and sufficient information on the 
ƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ƐƌĞĂĚĂďŝůŝƚǇĂŶĚƉŽƚĞŶƚŝĂůůǇƉƌŽďůĞŵĂƚŝĐŝƚĞŵƐŝŶƚŚĞ>DY-2.1. A 









3.3.3 Sample population inclusion/exclusion criteria 
The sample population involved in the development and validation of the LMQ was 
given consideration. Across all studies, participants were adults using at least one long-
term prescription medicine for any disease/condition. The LMQ was intended to assess 
ĂĚƵůƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐĂŶĚĂůůƉĂƌƚŝĐŝƉĂŶƚƐ were 18 years or older. Participants  using 
medicines contributed to generating, revising, and testing items in the LMQ, which 
covered issues relevant to them. Patient and public involvement is indispensable  in 
the development of novel health interventions (and tools) to draw on their 
experiences and perspectives.169   
 
Participants were excluded from the study if: self-reporting to be too unwell to 
complete the questionnaires (e.g. those reporting severe dexterity problems); unable 
to read English as the language used in all study tools; and if using prescription 
medicines only for acute illnesses (e.g. antibiotics for an short-term infection). Across 
all studies described in this thesis, the questionnaires/study tools were only available 
in English as time, costs, and human resource constraints precluded their translation to 
other languages.  
3.3.4 Study setting 
Recruitment for different phases of the research programme was conducted via 
multiple research settings: public places, community pharmacies, GP practices, and 
hospital outpatient clinics. In Phase 1b (Chapter 4), street surveys were conducted in 
busy areas of Kent and Medway (such as leisure centres, parks, bus/train stations, 
entrances of shopping centres, community libraries) aiming to access a socio-
demographically diverse sample.162 With nearly half of all adults using prescription 
medicines in England,31 the general public provided a suitable pool of potential 
participants. The public was relatively more accessible than patients in NHS settings 
owing to relatively lengthy/bureaucratic procedures associated with participant 
recruitment (such as applications for research governance and NRES approvals).  
 
Nonetheless, a purposive sample of community pharmacies and GP practices in Kent 
and Medway were engaged to ensure that questionnaire development and testing also 
involved NHS patients using long-term prescription medicines. Hospital outpatient 
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clinics at Medway NHS Foundation Trust, were selected, owing to their clinically 
diverse patient population. As the largest and busiest hospital in Kent, the hospital 
serves over 650,000 patients per annum within the NHS south-east coast region.170 
The relatively high footfall of patients was exploited to generate high response rates in 
a short space of time. 
 
All research sites were closely located to the Medway School of Pharmacy (the 
Universities of Greenwich and Kent) and were convenient to access. Capturing 
experiences of primary- and secondary-care users and the public provided an initial 
test of usability and acceptability of the LMQ tool in different settings. Figure 3-1 
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3.3.5 Data management 
Data analysis software 
Quantitative data were manually entered (or downloaded from Qualtrics©) into IBM 
SPSS version 22 that was later upgraded to version 23 and then 24, within which most 
data were analysed. Analysis of Moment Structures (IBM AMOS ® version 22), was 
used in confirmatory factor analysis in Phase 3 (described in Chapter 6). All qualitative 
interview data were managed in NVIVO© version 10 (QSR International Pty Ltd), and 
Microsoft Excel 2013 spread sheets were used to manage participant feedback on an 
interim questionnaire reported in Chapter 5. Monte Carlo PCA, a specific web-based 
programme,171 was used for parallel analyses in Chapters 4 and 6.   
 
Quality assurance  
a)  Handling missing data 
All data sets derived from questionnaires were screened for entry errors and missing 
data to minimise biased findings. The most traditional approaches for dealing with 
missing data include: a) Mean imputation. This involves replacing any missing values 
with estimated means scores, which may lead to misleading or biased results and is 
not commonly recommended.172 W174 b) Pairwise-deletion, which exploits all available 
data175 by excluding only participants with missing values per analysis, may lead to 
distorted or inconsistent estimates owing to variations in sample sizes across studies.  
c) Listwise-deletion is a simple way of eliminating all participants with missing values 
on any variable to have complete datasets.172,173,175 d) Other complex techniques (i.e. 
full information maximum likelihood and expectation maximization) require advanced 
software and are rarely used to handle missing data176 despite producing the least 
biased results.172,173 Of these techniques, listwise deletion was mostly selected as a 
simpler option to ensure consistency of sample sizes per study when sample sizes were 
not greatly reduced. Pairwise analyses were mainly used where sample sizes would be 








b) Assessing normality of responses & presence of outliers 
The distribution of responses was examined in all data sets by using histograms and 
normality Q-Q plots. Where tests for univariate normality (Kolmogorov-Smirnov test 
and Shapiro-Wilk test) were conducted, a non-significant p-value (p> 0.05) indicated 
normal distribution of variables. Skewness and kurtosis were estimated in some 
studies. The two indices of normality portray the score distribution and how tilted or 
peaked it is; values around one in absolute value support normal distribution of 
data.177 Visual inspection  of data for outliers, by means of scatter plots or box plots, 
was conducted in some studies; outliers are participants with scores differing markedly 
from those of others in the dataset.173 
 
c) Reverse scoring of items 
Although intended to measure a negative construct (medicine burden), the LMQ had a 
mixture of positively-phrased and negatively-phrased statements to minimise 
 ‘automatic ? responding. Prior to reverse coding, each item response was coded as 1-2-
3-4- or 5 to reflect strongly agree, agree, neutral, disagree, or strongly disagree 
respectively. To ensure that higher scores reflected worse experiences of medicine use 
(higher medicine burden), negatively-phrased items were re-coded to give higher 
weights to  those in agreement with such statements. For instance, prior to reverse 
scoring a negatively-phrased item (e.g. I find getting my prescriptions from the doctor 
difficult) strongly agree was coded as 1, but after  ‘reverse scoring ? a score of 5 
indicated worse experience with that aspect of medicine use. Reverse scoring also 
aided interpretation of factor analysis results, and accurate estimation of internal 











3.3.6 Qualitative data analysis 
Qualitative data were obtained and used in various phases of the research programme. 
These comprised: original patient interviews from which the concepts and items in the 
LMQ-1 were derived;23 cognitive interviews; and descriptive free-text comments from 
an open-ended question in the LMQ ( ‘If you have any other views about how your 
medicines affect your day-to-day life, please describe them ?). Free-text comments were 
analysed thematically, and used for item generation in Chapter 5. In Chapter 9, free-
text comments were also used to complement (and illustrate) quantitative findings on 
prevalence of medicine-related difficulties in the sample populations. 
To identify new content for the LMQ, reanalysis of the original 21 qualitative 
interviews23 was conducted thematically, using techniques akin to framework analysis. 
The 8-domain thematic framework proposed by Krska and colleagues23 was used to 
code medicine use experiences into: impact on daily living, side effects, relationships 
with health providers, efficacy, attitudes, practicalities, information and control over 
medicines use. Any codes falling outside of these themes (e.g. about cost of medicines) 
were considered as potential gaps in the LMQ instrument. Codes about side effects 
and impact on daily living were reviewed, some of which were used to generate new 
items in these domains. As already described, new items and existing items in the 
questionnaire were tested using cognitive interviews. In Chapter 5, cognitive interview 
data were analysed descriptively, using procedures akin to constant comparison,178 by 
grouping similar comments  per LMQ statement and linking them, so as to identify 
potential questionnaire problems. Further descriptions of methods used to analyse 
cognitive interviews are included in Chapter 5 (See section 5.2.6). The interview 
comments were compiled for each item in specially designed Excel spreadsheets 
(Appendix 16), and analysed both on an item-by-item basis, and comparatively to 
assess potential questionnaire problems, including comprehension difficulties. 
Comments about each item were compared across all participant responses, and 
comprehension problems assessed and documented. The rationale for taking this 
analytical approach to analyse cognitive interviews was discussed in-depth in section 





3.3.7 Choice of measurement framework ʹClassical Test Theory 
There are two measurement frameworks, with different theoretical assumptions, that 
can be applied in questionnaire validation: classical test theory (CTT) and item 
response theory (IRT). Factor analysis is a typical application of CTT and will be 
described in a later section. This subsection explores the rationale for using CTT, as the 
most appropriate overarching measurement framework applied in Chapters 4 and 6.  
 
CTT is a centurial, predominant, measurement theory in health services research, 
which has been widely used in questionnaire validation.179 CTT simply proposes that 
 ‘ĂŶǇŽďƐĞƌǀĂƚŝŽŶ ?ŽƌŝƚĞŵƐĐŽƌĞ ?ŝƐĐŽŵƉŽƐĞĚŽĨƚwo components: a true score and an 
ĞƌƌŽƌĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞŽďƐĞƌǀĂƚŝŽŶ ?.118 In other words, observed item scores in a 
completed questionnaire (e.g. coded as 1-2-3-4- or 5 for the level of agreement with 
each LMQ statement) are the result of actual scores (indicating the level of attribute) 
and random error inflicted by external factors. Highly reliable instruments should 
produce observed scores that are closer to true scores, with lower measurement 
error.179  
Summing up item scores to generate total scores is a common way of scoring 
questionnaires founded on CTT. However, there are methodological challenges with 
this method and its assumptions. One assumption is that each item contributes equally 
to the total score on a scale, and that summation may not account for weights of 
individual items and the extent to which they reflect the underlying construct.118 
Summation of scores also assumes that all items are measured on the same scale. 
Nevertheless, the 5-point Likert scale was assumed to be continuous (having an equal 
interval) and thus enabled estimation of total scores, despite mixed debates about 
whether Likert-type scales are continuous or ordinal.172,180 
 
Although CTT applications are easier to use, interpret, and are accessible in statistical 
software (such as SPSS), CTT has debatable assumptions. ƐƚŚĞ ‘ƐŽĨƚĞƌƚŚĞŽƌǇ ? ?dd
ŵŽĚĞůƐĂƌĞƚŚŽƵŐŚƚƚŽƵŶĚĞƌĞƐƚŝŵĂƚĞŵĞĂƐƵƌĞŵĞŶƚĞƌƌŽƌƐďǇĂƐƐƵŵŝŶŐƚŚĂƚ ‘ QƚŚĞ
ĂǀĞƌĂŐĞĞƌƌŽƌ ?ƐƵŵŵĞĚŽǀĞƌĂůůŽĨƚŚĞŝƚĞŵƐŝƐǌĞƌŽ ?,118 implying that all sources of 




IRT, the alternative measurement framework rooted in educational testing (including 
founder works of Georg Rasch,1960181), may precisely estimate measurement error 
and permits only thĞ ‘ďĞƐƚ ?ŝƚĞŵƐ ?ĂƚůĞĂƐƚŝŶĂƐƚĂƚŝƐƚŝĐĂůƐĞŶƐĞ )ƚŽƉŽƉƵůĂƚĞĂŶ
instrument.118 However, it has not gained much recognition in the development and 
validation of health-related measures.118 For instance, only 1 in 15 studies in the 
systematic review described in Chapter 2 employed Rasch analysis, an application of 
IRT, to evaluate a measure of medicine-related quality of life.134 Despite taking into 
ĐŽŶƐŝĚĞƌĂƚŝŽŶƉĂƌƚŝĐŝƉĂŶƚƐ ?ůĞǀĞůŽĨĂƚƚƌŝďƵƚĞƉĞƌŝƚĞŵ ?Ğ.g. level  of quality of life), IRT 
is criticised for being mostly theoretical.118 IRT not only uses complex mathematical 
terminology but also has rigid assumptions. Particularly, IRT demands uni-
dimensionality of the questionnaire whereby all items are expected to directly 
measure one construct. Streiner et al (2015) ĐůĞĂƌůǇƐƚŝƉƵůĂƚĞƐƚŚĂƚ ‘/ZdĐĂŶŶŽƚďĞƵƐĞĚ
when the underlying construct [such as medicine burden] is itself multifaceted and 
comƉůĞǆ ? ?118 As previously described in Chapters 1 and 2, medicine burden is a 
multidimensional construct covering a range of experiences. Therefore, it was deemed 
inappropriate to adopt the IRT approach. It also demands extensive specialist 
knowledge, skills and software to perform analyses, unlike CTT models that were easy 
to compute. The next subsection explores factor analysis, in depth, as the predominant 
technique, and application of CTT, used in Chapters 4 and 6. 
3.3.8 Factor analysis  
3.3.8.1 Underlying principles 
Factor analysis, a multivariate statistical technique, was used as the predominant 
technique to validate the LMQ, examining the extent to which it measured medicine 
burden as the hypothesised construct (i.e. construct validation). It elucidated the 
>DY ?Ɛdimensional structure and its constituent domains.    
 
Principles underlying factor analysis involve correlations - there must be adequate 
relationships among items for it to work.127 Extensively reported in psychometrics 
literature, conventional PĞĂƌƐŽŶ ?ƐĐorrelations were used in all factor analyses to 
derive factors. WĞĂƌƐŽŶ ?ƐĐŽƌƌĞůĂƚŝŽŶƐĂƐƐƵŵĞlinearity among items rated on an 
interval (or continuous) scale; LMQ items were rated on a 5-point Likert-type scale 
assumed to be continuous.  
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Mathematically, factors are weighted combinations (or clusters) of inter-related 
items.127 For instance, the first factor (denoted as F1 ) in the 60-item LMQ-1 is 
represented as: F1 = w1, 1 X1 +w1,2X2 A? ?ǁ60,60X60. Weights for all items are denoted by 
w1,1 , w1,2 to w60, 60 with subscripts referring to factor- and item- numbers respectively.   
Thus, w1, 2 depicts the weight for the second item contributing to the first factor. Items 
are represented as X1  to X60. There are as many factors as there are items, and criteria 
for selecting factors will be discussed in a later section (section 3.3.8.3). Generally, 
factor analysis aids data reduction175,182 whereby  a large number of items is refined to 
fewer coherent factors. In this thesis, factors are synonymously described as 
components, domains, dimensions, subscales, or constructs, depending on the context 
and psychometric literature.   
 
3.3.8.2 Types of factor analyses 
Two major approaches to factor analysis were employed: exploratory factor analysis 
(EFA) and confirmatory factor analysis (CFA). As the name suggests, EFA is exploratory 
and assumes no prior hypotheses.174,175 EFA was most relevant in preliminary work to 
investigate relationships among items and to generate hypotheses about factors127 
(domains) in different versions of the LMQ. CFA is an advanced statistical procedure, 
part of structural equation modelling (SEM). It is useful as a hypothesis-testing 
approach. Informed by EFA findings, CFA was used to confirm the interrelations among 
items and domains,127,172 and to assess a shorter version of the LMQ (the LMQ-3) as a 
measure of an overarching  construct of medicines burden. Briefly, CFA models are 
evaluated against statistical criteria (model fit indices ) ?ĂŶĚŝĨŶŽƚŵĞĞƚŝŶŐ ‘ŐŽůĚĞŶ ?
rules, pre-specified models can be modified and alternative ones investigated.172,180,183  
 
The next subsection provides an overview of the procedures used in EFA, with specific 









3.3.8.3 Procedures for EFA 
EFA procedures are iterative and multistep. To assess factorability or suitability of data 
for factor analysis, the strength of inter-item correlations and sample size were 
examined. Correlation coefficients above 0.3 among most items, are adequate for 
factor analyses.175,182 Kaiser-Meyer-Olkin measure of sampling adequacy (KMO) and 
ĂƌƚůĞƚƚ ?ƐƚĞƐƚŽĨƐƉŚĞƌŝĐŝƚǇ were also used to evaluate the  adequacy and statistical 
significance of relationships among items.175,184 A KMO value above 0.6 (range, 0 to 1) 
and ĂƌƚůĞƚƚ ?Ɛp-value < 0.05 indicates data are factorable.175 Subsequent steps, 
described below, involve selecting appropriate factor extraction techniques. 
 
a) Choosing a factor extraction technique 
Factor extraction techniques help to identify the smallest and most conceptually 
meaningful set of factors that can best explain the interrelationships among items.175  
A common aim of factor extraction is to attain simpler (or parsimonious) factor 
solutions. Parsimony, in the EFA sense, refers to achieving the least number of factors 
accounting for the maximum ǀĂƌŝĂďŝůŝƚǇĂĐƌŽƐƐĂůůƉĂƌƚŝĐŝƉĂŶƚƐ ?scores (variance). If the 
first few interpretable factors can account for most of the variance, then the remaining 
factors can be ignored with minimal loss of information.127 Popular extraction 
techniques include principal components analysis (PCA), common factor analysis using 
principal axis factoring (PAF), and maximum likelihood estimation (ML). 
 
PCA estimates components (factors) by extracting the total variance of each item in 
the questionnaire.175 To clarify, the total variance of an item has two parts: the fraction 
of variance that is common to all other items in a data set (common variance), and the 
fraction of variance that is specific to each item, including variations arising from 
measurement error (unique variance).174 Due to its assumptions that embrace possible 
measurement error, PCA is controversially, sometimes, dismissed as a factor analytic 
technique. PAF uses common variance among items to derive factors while eliminating 
error variability from items.182 Nonetheless, some authors acknowledge that PCA and 
common factor analysis [with PAF]  ‘ Qare not competing techniques, as both methods 
facilitate a different purpose... ? ?185 PCA is most applicable in data reduction, and was 
used in Chapter 4 to reduce the 60-item questionnaire to a shorter interim version (the 
LMQ-2).   
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PAF was used in Chapter 6 to explore common factors (domains) underlying the LMQ-
3.  
The type of data and its distribution patterns also influences the choice of a factor 
analytic technique. PAF makes no assumptions about the distribution of responses, 
unlike ML that is more suitable for analysing symmetric data with four or more 
response categories.172,180 ML was used in Chapter 6 for CFA.  
 
b) Factor retention - determining the optimal number of factors  
Three criteria for factor retention are: a) Kaiseƌ ?ƐĞŝŐĞŶǀĂůƵĞ ?AN ? )ƌƵůĞ- the eigenvalue 
of a factor shows the proportion of variance explained by that factor. b) ĂƚƚĞůů ?Ɛ^Đree 
plots of eigenvalues against their corresponding factors; only factors above and to the 
left of inflexion points or sudden breaks in the plot are retained, as these account for 
most of the variance in the dataset.175 Interpretation of scree plots, and <ĂŝƐĞƌ ?Ɛ
criteria, is relatively subjective and both are criticised for retaining too many factors.175 
c) Parallel analysis is a more objective and accurate test,127,171 whereby observed 
eigenvalues are systematically compared with average randomly-generated 
eigenvalues (from a computer programme). Factors are only retained if observed 
eigenvalues exceed the latter values,175 indicating that they are not merely occurring 
by chance. A potential limitation of parallel analysis techniques lies in probable 
 ‘variation in the results [that] becomes increasingly small and essentially disappeĂƌƐ ? 
with bigger data sets.186  
Irrespective, all three criteria for factor retention were triangulated to confirm the 
number of domains in the LMQ. 
 
c) Factor rotation 
Factor rotation helps display the pattern of factor loadings, as correlations between 
items and factors, in simpler and interpretable ways.175 Two main rotation techniques 
either allow uncorrelated/independent factors (orthogonal rotation e.g. varimax) or 
correlated factors (oblique rotation e.g. promax).175,182 In this research programme, 
oblique rotation techniques were used during EFA due to hypothesised inter-
correlations among LMQ domains. Oblique rotations are commonly recommended in 
psychology-related studies where constructs (such as those underlying medicine 




d) Criteria for item retention/reduction 
Decisions on item retention of deletion were made by both qualitatively reviewing 
each statement in the LMQ, and employing statistical criteria. Items were retained if 
their factor loadings were ĂĚĞƋƵĂƚĞ ?ĂƚůĞĂƐƚA? ? ? ?).182 Factor loadings represent the 
relative importance of each item to its corresponding domain (factor). Factor loadings 
<0.3, 0.3-0.5, and A? 0.5 indicate weak, moderate and stronger associations among 
items and their corresponding domains respectively.187 Although, higher item loadings 
are desirable for reliable subscales (or purer measures), there is a need to minimise 
substantial item loss from a questionnaire.188 In addition, items with high 
communalities (>0.4) were preferable as they represented a higher proportion of 
shared(common) variance.187 Items cross loading on two or more factorƐ ?A? ? ? ? )ǁĞƌĞ
candidates for deletion, since they could be measuring a different concept/multiple 
concepts;175 qualitatively reviewing the meanings and relevance of such items, and 
discussions with supervisors, guided item deletions. 
 
e) Naming of factors 
Naming of factors (domains) was based on statistical findings, and the qualitative 
meaning of items common to a domain. Items loading most strongly on the same 
factor (known as marker items) were examined to understand the concepts they 
reflected. Discussions were also held with the supervision team to agree on 
nomenclature of the domains in an interim version (LMQ-2) and in the final version of 













3.3.8.4 Reliability analysis ʹ internal consistency and test-retest reliability 
Internal consistency is a common measure of reliability. This test is relatively easy to 
perform, compared to test-retest reliability, which was examined in Chapter 8, as it 
uses data from a single survey completion.118 ƌŽŶďĂĐŚ ?Ɛalpha coefficient (ɲ )ŝƐa 
popular index of internal consistency. It depicts relationships among a set of items in a 
subscale (factor). ƌŽŶďĂĐŚ ?ƐɲǀĂůƵĞƐA? ? ? ?ĂƌĞĂĐĐĞƉƚĂďůĞ ?ďƵƚǁŚĞŶŵĞĂƐƵƌŝŶŐ
psycholoŐŝĐĂůĐŽŶƐƚƌƵĐƚƐɲAM ? ? ?ĂƌĞƌĞĂůŝƐƚŝĐ ?ƌŽŶďĂĐŚ ?Ɛɲ ?ǁŚŝĐŚŝƐĚŝƌĞĐƚůy 
proportional to the number of items in a subscale, has attracted differing criticisms 
with respect to its usefulness as a measure of scale reliability or uni-dimensionality of 
subscales (ƚŚĞ ‘ĞǆƚĞŶƚƚŽ which items in a scale measure the same thing ?).189 This 
controversial evidence against Cronbach´s alpha is relatively surpassed by the 
overwhelming psychological literature reporting it as the sole measure of reliability. 
Moreover, not much is known about alternative, albeit complex, indices of internal 
consistency reliability.190 Therefore, Cronbach ?s alpha is reported in Chapter 6 to 
reflect internal consistency of LMQ-3 subscales.  
 
Test-retest reliability of the LMQ-3 was assessed by multiple methods (^ƉĞĂƌŵĂŶ ?Ɛ
correlations and agreement between scores using intraclass correlation coefficients-
ICCs). Inter-rater reliability (involving multiple raters) was not necessary since the LMQ 
is a self-reported measure designed for use by only one person. 
 
3.3.8.5 Other statistical analyses 
This subsection provides an overview of other statistical analyses used in different 
studies constituting this thesis. Descriptive statistics were reported as frequencies and 
percentages for categorical variables, and means (standard deviation) or medians 
(range) for continuous variables. Chi-square tests were used to compare proportions 
for categorical variables. When comparing normally-distributed mean scores across 2 
ŽƌA? ?ŐƌŽƵƉƐ, independent samples t-tests or one-way ANOVA were used 
respectively.174 The equivalent non-parametric tests, Mann-Whitney test or Kruskal-





To understand predictors of medicine burden in Chapter 9, simple and multiple linear 
regressions ǁĞƌĞƵƐĞĚ ?^ƉĞĂƌŵĂŶ ?Ɛcorrelations were also used in Chapter 7 to 
investigate relationships between LMQ-3 scores and those obtained for measures of 
treatment satisfaction and HRQoL. Throughout this thesis, a probability value (p-value) 
below 0.05 represents statistical significance.  
3.3.9 Sample size across studies 
 There is an absence of clear guidance and lack of consensus regarding a priori sample 
size estimation for studies into questionnaire development, and for newly-developed 
patient reported outcomes measures.191 The common finding is that the sample size 
recommendations vary across different analytical procedures, but should be adequate 
for the intended research objective or data type.191  
 
Across the research programme, the number of participants per study ranged from 11 
cognitive interviewees to over 1000 survey responses. The qualitative interviews, of 
which there are no rules of thumb for sample size determination, depended on 
saturation of questionnaire-related issues under investigation, and provision of enough 
data to address the study objective. Sample sizes for the quantitative studies were 
dependent on the type of analytical procedure. For instance, in exploratory factor 
analysis  ‘ŝƚŝƐŶŽƚƚŚĞŽǀĞƌĂůůƐĂŵƉůĞƐŝǌĞƚŚĂƚŝƐŽĨĐŽŶĐĞƌŶ - rather, the ratio of 
participants to items in the questionnaire, with a 5:1 or 10:1 ratio commonly 
recommended.175,182 This implies that for a 60-item LMQ-1, at least 300 responses 
were adequate for EFA. A sample size of at least 150 participants is sufficient for 
estimating measurement models in confirmatory factor analysis.183,191,192 In terms of 
reliability assessment, a test-retest sample size of at least 50 participants is 
recommended122 but Chapter 2 revealed some stability studies64 involving as few as 
ten participants. Assumptions for sample size adequacy were tested for different 








Chapter 4 Adaptation and 
further development of the 
original LMQ 
Acknowledgements   
This phase of work was accomplished by myself, though four undergraduate students 
helped with data collection and part of the data entry. I managed and double checked 
all data entries, analysed, and interpreted all the findings presented in this chapter. 
The original questionnaire used in this chapter (LMQ-1) was developed by my primary 
supervisor (JK), and I adapted it for further development in this thesis chapter. The 
findings presented in this chapter were published in Patient Preference and 
Adherence193 under the open accĞƐƐŵŽĚĞůƚŚĂƚĂůůŽǁƐ ‘ĨƌĞĞƵƐĞŽĨ original works of all 
types for personal, research and educational use. ? 
4.1 Introduction  
In Chapter two, the systematic literature review identified the original 60-item Living 
with Medicines Questionnaire (labelled as the LMQ-1) as a promising measure 
specifically designed to measure overall medicine burden in the UK population,119 but 
which required further development and psychometric testing, and item reduction 
into a more manageable tool. The present chapter describes a study conducted to 
further assess and shorten the LMQ-1 involving a larger sample of participants using 
long-term prescription medicines in the UK. I describe steps taken to further develop 
and investigate the LMQ-1. 
 
To contextualise this study and its contribution to this thesis, brief background 
information about the history of LMQ-1 development is provided. Originally developed 
by Krska et al (2014),119 the LMQ-1 was founded on qualitative interview data from 21 
adult patients using multiple prescription medicines (A? 4) long-term (for A? 1 year) in 
primary care settings of north-west England.23 The first draft of the LMQ-1 was 
reported to undergo several stages of preliminary testing including item generation, 
deletions, and rewordings that led to the 60-item instrument plus a free-text open 
question.119 Face and content validation of early drafts, to evaluate item meanings and 
relevance and ease of completion, was reported.119 The questionnaire also had a free-
text open question.  
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All items were rated on a 5-point Likert-type scale (as strongly agree, agree, neutral, 
disagree, or strongly disagree), which had also undergone a series of revisions and 
testing. Despite relevant pretesting, the LMQ-1 was tested on small samples of 
patients and further tests (using a larger sample) were necessary to check 
performance at population level and to examine the hypothesised qualitative domains 
and appropriateness of the tool. Moreover, initial factor analyses revealed inconsistent 
results across earlier versions of the LMQ, and constructs reported from the qualitative 
study23 (relationships with health professionals, practicalities, information, efficacy, 
side effects, attitudes, impact and control) required further validation. This chapter 
uses a larger sample population to enable item reduction and further psychometric 
testing, including construct validation, of the LMQ-1.   
 
Aim and objectives 
The aim of the study presented within this chapter was to assess and investigate the 
domains underlying the LMQ-1 using a UK sample population of adults using 
prescription medicine(s). 
 
Specific objectives were: 
x To reduce the number of items in the LMQ-1 into a shorter instrument;  
x To examine the domains underlying the LMQ-1, and identify and explore any 
domains that were not covered to improve the instrument. 
4.2 Methods 
The previous chapter outlined general methodology and methods employed 
throughout this doctoral thesis. This section discusses the methods specific to this 
study, which was conducted over the period June 2014 to December 2014. Ethics 
approval was granted by Medway School of Pharmacy Research Ethics Committee 
(Appendix 3). Consent for this anonymous survey-based study was implied by return or 





4.2.1 Study instrument- The LMQ-1  
Appendix 4 shows the LMQ-1 as the primary instrument used in this study. The LMQ-1 
was a 60-item questionnaire with 34 positively phrased and 26 negatively phrased 
statements (items) scored on a 5-point Likert-type scale. This version of the 
questionnaire was produced in paper and electronic formats.  
 
4.2.2 Study population 
Members of the general public were targeted for this study, as the proportion of 
people using long-term medicines in England is high (over 50%)31 and it enabled access 
to a diverse population. Inclusion criteria were: adults, using long-term prescription 
medicines, and living in the UK. All potential participants were required to answer 
screening questions to ensure they met inclusion criteria before completing the 
instrument.  
 
4.2.3 Questionnaire distribution  
A mixed-methods approach to questionnaire distribution was used to maximise both 
response rates and diversity of demographic characteristics. The two main methods of 
distribution were used: a) Paper questionnaires distributed to both the general public 
using street intercept and to community pharmacy users in south-east England. b) An 
on-line survey available to the UK general public, recruited via social media and health 
websites. All participants were given information about the study purpose prior to 
participation, either as an additional leaflet (paper version) or at the start of the 
questionnaire (on-line version). 
 
4.2.3.1 Distribution of questionnaires through street-intercept methods 
Street-intercept survey methods are reported to facilitate access to people in harder-
to-reach areas of the target population.194 Street surveys yield wider, representative, 
socio-demographic profiles, in terms of age, education or employment194 and are also 
a cost-effective distribution method for paper surveys.162 The street-intercept 
recruitment technique involved personal distribution of questionnaires to people in 
public areas of Medway towns of Rochester, Chatham, Gillingham, and Strood (See 
Figure 3-1). Potential participants were consecutively approached while waiting at bus 
and train stations, leisure centres or exiting major shopping centres, and sitting in 
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outdoor cafes, sitting in town squares, or walking in parks. Most survey distribution 
was conducted on weekdays between 9.00am to 5.00pm. Occasionally, paper surveys 
were distributed on Saturdays and Sundays, between 9.00am to 1.00pm, to target 
people doing weekend activities (e.g. shopping, going to or from congregations), and 
to recruit those who may have been missed during weekday working hours. Brief 
introduction about the study and polite gestures were employed to encourage 
participation in this phase of research. 
 
Although more people could be approached using street-intercept methods, the 
response rates were not promising and more people were likely to reject the survey.  
This was possibly due to lack of time or interest in the research, or even perceived 
sensitivity of the research topic in the public recruitment setting. Some participants 
showed concerns about discussing their medicines (or health condition) on ƚŚĞ ‘ƐƚƌĞĞƚ ?,
while others felt they should be talking to health professionals about their medicines 
instead of researchers. All street survey participants were encouraged to take the 
questionnaire away for completion at their convenience (and in privacy), along with an 
information sheet, and a pre-paid (freepost) envelope for return. Only a few offered to 
complete the survey while waiting in public areas and returned it to the researcher in a 
sealed envelope.  
 
4.2.3.2 Questionnaires and flyers dropped off at public places  
Another method used to recruit the general public in this study involved dropping off 
printed questionnaires (in survey packs) and advertising flyers at designated public 
places in local areas of Medway. Survey packs contained the questionnaire, a 
participant information leaflet, and a pre-paid postage envelope. The study packs were 
prominently placed in selected public locations (such as libraries, community centres, 
or churches) to enhance visibility of the study, and encourage participation.  
Permission to advertise the study in this way was sought from area managers of 
public/private places. Eligible participants would pick up the study pack, complete the 
survey, and post it back at their convenience. In addition to covering inclusion criteria, 
the flyers also provided details of a link to the web-based survey, for those wishing to 




4.2.3.3 Recruitment of community pharmacy users  
Questionnaire distribution to community pharmacy users increased the likelihood of 
reaching people using long-term medicines. The paper survey was distributed to users 
of small-to-medium size community pharmacies (independently owned), located in 
Medway towns of Gillingham, Chatham and Rochester. Pharmacies located close to 
high streets and GP surgeries were selected owing to a higher probability of people 
entering the pharmacy itself. Multiple-chain pharmacies, such as Boots, were not 
involved in this study due to time-constraints associated with seeking additional 
research governance for recruitment. Moreover, it was assumed that there were no 
differences in characteristics of people visiting independent or multiple-chain 
community pharmacies. 
 
An introductory (or invitation) letter (Appendix 5), pharmacist information sheet 
(Appendix 6), and a copy of the questionnaire (Appendix 4), were posted to each 
selected community pharmacy. The invitation letter, which provided a general study 
overview (including aims and rationale), asked permission to visit and distribute study 
packs to clients at pharmacy premises. After a 1-2-week interval, telephone calls were 
made to the pharmacist in charge asking if they had received the invitation study pack 
and to verbally ask permission to use the pharmacy premises. A replacement pack was 
provided, on request, to pharmacies that reported loss or no receipt of the first study 
invitation pack. Only pharmacies that granted permission to distribute surveys in their 
premises were visited, at different times of the day, during agreed operating hours, to 
recruit participants.  
 
Potential participants were approached consecutively after completing their initial 
transaction (e.g. filling a prescription), and offered brief verbal study information, 
screened for eligibility, and asked to consider taking part. If they met all the inclusion 
criteria, potential participants were asked to complete the LMQ-1 questionnaire in the 
community pharmacy (e.g. while waiting for their medicines or products to be 
dispensed) or allowed to take it away to complete it at their convenience. On-site 
ƐƵƌǀĞǇĐŽŵƉůĞƚŝŽŶǁĂƐĚĞƉĞŶĚĞŶƚŽŶƉĂƌƚŝĐŝƉĂŶƚƐ ?ǁĂŝƚŝŶŐƚŝŵĞ ?ĂŶĚlayout and 
waiting space in pharmacy premises. Completed questionnaires were returned directly 
by hand, to the researcher, in sealed envelope or in a pre-paid (freepost) envelope at 
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the Medway School of Pharmacy. Every questionnaire given to potential participants 
was accompanied by a participant invitation letter and patient information leaflet 
(Appendix 7). All information was deemed free of any unsubstantiated claims or 
benefits. 
 
4.2.3.4 On-line survey distribution 
An electronic version of the LMQ-1 was designed and launched using Qualtrics©. The 
on-line survey was open for a relatively longer period (approximately a year). The on-
line survey was open to the UK general public to reach people from a wider 
geographical distribution, including the housebound, but was more likely to reach 
those with higher education and socioeconomic status.118,162 The link to the survey was 
promoted via social media and health websites.  
 
On social media (Facebook and Twitter), links to the on-line survey were posted 
alongside brief information about the study (and inclusion criteria); this was done via 
designated social-media accounts for the LMQ project. Target patient groups/fora 
ǁĞƌĞ ‘ĨŽůůŽǁĞĚ ?ĂŶĚƚŚĞŝƌƉŽƐƚƐ ‘ůŝŬĞĚ ?ĨĂǀŽƌŝƚĞĚ ?, ĂŶĚƌĞĐƌƵŝƚŵĞŶƚƉŽƐƚƐ ‘ŚĂƌƐŚƚĂŐŐĞĚ ? 
as a strategy to increase visibility and response rates to the survey on social media. 
Participants were also encouraged to share the survey link with people they felt would 
be interested to complete it (snowball technique).  
 
Health websites were also used for on-line recruitment in this study phase. Permission 
to distribute a link to the survey on specific websites was granted by administrators. 
These were asked to post an invitation message, recruitment text (and inclusion 
criteria), and a survey link on their websites/fora. A list of websites or fora that took 











Atrial Fibrillation Association 
B & BF- Bladder and Bowel Foundation 
Back Up Trust 
Blood Pressure UK 
Diabetes UK 
Epilepsy Action 
Lupus Patients Understanding & Support 
Lymphoedema Support Network  
Macmillan 
National Eczema Society 
National Osteoporosis Society 
Oesophageal Patients Association 
Pain Concern 
Sarcoidosis Association 
SIA- Spinal Injuries Association 
The HIV Support Centre 
The Hysterectomy Association 
The ITP Support Association 
The ME Association 













4.2.4 Data preparation 
Data were managed and analysed using IBM SPSS (version 22). On-line survey 
responses were downloaded from the provider website (Qualtrics©). Two databases 
were set up to handle paper and on-line surveys separately, then checked for errors 
and merged for analysis. Any significant differences in participant characteristics 
resulting from questionnaire distribution methods were examined using Chi-squared 
tests. Questionnaires with fewer than 50% of item completed were excluded from 
further analysis. As described in section 4.2.1, the 60-item LMQ-1 had a mixture of 
positively phrased and negatively phrased statements. Reverse scoring of negatively 
phrased items enabled uniformity in the direction of responses, such that higher 
scores depicted worse experiences with medicine use (higher burden). 
4.2.5 Principal components analysis 
The correlation matrix was examined for intercorrelations among items, and the 
Kaiser- Meyer-Olkin (KMO) measure of sampling adequacy ĂŶĚĂƌƚůĞƚƚ ?ƐdĞƐƚŽĨ
Sphericity computed to assess factorability of data.175 For item reduction, PCA was 
conducted on the combined dataset using oblique rotation techniques (promax), 
assuming inter-correlations  among underlying components (factors).188 In addition to 
scree plots and KaisĞƌ ?ƐƌƵůĞ ?ĞŝŐĞŶǀĂůƵĞAN 1), parallel analysis (Monte Carlo PCA171) 
was used to confirm the number of appropriate factors. All items were then reviewed 
for potential floor or ceiling effects (i.e. items with more than 50% of answers 
concentrated in the first or last answer category), and item skewness and kurtosis 
explored. This process enabled decisions to be made on item reduction. 
 
4.2.6 Reliability analysis 
Internal consistency for the LMQ-1 was evaluated using ƌŽŶďĂĐŚ ?ƐĂůƉŚĂ ?ɲ ), and 
changes in alpha following deletion of individual items from subscales used to further 







4.2.7 Analysis of responses to the open question 
As previously described in the introductory sections, the LMQ-1 instrument included a 
free-text comments box that allowed respondents to add any other views about how 
medicines affected their day-to-day life. To assess whether there were any outstanding 
issues not covered by the instrument, responses were analysed thematically using the 
eight themes identified in the patient interviews from which the original item pool was 
derived.23 Any other comments not fitting these themes were considered as potential 
gaps in the content of the LMQ-1 and used in the subsequent chapter to improve the 
instrument.  
4.3 Results 
4.3.1 Response rates 
A total of 507 responses were obtained using paper questionnaires (45.6% of all those 
meeting inclusion criteria), with more than half the respondents having been recruited 
from nine purposively selected community pharmacies (60.5%, n=307). A total of 670 
participants completed the on-line survey (68.4% of the 979 participants accessing the 
survey link), via health websites (38.2%, n=374) and social media (30.2%, n= 296). A 
few others accessed the survey via the survey link on flyers (1.1%, n=11) distributed in 
public areas of Medway towns.  
4.3.2 Distribution of responses, assessing missing data, and floor and ceiling effects 
Of the 1177 survey responses in the combined data set (paper and on-line), 544 
(46.2%) questionnaires were fully completed on all items in the original 60-item pool. 
Item-level response rates revealed that most questions were completed by over 90% 
of participants except for five items with the lowest completion rates (49.8% -50.2%) 
(see the 3rd column of Table 4-1). Most items had skewness and kurtosis statistics < 
1.0, suggesting a tendency to univariate normality of the dataset. Raw mean scores, 
before reverse coding, on all items ranged from 2.13 (SD ±0.71) to 4.60 (SD±1.02) 
indicating that average responses were ŶĞŝƚŚĞƌĂƚƚŚĞƐĐĂůĞ ?ƐĨůŽŽƌŶŽƌĂƚĐĞŝůŝŶŐ. Only 5 
of 60 items had both skewness and kurtosis statistics greater than one in absolute 
value, including ĂŶŝƚĞŵǁŝƚŚ ? ? ? ?A?ŽĨƌĞƐƉŽŶƐĞƐĂƚƚŚĞƐĐĂůĞ ?ƐĐĞŝůŝŶŐ ? ‘Q4-My 






























Q1 The instructions on my medicines are easy to follow 1224(99.2) 4.28(0.77) 4.35 (0.699) 4.24 (0.796) 0.015 -1.258 2.350 
Q2 I find getting my prescriptions from the doctor difficult 1220(98.9) 3.72(1.16) 3.79 (1.097) 3.67(1.193) 0.069 -0.756 -0.328 
Q3 I find getting my medicines from the pharmacist 
difficult. 
1219(98.8) 3.93(1.07) 4.15 (0.969) 3.77(1.121) <0.001 -0.995 0.327 
Q4 My medicines are important to me^ 1215(98.5) 4.60(0.71) 4.51 (0.789) 4.69 (0.603) <0.001 -2.182 5.839 
Q5 I find opening the packaging of my medicines difficult 1223(99.1) 3.73(1.16) 3.82 (1.130) 3.65(1.194) 0.018 -0.708 -0.498 
Q6 I am concerned about running out of medicines. 1226(99.4) 2.62(1.24) 2.95(1.243) 2.38(1.172) <0.001 0.407 -0.970 
Q7 It is difficult to identify which medicine is which. 1222(99.0) 3.93(1.06) 4.06(1.018) 3.83(1.089) <0.001 -1.026 0.463 
Q8 It is easy to keep to my medicines routine. 1225(99.3) 3.67(1.12) 3.91(1.030) 3.51(1.142) <0.001 -0.718 -0.328 
Q9 I would be concerned if I forgot to take my medicines # 1223(99.1) 2.13(1.02) 2.32(1.034) 2.00(1.001) <0.001 0.809 -0.019 
Q10 I am concerned that I may forget to take my medicines 1223(99.1) 2.92(1.16) 3.22(1.172) 2.72(1.170) <0.001 0.061 -1.038 
Q11 I am concerned about experiencing side effects 1224(99.2) 2.26(1.10) 2.50(1.126) 2.08(1.033) <0.001 0.646 -0.459 
Q12 I am concerned about possible damaging long-term 
effects of taking medicines. 
1226(99.4) 2.14(1.12) 2.39(1.144) 1.97 (1.079) <0.001 0.821 -0.224 
Q13 Taking medicines is routine for me 1224(99.2) 4.07(0.96) 3.84(1.054) 4.26(0.836) <0.001 -1.264 1.508 
Q14 I am comfortable taking the medicines I have been 
prescribed. 
1227(99.4) 3.79(1.02) 4.05(0.846) 3.61 (1.089) <0.001 -0.848 0.126 
Q15 I am comfortable with the times I should take my 
medicines. 
1227(99.4) 3.94(0.86) 4.05(0.770) 3.87(0.902) <0.001 -0.944 0.964 
Q16 I find the patient leaflet in my medicines containers 
useful. 
1227(99.4) 3.70(1.00) 3.82(0.953) 3.60(1.020) <0.001 -0.677 0.002 
Q17 I find using my medicines difficult. 1223(99.1) 4.00(0.88) 4.09(0.856) 3.92(0.898) 0.001 -0.993 1.198 
Q18 I am satisfied with the effectiveness of my medicines. 1219(98.8) 3.47(1.08) 3.80(0.891) 3.23(1.140) <0.001 -0.573 -0.374 
Q19 I am concerned that I am too dependent on my 
medicines. 
1224(99.2) 3.09(1.19) 3.28(1.119) 2.98 (1.219) <0.001 -0.100 -0.929 
Q20 I am confident speaking to my doctor(s) about my 
medicines. 
1223(99.1) 3.89(1.13) 4.00(0.953) 3.80(1.245) 0.003 -0.959 0.088 
Q21 I understand what my doctor(s) tell me about my 
medicines. 
1223(99.1) 4.02(0.92) 4.06(0.848) 3.99(0.977) 0.214 -1.076 1.254 
Q22 The information my doctor(s) gives me about my 
medicines is useful. 
1223(99.1) 3.61(1.09) 3.90(0.936) 3.41(1.154) <0.001 -0.604 -0.248 






























Q23 I am confident speaking to my pharmacist about my 
medicines. 
1226(99.4) 3.82(1.08) 4.21(0.815) 3.53(1.159) <0.001 -0.684 -0.341 
Q24 I understand what my pharmacist tells me about my 
medicines. 
1225(99.3) 4.03(0.86) 4.27(0.710) 3.87(0.903) <0.001 -0.788 0.603 
Q25 The information my pharmacist gives me about my 
medicines is useful. 
1225(99.3) 3.88(0.93) 4.20(0.764) 3.66(0.972) <0.001 -0.658 0.225 
Q26 I sometimes run out of medicines 1215(98.5) 3.05(1.23) 3.22(1.221) 2.96(1.235) <0.001 0.015 -1.311 
Q27 I accept that I have to take medicines long term 1217(98.6) 4.17(0.88) 3.98(0.973) 4.32(0.786) <0.001 -1.468 2.647 
Q28 My medicines allow me to live my life as I want to 1217(98.6) 3.45(1.15) 3.71(0.943) 3.26(1.239) <0.001 -0.456 -0.686 
Q29 My life revolves around using my medicines. 1219(98.8) 3.11(1.23) 3.35(1.157) 2.93(1.245) <0.001 -0.186 -1.046 
Q30 My medicines live up to my expectations. 1213(98.3) 3.25(1.04) 3.58(0.840) 3.00(1.090) <0.001 -0.368 -0.438 
Q31 My medicines prevent my condition getting worse 620(50.2)* 3.89(0.95) 3.92(0.904) 3.73(1.134) 0.117 -0.898 0.690 
Q32 Taking medicines interferes with my social life 619(50.2)* 3.77(1.05) 3.82(1.011) 3.47(1.206) 0.006 -0.904 0.250 
Q33 I trust the judgement of my doctor(s) in choosing 
medicines for me. 
615(49.8)* 3.70(0.99) 3.79(0.952) 3.24(1.110) <0.001 -0.807 0.330 
Q34 I have to put a lot of planning and thought into taking 
my medicines. 
617(50.0)* 3.35(1.17) 3.47(1.131) 2.79(1.112) <0.001 -0.359 -0.798 
Q35 Taking medicines causes me problems with daily tasks 
(such as work, housework, hobbies). 
616(49.9)* 3.84(1.09) 3.91(1.052) 3.46(1.211) <0.001 -0.931 0.215 
Q36 I am unhappy with the extent to which my medicines 
interact with alcohol. 
1218(98.7) 3.56(1.60) 3.65(1.094) 3.49(1.029) 0.011 -0.334 -0.435 
Q37 Taking medicines affects my driving ability. 1212(98.2) 3.82(1.04) 3.89(0.989) 3.77(1.064) 0.050 -0.659 -0.131 
Q38 I worry that I have to take several medicines at the 
same time. 
1220(98.9) 3.46(1.17) 3.62(1.131) 3.35(1.179) <0.001 -0.312 -0.926 
Q39 The side effects I get are worse than the problem for 
which I take medicines. 
1220(98.9) 3.76(1.09) 3.98(0.958) 3.61(1.156) <0.001 -0.722 -0.141 
Q40 I worry that my medicines may interact with each 
other. 
1218(98.7) 3.23(1.22) 3.47(1.164) 3.07(1.220) <0.001 -0.105 -1.044 
Q41 I can choose whether or not to take my medicines. 1195(96.8) 2.42(1.30) 2.56(1.275) 2.31(1.312) 0.001 0.518 -1.021 
Q42 My doctor(s) spend enough time discussing my 
medicines with me. 
1198(97.1) 3.12(1.20) 3.33(1.132) 2.96(1.229) <0.001 -0.239 -1.010 
Q43 I know enough about my medicines 
 
1198(97.1) 3.75(0.99) 3.75(0.917) 3.76(1.044) 0.949 -0.775 0.115 































Q44 I am able to balance my day-to-day life with taking 
medicines. 
1196(96.9) 3.87(0.93) 3.96(0.856) 3.80(0.989) 0.004 -0.993 0.914 
Q45 There is enough sharing of information about my 
medicines between the different health professionals 
providing my care. 
1194(96.8) 3.03(1.17) 3.41(1.044) 2.74(1.187) <0.001 -0.168 -0.827 
Q46 I have a say in the brands of medicines I use. 1196(96.9) 2.17(1.11) 2.36(1.061) 2.03(1.120) <0.001 0.835 -0.100 
Q47 I always follow my doctor(s) advice about my  
medicines. 
1201(97.3) 3.78(0.97) 3.98(0.784) 3.63(1.065) <0.001 -0.876 0.395 
Q48 I sometime feel I need to get information from other 
sources (such as books, friends, internet). 
1198(97.1) 2.28(1.19) 2.80(1.235) 1.89(1.008) <0.001 0.794 -0.402 
Q49 I can change times I take my medicines if I want to 1199(97.2) 3.06(1.19) 2.93(1.160) 3.16(1.214) 0.001 -0.204 -1.105 
Q50 The health professionals providing my care know 
enough about me and my medicines. 
1196(96.9) 3.18(1.21) 3.56(1.079) 2.90(1.224) <0.001 -0.306 -0.911 
Q51 My medicines are working 1198(97.1) 3.75(0.96) 4.01(0.750) 3.55(1.053) <0.001 -0.834 0.482 
Q52 I can adapt my medicine-taking to my lifestyle 1192(96.6) 3.46(1.05) 3.60(0.973) 3.34(1.097) <0.001 -0.565 -0.362 
Q53 My doctor(s) listen to my opinions and concerns about 
my medicines. 
1197(97.0) 3.42(1.09) 3.68(0.954) 3.22(1.152) <0.001 -0.603 -0.329 
Q54 I can vary the dose of the medicines I take. 1195(96.8) 2.44(1.21) 2.39(1.148) 2.48(1.247) 0.178 0.551 -0.813 
Q55 I get too much information about my medicines 1192(96.6) 3.97(0.89) 3.79(0.931) 4.12(0.820) <0.001 -0.939 1.174 
Q56 Changes in daily routine cause problems with my 
medicines. 
1189(96.4) 3.10(1.18) 3.43(1.131) 2.85(1.167) <0.001 -0.135 -1.113 
Q57 My doctor(s) takes my concerns about side effects 
seriously. 
1187(96.2) 3.19(1.04) 3.42(0.959) 3.02(1.080) <0.001 -0.281 -0.459 
Q58 My medicines have an adverse effect on my sexual life. 1184(95.9) 3.30(1.11) 3.50(1.037) 3.15(1.149) <0.001 -0.260 -0.514 
Q59 The side effects are worth it for the benefits I get from 
my medicines. 
1191(96.5) 3.27(0.97) 3.27(0.951) 3.25(0.976) 0.790 -0.286 -0.021 
Q60 The medicines I use have an adverse effect 
on the holidays I can take. 
1188(96.3) 3.59(1.124) 3.77(1.047) 3.45(1.163) <0.001 -0.574 -0.382 
Table 4-1 Distribution of responses to the 60-item LMQ-1 obtained using paper-based and on-line survey datasets 
 
*Items with the lowest response rates due to an error of omission in the first available on-line survey, which was later realised and corrected.  ^ item with highest 
overall mean score; # item  with lowest mean score
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4.3.3 Participant characteristics 
More females completed both paper (62.1%, n=306) and on-line (81.6%, n=542) 
surveys than males (p<0.001), with overall age of participants ranging from 18 to 90 
years. Younger respondents (< 65 years), and those with college/further education 
mostly completed the on-line survey, whereas more people aged 65 or over returned a 
paper survey (p<0.001). Overall, most participants (85.6%, n=992) used up to and 
including eight prescription medicines, 9.7% (n=113) needed assistance with using 
their medicines, and 27.9% (n=326) paid for their NHS prescription medicines. Table 4-




Characteristic  Paper survey  
 n (%) 
On-line survey  
 n (%) 
Total sample  
 n (%) 
Gender  Female 306(62.1) 542(81.6) 848 (73.3) 
 Male 187(37.9)(n=493) 122(18.4) (n=664) 309 (26.7) (n=1157) 
Age (years) 18-29 48(9.7) 93(13.9) 141(12.1) 
 30-49 98(19.7) 258(38.7) 356(30.6) 
 50-64 143(28.8) 254(38.1) 397(34.1) 
 65 or over 208(41.8)(n=497) 62(9.3) (n=667) 270(23.2)(n=1164) 
Education level Bachelor degree 
or higher  
148 (30.5) 301(45.2) 449(39.0) 
 College level 140(28.8) 258(38.7) 398(34.5) 
 Secondary level 145(29.8) 93(14.0) 238(20.6) 
 Up to primary 53 (10.9) (n=486) 14 (2.1)(n=666) 67(5.8) (n=1152) 
Employment  Employed 176(35.8) 324(49.0) 500(43.4) 
 Unemployed 74(15.1) 182(27.5) 256(22.2) 
 Retired 241(49.1)(n=491) 155(23.4)(n=661) 396(34.4)(n=1152) 
Ethnicity White 408(83.8) 613(93.4) 1021(89.3) 
 Asian/Chinese 27(5.5) 28(4.3) 55(4.8)  
 African/Caribbean 44(9.0) 6(0.9) 50(4.4) 
 Mixed   8(1.6)(n= 487) 9(1.4) (n=656) 17(1.5)  (n=1143) 
Number of  medicines  
 1-4 261(53.2) 302(45.2) 563(48.6)  
 5- 8 176(35.8) 253(37.9) 429(37.0) 
 A? ? 54(11.0) (n= 491) 113(16.9)(n= 668) 167(14.4)(n= 1159) 
Requires assistance with using medicines 
 No 453(91.5) 596 (89.4) 1049 (90.3) 
 Yes* 42(8.5) (n= 495)   71(10.6)   (n= 667) 113 (9.7) (n=1162) 
Pay for prescriptions 
 No 349(71.7) 494(72.0) 843(72.1) 
 Yes 138(28.3)(n=487) 188(27.4)(n=682) 326(27.9)(n=1169) 
Table 4-2 Characteristics of participants completing theLMQ-1 survey 
 
Notes; *Carers included spouse/partner, relative, friends, nurse, support workers, and support group   
Due to variations in the completion of questions for participant characteristics, and resulting missing 
data, percentages are calculated separately for those answering each question; this explains the 


























4.3.4 Results of the principal components analysis 
A total of 544 fully completed responses (listwise deletion of missing data) were 
subjected to PCA. The KMO statistic (0.888) was greater than the recommended value 
ŽĨA? ? ? ?and Bartlett's Test of Sphericity was significant (approx. chi-square =9788.903, 
df= 861, p<0.001), implying data were factorable.187,188 Moreover, inter-item 
correlation coefficients were adequate and did not reveal multi-collinearity (r < 0.8),174 
which also encouraged PCA. 
DƵůƚŝƉůĞĐƌŝƚĞƌŝĂǁĞƌĞƵƐĞĚƚŽĂŝĚĚĞĐŝƐŝŽŶƐŽŶƚŚĞŶƵŵďĞƌŽĨĨĂĐƚŽƌƐƚŽƌĞƚĂŝŶ P<ĂŝƐĞƌ ?Ɛ
criterion (eigenvalue > 1), scree plots, and parallel analysis.187 The initial solution 
resolved into 14 components with eigenvalues > 1, and explained 61.1% of the total 
variation. Inspection of the scree plot revealed two sudden breaks at the 5th and 9th 
component (See Figure 4-2), suggesting between five and nine underlying domains.  
 
Figure 4-2 Scree plot illustrating the number of components (domains) in the LMQ-1  
 
Note; The plot shows two possible points of inflexion (breaks in the curve) at components 5 and 9, 







Points of inflexion  
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To verify the findings from the scree plot, parallel analysis ( by Monte Carlo PCA171) 
was used and it confirmed eight components with observed eigenvalues exceeding 
criterion values (See Table 4-3). PCA was re-run and the number of components fixed 
to eight. The resulting 8-factor solution (Table 4-5) explained 57.4% of the total 
variation, and was conceptually interpretable. 
 





1 9.962 1.4519 Accept 
2 4.036 1.4163                Accept 
3 2.367 1.3878                Accept 
4 2.076 1.3637   Accept 
5 1.976 1.3412                Accept 
6 1.724 1.3242                Accept 
7 1.515 1.3055                Accept 
8 1.389 1.2868                Accept 
9 1.152 1.2686                Reject 
10a 1.110 1.2526                Reject 
Table 4-3 Comparing eigenvalues using parallel analysis (LMQ-1) 
 
Notes; * Generated randomly for 60 variables, in 100 replications using Monte Carlo PCA.171  
 aOnly 10 of 60 components are shown in the table; the remaining components also had observed 
























4.3.5 Item reduction  
Items with poor factor loadings < 0.3 and/ŽƌĐƌŽƐƐůŽĂĚŝŶŐƐŽĨA? ? ? ?on two or more 
factors were deleted upon judgement that they did not fit well in underlying 
domains.174,182,187 Five items with ceiling effects (showed in Table 4-1) were retained as 
their factor loadings exceeded the minimum threshold for item retentŝŽŶ ?A? ? ? ?), and 
were also judged as conceptually relevant.  
This resulted in removal of eighteen items (n=18) from the original item pool (See 
Table 4-4), leaving 42 items. 
 
 
  Item/Statement 
Q6- I am concerned about running out of medicines 
Q9-I would be concerned if I forgot to take my medicines 
Q10-I am concerned that I may forget to take my medicines 
Q14-I am comfortable taking the medicines I have been prescribed 
Q15 -I am comfortable with the times I should take my  medicines 
Q16 -I find the patient leaflet in my medicines containers useful 
Q19-I am concerned that I am too dependent on my medicines 
Q26-I sometimes run out of medicines 
Q36-I am unhappy with the extent to which my medicines interact with alcohol 
Q39-The side effects I get are worse than the problem for which I take the medicines 
Q43-I know enough about my medicines 
Q44-I am able to balance my day to day life with taking medicines 
Q46-I have a say in the brands of medicines I use) 
Q47-/ĂůǁĂǇƐĨŽůůŽǁŵǇĚŽĐƚŽƌ ?ƐĂĚǀŝĐĞĂďŽƵƚmedicines 
Q48-I sometime feel I need to get information from other sources (such as books, friends, internet) 
Q55-I get too much information about my medicines 
Q58-My medicines have an adverse effect on my sexual life 
Q59-The side effects are worth it for the benefits I get from my medicines 
Table 4-4 Items deleted from the LMQ-1 
 







4.3.6 The resultant LMQ-2 factor solution 
The 42-item factor solution, which was labelled as the LMQ-2, is shown in Table 4-5. 
Emerging factors were interpreted as: patient-doctor relationships and communication 
about medicines (9 items); interferences to daily life (8 items); practicalities (7 items); 
effectiveness (4 items); patient-pharmacist communication about medicines (3 items); 
acceptance of medicine use (4 items); autonomy/control over medicine use (4 items) 
and concerns about potential harm (3 items). Subscales have internal consistency 







LMQ-2 subscale/Items Components 
1 2 3 4 5 6 7 8 
1.Patient-doctor relationships and communication about medicines  (9 items, ɲA䄃? ? ? ? ? ? 
Q53. My doctor(s) listen to my opinions and concerns about my medicines. .887 .012 -.123 .062 -.080 -.030 .094 -.044 
Q22.The information my doctor(s) gives me about my medicines is useful. .846 -.099 .029 -.043 .116 -.074 .017 -.003 
Q42. My doctor(s) spend enough time discussing my medicines with me. .805 .057 .034 -.159 -.075 .087 -.010 .030 
Q20. I am confident speaking to my doctor(s) about my medicines. .791 .012 .062 -.049 .022 .015 .020 -.176 
Q57. My doctor(s) takes my concerns about side effects seriously .728 .054 -.155 .183 -.142 -.037 -.053 -.091 
Q21. I understand what my doctor(s) tell me about my medicines. .658 .037 .044 -.171 .197 .119 .087 -.082 
Q50. The health professionals providing my care know enough about me and my medicines. .592 -.100 .025 .180 .062 -.059 -.028 .137 
Q33. I trust the judgement of my doctor(s) in choosing medicines for me. .542 -.001 .031 .314 .015 -.159 -.129 .001 
Q45. There is enough sharing of information about my medicines between the different health 
professionals providing my care. 
.542 -.028 .004 .058 .062 -.003 .004 .209 
2.Interferences  to daily life (8 itĞŵƐ ?ɲA? ? ? ? ? ? ? 
Q32. Taking medicines interferes with my social life. -.009 .849 -.039 .064 .015 .067 .008 -.092 
Q35. Taking medicines causes me problems with daily tasks (such as work, housework) -.048 .820 -.089 .091 .046 -.037 .035 -.047 
Q60. The medicines I use have an adverse effect on the holidays I can take. -.052 .730 -.012 .177 -.005 .006 -.019 -.150 
Q29. My life revolves around using my medicines. -.120 .698 -.052 .181 -.022 -.317 .100 -.143 
Q37. Taking medicines affects my driving ability .002 .686 -.110 .029 .040 .026 -.122 -.077 
Q34. I have to put a lot of planning and thought into  taking my medicines .068 .618 .041 -.192 -.044 -.180 -.171 .121 
Q38. I worry that I have to take several medicines at the same time .140 .592 .087 -.059 -.073 .046 .047 .135 
Q56. Changes in daily routine cause problems with my medicines. .024 .558 .105 -.214 .070 -.009 -.136 .188 
 ? ?WƌĂĐƚŝĐĂůŝƚŝĞƐ ? ?ŝƚĞŵƐ ?ɲA? ? ? ? ? ? ? 
Q7. It is difficult to identify which medicine is which. -.133 -.037 .773 -.034 .046 .030 .073 .019 
Q1. The instructions on my medicines are easy to follow. .059 -.163 .683 .139 -.045 .051 .006 -.066 
Q5. I find opening the packaging of my medicines difficult -.048 .002 .640 .017 -.062 -.052 .109 -.002 
Q2. I find getting my prescriptions from the doctor difficult. .244 -.064 .635 .087 -.163 -.043 -.192 -.121 
Q3. I find getting my medicines from the pharmacist difficult -.099 .041 .628 .259 .089 -.165 -.175 -.146 
Q17 I find using my medicines difficult. -.027 .295 .465 -.087 .040 .208 .134 -.019 
Q8.  It is easy to keep to my medicines routine. .027 .083 .400 -.049 .009 .221 .011 .116 
Table 4-5 The 42-item 8-factor solution of the Living with Medicines Questionnaire version 2 (LMQ-2) 
 
Notes; Extraction method - Principal Component Analysis; Rotation MeƚŚŽĚ PWƌŽŵĂǆǁŝƚŚ<ĂŝƐĞƌEŽƌŵĂůŝǌĂƚŝŽŶ ?ɲA?ƌŽŶďĂĐŚ ?ƐĂůƉŚĂ 
N= 544 fully completed responses were used. The numbers in bold represent substantive factor loadings ( A? 0.4) showing items that are adequately associated with a specific 





LMQ-2 subscale/Items Components 
1 2 3 4 5 6 7 8 
 ? ?ĨĨĞĐƚŝǀĞŶĞƐƐ ? ?ŝƚĞŵƐ ?ɲA? ? ? ? ? ? ?         
Q18. I am satisfied with the effectiveness of my medicines -.066 037   .161 .698 .102 -.051 .041 .129 
Q30. My medicines live up to my expectations  .073 .088 -.014 .694 -.008 .084 .054 .092 
Q51. My medicines are working. .090 -.007 .060 .685 .019 .008 .181 .137 
Q31. My medicines prevent my condition getting worse. .040 .033 .041 .650 -.070 .168 -.137 -.049 
5.Patient-pharmacist communication about ŵĞĚŝĐŝŶĞƐ ? ?ŝƚĞŵƐ ?ɲA䄀  ? ? ? ? ? ?        
Q25. The information my pharmacist gives me about my medicines is useful. .030 .000 -.039 .049 .911 -.026 -.045 -.036 
Q23. I am confident speaking to my pharmacist about my medicines .034 .030 -.055 .037 .879 .002 -.041 .027 
Q24. I understand what my pharmacist tells me about my medicines. -.012 .014 .008 -.042 .936 .013 .006 -.035 
 ? ?ĐĐĞƉƚĂŶĐĞŽĨŵĞĚŝĐŝŶĞƵƐĞ ? ?ŝƚĞŵƐ ?ɲA? ? ? ? ? ? ? 
Q13.Taking medicines is routine for me -.019 .010 .060 -.114 -.030  .824 .001 .008 
Q27. I accept that I have to take medicines long term -.011 -.088 -.107 .254 -.049 .739 -.130 -.006 
Q4.   My medicines are important to me. -.084 -.232 .097 .083 .053 .494 -.068 -.093 
Q28. My medicines allow me to live my life as I want to. .050 .185 -.045 .278 .098 .483 .102 .037 
 ? ?ƵƚŽŶŽŵǇ ?ĐŽŶƚƌŽůŽǀĞƌŵĞĚŝĐŝŶĞƵƐĞ ? ?ŝƚĞŵƐ ?ɲA? ? ? ? ? ? ?
Q54. I can vary the dose of the medicines I take -.002   -.245 -.010 .064 .028 -.092 .763 -.049 
Q49. I can change the times I take my medicines if I want to. .002 .077 -.061 -.021 -.128 .086 .752 -.111 
Q41. I can choose whether or not to take my medicines. .034 -.103 .115 -.106 .035 -.301 .592 .043 
Q52. I can adapt my medicine-taking to my lifestyle. .038 .106 .037 .194 -.004 .050 .592 .029 
 ? ?ŽŶĐĞƌŶƐĂďŽƵƚƉŽƚĞŶƚŝĂůŚĂƌŵ ? ?ŝƚĞŵƐ ?ɲA? ? ? ? ? ?  
Q11. I am concerned about experiencing side effects. -.053 -.041 -.051 .040 -.003 -.013      -.021 .925 
Q12. I am concerned about possible damaging long term effects of taking medicines -.055 -.120 -.099 .205 -.029 -.019 -.080 .902 
Q40. I worry that my medicines may interact with each other .053 .329 .163 .011 -.068 -.061 .048 .421 
Table 4-5 The 42-item 8-factor solution of the Living with Medicines Questionnaire version 2 (LMQ-2) 
 
Notes; Extraction method - WƌŝŶĐŝƉĂůŽŵƉŽŶĞŶƚŶĂůǇƐŝƐ ?ZŽƚĂƚŝŽŶDĞƚŚŽĚ PWƌŽŵĂǆǁŝƚŚ<ĂŝƐĞƌEŽƌŵĂůŝǌĂƚŝŽŶ ?ɲA?ƌŽŶďĂĐŚ ?ƐĂůƉŚĂ 
EA? ? ? ?ĨƵůůǇĐŽŵƉůĞƚĞĚƌĞƐƉŽŶƐĞƐǁĞƌĞƵƐĞĚ ?dŚĞŶƵŵďĞƌƐŝŶďŽůĚƌĞƉƌĞƐĞŶƚƐƵďƐƚĂŶƚŝǀĞĨĂĐƚŽƌůŽĂĚŝŶŐƐ ?A? ? ? ? )ƐŚŽǁŝŶŐŝƚĞŵƐthat are adequately associated with a 
specific domain/subscale of the LMQ-2.
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4.3.7 Free-text comments ʹ content coverage 
Nearly a third of respondents (30.6%, n=360) provided free-text comments in the 
paper and on-line questionnaires, a total of 421 different comments, most of which 
supported the original content domains (97.2%).  
 
In particular, there were 76 comments describing the impact of using medicines, many 
(n=71) of which were negative, revealing medicine-related disruption to daily activities, 
such as work. The need to plan/adjust personal schedules to cope with medicine-
related demands, such as dose timing, food-requirements, storage-requirements, and 
need for blood tests, was perceived to be time- and energy-consuming. For instance, a 
ƉĂƌƚŝĐŝƉĂŶƚĐŽŵŵĞŶƚĞĚƚŚĂƚ ‘My worries are primarily around making sure I have my 
insulin with me, that I don't leave it at home/work, that I have spare pens & testing 
equipment available and that when going [somewhere] there's the facility to store 
insulin (i.e. fridge) ? ? 
 
 Sixty five comments described the impact of side effects on daily activities (such as 
work, driving), personal life (including personal-identity, self-image, sexuality) and 
socialisation, with some side effects described as disabling and reducing quality of life.  
As an example, one participant commented  that  ‘ Qthe side effects of my SSRI 
 ?ĂŶƚŝĚĞƉƌĞƐƐĂŶƚƐ ? ?ĐŽŵƉůĞƚĞĂƐĞǆƵĂůŝƚǇ ? ?are still life altering in a very negative and 
ƉĞƌŵĂŶĞŶƚǁĂǇ ? ? 
 
In relation to efficacy (or perceived lack of efficacy), 61 comments described 
dependence on medicines for symptom relief, performance of daily activities, and 
prolonging life, while others desired alternative treatment options. For instance, one 
participant indicated that  ‘ǁŝƚŚŽƵƚĂůůŵǇƉĂŝŶĂŶĚŶĞƌǀĞŵĞĚŝĐĂƚŝŽŶ/ǁŽƵůĚďĞƵŶĂďůĞ
to get out of bed, move around and live and sleep so they are integral to keeping me 
mobile as the pain is overpowering ..so I have no choice if I want to live my life at all 
but to take high doses of pain meds to get through each day ? and yet another 
participant acknowledged  that  ‘/need more pain relief but unable to find anything that 




Comments about practicalities (n=60) included concerns about running out of 
medicines, the need for more suitable packaging and labelling of medicines, as well as 
tools to support medicines use, such as compliance aids. Example comments were:  ‘life 
would be so much easier if I could write on the packet e.g. M T W T F S S  etc. but they 
seem to delight in packaging them in stuff you can ?ƚǁƌŝƚĞŽŶ ? ĂŶĚ ‘the constantly 
changing shape, colour and packaging of tablets with each re-issue is confusing - I 
understand the NHS has to get best value for medicines and this means changes to 
supply but it is very confusing for patients ? ? 
 
Relationships with healthcare providers were mentioned in 58 comments, many 
suggesting that discussions of medicines were inadequate, and failed to consider 
ƉĂƌƚŝĐŝƉĂŶƚƐ ?ĐŽŶĐĞƌŶƐ ?&ŽƌŝŶƐƚĂŶĐĞ ?ŽŶĞƉĂƌƚŝĐŝƉĂŶƚŝŶĚŝĐĂƚĞĚƚŚĂƚ ‘ƚŶŽƚŝŵĞĞǀĞƌŚĂƐ
a doctor discussed side effects or interactions between my  medicines. I cannot imagine 
ever meeting a doctor who cares enough about to be remotely interested. Do they 
exist? ? Some participants lacked trust and confidence in providers, and desired 
comprehensive, updated and meaningful information about the risks and/or benefits 
of their medicines; however, only 19 comments described searching for additional 
information mostly on-line. An example comment regarding patient-doctor 
communication was  ‘/ǁŽƵůĚůŝŬĞĚŽĐƚŽƌƐƚŽŐŝǀĞŵŽƌĞŝŶĨŽƌŵĂƚŝŽŶŽŶƚŚĞĞĨĨĞĐƚƐŽĨ
taking medicine for life and risks of higher doses-they only ever give one type [of 
ŝŶĨŽƌŵĂƚŝŽŶ ? ? ? ? ? ? 
 
Fifty-nine ĐŽŵŵĞŶƚƐĂƌƚŝĐƵůĂƚĞĚƉĂƌƚŝĐŝƉĂŶƚƐ ?general attitudes towards medicines use, 
including worries about adherence, dependence, interactions, and concerns about 
branded/generic medicines. Example comments were:  
  ‘Sometimes foƌŐĞƚƚŽƚĂŬĞŵǇƚĞĂƚŝŵĞƚĂďůĞƚƐ ?can be a worry ?;  
 µI take more than one medicine, some I am addicted to so cannot stop even if I 
 wanted to ?;  
  ‘/ now take up to 27 tablets and 7 injections a day. I am very concerned about 
 ƚŚĞŝŶƚĞƌĂĐƚŝŽŶŽĨƐŽŵĞŽĨƚŚĞƐĞŵĞĚŝĐŝŶĞƐ ?; and 
  ‘I find different brands of medication and their efficacy can vary a lot-I take 




 Of the comments falling outside the eight themes initially defined by Krska et al,119 a 
few comments (n=8) described concerns about the costs associated with using long-
term prescription medicines, an issue not included in the LMQ-1, illustrated by one 
participant:  ‘the cost of my medicines is my biggest concern. I have a prepayment card 
ƚŚĂƚŚĞůƉƐ ?ǁŝƚŚŽƵƚďĞŝŶŐĂďůĞƚŽĂĨĨŽƌĚƚŚĂƚ/ǁŽƵůĚĨŝŶĚƚŚĞĐŽƐƚǀĞƌǇĚŝĨĨŝĐƵůƚ ?/ĚŽŶ ?ƚ
ƚŚŝŶŬƐŽŵĞƉĞŽƉůĞĐŽƵůĚŵĂŶĂŐĞ ? ? dŚĞƌĞƐƚŽĨƚŚĞĐŽŵŵĞŶƚƐĚĞƐĐƌŝďĞĚƉĂƌƚŝĐŝƉĂŶƚƐ ?
health-related problems and other non-medicine-related issues. 
4.4 Discussion  
This chapter reported a study designed to investigate the domains underlying the 60-
item LMQ-1, which was shortened to a 42- item version (the LMQ-2) using a combined 
dataset obtained from the UK general public and users of community pharmacies in 
south-east England. The findings revealed eight domains within the LMQ-2: patient-
doctor relationships and communication about medicines; patient-pharmacist 
communication about medicines; interferences to daily life; practicalities; 
effectiveness; autonomy/control over medicine use; concerns about potential harm; 
and acceptance of medicine use. These domains closely match those identified from 
qualitative research (in-depth interviews with 21 patients) on which the original 
instrument was based. Additional comments added by questionnaire respondents 
within this study also supported these domains, which are thought to relate to an 
over-arching construct of medicines burden for which no measure currently exists. 
 
Qualitative findings also identified themes relating to relationships and communication 
with health professionals, except that statistical analyses in this chapter identified 
domains specific to doctor- and pharmacist-related relationships or communication in 
the LMQ-2. Unlike the qualitative themes in the originator study,23 the present study 
ĚŝĚŶŽƚƌĞǀĞĂů ‘information about medicines ?as a separate domain in the LMQ-2. 
Issues around medicine-related information merged in the respective domains 
covering doctor or pharmacist communication. Patient-provider communication about 
ŵĞĚŝĐŝŶĞƐŚĂƐďĞĞŶĚŽĐƵŵĞŶƚĞĚĂƐĂĨĂĐƚŽƌĂĨĨĞĐƚŝŶŐƉĂƚŝĞŶƚ ?ƐĞǆƉeriences of 
medicine use in other qualitative and quantitative studies.23,87,136,137 Relationships with 
health professionals supplying prescriptions/medicines and information sharing may 
influence both commitment to taking medicines and perceptions of effectiveness,195 
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with poor relationships and communication becoming burdensome to some 
individuals due to consultation styles, the amount of information provided, conflicting 
information and lack of continuity of care.196,197 Observational research shows that 
overall treatment burden may ďĞĐŽŵƉŽƵŶĚĞĚďǇƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨŵĞĚŝĐŝŶĞ
use being neglected during consultations.101 
 
In terms of medicine effectiveness, the LMQ-2 was found to have a domain 
corresponding with  ‘ĞĨĨŝĐĂĐǇ ? in the original qualitative themes from which the 
questionnaire was derived. Perceptions of efficacy and concerns about negative effects 
of medicines are widely reported in the literature.  ‘Concerns about potentiĂůŚĂƌŵ ? and 
medicine-related risks emerged as a unique domain in the LMQ-2, covering issues 
around long-term effects, and drug-drug interactions. However, the  ‘ƐŝĚĞĞĨĨĞĐƚƐ ? 
theme revealed in the qualitative interviews did not emerge as a separate domain in 
the LMQ-2, but generated a significant number of free-text comments. In fact, three 
side-effect-related items ( ‘The side effects I get are worse than the problem for which I 
take the medicines ?;  ‘My medicines have an adverse effect on my sexual life ?;  ‘The side 
effects are worth it for the benefits I get from my medicines ?), and two items relating to 
other concerns about medicines ( ‘I am concerned that I am too dependent on my 
medicines ?;  ‘I am unhappy with the extent to which my medicines interact with 
alcohol ?), though conceptually relevant and described in medicine-related narratives of 
the lay public,21,81 did not meet the statistical/psychometric criteria to be included in 
the LMQ-2. Perceptions of efficacy and concerns about negative effects of medicines 
are widely reported in the literature, with most patients weighing benefits from 
medicines against any associated harms or burden.108,109   
 
Practicalities involved in using medicines (e.g. accessing prescriptions, identifying and 
ŽƉĞŶŝŶŐƉĂĐŬĂŐŝŶŐ )ǁĞƌĞƌĞǀĞĂůĞĚŝŶďŽƚŚƚŚĞƉƌĞƐĞŶƚƐƚƵĚǇĂŶĚƚŚĞŽƌŝŐŝŶĂƚŽƌƐ ?
qualitative study.23 dŚĞ ‘ŝŵƉĂĐƚŽĨŵĞĚŝĐŝŶĞƐŽŶĚĂŝůǇůŝĨĞ ? theme, from the originator 
in-depth interviews, was also identified in the present study but relabelled to reflect 
medicine-related  ‘ŝŶƚĞƌĨĞƌĞŶĐĞƐ ? in the LMQ-2. For instance, two marker items, as 
items loading most strongly on the  ‘ŝŶƚĞƌĨĞƌĞŶĐĞ ? factor, related to medicine-related 
disruptions to social life and to daily tasks (including work), and the change in domain 
nomenclature was thought to specify the negative impact of medicines.  
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Many people on long-term medicines endure inconveniences associated with their use 
while reluctantly accepting the need for treatment.88,195,198 dŚĞ ‘attitudes towards 
medicines ? theme, identified in the originator interviews, seemed to relate to 
 ‘ĂĐĐĞƉƚĂŶĐĞŽĨŵĞĚŝĐŝŶĞƵƐĞ ? in the LMQ-2 domains covering items (e.g.  ‘I accept that I 
have to take medicines long term ?).  
 
The domain  ‘ĂƵƚŽŶŽŵǇ ?control ŽǀĞƌŵĞĚŝĐŝŶĞƵƐĞ ? in the LMQ-2 was as hypothesised 
in the originator qualitative interviews, and covered items around autonomy to varying 
regimen dosing or timing. Regimens that are inconvenient (or inflexible) may lead to 
perceived lack of control or autonomy.95 Perceived inability to modify regimens as well 
as experiences of adverse effects may add to the overall burden through interfering 
with daily activities.88 
 
In addition, free-text comments indicated that further development work might need 
to incorporate cost-related items in a revised LMQ instrument. Chapter 1 revealed that 
prescription medicine costs may impose financial burden, and the literature indicates 
consequences that negatively impacts on individual wellbeing, family and social life 
and exacerbate treatment burden.44,46,48,88 Further studies may generate and test cost-
related items to fill the gap in the LMQ-2. 
 
Despite missing dimensions, the LMQ-2 appears to be more comprehensive than 
existing instruments (reported in Chapter 2) purporting to evaluate patient 
experiences of medicines use. The generic nature of this questionnaire contributes to 
its potential usefulness in identifying a wide range of issues arising from medicines use 
either in single conditions or in patients with multi-morbidity; most of the domains 
elicited have been cited88 as particularly burdensome to users of long-term medicines. 
However, future studies are desirable to not only incorporate deficient domains but 
also to revise/refine the questionnaire even further and confirm its suitability as a 







Study strengths and limitations 
Although item-level response rates were generally high, potentially indicating interest 
in the medicine-related issues covered in the questionnaire, missing data led to 
variations in sample sizes across different statistical procedures reported in this 
chapter. Nevertheless, assumptions for sample size adequacy were met for the 
analytical procedures, and initial pilot data were obtained from demographically 
diverse settings in the UK. 
Elimination of poorly performing items was conducted using psychometrically sound 
criteria and discussions between the researcher and the supervision team. However, 
the item reduction process may have led to loss of potentially relevant items that 
require further consideration in subsequent studies. One item ( ‘My medicines are 
important to me ?), with significant ceiling effects, was retained in the LMQ-2 despite 
possible acquiescence bias (tendencies to agree with a statement even when in 
doubt). Nonetheless, other items in the LMQ-2 did not reveal excess skewness in score 
distribution, commonly found with measures of treatment satisfaction.109  
 
Potential obsequiousness bias (the tendency to alter responses in the way perceived as 
socially desirable), a common methodological problem with self-report measures, was 
minimised by the use of different self-report methods (paper and on-line), encouraging 
completion outside of standard health-facilities, in diverse public settings. 
4.5 Chapter summary 
This thesis chapter provides an initial understanding and clarification of the domains 
underlying the Living with Medicines Questionnaire, and proposes a shorter 42-item 
instrument (the LMQ-2). The chapter provides ĂŶŝŶŝƚŝĂůƚĞƐƚŽĨƚŚĞŝŶƐƚƌƵŵĞŶƚ ?s 
construct validity, but highlights the need for further research work on the instrument, 
particularly incorporating missing content about cost-related burden, and item 
generation in deficient domains (especially the impact of side effects). Inevitably, 
revisions to the instrument will demand further retesting. Nonetheless, the findings 
reported in this chapter are promising and suggest that most of the domains 
underlying LMQ instrument closely resemble the themes derived from the originator 
qualitative study (on which the questionnaire was based) that explored medicine-
related issues in long-term users of medicines.  
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Chapter 5 Revising the LMQ-2 
and testing face/content validity  
5.1 Introduction 
Streiner and colleagues (2015) ƐƉĞĐŝĨǇƚŚĂƚ ‘ŵŽƐƚŽĨƚŚĞƐĐĂůĞƐ ?ŽƌƋƵĞƐƚŝonnaires] that 
have stood the test of time have been revised, re-ƚĞƐƚĞĚ ?ĂŶĚƚĞƐƚĞĚĂŐĂŝŶ ?.118 
DŽƌĞŽǀĞƌ ? ‘ĂƐŽƵƌƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞĐŽŶƐƚƌƵĐƚǁĞĂƌĞŵĞĂƐƵƌŝŶŐĞǀŽůǀĞƐ ?ǁĞŽĨƚĞŶ
ŶĞĞĚƚŽƌĞǀŝƐĞƚŚĞƐĐĂůĞƐĂĐĐŽƌĚŝŶŐůǇ ? ?118 The original Living with Medicines 
Questionnaire (LMQ-1) was developed as a multidimensional generic measure of the 
experience of using prescription medicines for people with long- term illnesses.119 The 
previous chapter (Chapter 4) described development of a shorter, 42-item version 
(LMQ-2), but also revealed  a few gaps in  the LMQ-2.  
 
Particularly, the LMQ-2 lacked items about prescription costs and their impact on 
those using medicines long-term. It is estimated that 80% of  the English population 
aged 19-59 pays for their prescriptions, and up to 73% of people living with long-term 
conditions pay for their prescriptions.47,102 Many of these individuals may experience 
cost-related pressures and concerns, which may lead to non-adherence.52 A cost-
related component was worth incorporating into the LMQ-2.  
 
In addition, the impact of side effects was not clearly assessed by the LMQ-2, with the 
 ‘Ɛide effects element ? not emerging during the factor analyses described in Chapter 4. 
Regardless, side effects are noteworthy in ƉĂƚŝĞŶƚ ?Ɛexperience of medicine use owing 
to their impact on health and wellbeing, quality of life, and intrusions to lifestyle.48,81,92 
The impact of medicines on social life (leisure activities and social relationships) was 
also not explored in the LMQ-2. Some medicines may impact on ability to sustain 
ordinary conversations with friends or family, and thus could affect social interactions, 
while others fear possible interactions between medicines and social drinks (such as 
alcohol).81 Disease-specific measures of social support/conflict in chronic illness refer 
to understanding (or misunderstandings) by family members, and the challenges of 
planning activities that align with medicine regimes.199,200 To consolidate the LMQ-2, 
there was a need to incorporate relevant items to fill the gaps in the LMQ-2, as well as 
to review existing items.  
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There are multiple sources of items, and during questionnaire development patient-
generated data, the literature (or theory), and existing scales can be used (See Table 2-
3). Existing scales (such as the LMQ-2) are a particularly useful source of items; they 
save time and resources involved in de novo item generation, and items in such scales 
have been pretested.118,127 Following item generation and selection for missing 
dimensions (cost, side effects, and social impact), and rewording existing LMQ-2 items, 
the revised questionnaire (LMQ-2.1) was subjected to cognitive testing.  
 
Responding to survey questions is a complex cognitive task.163 It involves processes 
such as comprehension of meanings of specific words and phrases in a questionnaire 
item; recalling relevant information necessary to answer a specific question; decision 
and judgement; and actual response formulation.163,164  Flaws and errors may arise, at 
any of these processes, while responding to questionnaire items 165 W168 Standard 
guidance on the development of patient-reported instruments stipulates that all 
questionnaire-items are assessed for patient understanding, including adequate 
readability of items for the intended population.124 To minimise measurement errors, 
it is pertinent that  participants understand instructions, items, and response options 
(answers) in the way that is intended and any potential problems are 
documented.164,167 
Qualitatitve interview techniques, particularly cognitive interviewing, allow direct 
patient input into questionnaire understandability, layout, and format.124  Cognitive 
interviews are commonly used for pretesting and optimising questionnaires in 
development, to ensure that questions are interpreted as intended, and ultimately to 
improve data quality.166 Cognitive interviewing facilitates early identification of 
questionnaire problems, which may affect response rates, data quality, and 
questionnaire reliability and validity.165,166 It also provides a basis for revising 
problematic items during questionnaire development. Cognitive interview data also 
contributes to content validation of existing instruments, by ensuring that they cover 
 ‘ƚŚĞŵŽƐƚŝŵƉŽƌƚĂŶƚ QĐŽŶĐĞƉƚƐĂŶĚŝƚĞŵƐ ?ĂŶĚƚŚĂƚŝƚĞŵƐĂƌĞĐŽŵƉůĞƚĞ ?ƌĞůevant 
(appropriate), and ƵŶĚĞƌƐƚĂŶĚĂďůĞƚŽƚŚĞƉĂƚŝĞŶƚ ? ?124 Thus to study these issues, the 
revised LMQ (LMQ-2.1) was tested to gather data about potential questionnaire 
problems, all of which can supplement psychometric data on properties of 
questionnaires undergoing development.  
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Aim and objectives 
This aspect of the thesis aimed to generate new questionnaire content for missing 
domains, revise existing items in the LMQ-2, and cognitively test questionnaire content 
(and relevance) in a suitable target population so as to attain a more comprehensive 
questionnaire. 
Objectives were: 
x To revise the LMQ-2 by generating new items for deficient domains and 
reviewing existing ones. 
x To assess face and content validity of the resulting interim version (LMQ-2.1),  
by gaining feedback on  questionnaire  content. 
 
5.2 Methods 
This study was reviewed by the Medway School of Pharmacy School Research Ethics 
Committee (SREC), and ethics approval was granted in May 2015 (see Appendix 8). 
5.2.1 New item generation  
During questionnaire development, a relatively large item pool is advisable. A multi-
source and stepwise item generation process was conducted. Firstly, I reviewed 
qualitative literature (i.e. verbatim quotes) exploring patient perceptions and 
experiences of prescription costs, side effects, and social impact of medicine use. In 
addition, medicine-related questionnaires were assessed to check for potentially 
relevant items with respect to the three deficient domains. Secondary data based on 
the 21 patient interviews that informed LMQ-1 development,23 were re-analysed by 
recoding medicine use issues into the original eight domains (similar to framework 
analysis), and examining thĞ ‘ŝŵƉĂĐƚ ?ĂŶĚ ‘ƐŝĚĞĞĨĨĞĐƚƐ ?ĚŽŵĂŝŶƐƚŽŐĞŶĞƌĂƚĞŶĞǁ
statements from these areas. In addition, medicine use issues that fell outside of this 
framework, particularly cost-related difficulties, were reviewed to aid  new item 
generation. In addition, free-text survey responses  gathered using the LMQ-1 (Chapter 
4), were also reviewed to identify relevant issues relating to prescription costs, side 





After discussion of potential new items, the proposed item pool was further screened 
and irrelevant, vague or redundant statements eliminated by collaborative efforts. A 
total of 12 statements were newly generated: cost (n=4), side effects (n=3), and social 
impact of medicines (n=2).  
 
In addition, three global items, rated on visual analogue scales (VAS) to ascertain 
concepts measured by the LMQ  W global satisfaction, global burden and global 
optimisation  W were developed and tested. New items proposed during the item 
generation phase are shown in Table 5-1. 
Items Source 
Cost-related statements  
1 I worry about paying for my medicines.  1,2 
2 I have to pay more than I can afford for my medicines. 1,2 
3 I sometimes have to choose between buying basic essentials or 
medicines. 
1,2 
4 /ĚŽŶ ?ƚŵŝŶĚƉĂǇŝŶŐĨŽƌŵǇŵĞĚŝĐŝŶĞƐďĞĐĂƵƐĞ/ŶĞĞĚƚŚĞŵ ? 1 
Statements about side effects  
1 The side effects I get from my medicines are bothersome. 1 
2 The side effects I get from my medicines interfere with my day-to-day life 
(e.g. work, housework, sleep). 
1 
3 The side effects I get from my medicines adversely affect my well-being. 1 
Statements about impact on social life    
1 My medicines can interfere with my social relationships. 
Reworded after cognitive interviews:   
My medicines interfere with my social relationships. 
1 
2 My medicines affect what I can eat or drink. 
Reworded after cognitive interviews: 
I am concerned that my medicine(s) affect what i can eat or drink. 
1 
Global items to assess concepts measured by the LMQ-2  
VAS 1 Taking everything into account, how satisfied are you with your 
medicines?  
3 
VAS 2 How optimal do you feel your medicines are for you? 4 
 Reworded after cognitive interviews: 
On balance, do you feel your medicines are right for you? 
 
VAS 3 Overall, how much of a burden do you feel your medicines are to you? 5 
Table 5-1 New items generated about cost, side effects, and social impact. 
 
Notes; Source of new statements or words used in the revised questionnaire:  
1. Patient interviews and free-text survey data 
2. Prescription Charges Coalition, England (2013/2014)47,102 
3. Atkinson et al (2005)74 
4. Royal Pharmaceutical Society (2013)1 




5.2.2 Revision of existing items 
Following new item generation, existing items in the LMQ-2 and some socio-
demographic variables were reviewed. I also suggested items which required 
rewording or adaptation from the original questionnaire (LMQ-1), based on the 
findings of factor analyses described in Chapter 4. Discussions were held with my 
supervisors to agree proposed revisions to original items, and to resolve any wording 
issues. Subsequently, a 58-item interim version of the questionnaire (LMQ-2.1) was 
created as a product of item addition, rewording, and deletions (See Appendix 14).  
 
5.2.3 Cognitive interviews- Assessing item comprehension in the LMQ-2.1 
Qualitative cognitive interviewing methodology was used. Following new item 
generation and revisions, I tested the resultant instrument, the LMQ-2.1, using 
cognitive interviews. This interim version was a six-page instrument including 58-
Likert-type statements, the three VAS (global satisfaction, global burden and global 
optimisation), and a free-text question. Likert-type items have 5-point response 
options rated from strongly agree to strongly disagree, with a neutral mid-point. On 
the VAS, which are 10-cm lines with diametrically opposing words at the anchors, 
respondents were asked to mark the point that corresponds to their perceived state of 
satisfaction, burden, or optimisation of the medicine use experience. The last page 
covered participant demographics. 
 
Two paper-based formats were created based on the order and grouping of items: an 
intermixed version (LMQ-2.1-I) with a relatively random order of items throughout the 
questionnaire, and a grouped/labelled version (LMQ-2.1-GL). In the latter version, 
Likert-type items were subdivided and ordered into thematic groups (domains) relating 
to prescription medicine use experiences: access, practical issues, cost, effectiveness, 
concerns, side effects, routine of medicine use, perceived interference to day-to-day 
life, impact on social life, communication with pharmacist(s), communication with 
doctor(s), and perceived control or autonomy over medicine use. This was intended to 







5.2.4 Study population and recruitment 
Members of a general public engagement group at the Medway School of Pharmacy 
(known as the PIPS group), which meets regularly to discuss on ongoing medicine-
related research, were involved in development of the instrument. At two different 
face-to-face meetings, the researcher (BK) presented verbal information about the 
study and sought general opinions on the instrument. They were also invited to 
consider taking part in the study as participants (if they met the inclusion criteria: 18 
years or older, using long-term prescription medicines, able to read and communicate 
in English, and were living in England at the time of the study), and/or to recruit others 
known to them (snowball technique).  
 
Approximately 2-3 weeks after the meetings, written invitations (Appendix 9) and 
study packs  were posted to each PIPS member who provided their full postal address. 
Each study pack contained: a general cover letter, a participant invitation letter, 
information sheet, consent form, participant details form (See Appendices 10-12 
respectively), and prepaid-post envelope for returning the latter two documents.  
Participants willing to participate in the snowball recruitment were given additional 
study packs for distribution during the subsequent month, and a preprinted form with 
a short, introductory message to use during recruitment (See Appendix 13).  
 
All consenting participants were contacted by telephone and/or email to schedule an 
interview at a time and place of their choosing. A follow-up telephone call was made a 
few days before the appointment to confirm interest and voluntary participation in the 
study. Respondents were sampled to represent diverse age ranges, gender, and 










5.2.5 Interview procedures  
/ŶƚĞƌǀŝĞǁƐǁĞƌĞĐŽŶĚƵĐƚĞĚŝŶƐƵŝƚĂďůĞƌŽŽŵƐĂƚƚŚĞ^ĐŚŽŽů ?ŽƌĂƚƉĂƌƚŝĐƉĂŶƚ ?ƐŚŽŵĞƐ
according to interviewee preferences to ensure their comfort and ease. Interviews, 
which lasted about an hour (range 40 minutes to 1.5 hours), were conducted to elicit 
thoughts or ideas about the questionnaire wording, layout, and concepts covered in 
the LMQ instrument. The intermixed version (LMQ-2.1-I in Appendix 14) was 
presented to and completed by all participants during the interviews, while the 
grouped version (LMQ-2.1-GL in Appendix 15) was viewed at the end of each interview 
to compare its format to the LMQ-2.1-I. Participants were reminded that the overall 
purpose of the interview was to evaluate the questionnaire, rather than share their 
personal experiences about living with medicines. 
 
Before and during the interview, participants were asked to think aloud (or talk out 
their thoughts) while completing each item, saying whatever came up in their mind. 
General instructions for the interview included: reading each survey item out aloud, 
responding to the item, thinking out loud, and/or answering the probe question(s). As 
previously discussed in Chapter 3 (section 3.3.2.3), follow-up questions were employed 
to supplement the think-aloud process, particularly when unobvious answers and 
potential questionnaire problems were encountered.  
 
The interviewer used both pre-scripted probes (in the interview guide  W See Appendix 
2), and spontaneous probes that were spurred by a parƚŝĐŝƉĂŶƚ ?ƐƌĞƐƉŽŶƐĞƚŽĂŶŝƚĞŵ ?
Pre-scripted probes were omitted when the interviewer felt that they were already 
answered through the think-aloud process. KƚŚĞƌƉƌŽďĞƐǁĞƌĞƵƐƵĂůůǇ ‘ƚŚŽƵŐŚƚƵƉ ? 
during any given interview, and tailoƌĞĚƚŽŝŶƚĞƌǀŝĞǁĞĞ ?ƐƌĞƐƉŽŶƐĞƐ ?This probe mixture 
was thought to achieve a balance between consistency across interviews and having a 
 ‘ŶĂƚƵƌĂů ? ?ĐŽŶǀĞƌƐĂƚŝŽŶĂů-type, interview.167,168 Facial expressions, and non-verbal cues 
(including hesitation, pausing, mumbling, sighing, or intentional skipping of items) 
were observed, and also used to detect potentially problematic questions, and to 
assess difficulties experienced while completing the questionnaire. Participants were 
ŶŽƚ ‘ŚĞůƉĞĚ ?with answering the questionnaire to simulate completion of self-reported 
instruments in practice.94  
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All interviews were audio-recorded, and relevant information used to supplement 
shorthand field-notes (and annotations on questionnaires). ZĞƐƉŽŶĚĞŶƚƐ ? 
questionnaires were stored, and used in data analysis. 
 
5.2.6 Data analysis 
ůƚŚŽƵŐŚƚŚĞƌĞĂƌĞŶŽ ‘ŐŽůĚ ?ƐƚĂŶĚĂƌĚŐƵŝĚĞůŝŶĞƐĨŽƌĂŶ ůǇƐŝŶŐĐŽŐŶŝƚŝǀe interview data 
during questionnaire development, a common aim is to identify problematic areas in a 
questionnaire,167 and potential threats to instrument validity.163,165,166  
A number of coding systems for categorising questionnaire problems exist, and these 
broadly cover the same domains of questionnaire problems. In a recent study, Buers et 
al166 recommend the Willis coding system for analysing questionnaire problems with 
ƐƵŐŐĞƐƚŝŽŶƐƚŚĂƚ ‘it provides more detailed codes that indicate specific directions for 
ƌĞǀŝƐŝŽŶƐ ?.166 However,there is  inconclusive evidence that fails to confirm whether 
ƵƐŝŶŐƐƵĐŚĐŽĚŝŶŐƐǇƐƚĞŵƐ ‘ĂĐƚƵĂůůǇ ?ŵĂŬĞ a difference during identification of 
questionnaire problems.166 Moreover ?ƚŚĞƐĞƐŽŵĞǁŚĂƚ ‘ƐƚĂŶĚĂƌĚŝƐĞĚ ?analyses of 
interview data are not only extremely time-consuming, but also dependent on the 
technique(s) used during cognitive testing.168  
 
There are suggestions that for relatively quicker revisions, and in instances of limited 
resources to allow in-ĚĞƉƚŚĂŶĂůǇƐŝƐ ? ‘reliance on written outcome notes alone may be 
ƐƵĨĨŝĐŝĞŶƚ ?.168 For instance, in the development of an instrument to assess health-
related quality of life among children and adolescents, Irwin and colleagues201 
compiled and analysed interview comments for all items to assess questionnaire 
ƉƌŽďůĞŵƐ ?ĂŶĚŶŽ ‘ĨĂŶĐǇ ?ĐŽĚŝŶŐƐǇƐƚĞŵƐǁĞƌĞƵƚŝůŝƐed. Research specific to medicine-
related questionnaires94 employs traditional qualitative techniques, akin to constant 
comparison178 to group similar comments together and to identify questionnaire 
problems. In the present study, recruitment was terminated after the 11th interview, as 
it became clear that  ‘ƐĂŵƉůŝŶŐƌĞĚƵŶĚĂŶĐǇ ? ?which tends to occur after 8-15 
interviews,127 had been attained and ŶŽ ‘ŶĞǁ ?ƋƵĞƐƚŝŽŶŶĂŝƌĞƉƌŽďůĞŵƐĞŵĞƌŐĞĚĨƌom 






In this study, interview comments were compiled for each item in specially designed 
Excel spreadsheets (Appendix 16), and analysed both on an item-by-item basis, and 
comparatively to assess potential questionnaire problems, including comprehension 
difficulties. This made it easier to compare comments about each item across all 
participant responses, and to explore the proportion of participants perceiving an item 
to be problematic. Questionnaire problems that emerged repeatedly were 
documented. Unique interpretations of items, different from those intended by 
developers, were also examined. Such problems, if left unaddressed, may emerge 
more frequently in an actual survey, and impact on data quality.168 WĂƌƚŝĐŝƉĂŶƚƐ ?
recommendations for item retention, rewording, rephrasing, or deletion of individual 
words, phrases or sentences, were also examined. A summary analysis report was 
compiled, and discussions held with supervisors on how to address items agreed as 
problematic, and to make further revisions to the LMQ instrument. 
 
5.3 Results  
5.3.1 Participant characteristics 
Eleven adults (55% males), aged 42-75 years, participated in the cognitive interviews. 
Most participants used four or fewer prescription medicines (range, 1-12), once or 
twice daily, in tablet/capsule formulations. The study population was generally 
balanced with respect to educational level, but the majority were retirees, most of 
whom were exempt from prescription charges. All participants resided in areas of 





Characteristic  n (%) 
Gender Female 5 (45) 
 Male 6 (55) 
Age (years) 30-49 1(9) 
 50-64 5(46) 
 65-74 3(27) 
 A? ? ? 2(18) 
Educational level University 4(36) 
 Technical College/Apprenticeship 3(27) 
 School 4(36) 
Employment Retired 8(73) 
 Employed 1(9) 
 Unemployed 1(9) 
 Other¥ 1(9) 
Ethnicity White 9(82) 
 Asian 1(9) 
 Black 1(9) 
Number of 
medicines 
A? ? 5(46) 
5-9 4(36) 
 A? ? ? 2(18) 
Frequency of 
medicine use 
Once per day 4(36) 
Twice per day 3(27) 
 Three times per day 1(9) 
 More than three times per day 1(9) 
 Other^ 2(9) 
Formulation Tablets/capsules 10(91) 
 Any other form(s) 4(36) 
Pay for medicines Yes 1(9) 
 No 10(91) 




Table 5-2 Characteristics of participants completing the cognitive interviews 
 












5.3.2 Interview findings 
According to standard guidance on reporting patient understanding of self-completion 
instruments,124 documentation of questionnaire issues, such as item comprehension 
and modifications (deletions or revisions), use of response options and perceptions of 
underlying concepts is beneficial to contributing to instrument validity. This section 
describes the findings of interview analyses. 
5.3.3 Questionnaire instructions and use of visual analogue scales 
All participants reported clarity of general instructions, provided on the coverpage, for 
questionnaire completion. Responses to probes around general instructions elicited 
comments such as  ‘ ? ?ĨŝŶĞ ?ǀĞƌǇĐůĞĂƌ ?P4  aŶĚ ‘ǀĞƌǇĐůĞĂƌ ?W ? ?Nevertheless, observation 
of participants revealed some of them skipping the instructions only to return, and 
check  them upon encountering problematic items. Of the question-specific 
instructions, particularly those refering to visual analogue scales (VAS), a sample 
shown in Figure 5-1, findings suggest that most participants understood the 
instructions and had a clear understanding ŽĨǁŚĞƌĞƚŽ ‘mark on ƚŚĞůŝŶĞǁŝƚŚĂŶ ‘y ?at 
ƚŚĞƉŽƐŝƚŝŽŶƚŚĂƚďĞƐƚƌĞĨůĞĐƚƐ ? ? their  perceived state of satisfaction, burden, or 
optimisation of medicines use, stressing that  ‘ŝŶƐƚƌƵĐƚŝŽŶƐĂƌĞĐůĞĂƌ ? ?P7. A few 
complemented the VAS-type of questions saying  ‘..its a great way to measure, the 
scale is a great way to ŵĞĂƐƵƌĞ ? ? ?W ?. Some participants implied that prior exposure to 
answering VAS-type questions helped them respond:  ‘/ŚĂǀĞƐĞĞŶƚŚĞƐĞďĞĨŽƌĞ ? ?will 
respond] roughly in the middlĞ ?P3. Only one participant was not condfident about 
where to mark on the line, while another recommended the use of boxes with 
numbers (to replace the line) and implied that he was not sure of the difference 
between a  ‘5 ? and  ‘6 ? on the line (See Figure 5-1). 
 




5.3.4 Item comprehension and modifications 
Table 5-3 provides a summary item-by-item analysis, and shows no major 
comprehension problems among most items. In this study, a major comprehension 
ƉƌŽďůĞŵǁĂƐĚĞĨŝŶĞĚĂƐ ‘a failure of comprehension of a key term [in an itĞŵ ? ?, which 
ŵĂǇŶŽƚĐůĞĂƌůǇĚĞŵŽŶƐƚƌĂƚĞ ‘alternate, but reasonable, interpretations of the 











1 I find getting my prescriptions from the doctor  difficult No major comprehension problem identified 
1 (9%) preferred reference to a specific type of prescription (e.g. repeat prescription) 
2 I find getting my medicines from the pharmacist  difficult No major comprehension problem identified 
1 (9%) preference for positive wording 
2 (18%) Spoke of chemist rather than pharmacist 
3 I find the written instructions on how to use my medicines 
easy to understand.  
No major comprehension problem identified 
4 (36%) spoke of  ‘instructions on the label/packet/packaging/box/patient information leaflet ? 
4 Taking medicines is routine for me No major comprehension problem identified 
5 I am satisfied with effectiveness of  my medicines No major comprehension problem identified 
6 I would be worried if I forgot to take my medicines No comprehension problem identified 
3(27%) perceived a subtle/no difference between this item 6 and item 16 
7 I am comfortable with the times I should take my  medicines No major  comprehension problem identified 
8 I worry about paying for my medicines No major comprehension problem identified 
Some confusion of response options 
 ? ? ? ?A? ?ĐŚŽƐĞ ‘ƐƚƌŽŶŐůǇĚŝƐĂŐƌĞĞ ? ?ŝŶƐƚĞĂĚŽĨŶĞƵƚƌĂůŽƉŝŶŝŽŶ ? ?ĞǀĞŶǁŚĞŶĞǆĞŵƉƚĨƌŽŵ
prescription charges 
9 I worry that I have to take several medicines at same time No major comprehension problem identified 
10 I would like more say in the brands of medicines I use No major comprehension problem identified 
1 (9%) proposed addition of  ‘ when switching from the original drug ? 
11 I trust the judgement of my doctor(s)in  choosing medicines 
for me 
No major comprehension problem identified 
12 It is difficult to identify which medicine is which No major comprehension problem identified 
1 (9%) preferred positive wording (i.e. use of easy rather than difficult) 
13 My pharmacist tells me enough about my medicines No major comprehension problem identified 
3(27%) spoke of  ‘ ? ?ŝĨ/ĂƐŬ ?ƚĂůŬƚŽƚŚĞŵ ? 
1(9%) preferred  ‘ǁŚĂƚ ?ƐĂǀĂŝůĂďůĞŽƌǁŚĂƚ/ŶĞĞĚƚŽŬŶŽǁĂƚƚŚĂƚƐƚĂŐĞ ? rather than  ‘enough ?. 
14 I am concerned about possible damaging long term effects of 
taking medicines 
No major comprehension problem identified 
 
15 I feel I need more information about my medicines No major comprehension problem identified 
1(9%) preferred  ‘ŝŶĨŽƌŵĂƚŝŽŶƐƵĨĨŝĐŝĞŶƚĨŽƌŵĞ ? ? 
16 I am concerned that I may forget to take my medicines No major  comprehension problem identified 
3(27%) perceived a subtle/no difference between this item 16 and item 6 





Item No Original Statement Comprehension  
17 I can vary the dose of the medicines  I take No major comprehension problem identified 
18 I find  opening the  packaging of my medicines difficult No major  comprehension problem identified 
19 I can choose whether or not to take my medicines No major  comprehension problem identified 
20 My doctor listens to my opinions about my medicines   No major  comprehension problem identified 
4 (36%) spoke of  ‘ ?ŝĨ/ĂƐŬŚƵŵ ?ŝĨ/ƚĂůŬƚŽŚŝŵ ?ǁŚĞŶĐŽŶƐƵůƚĞĚ ? ? ? ? 
21 My medicines prevent my condition getting worse No major  comprehension problem identified 
2 (18%) proposed addition (...may prevent... ? or alternative wording  ‘...put my condition under 
control... ? 
22 I am concerned that I am too dependent on my medicines Comprehension problem identified 
3(27%) misinterpreted the word  ‘dependent ? as  ‘addicted ?. Most interpreted statement as 
 ‘being reliant on medicines ? 
23 I am unhappy with the extent to which my medicines interact 
with alcohol 
No major  comprehension problem identified 
6(55%) suggested replacing the word  ‘unhappy ? with words such as  ‘concerned/ 
worried/anxious ?  
Most participants were observed to pay most attention to the last five words  ‘ ?ŵǇŵĞĚŝĐŝŶĞƐ
interact with alcohol. ? 
24 I worry that my medicines may interact with each other No major comprehension problem identified 
1 (9%) perceived repetition between item 24 & item 9 
25 My medicines interfere with my social activities No major  comprehension problem identified 
Most participants referred to individual leisure activities, as well as social activities. 
1 (9%) proposed replacing the word  ‘interfere ? with  ‘impact ?. 
26 I am concerned about experiencing  side effects No major  comprehension problem identified 
27 My doctor takes my concerns about side effects seriously No major comprehension problem identified 
4 (36%) spoke of  ‘ ?ŝĨ/ƐƉĞĂŬ ?ƚĂůŬƚŽŚŝŵ ?ŚĞƌ ? ? ? ? 
28 The side effects I get are worse than the problem for which I 
take medicines 
No major  comprehension problem identified 
2 (18%) proposed addition of  ‘ ?ƚŚĞƐŝĚĞĞĨĨĞĐƚƐĐĂŶďĞǁŽƌƐĞŽƌĐĂŶŐĞƚǁŽƌƐĞ ?;  
Statement revised to include  ‘dŚĞƐŝĚĞĞĨĨĞĐƚƐ/ŐĞƚĂƌĞƐŽŵĞƚŝŵĞƐǁŽƌƐĞ ? ? 
29 The side effects I get from my medicines interfere with my 
day-to-day life (e.g. work, housework, sleep) 
No major  comprehension problem identified 




30 I can adapt my medicine-taking to my lifestyle Comprehension problem identified: 2 (18%) participants had problems understanding part or 
the entire statement  ‘ ? ? ?/ƌĞĂůůǇĚŽŶ ?ƚƵŶĚĞƌƐƚĂŶĚƚŚĂƚŽŶĞ ?/ǁŝůůƉƵƚŶĞƵƚƌĂůŽŶƚŚĂƚŽŶĞ... ? P7 
31 I have to put a lot of planning and thought into taking my 
medicines 
No major comprehension problem identified 
1 (9%) participant preferred inclusion of the word  ‘sometimes ? in the statement. 
32 /ĚŽŶ ?ƚŵŝŶĚƉĂǇŝŶŐĨŽƌŵǇŵĞĚŝĐŝŶĞƐďĞĐĂƵƐĞ/Ŷeed them. 
 
No major comprehension problem identified 
1 (9%) preferred the use of  ‘do not ?, another one preferred negative wording  ‘I mind ƉĂǇŝŶŐ ? ? ? ? 










33 My doctor tells me enough about my medicines No major comprehension problem identified 
2 (18%) perceived repetition/confusion between this item 33  & item 13 about pharmacist 
34 My medicines live up to  my expectations No major  comprehension problem identified 
1(9%) acknowledged the word  ‘expectations ? as very broad. 
35 I am confident speaking to my doctor (s) about my medicines No major  comprehension problem identified 
1(9%) proposed negative wording to include  ‘/ĂŵŶŽƚĐŽŶĨŝĚĞŶƚ ? ? ? ? 
36 I am confident speaking to my pharmacist about my medicine No major  comprehension problem identified 
1(9%) proposed negative wording to include  ‘/ĂŵŶŽƚĐŽŶĨŝĚĞŶƚ ? ? ? ? 
37 My medicines affect what I can eat or drink No major  comprehension problem identified 
1(9%) proposed inclusion of examples of drinks (e.g. tea, coffee, juice) 
38 The medicines I use have an adverse  effect on the holidays I 
can take 
No major comprehension problems: 5(45%) interpreted the statement as  ‘medicines 
stopping/preventing holidays ?, while a few had concerns about the words  ‘adverse effect ? 
39 I can change the times I take my medicines if I want to No major  comprehension problem identified 
3(27%) perceived a similarity between item 39, item 17, and item 19 
40 It is easy to keep my medicines routine No major  comprehension problem identified 
4(36%) perceived repetition or subtle differences between item 40 & item 4  
41 Changes in daily routine cause problems with  my medicines No major comprehension problem identified 
 ? ? ? ?A? ?ƉƌŽƉŽƐĞĚĂĚĚŝƚŝŽŶŽĨ ‘ĐĂŶ ?Žƌ ‘ĐŽƵůĚ ?ĐĂƵƐĞƉƌŽďůĞŵƐ ? ? 
Revised to  ‘Changes in daily routine causes problems with my medicines. ? 
42 Taking medicines affects my driving No major comprehension problem identified 
 
43 I find using my medicines  difficult No major  comprehension problem identified 
2(18%) felt the word using is very broad including opening packaging, dispensing and self-
administering of medicines  
44 I accept that I have to take medicines long term. No major  comprehension problem identified 
45 I understand what my doctor(s) tell me about my medicines No major  comprehension problem identified 
3(27%) perceived repetition item 45 & item 33  
46 I understand what my pharmacist tells me about my 
medicines. 
No major  comprehension problem identified 
2(18%) perceived a similarity between item 46 & item 13 & item 36 
47 The side effects I get from my medicines are bothersome. No major comprehension problem identified 
6(55%) proposed alternative words to bothersome, including inconvenient/distracting, 
troublesome, worrying or worry me, or causing a nuisance. 
 







Original Statement  
Comprehension  
48 I sometimes have to choose between buying basic essentials 
or medicines 
No major  comprehension problem identified 
1(9%) perceived statement to be sensitive/embarrassing to answer  
1(9%) proposed ending the statement with  ‘if you have to buy ?. 
49 My medicines allow me to live my life as I want to. No major  comprehension problem identified 
50 I have to pay more than I can afford for my medicines No major  comprehension problem identified 
1(9%) perceived statement to be sensitive/embarrassing to answer  
51 The health professionals providing my care know enough 
about me and my medicines 
No major  comprehension problem identified 
2(18%)  participants wanted specification of the type of health professional, while 1(9%) insisted 
that it should remain general to include others besides doctors and pharmacists 
52 Taking medicines causes me problems with daily tasks (such as 
work, housework, hobbies) 
No major  comprehension problem identified 
2(18%) perceived redundancy of items about the impact of medicines of everyday activities 
53 My medicines interfere with my social relationships 1(9%) indicated comprehension  problems 
2(18%) proposed inclusion of  ‘interaction with friends and family ? 
54 My medicines interfere with my sexual life No major  comprehension problem identified 
1(9%) perceived this statement as sensitive 
55          The side effects I get from my medicines adversely affect my 
well-being. 
No major comprehension problems:  
diverse interpretations of the word  ‘wellbeing ? 
 
56 My medicines are working No major comprehension problem identified 
 
57 The side effects are worth it for the benefits I get from my 
medicines 
No major  comprehension problem identified 
1(9%) perceived it to be irrelevant 
58 My life revolves around using my medicines No major  comprehension problem identified 
 
    VAS 1 Taking everything into account, how satisfied are you with 
your medicines?  
No major  comprehension problem identified 
    VAS 2 How optimal do you feel your medicines are for you? Major comprehension problem identified 
11(100%) revealed significant comprehension problems owing to the word  ‘optimal ?. Arose 
from technical nature of the word  ‘optimal ? 
    VAS 3 Overall, how much of a burden do you feel your medicines are 
to you? 
No major  comprehension problem identified 
1(9%) perceived it as irrelevant  ‘ /ĚŽŶ ?ƚƚŚŝŶŬŵĞĚŝĐŝŶĞƐĂƌĞĂďƵƌĚĞŶ ?ƚŚĞǇĂƌĞƚŚĞƌĞĨŽƌĂ
reason ? P10 
Table 5-3 Item-by-item analysis of potential comprehension problems in the interim instrument (LMQ-2.1)
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5.3.4.1 Potentially problematic items, and revisions 
Potentially problematic items, items with major comprehension problems, and their 
revisions, are discussed sequentially in the section below. 
Item 22 
Although most participants correctly interpreted item 22,  ‘I am concerned that I am 
too dependent on my medicines ? ? as being reliant on medicines, a few others (n=3, 
 ? ?A? )ŵŝƐŝŶƚĞƌƉƌĞƚĞĚƚŚĞǁŽƌĚ ‘ĚĞƉĞŶĚĞŶƚ ?ƚŽƐǇŶŽŶǇŵƵƐůǇŵĞĂŶ ‘ĂĚĚŝĐƚĞĚ ?. In the 
context of medicine use, lay concerns about prescription medicine dependency or 
tolerance are not uncommon.21,81 ǀĞŶƐŽ ?ŽďƐĞƌǀĂƚŝŽŶŽĨŝŶƚĞƌǀŝĞǁĞĞƐ ?ŶŽŶ-verbal 
expresƐŝŽŶƐƐƵŐŐĞƐƚĞĚƚŚĂƚƚŚĞǁŽƌĚƐ ‘ƚŽŽĚĞƉĞŶĚĞŶƚ ?had a negative connotation to 
them. In fact, 82% (n=9) responded with a neutral, disagree, or strongly disagree on 




Despite no comprehension difficulties, item 23,  ‘I am unhappy with the extent to which 
my ŵĞĚŝĐŝŶĞƐŝŶƚĞƌĂĐƚǁŝƚŚĂůĐŽŚŽů ? ? attracted diverging comments. At least half (55%, 
n=6) of all participants  ǁĞƌĞĐŽŶĐĞƌŶĞĚĂďŽƵƚƚŚĞǁŽƌĚ ‘ƵŶŚĂƉƉǇ ? ?and suggested 
rĞƉůĂĐŝŶŐŝƚǁŝƚŚǁŽƌĚƐƐƵĐŚĂƐ ‘ĐŽŶĐĞƌŶĞĚ ?ǁŽƌƌŝĞĚ ?ŽƌĂŶǆŝŽƵƐ ?. For instance, a 
participant stressed that:  
  ‘ ?ŝƚ ?ƐŶŽƚƐŽŵƵĐŚ ‘ƵŶŚĂƉƉǇ ?...coz this would mean I am an alcoholic...I am 
 ĐŽŶĐĞƌŶĞĚŽƌ/ĂŵĂŶǆŝŽƵƐŽƌ/ĂŵǁŽƌƌŝĞĚ ? ‘hŶŚĂƉƉǇ ? denotes that I have 
 alcoholic habits, and people may not like that question because it is making you 
 think about ĂůĐŽŚŽůŝĐŚĂďŝƚƐ ?ĂŶĚƚŚŝƐŝƐŶŽƚǁŚĂƚŝƚ ?ƐĂďŽut? This is not an 
 alcoholics' ƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ŝƚ ?ƐĂďŽƵƚŵĞĚŝĐŝŶĞƐĂŶĚƚŚĞŝƌrelationship with 
 ĂůĐŽŚŽů ? ? ? ?P3. 
 
Even so, observation of the reading patterns of most participants indicated that many 
participants paid little attention to the middle text of item 23,  ‘...with the extent to 
whiĐŚ ? ? ? ?, and subsequently ƚŚĞƐƚĂƚĞŵĞŶƚǁĂƐƌĞƉŚƌĂƐĞĚƚŽ ‘I am concerned that my 







Although most participants had a clear understanding of item 25,  ‘My medicines 
inteƌĨĞƌĞǁŝƚŚŵǇƐŽĐŝĂůĂĐƚŝǀŝƚŝĞƐ ?, they mostly referred to individual leisure activities 
such as running, walking, gardening, as well as social activities like going to the pub 
with some friends. Consequently, the statement was reworded to  ‘DǇŵĞĚŝĐŝŶĞƐ
ŝŶƚĞƌĨĞƌĞǁŝƚŚŵǇƐŽĐŝĂůŽƌůĞŝƐƵƌĞĂĐƚŝǀŝƚŝĞƐ ? ?
Item 30 
A few (18%, n=2) participants perceived compƌĞŚĞŶƐŝŽŶƉƌŽďůĞŵƐǁŝƚŚŝƚĞŵ ? ? ? ‘I can 
adapt my medicine-ƚĂŬŝŶŐƚŽŵǇůŝĨĞƐƚǇůĞ ?. One ƉĂƌƚŝĐŝƉĂŶƚĨĞůƚƚŚĞǁŽƌĚ ‘adĂƉƚ ?was 
difficult in spite of having a general understanding of the entire statement:  ‘adapt, 
ƚŚĂƚ ?ƐĂĚŝĨĨŝĐƵůƚǁŽƌĚ ?ĐŚĂŶŐĞƉĞƌŚĂƉƐ ? ?W ? ?Another participant failed to make sense 
of the entire statement:  ‘ ? ? ?/ƌĞĂůůǇĚŽŶ ?ƚƵnderstand that one, I will put neutral on that 
ŽŶĞ ? ? ? ?P7. As a result, the statĞŵĞŶƚǁĂƐƌĞǁŽƌĚĞĚƐůŝŐŚƚůǇƚŽ ‘I can adapt using my 
ŵĞĚŝĐŝŶĞƐƚŽĨŝƚŵǇůŝĨĞƐƚǇůĞ ? ? 
Items 13 and 33 
The two statements about doctor and pharmacist communication about medicines, 
with similar endings in item phrasing, ( ‘ ?ƚĞůůƐŵĞĞŶŽƵŐŚ ?), were perceived as 
repetitious and elaborated upon by some participants. While referring to item 13 ? ‘My 
pharmacist telůƐŵĞĞŶŽƵŐŚĂďŽƵƚŵǇŵĞĚŝĐŝŶĞƐ ?, a participant exclaims:  
  ‘My pharmacist tells me enough, If I ask...I understaŶĚƚŚĞƋƵĞƐƚŝŽŶ ?/ĚŽŶ ?ƚ
 think ƉŚĂƌŵĂĐŝƐƚŽĨƚĞŶƚĞůů ?ƚŚĞǇũƵƐƚĚŝƐƉĞŶƐĞƵŶůĞƐƐǇŽƵĂƐŬ ?ďƵƚŝƚ ?ƐĐůĞĂƌ ?/Ĩ
 you ask, they ǁŝůůƚĞůůǇŽƵ ?ďƵƚŝĨǇŽƵĚŽŶ ?ƚĂƐŬ ?ƚŚĞǇǁŝůůũƵƐƚŐŝǀĞǇŽƵ the drug, 
 and often it is the assŝƐƚĂŶƚ ?P4. 
 
 As a result, items 13 and 33 were rephrased to reflect patient autonomy over 
aĐƋƵŝƌŝŶŐŵĞĚŝĐŝŶĞŝŶĨŽƌŵĂƚŝŽŶ P ‘I get enough information about my medicines from 










Item 38  W my holidays and my medicines 
ZĞƐƉŽŶƐĞƐƚŽŝƚĞŵ ? ? ? ‘The medicines I use have an adverse effect on the holidays I can 
ƚĂŬĞ ?, suggested potential interpretation problems. Nearly half (45%, n= 5) interpreted 
the statement to mean medicines prevent taking holidays: 
   ‘ ?/ĚŽŶ ?ƚŬŶŽǁǁŚĂƚǇŽƵŚĂǀĞƚŽďĞƚĂŬŝŶŐĨŽƌǇŽƵƚŽ ƐĂǇ/ĐĂŶ ?ƚŐŽŽŶŚŽůŝĚay, 
 ďĞĐĂƵƐĞŽĨǁŚĂƚ/ĂŵƚĂŬŝŶŐ ?P8.  
 
Other pĂƌƚŝĐŝƉĂŶƚƐĐŽŵŵŽŶůǇƚĂůŬĞĚŽĨ ‘ƉůĂŶŶŝŶŐŚŽůŝĚĂǇƐ ? while responding to this 
statement. To demonstrate this, a few participants articulated that: 
   ‘ ?ŝƚĚŽĞƐŶ ?ƚƐƚŽƉŵǇŚŽůŝĚĂǇƐ ?ŝƚĂĨĨĞĐƚƐŝƚ ?ůŝŬĞƉůĂŶŶŝŶŐŚŽǁƚŽŐŽƚŚƌŽƵŐŚ
 ĐƵƐƚŽŵƐǁŝƚŚŵĞĚŝĐŝŶĞƐ ?P10  
 
  ‘  ?ǇŽƵĐĂŶĂůǁĂǇƐŐĞƚĂďŽƵƚƚŚŝŶŐƐ ?ĐĂŶ ?ƚǇŽƵ ?hŶůĞƐƐǇŽƵŚĂǀĞƚŽƚĂŬĞŽǆǇŐĞŶ
 cylinders with you ? ? ?ǁŚŝĐŚ ?ŵĂŬĞŝƚĚŝĨĨŝĐƵůƚƚŽƉůĂŶŚŽůŝĚĂǇƐ ?ƉĞƌŚĂƉƐ ? ?W ? 
 
Other participants worried about getting enough supplies before going on holidays, 
and suggesƚĞĚƌĞƉŚƌĂƐŝŶŐƚŚĞƐƚĂƚĞŵĞŶƚƚŽ ‘ Qmy medicine may interfere with my 
holiday plan...the question needs ƚŽďĞĐŚĂŶŐĞĚ ? ?P4.  Still within item 38, the phrase 
 ‘adverse ĞĨĨĞĐƚ ?also attracted a few concerns:  
  ‘I think people would take it [adverse effect] as they can't go, possibly you 
 would want to know whether it means ǇŽƵĐĂŶŐŽŽŶŚŽůŝĚĂǇŽƌŶŽƚ ? ?P6   
 
  ‘...ĂĚǀĞƌƐĞĞĨĨĞĐƚĐŽƵůĚŵĞĂŶƐŝĚĞĞĨĨĞĐƚ ? ? P4.  
 
Subsequently, item 38 was rephrased to  ‘The medicines I use make it difficult to plan 
ŚŽůŝĚĂǇƐ ? ? 
Item 39   
Although no comprehension problems were detected while responding to item 39 ? ‘I
can change the times I ƚĂŬĞŵǇŵĞĚŝĐŝŶĞƐŝĨ/ǁĂŶƚƚŽ ?,  a few (n=3, 27%) participants 
acknowledged similarities with ŝƚĞŵ ? ? ? ‘I can vary the dose of the medicines I take ? ? 
and item 19 ( ‘I can choose whetŚĞƌŽƌŶŽƚƚŽƚĂŬĞŵǇŵĞĚŝĐŝŶĞƐ ? ?, which all relate to 
perceived autonomy/control over medicines:   
  ‘  ?ŶƵŵďĞƌ ? ? ?ŝƐŶ ?ƚƚŚĂƚƐŽŵĞǁŚere else or very similar to [ flips back to items 
 17 and 19] , we have been ƚĂůŬŝŶŐĂďŽƵƚŝƚ ?ǀĞƌǇƐŝŵŝůĂƌ ?P6. 
 
Indeed, a participant proposed merging these statements:  
  ‘ ..., but it is linŬĞĚƚŽŝƚĞŵ ? ? ?ǇŽƵĐŽƵůĚƉƵƚƚŚĂƚĂƐ ‘/ĐĂŶǀĂƌǇƚŚĞĚŽƐĞĂŶĚ
 ƚŝŵĞƐ/ƚĂŬĞƚŚĞŵĞĚŝĐŝŶĞƐ ? ? ? ?P3.   
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Subsequently, minor changes were made to item 39  ? ‘I can change the times I take my 
ŵĞĚŝĐŝŶĞƐŝĨ/ǁĂŶƚƚŽ ? ? ?ǁŝƚŚĚĞůĞƚŝŽŶŽĨƚŚĞĞŶĚŝŶŐ ‘ QŝĨ/ǁĂŶƚƚŽ ?. 
 
Item 40 
Although item 40  ? ‘It is easy to keep my medicines routine ? ? was understood by all 
participants, nearly half (n=4, 36%) perceived repetition or subtle differences with item 
4  ? ‘TakŝŶŐŵĞĚŝĐŝŶĞƐŝƐƌŽƵƚŝŶĞĨŽƌŵĞ ? ?. While trying to differentiate the two items, a 
participant articulates that: 
  ‘/ƚŚŝŶŬƚŚĞǇĂƌĞĂůŵŽƐƚƐŝŵŝůĂƌ ?ĂƌĞŶ ?ƚƚŚĞǇ ?EƵŵďĞƌ ? ?ŝƐĂƐŬŝŶŐŝĨǁĞĨŝŶĚŝƚ
 ĞĂƐǇ ?ĂŶĚŶƵŵďĞƌ ?ŝƐĂƐŬŝŶŐǁŚĞƚŚĞƌŝƚ ?ƐũƵƐƚƌŽƵƚŝŶĞ ?ŶŽƚǁŚĞƚŚĞƌŝƚŝƐĞĂƐǇ ?
 With the routine ŝƚŐĞƚƐĞĂƐǇ ?ĚŽŶ ?ƚǇŽƵƚŚŝŶŬ ? ?P6.  
 
Similarly, another participant ŵĞŶƚŝŽŶĞĚƚŚĂƚ ‘It is [referring to item 40] roughly the 
same kind oĨƋƵĞƐƚŝŽŶ ?ĂƐŝƚĞŵ ? ?/ƚŚŝŶŬ ? ?P4 and when probed about possible item 
ĚĞůĞƚŝŽŶƐƚƌĞƐƐĞƐƚŚĂƚ ‘ QďƵƚ/ǁŽƵůĚŬĞĞƉŝƚƚŚĞƌĞ ?W ? ?Consequently, both statements 
were retained in the questionnaire, to be explored in future statistical testing. 
 
Item 45 
While responding to item 45  ? ‘I understand what my doctor(s) tell me about my 
ŵĞĚŝĐŝŶĞƐ ? ?, a few participants (n=3, 27%) perceived repetitiveness with the 
aforementioned item 33  ? ‘My doctor tells me enough about my medicineƐ ? ?:  
  ‘ ǁŽǁ ?ƚŚĂƚŽŶĞĂŐĂŝŶ ?ƚŚĂƚ ?ƐƉŽƉƉĞĚƵƉďĞĨŽƌĞ ?ƚŚĂƚŽŶĞŝƐĚŽĐƚŽƌ ?ǁĞŚĂĚĂ
 ĚŽĐƚŽƌŽŶĞ ?ǇĞĂŚ ? ? ?Ĩlips back to previous page] you are being asked the  same 
 question with a different angle to see if you are being consistent with your 
 answers...they [items 45 and 33] are saying the samĞƚŚŝŶŐ ?P3 
 
    ‘ ?ŝƚŝƐƐŝŵŝůĂƌƚŽŽŶĞƋƵĞƐƚŝŽŶďĞĨŽƌĞ ?/ƚŚŝŶŬ ? there was one question about 
 my doctor tells me enough about my medicines [item 33], I saw there was a 
 ƋƵĞƐƚŝŽŶůŝŬĞƚŚŝƐ ?ĂŶǇǁĂǇ/ĚŽŶ ?ƚƚŚŝŶŬĚŽĐƚŽƌƐƚĞůůƉĞŽƉůĞĞŶŽƵŐŚ ? ?P4 
 
Item 46 
Similarly, two (18%) participants perceived repetitiveness among items in the 
pharmacist-communication domain [items 13, 36, and 46]. For instance, while reading 







Although generally comprehensible, a few participants perceived side-effect-related 
statements 47 ( ‘The side effects I get fƌŽŵŵǇŵĞĚŝĐŝŶĞƐĂƌĞďŽƚŚĞƌƐŽŵĞ ? ?, 28 ( ‘The 
side effects I get are worse than the problem for which I take medicines), and 29 ( ‘The 
side effects I get from my medicines interfere with my day-to-day life (e.g. work, 
ŚŽƵƐĞǁŽƌŬ ?ƐůĞĞƉ ? ? ? to be repetitious or redundant. For instance, one participant was 
hesitant to respond to statement 47 as he felt that it was related to items 28 and 29 
ĐŝƚŝŶŐƚŚĂƚ ‘ Q ?both statements are talking about thĞƐĂŵĞƚŚŝŶŐ ?ƚŚĞƐŝĚĞĞĨĨĞĐƚƐ ? ?P1. 
 
 Similarly, while responding to item 29, some participants mentioned that  ‘  ?ĂůŽƚ of 
ƉĞŽƉůĞǁŽƵůĚƐĂǇǁŚĂƚ ?ƐƚŚĞĚŝĨĨĞƌĞŶĐĞďĞƚǁĞĞŶ ?ƚŚŝƐŽŶĞ ?ĂŶĚƚŚĞŽŶĞ before [item 28] 
coz if they [side effects] are really bad of course they are going to interfere with your 
ĚĂǇƚŽĚĂǇůŝĨĞ ? ?P6. The three side-effect-related items were retained for further 
statistical testing.  
Item 51 
Although no comprehension problems were detected from item 51 ( ‘The health 
professionals providing my care know enough about me and my medicines ? ? ?two 
pĂƌƚŝĐŝƉĂŶƚƐƉĞƌĐĞŝǀĞĚƚŚĞƚĞƌŵ ‘ŚĞĂůƚŚƉƌŽĨĞƐƐŝŽŶĂůƐ ?as too general, and thus 
proposed specification to doctors/pharmacist:  
  ‘ ?ƚŚĞŵĂŝŶŚĞĂůƚŚƉƌŽĨĞƐƐŝŽŶĂůƐƚŚĂƚĂƌĞŵŽƌĞĐŽŶĐĞƌŶĞĚĂďŽƵƚŵĞdicines, its 
 only doctors and pharmacists that are more concerned about my medicines not 
 ĂŶǇŽƚŚĞƌ ? ? ? ?P1 
  ‘ ?ŝƚŚŝŶŬŝƚƐŚŽƵůĚďe the doctor or the pharmacist e.g. My pharmacist/doctor 
 providing my care know enough about me and my medicines ? ?P4. 
 
On the contrary, one participant assĞƌƚĞĚƚŚĂƚƚŚĞƐƚĂƚĞŵĞŶƚ ?ǁŝƚŚ ‘ŚĞĂůƚŚ
ƉƌŽĨĞƐƐŝŽŶĂů ?wording, encompasses all others personnel involved in patient care:  
  ‘ƚŚĂƚ ?ƐĐůĞĂƌ ?ďƵƚǁŚĞŶǇŽƵƐĂǇŚĞĂůƚŚĐĂƌĞƉƌŽĨĞƐƐŝŽŶĂůs, who do you mean by 
 that? I think what comes to my mind is that a nurse comes to my home and 
 gives me my medicines, like if I was too ill, nurse advising me, like in hospital ? ?
           P11.   







Item 55  
Although generally understood, item 55 ( ‘The side effects I get from my medicines 
adversely affect my well-being ? ? attracted diverse interpretations, with some 
participants expressing diffiĐƵůƚŝĞƐƵŶĚĞƌƐƚĂŶĚŝŶŐƚŚĞƚĞƌŵ ‘ǁĞůůďĞŝŶŐ ?.  
  ‘ ? ?/ƚŚŝŶŬǁĞůůďĞŝŶŐ ?ŚŽǁĚŽǇŽƵĚĞƐĐƌŝďĞǁĞůůďĞŝŶŐ ? ?ŚĞƐŝƚĂƚĞƐ ? ?ĨŽƌŵĞ ?ŝƚ ?Ɛ
 more about my physical wellbeing, basically how  i feel, ĐŽǌ/ĚŽŶ ?ƚ understand 
 it, I am having difficulty understanding it.. May be quality of life, i am not sure 
 quality of ůŝĨĞŝƐƵŶĚĞƌƐƚŽŽĚďǇĞǀĞƌǇďŽĚǇ ?P4 
 
Regardless, other participants spoke of physical, mental, and emotional wellbeing, 
suggesting comprehension. 
  ‘ ?ǁĞůůďĞŝŶŐ ?ǁŚĂƚĂďŽƵƚĂďŝůŝƚǇ to do certain tasks, rather than wellbeing, 
 [hesitates] it could be concentration that sort of thing, ŝƚ ?ƐŵŽƌĞŽǀĞƌĂůů ?ŵŽƌĞ
 generaliseĚ ?P5 
  ‘ ?ĂĨĨĞĐƚŝŶŐǇŽƵƌǁĞůůďĞŝŶŐŝƐďĂƐŝĐĂůůǇŚŽǁǇŽƵĂƌĞĐŽƉŝŶŐĚĂǇƚŽĚĂǇ ?P6 
  ‘..just basically feeling below per ?ĨĞĞůŝŶŐĨůĂƚ ?ŽƵƚŽĨƐŽƌƚƐ ?P10 
 
Visual Analogue Scale 2  W ƚŚĞǁŽƌĚ ‘ŽƉƚŝŵĂů ?
Perhaps, the most problematic question encountered by all participants was the 
second visual analogue scale ( ‘How optimal do you feel your medicines are for you? ? ?,
which provĞĚĚŝĨĨŝĐƵůƚƚŽƵŶĚĞƌƐƚĂŶĚ ?dŚĞƚĞĐŚŶŝĐĂůǁŽƌĚ ‘ŽƉƚŝŵĂů ?, originating from 
the recent medicines optimisation agenda by the Royal Pharmaceutical Society,1 was 
mostly unfamiliar and its intended meaning was not at all clear to most participants.  
 
ŝǀĞƌƐĞŝŶƚĞƌƉƌĞƚĂƚŝŽŶƐŽĨ ‘ŽƉƚŝŵĂů ?included terms such as optional, optimum target, 
satisfaction, or effective. 
  ‘ ?ƚŚĂƚŽƉƚŝŵĂů ?/ǁĂƐĂďŝƚƐƉŽŽĨĞĚŽŶƚŚĂƚ ?ĚŽĞƐŝƚŵĞĂŶŚŽǁ ‘ŽƉƚŝŽŶĂů ?/ĐĂŶ
 take it, what does it mean in your eyes, I mean ŽƉƚŝŵĂů ? ?/ĚŝĚŶ ?ƚƋƵŝƚĞŬŶŽǁ
 what you mean by that, to be honest. Do you mean how good do you feel your 
 medicines are for you ? ? ? ? ?P2 
 
  ‘,ŽǁŽƉƚŝŵĂů ?ƚŚĂƚ ?ƐĂŐŽŽĚŽŶĞ ?tŚĂƚĚŽǇŽƵŵĞĂŶďǇŽƉƚŝŵĂů ?/ĚŽŶ ?ƚ
 ŬŶŽǁ ? ?ŝƚ ?Ɛ not clear, I am gonna put a question mark on this one, ĐŽǌ/ĚŽŶ ?ƚ
 ŬŶŽǁǁŚĂƚŝƚŵĞĂŶƐ ?W ?
 
The statement was subsequently revised to  ‘On balance, do you feel your medicines 




5.3.4.2 Response options 
Standard guidance124 recommends that item response options should: have adequate 
instructions for use; be clear and ordered appropriately; reflect distinction among 
response choices; and minimise floor or ceiling effects. In this study, most participants 
did not have problems using the five-Likert type, ordinal, scale ranging from strongly 
agree to strongly disagree. Some participants desired more spread out distribution of 
response options. For instance, one participant felt that:  
  ‘ ? ?ƚŚĞƌĞƐŚŽƵůĚďĞĂŶĞǆƚƌĂďŽǆƐĂǇŝŶŐ ‘ƐŽŵĞƚŝŵĞƐ ? ?ďĞƚǁĞĞŶŶĞƵƚƌĂůĂŶĚ
 agree].. ?ŝƚ ?Ɛnot an everyday problem, but havŝŶŐĂƐŽŵĞƚŝŵĞƐŽƉƚŝŽŶĐŽƵůĚĚŽ ? ? 
           P9.  
Although the questionnaire asks for personal views, opinions or experiences, some 
participants referred to general opinions while responding to certain statements. For 
instance, while responding to item  ? ? ‘I worry about paying for my medicines), a 
participant who did not pay for his prescription medicines, erroneously selected an 
 ‘ĂŐƌĞĞ ?ƌĞƐƉŽŶƐĞƵƉŽŶƌĞĨĞƌƌŝŶŐƚŽŐĞŶĞƌĂůŽƉŝŶŝŽŶ ? 
  ‘ ?/ǁŽƌƌǇĂďŽƵƚƉĂǇŝŶŐĨŽƌŵǇŵĞĚŝĐŝŶĞƐ ?ǇĞƐǀĞƌǇĐůĞar, but personally, it 
 ĚŽĞƐŶ ?ƚbother me in one way or the other. But for some people, if they are 
 ƉĂǇŝŶŐĨŽƌŵŽƌĞƚŚĂŶŽŶĞŵĞĚŝĐĂƚŝŽŶ ? ?P4  
 
,ŽǁĞǀĞƌ ?ƚŚĞƵƐĞŽĨ ‘ŶĞƵƚƌĂůŽƉŝŶŝŽŶ ? ?ĂƐƚŚĞŵŝĚ-point response option, was variable. 
tŚŝůĞƐŽŵĞƉĂƌƚŝĐŝƉĂŶƚƐƐĞůĞĐƚĞĚ ‘ŶĞƵƚƌĂůŽƉŝŶŝŽŶ ?ǁŚĞŶĂƐƚĂƚĞŵĞŶƚǁĂƐŶŽƚ
ĂƉƉůŝĐĂďůĞƚŽƚŚĞŵ ?ĂƐƐƚŝƉƵůĂƚĞĚŝŶƚŚĞŐĞŶĞƌĂůŝŶƐƚƌƵĐƚŝŽŶƐ ) ?ŽƚŚĞƌƐƐĞůĞĐƚĞĚ ‘ŶĞƵƚƌĂů ?
mistakenly, and when they did not fully understand the statement:  ‘ ?/ƌĞĂůůǇĚŽŶ ?ƚ
understand that one, /ǁŝůůƉƵƚŶĞƵƚƌĂůŽŶƚŚĂƚŽŶĞ ? ?P7 
 
5.3.4.3 Perceptions of concepts (constructs) measured the by LMQ 
General probing was used to elicit perceptions of the concepts evaluated by the LMQ.  
DŽƐƚƉĂƌƚŝĐŝƉĂŶƚƐŚĂĚĂĐŽƌƌĞĐƚƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞŝŶƐƚƌƵŵĞŶƚ ?ƐĐŽŶĐĞƉƚƐ ?ƉƵƌƉŽƐĞ ?
One participant felt that the questionnaire was looking at the impact of medicines on 
day-to-day life:  ‘ ?ŝƚ ?ƐũƵƐƚǇŽƵǁĂŶƚƚŽŬŶŽǁǁŚĞƚŚĞƌŵĞĚŝĐines are having an impact 
on your daily life ? ? ? ?W ? ?A few others perceived the questionnaire as a measure of 
positive experiences of medicine use, and patient satisfaction.  
  ‘I think it [the LMQ] is trying to get experience of medication and satisfaction 
 with medication, it is teasing out how people feel about medication, are they 
 ŚĂƉƉǇǁŝƚŚŝƚ ?ĂƌĞƚŚĞǇƐĂƚŝƐĨŝĞĚǁŝƚŚŚĞĂůƚŚĐĂƌĞƉƌŽĨĞƐƐŝŽŶƐ ?/ĚŽŶ ?ƚƚŚŝŶŬƚŚŝƐ




Respondents were asked to give tŚĞŝƌŽƉŝŶŝŽŶƐĂŶĚƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨ ‘ŵĞĚŝĐine 
ďƵƌĚĞŶ ?ĂŶĚǁŚĞƚŚĞƌƚŚĞ>DYspecifically assessed this concept. Although most 
ƵŶĚĞƌƐƚŽŽĚƚŚĞǁŽƌĚ ‘ďƵƌĚĞŶ ?, as demonstrated by a participant:  
  ‘ ?/ƚŚŝŶŬďƵƌĚĞŶ ?ƉĞŽƉůĞŵĂǇƵŶĚĞƌƐƚĂŶĚŝƚ ?/ĨǇŽƵůook at the word ďƵƌĚĞŶ ?ŝƚ ?Ɛ
 a ǁĞŝŐŚƚ ?ŝƚ ?ƐĂůŽĂĚ ?ŝƚǁĂƐŶ ?ƚƚŚĞƌĞ ď ĨŽƌĞ ? ?P3 
 
Others seemed to disagree with the rationale of the concept of medicine burden:  
 ‘/ĚŽŶ ?ƚƚŚŝŶŬŵĞĚŝĐŝŶĞƐĂƌĞĂďƵƌĚĞŶ ?ƚŚĞǇĂƌĞƚŚĞƌĞĨŽƌĂƌĞĂƐŽŶ ? ?W ? ? 
Perceptions that the benefits of using medicines tend to outweigh negative 
experiences have been cited in other questionnaire-evaluation studies.94  
 
Another participant seemed to imply that the concept of medicine burden was a term 
more applicable to pharmacy professionals. 
 ‘/ĚŽŶ ?ƚŚĂǀe [medicine burden] gone up to 0 coz ŝƚ ?ƐŶŽďƵƌĚĞŶĂƚĂůůƚŽŵĞ ?I ĚŽŶ ?ƚ
know if the medical profession will see any of tŚŝƐ ?ĐŽŶĐĞƉƚ ? ?ŽƌǁŚĞƚŚĞƌŝƚ ?Ɛjust 




5.3.4.4 General layout and format, length, and item-ordering. 
Layout and format 
Generally, most participants did not report problems with the layout or format of the 
questionnaire. For instance, while referring to the general layout a participant said, 
 ‘ ? ? ?ƚŚĂƚ ?ƐŽŬĂǇ ?ƚŚĂƚ ?ƐŚŽǁǇŽƵǁŽƵůĚĨŝůůĂƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ƚŚĂƚ ?ƐĨŝŶĞ ? /ƚ ƐĂůůƐĞůĨ-
ĞǆƉůĂŶĂƚŽƌǇ ?ŝƚ ?ƐĞĂƐǇƚŽƵŶĚĞƌƐƚĂŶĚ ?ǇŽƵ ŐŽƚŝƚĂůůƚŚĞƌĞ ?ŚĂǀĞŶ ?ƚǇŽƵ ? ?P2  
Another participant commented that  ‘on the ǁŚŽůĞ ?/ƚŚŝŶŬŝƚ ?ƐƋƵŝƚĞŐŽŽĚ ?P6 
 
Questionnaire length 
Concerning the length of the questionnaire, a fair proportion of participants perceived 
the questionnaire as lengthy.  
  ‘ ?ŝƚ ?ƐůŽŶŐ ?ŝĨǇŽƵƐĞŶĚŝƚƚŽƉĞŽƉůĞƚŚĞǇǁŝůůŐŽ ?ŽŚŐŽƐŚ ? ?P4 
  ‘/ƚ ?ƐĐůĞĂƌto me, but might be a bit long. I think it might be a bit long for some 
 ƉĞŽƉůĞ ?ƉŽƐƐŝďůǇ ? ?P5  
  ‘ ?ŶƵŵďĞƌŽĨƋƵĞƐƚŝŽŶƐ ?ƚŚĂƚ ?ƐĂĚŝĨĨŝĐƵůƚŽŶĞ, I presume 10 basic ones that 
 would cover everything. May be just 10 things,  ?ŝƚĞŵƐ ? ?ǇŽƵĚŽŶ ?ƚǁĂŶƚƚŽŐĞƚ
 people fed up of reading all this, do you? You wanƚƚŚĞŵƚŽƌĞƐƉŽŶĚƚŽŝƚ ?ĚŽŶ ?ƚ




However, a few others had mixed feelings about the appropriate number of questions; 
some acknowledged the need to balance questionnaire length with the content 
coverage. 
  ‘ ?ĂĐƚƵĂůůǇ/ĚŝĚŶ ?ƚƚŚŝŶŬŝƚǁĂƐƚŽŽďĂĚ ?ŝŶƚĞƌŵƐ of length], you need it to be 
 that long so it gives you the picture that you waŶƚ ?P9 
 
  ‘I think the questions are enough. But you might get some comments like they 
 are ĂƉĂŝŶ ? ? ?ďƵƚĂƉĂƌƚĨƌŽŵƚŚĂƚ/ƚŚŝŶŬŝƚ ?ƐŽŬĂǇ ?W ? 
 
Questionnaire length was directly linked to item redundancy or repetitiveness, as a 
commonly described problem. One participant stressed that  ‘In there, there is a bit 
ƚŚĂƚƐĂǇƐĂůŵŽƐƚƚŚĞƐĂŵĞƚŚŝŶŐ ?P2, while another felt that  ‘sometimes it feels like you 
ĂƌĞŐŽŝŶŐŽǀĞƌƚŚĞƐĂŵĞƚŚŝŶŐ ?P9.   
Item-ordering 
A participant responding to item 32 ( ‘I ĚŽŶ ?ƚŵŝŶĚƉĂǇŝŶŐĨŽƌŵy medicines because I 
ŶĞĞĚƚŚĞŵ ? ? in the intermixed version (LMQ-2.1-I) expressed a typical concern about 
item ordering and grouping. 
  ‘ ?ŝƐŶ ?ƚƚŚĂƚ ?ŝƚĞŵ ? ? ?ƌĞĂůůǇŽƵƚŽĨƉůĂĐĞ ?ƐŚŽƵůĚŶ ?ƚƚhey be together with item 8 
 [I worry about paying for my medicines] they are exactly the same but worded 
 ĚŝĨĨĞƌĞŶƚůǇ ? ? ? ?P10 
 
Similarly, while responding to item 33 ( ‘My doctor tells me enough about my 
ŵĞĚŝĐŝŶĞƐ ? ?, the same participant stressed that  ‘ ?ƐŚŽƵůĚŶ ?ƚƚŚĞǇďĞƚŽŐĞƚŚĞƌ ?ǁŝƚŚ
related items]? Those about doctor and tŚŽƐĞĂďŽƵƚƉŚĂƌŵĂĐŝƐƚ ? ?P10  
 
Not surprisingly, further probing about questionnaire formats indicated that most 
participants preferred the grouped/labelled version (LMQ-2.1-GL) when compared to 
the intermixed version (LMQ-2.1-I).  
  ‘I would go with that one [the grouped and labelled] because it is guiding 
 people  to what is coming next. If you are doing it on your own, something like 
 that [grouping and labelling] could be helpful. The heading tells me what to 
 ĞǆƉĞĐƚ ?ŝƚ ?ƐĂbout ĐƌĞĂƚŝŶŐĞǆƉĞĐƚĂƚŝŽŶƐ ?/ƚŚŝŶŬŝƚ ?ƐůŝŬĞĚŽŝŶŐĂƉƌĞƐĞŶƚĂƚŝŽŶ ?
 you set the ĂŐĞŶĚĂ ?ŝƚƐŐŝǀŝŶŐƉĞŽƉůĞĂŶŝĚĞĂĂďŽƵƚǁŚĞre you are going with 
 the next ƋƵĞƐƚŝŽŶ ? ?P4 
 
  ‘that's good, it keeps your mind on that particular subject better. Grouping it all 




  ‘/ƚŚŝŶŬŝƚ ?ƐďĞƚƚĞƌ ?ĐŽǌŝƚŵĂŬĞƐŝƚĐůĞĂƌ ?ĂƐƚŽǁŚĂƚ ?ƐĞǆƉĞĐƚĞĚ ?ĂŶĚƚŽǁŚĂƚƚŚĞ
 questions actually mean ...if it was more spacious, I like the lay out of 
 ƚŚŝƐ ?ŐƌŽƵƉĞĚ ?ůĂďĞůůĞĚ ?ďĞƚƚĞƌ ?P6 
 
  ‘ ?/ƚŚŝŶŬƚŚĂƚ ?ƐĞĂƐŝĞƌ to understand [referring to grouped and labelled] ? P8 
  ‘ ?ŝƚ ?ƐĂůŵŽƐƚƚŚĞƐĂŵĞŽŶĞƐ ?ǇĞĂŚ ?/ŶŽƚŝĐĞĚƚŚĞǇĂƌĞŐƌŽƵƉĞĚ ?ƚŚŝƐŝƐƉƌŽďĂďůǇ
 better.  I would recommend this one [the grouped/laďĞůůĞĚ ? ?ŝƚ ?ƐĂůů ƋƵŝƚĞĐůĞĂƌ ?
           P2 
 
Some participants, on the other hand, could not immediately identify the differences 
between the two questionnaire versions. For instance, one participant felt that  ‘most 
of the questions are the same, at the enĚŽĨƚŚĞĚĂǇ ?ŝƚ ?ƐĂůůƚŚĞƐĂŵĞ ?P7, while another 
admits that  ‘I ĚŝĚŶ ?ƚƐĞĞƚŚĞŚĞĂĚŝŶŐ ?/ǁĂƐůŽŽŬŝŶŐĂƚ ƚŚĞƋƵĞƐƚŝŽŶƐ ?W ?  
 
Confidence in self-reporting 
Although most participants showed confidence in using the self-reported 
questionnaire, assessed by direct observation, a few others expressed concerns about 
their competency in assessing certain aspects of their medicine use experience. As an 
example, a participant responding to item 5  ? ‘I am satisfied with effectiveness of my 
medicines) articulated:  
  ‘ŶĞƵƚƌĂů ?ďĞĐĂƵƐĞƐŽŵĞƚŝŵĞƐǇŽƵĚŽŶ ?ƚŬŶŽǁǁŚĞƚŚĞƌƚŚĞǇĂƌĞĞĨĨĞĐƚive, until 
 you go for a review, and they check your blood pressure ?ƐŽǇŽƵĚŽŶ ?ƚ
 ŶĞĐĞƐƐĂƌŝůǇŬŶŽǁ ? ?P9 
 
 Similarly, while responding to item13 ( ‘my pharmacist tells me enough about my 
medicines ?) a participant wondered  ‘ ?ŚŽǁĚŽǇŽƵŬŶŽǁǁŚĂƚŝƐĞŶŽƵŐŚĂďŽut 












5.4  Discussion  
In this chapter, I found that the vast majority of items in the LMQ instrument were 
interpreted as intended, and the questionnaire was generally easy to use. Efforts were 
made to detect and eliminate potential flaws in the LMQ. Common questionnaire 
problems identified were: perceived repetitiveness/redundancy among items 
(especially those within an individual or in similar domains), lengthy nature of the 
questionnaire, variability in use of response options, misinterpretation of items (and 
specific words), and different perceptions of the overall concept measured by the 
LMQ. Such issues, if left unattended, may affect responses to a questionnaire and its 
validity. 
 
Direct patient input in instrument development, and testing patient understanding, is 
an essential process, which in addition contributes to evidence for content validity.124 
Cognitive interviewing is a widely used qualitative technique for evaluating and 
improving new instruments, including patient-reported questionnaires, to ensure 
appropriate content and comprehension by the target population.94,165,166,201 
Preliminary questionnaire validation, using a small number of participants, is a key 
aspect and step towards comprehensive psychometric validation.202  
^ŽŵĞŽĨƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞƉƌŽďůĞŵƐŝĚĞŶƚŝĨŝĞĚŝŶƚŚŝƐƐƚƵĚǇ ?ƉĂƌƚŝĐƵůĂƌůǇ ‘ǀĂƌŝĂƚŝŽŶŝŶ
ƚŚĞŝŶƚĞƌƉƌĞƚĂƚŝŽŶŽĨŝƚĞŵƐ ? ? have also been documented in other studies validating 
medicine-related questionnaires.94 As discussed previously, some participants may not 
always read instructions, and the presence of a researcher may also create an artificial 
situation and affect how respondents answer questions.94  
 
Perceived repetitiveness/redundancy among items was a commonly documented 
issue. Previous criticisms of LMQ versions indicated a lack of items covering side 
effects, cost, and social impact of medicines. To mitigate this, item generation included 
more items, intentionally, to fill these domains; thus, cognitive interview would serve 






Despite diverse contributions from interviewees, it was reassuring that, except for a 
few revisions to wording, not many substantial modifications to the LMQ were made, 
and all items were retained. Nevertheless, the length of the LMQ instrument warrants 
further item reduction and refinement, possibly in a further statistical factor analysis, 
which could also help assess item redundancy. 
 
Perhaps, another pertinent issue emerging from cognitive interview data relates to 
different perceptions of constructs measured by the LMQ instrument. As described in 
ƚŚĞƌĞƐƵůƚƐƐĞĐƚŝŽŶ ?ĂĨĞǁƉĂƌƚŝĐŝƉĂŶƚƐĐŚĂůůĞŶŐĞĚƚŚĞ>DYĂƐĂŵĞĂƐƵƌĞŽĨ ‘ŵĞdicine 
ďƵƌĚĞŶ ? ?ǁŝƚŚŽŶĞƉĂƌƚŝĐŝƉĂŶƚŶŽƚŝŶŐƚŚĂƚ ‘ŝƚ ?ƐŶŽƚŶĞŐĂƚŝǀĞ ? and a few others feeling it 
considered positive experiences (or satisfaction) with medicine use. Similar conceptual 
problems have been reported ǁŚŝůĞĞǀĂůƵĂƚŝŶŐĂŵĞĂƐƵƌĞŽĨ ‘inherent burden of drug 
ƚƌĞĂƚŵĞŶƚ ? ?94 ǁŚĞƌĞŶŽƚĂůůŝƚĞŵƐǁĞƌĞ ‘actually perceived as burdensome by the 
ƉĂƚŝĞŶƚƐ ? ?ĂŶĚ ‘respondents were unwilling to admit medication problems when they 
perceived no treatment alternatiǀĞƐ ? ?94 Perceptions that the benefits of using 
medicines outweigh negative medicine-related experiences are commonly 
documented.21,108,109 Before conclusive decisions can be made, there is a need to 
explore, in further studies, the vĂůŝĚŝƚǇŽĨƚŚĞ ‘ŵĞĚŝĐŝŶĞďƵƌĚĞŶ ?ĐŽŶƐƚƌƵĐƚĂƐĂŬĞǇ
concept hypothesised to underlie the Living with Medicines Questionnaire.  
Additional research may also check possible correlations with existing generic 
measures, particularly those considering satisfaction with prescription medicines.109  
 
ƵĞƚŽǀĂƌŝĂďŝůŝƚǇŝŶƚŚĞƵƐĞŽĨƌĞƐƉŽŶƐĞŽƉƚŝŽŶƐ ?ƉĂƌƚŝĐƵůĂƌůǇƚŚĞ ‘ŶĞƵƚƌĂůŽƉŝŶŝŽŶ ?ŽĨ
the 5-point Likert-type scale, there is need to explore opportunities for improvement 
in this area. A possible solution could be to eliminate the specific instruction for using 
this response option. The cover page of the questionnaire employed in the cognitive 
ŝŶƚĞƌǀŝĞǁƐ ?ƐƵŐŐĞƐƚĞĚƚŚĂƚ ‘if a statement does not apply to you, please tick the box for 
ŶĞƵƚƌĂůŽƉŝŶŝŽŶ ?. There are arguments against the use of neutral responses as 
midpoints,203 and an earlŝĞƌƌĞƐĞĂƌĐŚĞƌƐƚŝƉƵůĂƚĞƐƚŚĂƚ ‘there is no assurance 
whatsoever that a subject [ or participant] choosing the middle scale position harbours 
a neutral opinion. A subject's choice of the scale midpoint may result from: ignorance, 




Earlier versions of the LMQ , in which statements were rated as strongly agree, agree, 
mostly agree, do not agree, and strongly disagree, also included a  ‘ĚŽĞƐŶŽƚĂƉƉůǇ ? 
option for selected statements, which was later removed in subsequent revisions 
owing to challenges with data handling, factorability, and other analyses, a problem 
reported in similar studies.94 Moreover, further revisions to the instrument introduced 
ƚŚĞ ‘ŶĞƵƚƌĂůŽƉŝŶŝŽŶ ?ƌĞƐƉŽŶƐĞ ?ĂƐĂƌĞƉůĂĐĞŵĞŶƚƚŽ ‘ŵŽƐƚůǇĂŐƌĞĞ ?ƚŚĂƚƐĞƌǀĞĚĂƐ
midpoint option in earlier drafts of the instrument. Thus, with these considerations in 
mind, the instructions to using a neutral opinion were deleted from the cover page, to 
minimise confusion about the use of this response option. The visual analogue scales, 
which also lacked clearly marked midpoints and subdivisions, need further attention to 
minimise measurement problems for both end-users and researchers.    
 
The order in which questions are asked may affect survey data, and the 
selection/testing of appropriate item ordering during scale development is relevant.127  
Item ordering was an issue arising from the cognitive interviews. In this study, 
intermixed- and grouped/labelled- versions were tested qualitatively. The former 
covered a sequence of items, which were arranged such that consecutive items related 
to different domains, while the latter version included items clustered in meaningful 
domains.  
 
Choosing item ordering should consider the overall aim and purpose of the 
questionnaire. Intermixing items, haphazardly, may be more favourable when a 
questionnaire is intended to measure a psychological construct (such as medicine 
burden), and is recommended for newly developed measures.204 Nevertheless, 
intermixing questions may cause confusion to respondents, affect motivation, and 
cause response fatigue. Perceived repetitiveness of items, a problem encountered 
during cognitive interviews, may also be explained by intermixed ordering of items as 
participants perceived duplication among items belonging to the same domain. On the 
other hand, thematic item grouping minimises confusion (and response burden), 
encourages coherence in the flow of items, and eases cognitive demands related to 
completing questionnaires since the contextual meaning of individual items is 
considered.205 Krosnick and Presser (2010) suggest that item grouping reflects a more 
 ‘ƌĞĂůŝƐƚŝĐǁŽƌůĚƐĞƚƚŝŶŐƐ ?ǁŚĞƌĞĐŚŽŝĐĞƐĂƌĞƵƐƵĂůůǇŵĂĚĞǁŝƚŚŝŶĐŽŶƚĞǆƚ.206 
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Nonetheless, there is mixed guidance with respect to item-ordering and its impact on 
questionnaire properties.207,208 Recent empirical evidence is in favour of the 
intermixing of survey items to create measures that reflect true reliability values, as 
ŝƚĞŵŐƌŽƵƉŝŶŐƚĞŶĚƐƚŽĂƌƚŝĨŝĐŝĂůůǇŝŶĨůĂƚĞĂŵĞĂƐƵƌĞ ?ƐŝŶƚĞƌŶĂůƌĞůŝĂďŝůŝƚǇĂŶĚis thus 
regarded as unsuitable for new instruments.204 Thus, all subsequent studies employed 
an intermixed version of the Living with Medicines Questionnaire. 
 
Strengths and limitations 
This study involved a substantial assessment of the face and content validity of a 
revised version of the LMQ, with no further psychometric testing. Content validation 
ĂůůŽǁƐĞǀĂůƵĂƚŝŽŶŽĨĐŽŶĐĞƉƚƐĐŽǀĞƌĞĚďǇƚŚĞŝŶƐƚƌƵŵĞŶƚĨƌŽŵƵƐĞƌƐ ?ƉĞƌƐƉĞĐƚŝǀĞƐ ?ĂŶĚ
participants are able to assess the relevance of items to their treatment or 
condition.209 A combination of techniques, comprising think-aloud and verbal probing, 
were employed to elicit questionnaire-related issues, and to examine potential flaws 
with questionnaire items. Nevertheless, there are methodological challenges with 
respect to probing techniques (for instance choosing what to say/or not) during 
cognitive interviews.165,210 Although not documented, it was generally observed that 
ƉĂƌƚŝĐŝƉĂŶƚƐĨƌĞƋƵĞŶƚůǇĨŽƌŐŽƚƚŽ ‘ƚŚŝŶŬ-ĂůŽƵĚ ? ?ĂŶĚǁĞƌĞĞŝƚŚĞƌƌĞŵŝŶĚĞĚŽƌ probed to 
get them to say something. As such, the verbal probing tended to dominate the 
cognitive interviewing process, potentially biasing the findings.  
 
Although the sample population involved in questionnaire evaluation was generally 
balanced with respect to educational level and the number of medicines used, the 
majority of participants were retirees, most of whom did not pay for their medicines. 
However this reflects the reality of the English population, the majority of whom do 
not pay prescription charges.32 Although it is possible that, given this, the large 
majority of the sample population may have been unable to assess issues around cost-
related burden. Nonetheless, items in the cost domain were understandable and 
perceived relevant to those not exempt from prescription charges. Similarly, this group 
of participants mostly managed their own medicines independently- as is the case for 
the large majority of patients. Again, it is likely that patients who may need support 
ǁŝƚŚŵĞĚŝĐŝŶĞƐƵƐĞ ?Ğ ?Ő ?ƚŚŽƐĞƌĞƋƵŝƌŝŶŐĐĂƌĞƌƐ )ŵĂǇĂƐƐĞƐƐƚŚĞ ‘ƉƌĂĐƚŝĐĂůŝƚŝĞƐ ?ŝƐƐƵĞƐŝŶ
the questionnaire differently. 
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The version of the LMQ produced following these cognitive interviews provides a 
baseline for further quantitative testing in a large sample of people using regular 
prescription medicines, for any disease/condition. The cognitive interviewing process 
requires varying levels of expertise and experience for interviewers. The primary 
interviewer (BK) was a novice, however used pre-developed probes to guide the 
interview. She also had prior knowledge about the concepts covered in the instrument, 
and practiced interviewing skills beforehand, all of which may have smoothened the 
cognitive interview process,165 and enhanced validity of the findings. The potentially 
problematic items, which were elicited from the interviews, were resolved through 
discussions with my supervisors, and revisions made to item wording.  
 
5.5 Chapter summary  
The LMQ-2 was revised to incorporate new dimensions, and minor changes to the 
wording of individual statements were founded on patient-generated interview data, 
the literature, and discussions with my supervisors. Cognitive interviewing techniques 
contributed valuable information about face and content validity of the revised LMQ. 
It enabled questionnaire problems to be identified and addressed, as a step towards 
further instrument validation. Questionnaire properties, including acceptability, ease 











Chapter 6 Formulating the LMQ-




As described in previous chapters, the original 60-item Living with Medicines 
Questionnaire (LMQ-1) was designed to measure medicine burden. Following 
preliminary item reduction, Chapter 4 presented a 42-item version questionnaire 
(LMQ-2) with eight domains. However, this version lacked items about cost-related 
burden of prescription medicines, impact of side effects, and the social impact of using 
medicines, which are vital aspects of the ƉĂƚŝĞŶƚ ?Ɛmedicine use experience. The LMQ-
2 was therefore further developed to include these relevant factors. Chapter 5 
described the generation of a 58-item interim version of the questionnaire (LMQ-2.1), 
and face/content validation of the LMQ-2.1 with people on long-term medicines.   
 
Although an instrument may appear to measure what the developers intend it to 
measure at face value, it is worth ascertaining its underlying constructs using 
appropriate statistical methodology. Since the LMQ-2.1 was a product of several 
revisions (content addition, rewording, or deletions), as described in Chapter 5, it was 
deemed necessary to reinvestigate the dimensional structure of this interim version 
(LMQ- 2.1), so as to formulate and confirm a final questionnaire (LMQ-3). 
 
 ŽŶƐƚƌƵĐƚǀĂůŝĚĂƚŝŽŶŽĨ ‘ƌĞůĂƚŝŽŶƐŚŝƉƐĂŵŽŶŐŝƚĞŵƐ ?ĚŽŵĂŝŶƐ ?ŽƌĐŽŶĐĞƉƚƐ ?124 is 
indispensable for instruments undergoing development, as described in earlier 
chapters. In Chapter 4, factor analysis was employed for item reduction and to explore 
item groupings in earlier phases of LMQ development (LMQ-2). As described in the 
methodology section (Chapter 3), factor analysis is widely used in instrument 
validation and there are two common approaches: exploratory (EFA) or confirmatory 
factor analysis (CFA).188  In this chapter, EFA was initially used to explore the underlying  
questionnaire structure of LMQ-2.1, which generated hypotheses about item 
groupings. EFA also facilitated item reduction to formulate the LMQ-3. As described 
earlier, CFA explicitly tests and confirms a priori hypothesised associations among 




For this study, CFA was used to cross-validate the EFA-derived factor structure. As a 
more advanced statistical technique, part of structural equation modelling (SEM), CFA 
techniques are advantageous owing to their confirmatory approach to data analysis 
rather than the exploratory and descriptive  approaches employed in conventional 
EFA.180,183 It was also necessary to confirm the most appropriate representation of the 
ƋƵĞƐƚŝŽŶŶĂŝƌĞ ?Ɛ (LMQ-3) dimensional structure. &ĐĂŶĂƐĐĞƌƚĂŝŶƚŚĞ ‘ŐŽŽĚŶĞƐƐŽĨĨŝƚ ?
of a hypothesised model to sample data, and allows comparison of alternative 
measurement models (factor-ƐƚƌƵĐƚƵƌĞƐ )ƚŽƵŶĚĞƌƐƚĂŶĚƚŚĞ ‘ƐŝŵƉůĞƐƚ ?ĞǆƉůĂŶĂƚŝŽŶŽĨ
questionnaire dimensions.188 Revisions to the LMQ, described in Chapter 5, 
superficially tested a visual analogue scale, a global item, designed to assess perceived 
medicine burden. ůƚŚŽƵŐŚŐůŽďĂůŝƚĞŵƐĂƌĞƚŚŽƵŐŚƚƚŽďĞ ‘ƐƵƉĞƌŽƌĚŝŶĂƚĞĐŽŶĐĞƉƚƵĂůůǇ
ĂŶĚƉƐǇĐŚŽůŽŐŝĐĂůůǇ ? ? ?,109 they may not accurately assess specific dimensions of 
medicine burden. Thus, a hierarchical CFA approach was also used to test the 
hypothesis of whether (and to what extent) collectively all LMQ-3 domains relate to 
medicine burden as an overarching construct. Medicine burden is hypothesised to be a 
general factor underlying the LMQ-3.  
 
Aims and objectives 
 This psychometric validation study aimed to ascertain construct validity by: 
a) Condensing the 58-item questionnaire (LMQ-2.1) into a shorter instrument 
(LMQ-3), and exploring its dimensionality using EFA. 
b)  Confirming the LMQ-3 dimensional structure by testing the EFA-derived model 
and testing alternative measurement models using CFA.  















Ethics approval was granted by the Medway School of Pharmacy Ethics Committee 
(See Appendix 8). 
6.2.1 Study participants 
Similar to previous studies, study participants were members of the general public 
living in the UK, aged 18 years or over, and using at least one regular prescription 
medicine for any disease/condition. Participants completed screening questions to 
check their eligibility to participate in the study.  
6.2.2 Instruments 
Participants completed the LMQ-2.1, a 58-item variant of the Living with Medicines 
Questionnaire. It also had a free-text open question and a section for participant 
demographics. The LMQ-2.1 had three visual analogue scales (VAS), as described in 
Chapter 5, one of which asked respondents to self-report their overall medicine 
burden on a 10-ĐŵƐĐĂůĞ ?ƚŚĞĂŶĐŚŽƌƐǁĞƌĞ ? ‘ĨŽƌŶŽďƵƌĚĞŶĂƚĂůů ?ĂŶĚ 10 for 
 ‘ĞǆƚƌĞŵĞůǇďƵƌĚĞŶƐŽŵĞ ? ?An electronic version of this questionnaire was designed 
using Qualtrics©.  
6.2.3 Study recruitment procedures  
Data were gathered using an on-line survey accessible to UK residents. In this web-
based survey, recruitment of participants was conducted via: a) social media including 
Twitter and Facebook posts through patient organisations, and b) via health websites.  
With respect to social media, brief information about the study (and inclusion criteria) 
was posted to promote the survey. Using specially-designed social-media webpages for 
the LMQ project, the researcher (BK) posted a survey link on different social media 
platforms between August and October 2015. Twitter was mostly used owing to the 
large number of health- and patient- organisations already known to the LMQ project 
(purposive sampling); many of these had participated in an earlier study described in 
Chapter 4. To improve response rates, tweets were posted at different times of the 
day, target patient groups were followed on their social media sites, and their posts 
were liked to increase on-line visibility of the survey. Figure 6-1 shows a sample 
recruitment text on Twitter. 
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With respect to recruitment via health websites, permission to distribute the survey 
link was initially sought from personnel in-charge, via email (Appendix 17), upon 
provision of study information. Managers of health websites were asked to post an 
invitation message and screening inclusion criteria on their websites or other media 
(e.g. social media, electronic newsletters, or via email to their panellists), alongside an 
anonymous survey link.  
 
Out of 51 patient organisations contacted, 13(25.5%) agreed to take part in the study, 
and directly promoted the survey to potential participants. Table 6-1 below shows 
























 Table 6-1 Patient organisations that participated in the LMQ-2.1 on-line survey 
  
 Notes; ME, Myalgic Encephalomyelitis (also known as chronic fatigue syndrome);  
 MS, Multiple Sclerosis; ITP, Immune thrombocytopenic purpura, a bleeding disorder. 
 
 
 Patient organisation 
1 Backup Trust 
2 Epilepsy Action 
3 Epilepsy UK 
4 UK Health forum 
5 Lupus Patients Understanding & Support 
6 ME Association UK 
7 MS Trust  
8 Patient Information Forum 
9 National Osteoporosis Centre 
10 Stroke Association 
11 Thyroid UK 
12 The Hysterectomy Association 












6.2.4 Data preparation  
All data were assessed for the extent of missing responses. Participants with any 
incomplete Liker-type item (of the 58-item LMQ-2.1) were deleted from the entire 
dataset (listwise deletion of missing data), to maintain consistency of sample sizes for 
factor analyses. The remaining sample was then split into two analytical subsamples, 
by simple random sampling, to ensure unbiased distribution of participants and to use 
the data resourcefully.52 The first subset was used in EFA, while the other subset was 
used in CFA. As described in Chapter 3, items were scored on a 5-point scale (strongly 
agree to strongly disagree), and reverse scoring of negatively-phrased items ensured 
that higher scores reflected worse experiences of medicine use (higher medicine 
burden). 
 
Assessment of normal distribution of responses was aided by descriptive statistics 
(means, skewness, and kurtosis). Multivariate normality in the CFA subset of data were 
assessed ďǇDĂƌĚŝĂ ?ƐĐŽĞĨĨŝĐŝĞŶƚ, which needs to be less than p (p+2) where p is the 
number of items in the data set.211 Floor and ceiling effects (FCEs) were evaluated by 
checking the percentage of respondents endorsing the first and last answer category 
(strongly agree and strongly disagree) respectively. 
 
6.2.5 Data analysis 
6.2.5.1 EFA procedures 
The rationale for using different EFA techniques was described in Chapter 3, alongside 
general procedures for testing suitability of data for EFA. Restated here, EFA was used 
in preliminary analyses to explore relationships among items and domains underlying 
the LMQ-2.1. All 58 Likert-type items in the LMQ-2.1 were subjected to principal axis 
factoring (PAF) in SPSS version 22.  Oblique factor rotation (promax) was used since 
Chapter 4 revealed inter-correlations among domains underlying the LMQ-2; similarly, 
items in the LMQ-2.1 were also assumed to be inter-related. As noted earlier, the 
LMQ-2.1 included a global scale on medicine burden. This was not used in the factor 
analyses. Atkinson et al reports that global items, when combined with specific items 
during EFA, may confound interrelationships among subordinate constructs, leading to 
 ‘ĐƌŽƐƐ-ůŽĂĚŝŶŐŽĨ ?ƚŚĞ ?ŐůŽďĂůŝƚĞŵĂĐƌŽƐƐƚŚĞŵŽƌĞƐƉĞĐŝĨŝĐĨĂĐƚŽƌƐ ?.108 Thus, only Likert-
type items were used in EFA and CFA procedures. 
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Sample size adequacy for EFA was examined via Kaiser-Meyer-Olkin Measure (KMO).  
The adequacy of intervariable relationships (factorability), and absence of 
multicollinearity  were examined by ĂƌƚůĞƚƚ ?ƐdĞƐƚŽĨ^ƉŚĞƌŝĐŝƚǇ and WĞĂƌƐŽŶ ?Ɛ
correlation matrix respectively. 
 
To determine the appropriate number of factors underlying the EFA data, <ĂŝƐĞƌ ?Ɛ
criterion (eigenvalues > 1), scree plots, and parallel analysis were employed. <ĂŝƐĞƌ ?Ɛ
criterion demands that factors are retained only if their eigenǀĂůƵĞƐĂƌĞA? ?, an 
eigenvalue being a number associated with each factor indicating the proportion of 
variance in the items that can be accounted for by that factor.187,211 Interpretation of 
the scree plot is subjective,182 thus parallel analysis was also used to confirm the 
optimal number of factors (domains). 
 
Statistical criteria for item reduction during EFA were: low communalities (<0.3), poor 
loadings on the primary factor (< 0.3) and/or cross loading (>0.4) on two or more 
factors. In addition, items loading on unstable (weak) factors, having fewer than 3 
items per factor, were deleted.187   
 
In addition to statistical rules of thumb, qualitative scrutiny, and theoretical 
understanding was used to check the relevance of items and factors in the resultant 
factor solutions (or structures). Discussions were held with the supervision team to 
agree on a final factor solution. To name the factors, marker items indicating the 
strongest factor loadings were examined, and similarities with other items loading on 
the same factor were examined to derive factor nomenclature. The internal 











6.2.5.2 CFA procedures 
Following item reduction to a final shorter instrument, the LMQ-3 was subjected to 
CFA to confirm EFA-ĚĞƌŝǀĞĚŚǇƉŽƚŚĞƐĞƐƌĞŐĂƌĚŝŶŐƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ƐĚŝŵĞŶƐŝŽŶĂů
structure. Particularly, CFA examined the extent to which the domains elucidated by 
EFA techniques measured medicines burden as an overarching construct hypothesised 
to underlie the LMQ-3. CFA was based on maximum likelihood estimation (ML) in 
AMOS 22. The next subsections explore CFA methodological steps. 
Model specifications 
a) Path diagram and symbols used in CFA models  
As a preliminary step in performing CFA, a path diagram, which visually displays a priori 
specified relationshipƐĂŵŽŶŐǀĂƌŝĂďůĞƐ ?ĐĂŶďĞƵƐĞĚƚŽŝůůƵƐƚƌĂƚĞĂƋƵĞƐƚŝŽŶŶĂŝƌĞ ?Ɛ
dimensional structure.172,180  
Various conventional symbols can be used in CFA path diagrams:183   
[1] Circles or ellipses denote unobserved or latent variables (e.g. factors). In CFA, 
measurement error is taken into consideration. Measurement error is associated with 
items (also known as error terms), and with factors (referred to as residual terms). 
Both error terms and residual terms are also unobserved variables, and thus 
represented as circles or ellipses.183 
[2] Squares or rectangles denote observed variables (i.e. items or questions that were 
coded Q1 to Q58). 
 [3] Single-headed arrows denote the effect of one variable on another. They can be 
used to represent factor loadings between items and factors; the effect of error terms 
on specific items, or the effects of residual terms on factors.  
[4] Double-headed arrows represent correlations (or covariance) between two 
variables. See Figure 6-2 for an example of a path diagram. 
 
b) Model parameters, parsimony principle  & model identification 
Parameters are categorised as free or fixed. A free parameter is estimated (calculated) 
by the computer programme (AMOS). In CFA measurement models, parameters to 
estimate include factor loadings, factor variances and covariances (correlations), and 
error variances.183 A fixed parameter is set equal to a constant number. For example, 
the first factor loading for each factor can arbitrarily be set to 1 as a prerequisite to 
estimating free parameters. This is known as scaling the factors, and is a precondition 
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in CFA model estimation. It enables the computer programme to calculate factor 
variances and factor correlations.183  
 
tŚĞŶĂƉƌĞǀŝŽƵƐůǇ ‘ĨŝǆĞĚƉĂƌĂŵĞƚĞƌ ?ďĞĐŽŵĞƐĂ ‘ĨƌĞĞƉĂƌĂŵĞƚĞƌ ? ?ƚŚĞŶƚŚĞŵŽĚĞů
becomes more complex as there are more parameters to estimate. The opposite is 
also true. A model becomes simpler (or more parsimonious) when a free parameter 
becomes a fixed parameter, as fewer relationships among variables need to be 
explained. According to Kline  ? ? ? ? ? ) ? ‘ŐŝǀĞŶƚǁŽmodels with similar fit to the same 
ĚĂƚĂ ?ƚŚĞƐŝŵƉůĞƌŵŽĚĞůŝƐƉƌĞĨĞƌƌĞĚ ?ĂƐƐƵŵŝŶŐƚŚĞŵŽĚĞůŝƐƚŚĞŽƌĞƚŝĐĂůůǇƉůĂƵƐŝďůĞ ? ?183 
and this is known as the principle of parsimony. Models with fewer parameters to 
estimate are more parsimonious than those with more parameters to estimate.183,188 
 
Kline (2011) describes model complexity, which also relates to the total number of 
parameters to be estimated.183 The latter arĞůŝŵŝƚĞĚďǇƚŚĞŚŽǁŵĂŶǇ ‘ŽďƐĞƌǀĂƚŝŽŶƐ ?
are present for analysis. Different from samplĞƐŝǌĞ ?ƚŚĞƚĞƌŵ ‘ŽďƐĞƌǀĂƚŝŽŶƐ ? ? used in 
the context of CFA, represents known pieces of information (e.g. total number of 
correlations in the data matrix), also called sample moments.183 Observations/sample 
moments can be calculated as a function of the number of items in a data set:  
n (n+1)/2. For instance, the total observations in a 41-item questionnaire is, 41(42)/2 = 
861. For a model to be identified, or amenable to CFA, there should be more 
observations than free parameters, and model degrees of freedom (df) should be  
above zero;183 such models are said to be  ‘ŝĚĞŶƚŝĨŝĞĚ ? ?Degrees of freedom are 
equivalent to the differences between sample moments and the number of free 
parameters, and reflect the extent of model fit.183 A model with df <0 cannot be 
estimated (unidentified), while one with no degrees of freedom (df = 0) is just-










Types of CFA models hypothesised and tested 
Different types of CFA models were hypothesised and tested. 
a) First-order model 
A first-order model (factor structure) of the LMQ-3 was hypothesised and tested. First-
order factors are assumed to be at a single level, and there is one unidirectional path 
from each factor to its corresponding items.188 This model (hereafter known as Model 
1) was derived from the EFA structure. In preliminary CFA models, each item is 
hypothesised to load on only one factor, and zero loadings on all other factors are 
assumed (i.e. no cross loadings). The first factor loadings were arbitrarily set to 1 to 
assign a metric scale to each factor. Unlike items (observed variables) that have a scale 
(of 1 to 5 for strongly agree to strongly disagree), factors are unobserved (latent) 
variables and lack a natural scale. Similarly, measurement error terms associated with 
each item, represented by small circles e1 to e41 (See Figure 6-2), had their path 
coefficients set to 1 to estimate error variance, which is the variation in item scores not 





Figure 6-2 Hypothesised first order model for the LMQ-3 (Model 1) 
 
Notes; Int = interferences with day-to-day life;  Doct = patient-doctor relationships and communication 
about medicines; Effec =lack of effectiveness;  Conc = general concerns about medicines. Prac= Practical 






b) Second-order factor model 
The presence of at least three first-order factors with moderate intercorrelations (> 
0.5) provides the basis for testing a higher order (or hierarchical)  factor model.188 A 
second-order factor model was tested (hereafter known as Model 2). Unlike Model 1, 
it has two unidirectional paths away from the items. A second-order factor is 
measured indirectly through the first-order factors and their corresponding items.183  
In Model 2, the second-order factor was hypothesised to be one general, overarching, 
factor (medicine burden), measured through the factors and items highlighted in 
Model 1. Medicine burden was hypothesised to explain the variation among the LMQ-
3 domains. Standard criteria for testing hierarchical models were followed, including 
having at least three first-order factors with at least three items per factor.180,183,188 See 
Figure 6-5 for an example of a second-order model. 
 
Model evaluation  
In addition to examining parameter estimates, particularly the sign and sizes of factor 
loadings, overall fit of hypothesised models and the extent to which they fit the sample 
data were evaluated using multiple goodness-of-fit indices.180,183 
a) Chi-square statistic F2  
Chi-square statistic is an index of exact or absolute model fit that depicts similarity 
between observed covariance matrix and reproduced (predicted) covariance matrix. 
The latter matrix is predicted by the model, while the former matrix is derived from 
sample data.183 Unlike most traditional statistical tests, a non-significant chi-square 
ƉƌŽďĂďŝůŝƚǇ ?ƉA? ? ? ? ? )ŝƐĚĞƐŝƌĂďůĞĂƐĂŶŝŶĚŝĐĂƚŽƌŽĨŐ ŽĚ-fit, and implies that the 
reproduced covariance matrix is not significantly different from the observed 
covariance matrix.180 The chi-square statistic tests the exact-ĨŝƚŚǇƉŽƚŚĞƐŝƐƚŚĂƚ ‘there 
are no discrepancies between the population covariances and those predicted by the 
ŵŽĚĞů ?,183 and researchers are advised not to reject this hypothesis for p-values > 0.05. 
Increasing chi-square values  suggest  ‘ŐƌĞĂƚĞƌĚĞƉĂƌƚƵƌĞŽĨƚŚĞ ?reproduced] 
ĐŽǀĂƌŝĂŶĐĞŵĂƚƌŝǆĨƌŽŵƚŚĞŽďƐĞƌǀĞĚĐŽǀĂƌŝĂŶĐĞŵĂƚƌŝǆ ?.212 Regardless, the F2 index is 
largely criticised for being sensitive and/or dependent on sample size; F2  p-values are 
often significant with big sample sizes  ?A? ? ? ? )163. Subsequently, F2 statistic tends to 
over reject appropriately specified models and is, thus, seldom used as a sole index for 
examining model fit.173,176,180 
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b) Relative chi-square  
Relative chi-square (F2 /df), defined as a ratio of the chi-square value to degrees of 
freedom, is also an indicator of model fit.183 Similar to the previously described chi-
square statistic F2, relative chi-square index is also sensitive to sample size. Values less 
than 2-3 indicate good model fit.213 W215  
c) RMSEA 
Standard guidelines support the use of other fit indices that are less sensitive to 
sample size.176,216,217 One such a statistic is the Root Mean Square Error of 
Approximation (RMSEA) and its corresponding 90% confidence interval (CI 90%). The 
ZD^ƐƚĂƚŝƐƚŝĐŝƐ ‘ĂŵĞĂƐƵƌĞŽĨĨŝƚďĞƚǁĞĞŶƚŚĞ [observed covariance matrix and 
predicted covariance matrix] ĂĚũƵƐƚŝŶŐĨŽƌŵŽĚĞůĐŽŵƉůĞǆŝƚǇ ? ?188 RMSEA measures 
unexplained variance (residual), which constitutes the differences between the 
observed- and predicted covariance matrices.180 RMSEA values closer to 0 suggest 
perfect fit, and cut-ŽĨĨǀĂůƵĞƐA? ? ? ? ?ĚĞƉŝĐƚŐŽŽĚĨŝƚ ?180,188 RMSEA values above 0.10 
indicate poor or mediocre fit.180 
d) CFI and TLI 
The Comparative Fit Index (CFI) and Tucker-Lewis Index (TLI), which are incremental fit 
indices, are also less sensitive to sample size and account for model complexity, and 
thus are more reliable.176,188 CFI and TLI are conceptually similar and reflect the extent 
to which a model fits over an alternative model in which all variable are uncorrelated 
(knoǁŶĂƐƚŚĞĂƐƚŚĞ ‘ŶƵůů ?ŵŽĚĞů ).188 CFI and TLI values range from 0 to 1, depicting no 
fit to perfect fit respectively. Increasing CFI and/or TLI values indicate greater 
improvement in model fit over alternative models.176,183 Minimum values indicative of 
good or acceptable ĨŝƚĂƌĞA? ? ? ? ?-0.95.216,218,219 
 
Exploring sources of model misfit during CFA 
During CFA, it is appropriate to test respecified or modified models, especially if a 
priori hypothesised models are rejected.183 To locate and correct potential causes of 
misfit in Model 2 (Figure 6-5), and to identify parameter estimates contributing greatly 
to model misfit, modification indices were examined. Modification indices (MIs) are 
generated by the computer programme (AMOS) and show potential areas of 
ŵŝƐƐƉĞĐŝĨŝĐĂƚŝŽŶŝŶŵŽĚĞůƐ ?ĐĐŽƌĚŝŶŐƚŽ<ůŝŶĞ ? ? ? ? ? ) ?ĂŵŽĚŝĨŝĐĂƚŝŽŶŝŶĚĞǆƌĞĨůĞĐƚƐ ‘ƚŚĞ 
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amount by which the overall model chi-square statistic F2 would decrease if a 
particular fixed-to-ǌĞƌŽƉĂƌĂŵĞƚĞƌǁĞƌĞĨƌĞĞůǇĞƐƚŝŵĂƚĞĚ ? ?183  
 
Misspecification of measurement errors may also impact on model fit. Usually CFA 
models are hypothesised to have uncorrelated error terms and residual terms, which 
were defined previously; i.e. their correlations are preliminarily fixed to zero.  
Modification indices were used to reveal which correlations among error-terms 
needed to be free or estimated to improve model fit. Similarly, model misfit can occur 
due to misspecification of factor loadings. In CFA, items are preliminarily fixed to load 
on only one factor (i.e. cross loadings on all other factors are fixed to zero). 
Modification indices were also used to locate potential cross-loadings. When 
interpreting modification indices, values reflect the amount by which a chi-square 
value of the model would improve. The expected parameter change (epc) is an 
approximation of the magnitude or difference  in the estimate [from zero] for freely 




6.3            Results 
6.3.1 Survey response rates and sample size 
A total of 1223 participants accessed the on-line survey over a 3-month period, and 
most indicated they lived in the UK (73.5%, n= 900), were 18 years or older (73.2%, 
n=895), and used regular prescription medicines (72.6%, n= 888). After listwise 
deletion of missing data, a total of 729 participants had fully completed Likert-type 
items (approximately 59.6% response rate). However, some participants had missing 
data on different demographic questions (See Table 6-2). Most participants accessed 
the survey directly via social media, and health websites. Other participants accessed 
the survey link indirectly via emails, health magazines, or newsletters promoted by 
participating patient organisations. The dataset was divided into two subsets: EFA 
subset (n=366) and the CFA subset (n=363). 
6.3.2 Participant characteristics 
Within the total remaining sample, participants were of age range 18 to 82 years 
(mean (SD), 48.7 (11.6)). The majority were female (85.8%, n= 612). Most participants 
(46.4%, n=329) had attained University level of education. Participants used four 
medicines on average (median = 4, range 1-20). Characteristics of participants across 























Characteristics  Total Sample 
 n (%) 
EFA subset  
n (%) 
CFA subset  
n (%) 
Gender Female 612(85.8) 312 (86.7) 300(85.0) 
 Male 101(14.2)(n=713) 48 (13.3) (n=360) 53(15.0) (n=353) 
Age bracket 18-29 51(7.2) 25(7.0) 26(7.3) 
 30-49 314(44.0) 155(43.2) 159(45.0) 
 50-64 290(40.7) 153(42.6) 137(38.7) 
 A? ? ? 58(8.1) (n=713) 26(7.2) (n=359) 32(9.0) (n=354) 
Education level School 139(19.6) 73(20.5) 66(18.7) 
 Technical colleg/Appren® 179(25.2) 86(24.2) 93(26.3) 
 University 329(46.4) 161(45.2) 168(47.6) 
 KƚŚĞƌA䰀  62(8.8) (n=709) 36(10.1) (n=356) 26(7.4)(n=353) 
Employment status Employed 331(46.6) 163(45.8) 168(47.5) 
 Unemployed 84(11.8) 36(10.1) 48(13.5) 
 Retired 126(17.8) 67(18.8) 59(16.7) 
 Full-time student 20(2.8) 10(2.8) 10(2.8) 
 Other 149(21.0)(n=710) 80(22.5)(n=356) 69(19.5) (n=354) 
Ethnicity White 684(95.9) 345(96.1)  339(95.8) 
 Asian/Asian British     6(0.8)     3(0.8) 3(0.8) 
 Mixed     7(1.0)     1(0.3) 6(1.7) 
 Black/African/Caribbean     4(0.6)     2(0.6) 2(0.6) 
 Other   12(1.7) (n=713)     8(2.2) (n=359) 4(1.1) (n=354) 
Number of 
medicines 
1-4 432(60.5) 220(61.1) 212(59.9) 
5-9 219(30.7) 107 (29.7) 112(31.6) 
A? ? ?    63(8.8)(n=714) 33(9.2)(n=360) 30(8.5) (n=354) 
&ŽƌŵƵůĂƚŝŽŶƵƐĞĚܶ Tablets/Capsules 692(94.9) 349(95.3)  343(94.5) 
 Any other formulation 317(43.5) (n=729) 151(41.2) (n=366) 166(45.7) (n=363) 
Frequency of 
ŵĞĚŝĐŝŶĞƵƐĞܶ 
Once per day 329(45.1) 160 (43.7) 169 (46.5) 
 Twice per day 285(39.1) 151(41.2) 134(36.9) 
 Three times per day 149(20.4)  76(20.8) 73 (20.1) 
 > 3 times per day 120(16.5)  55(15.0) 65 (17.9) 
 Other times* 104(14.3) (n=729)  50(13.7) (n=366) 54(14.9) (n=363) 
Assisted in using 
medicines 
No- Independent 615(86.3) 306(85.2) 309(87.3) 
 Yes- Has a carer: 98(13.7) (n=713) 53(14.8) (n=359) 45(12.7)(n=354) 
          Spouse/Partner 67(68.4) 34(64.2)  33(73.3) 
         Relative 10(10.2)   9(17.0)   1(2.2) 
         Support worker   7(7.1)   4(7.5)   3(6..7) 
         Friend   2 (2.0)   1(1.9)    1(2.2) 
         Otherµ 12(12.3) (n=98)   5(9.4) (n=53)    7(15.6) (n=45) 
Pays for 
prescriptions 
No 493(69.0) 245 (68.1) 248(70.1) 
Yes 221(31.0) (n=714) 115 (31.9)) (n=360) 106(29.9)(n=354) 
Table 6-2 Characteristics of participants in the EFA and CFA subsamples 
 
Notes; Technical colleg/Appren®, Technical college or apprenticeship; 
 A䰀 ŝŶĐůƵĚĞƐĚŝƉůŽŵĂ ?ĐĞƌƚŝĨŝĐĂƚĞƐ ?ĐŽůůĞŐĞ ?ĂŶĚƉŽƐƚŐƌĂĚƵƚĞƋƵĂůŝĨŝĐĂƚŝŽŶƐ  
* includes medicines taken when necessary (PRN), different times of the week (e.g. 1-3 times a week), 
fortnightly, monthly, every three months, every 5 years. 
 µ included nurse, or multiple support from relatives, friends and carers 
ܶWĂƌƚŝĐŝƉĂŶƚƐĐŽƵůĚĐŚŽŽƐĞŵŽƌĞƚŚĂŶŽŶĞƌĞƐƉŽŶƐĞŽƉƚŝŽŶ ?ƚŚƵƐƉƌŽƉŽƌƚŝŽŶƐĂƌĞĞƐƚŝŵĂƚĞĚĨŽƌĞĂĐŚ of 






6.3.3 Distribution of responses 
Most responses to LMQ items were normally distributed (skewness values < 1); skew 
values tending to zero indicate symmetric distribution. As shown in Table 6-3, only five 
items had skewness and kurtosis values above one in absolute value. This may indicate 
potential floor/ceiling effects for these variables, which were considered for item 
reduction. One item,  ‘Q4 -Taking medicines is routine for me ?, had the highest ceiling 
ĞĨĨĞĐƚǁŝƚŚ ? ? ? ?A?ŽĨĂůůƌĞƐƉŽŶĚĞŶƚƐĞŶĚŽƌƐŝŶŐ ‘ƐƚƌŽŶŐůǇĂŐƌĞĞ ?ĂƐƚŚĞƚŽƉĂŶƐǁĞƌ
category. Regardless, all items had skewness < 2 and kurtosis values < 7; values below 



































Item Mean Skewness Kurtosis FCEs 
Q1-I find getting my prescriptions from the doctor difficult 3.743 -0.718 -0.494 4.5-31.3 
 Q2 - I find getting my medicines from the pharmacist 
difficult.       
3.716 -0.662 -0.475 3.5-28.5 
Q3-I find the written instructions on how to use my 
medicines easy to understand* 
4.033 -1.230 1.277 3.0-34.5 
Q4 -Taking medicines is routine for me.*        4.492 -1.825 4.475 0.7-59.1 ܶ 
Q5 - I am satisfied with the effectiveness of my medicines 3.448 -0.391 -0.683 4.0-15.6 
Q6- I am comfortable with the times I should take my 
medicines.*        
4.175 -1.122 1.859 0.2-33.3 
Q7-I worry about paying for my medicines 3.500 -0.410 -0.857 9.2-28.5 
Q8- If I forgot to take my medicines, it would worry me.    2.560 0.380 -0.903 18.6-4.5 
Q9-I worry that I have to take several medicines at the 
same time.         
3.197 -0.080 -0.885 6.9-13.9 
Q10-I would like more say in the brands of medicines I use 2.626 0.319 -0.762 20.8-7.7 
 Q11-I trust the judgement of my doctor(s) in choosing 
medicines for me.        
3.470 -0.493 -0.511 5.2-15.6 
Q12- It is difficult to identify which medicine is which    3.874 -0.825 0.132 1.7-26.8 
Q13-I get enough information about my medicines from 
my pharmacist.     
3.352 -0.374 -0.455 6.0-12.7 
Q14-I am concerned about possible damaging long term 
effects of taking medicines.  
2.153 0.907 0.045 32.3-4.0 
Q15-I feel I need more information about my medicines.         2.902 -0.037 -0.989 13.4-6.9 
Q16- I am concerned that I may forget to take my 
medicines  
3.003 -0.086 -1.133 10.2-7.7 
Q17-I can vary the dose of the medicines I take.         2.538 0.326 -1.181 23.6-4.2 
Q18-I find opening the packaging of my medicines difficult.      3.598 -0.689 -0.666 7.4-26.1 
Q19- My doctor(s) listen to my opinions about my 
medicines.        
3.445 -0.606 -0.348 6.5-13.9 
Q20-I can choose whether or not to take my medicines.         2.355 0.516 -1.094 35.5-5.2 
Q21-I am concerned that I am too reliant on my 
medicines.         
2.951 0.140 -0.915 9.2-9.4 
Q22-My medicines interfere with my social or leisure 
activities.         
3.290 0.281 -1.066 8.2-16.9 
Q23-My medicines prevent my condition getting worse.           3.653 -0.698 -0.225 4.7-21.6 
Q24-I am concerned that my medicines interact with 
alcohol.         
3.325 -0.304 -0.654 6.7-14.9 
Q25-I worry that my medicines may interact with each 
other 
2.844 0.154 -0.788 10.9-7.7 
Q26-The side effects I get are sometimes worse than the 
problem for which I take medicines.        
3.052 -0.081 -1.071 13.0-12.0 
Q 27-I am concerned about experiencing side effects.         2.197 0.844 0.134 25.7-2.7 
Q28-My doctor(s) take my concerns about side effects 
seriously.         
3.249 -0.381 -0.446 6.2-9.2 
Q29-The side effects I get from my medicines interfere 
with my day-to-day life (e.g. work, housework).         
2.861 0.206 -1.053 14-11 
Q 30-I have to put a lot of planning and thought into taking 
my medicines.         
3.235 -0.216 -1.012 6.8-12.9 
Q31-/ĚŽŶ ?ƚŵŝŶĚƉĂǇŝŶŐĨŽƌŵǇŵĞĚŝĐŝŶĞƐďĞĐĂƵƐĞ/ŶĞĞĚ
them.         
2.735 -0.310 -0.459 17.5-2.0 






Item Mean Skewness Kurtosis FCEs 
Q32-I get enough information about my medicines from 
my doctor(s).         
3.180 -0.287 -0.814 6.8-7.8 
Q33 -My medicines live up to my expectations.        3.175 -0.311 -0.546 7.1-7.1 
Q34-I can adapt using my medicines to fit my lifestyle.   3.033 -0.195 -0.774 9.1-6.1 
Q35-I am not confident speaking to my doctor(s) about my 
medicines.         
3.686 -0.779 -0.355 6.1-25.3 
Q36- I am not confident speaking to my pharmacist(s) 
about my medicines        
3.844 -0.888 0.139 2.6-27.6 
Q37-I am concerned that my medicines affect what I can 
eat or drink.         
3.342 -0.297 -0.882 6.6-17.1 
  Q38-The medicines I use make it difficult to plan holidays.  3.691 -0.841 0.18 5.4-22.2 
Q39-I can vary the times I take my medicines.          2.680 0.191 -1.067 14.3-3.6 
Q40-It is easy to keep to my medicines routine.         3.792 -0.773 0.092 0.5-18.4 
Q41-Changes in daily routine causes problems with my 
medicines.         
2.921 0.145 -1.052 7.0-7.0 
Q42-Taking medicines affects my driving.         3.500 -0.516 -0.478 7.8-21.3 
Q43-I find using my medicines difficult.         3.948 -0.747 0.587 0.5-23.9 
Q 44-I accept that I have to take medicines long term*  4.169 -1.495 2.549 2.6-39.7 
Q45-I understand what my doctor(s) tell me about my 
medicines.*            
4.003 -1.205 2.406 1.6-23.7 
Q46-The side effects I get from my medicines are 
bothersome.         
2.713 0.232 -0.932 17.4-7.4 
Q47-I sometimes have to choose between buying basic 
essentials or medicines.        
4.027 -0.745 -0.285 1.3-43.0 
Q48-I understand what my pharmacist(s) tell me about my 
medicines.         
3.964 -0.861 1.259 1.1-24.0 
Q49--I have to pay more than I can afford for my 
medicines.         
3.628 -0.364 -0.495 4.3-28.7 
Q50-The health professionals providing my care know 
enough about me and my medicines.         
3.123 -0.191 -1.024 10.7-11.8 
Q51-Taking medicines causes me problems with daily tasks 
(such as work, housework).         
3.298 - 0.291 -0.991 7.8-16.3 
Q52-My medicines allow me to live my life as I want to.         3.175 -0.118 -0.981 7.5-13.1 
Q53-My medicines interfere with my social relationships.        3.489 -0.543 -0.686 6.2-19.0 
Q54-My medicines interfere with my sexual life.         3.232 -0.251 -0.943 9.5-15.7 
Q 55 -The side effects I get from my medicines adversely 
affect my well-being.        
3.063 0.002 -1.018 9.5-13.0 
Q 56-My medicines are working.         3.650 -0.765 0.278 4.1-17.6 
Q57-The side effects are worth it for the benefits I get 
from my medicines.       
3.344 -0.374 0.246 4.6-9.8 
Q 58-My life revolves around using my medicines.         3.380 -0.370 -0.874 6.8-17.3 
Table 6-3 Distribution of responses to the 58-item interim tool (LMQ-2.1) 
 
Notes; FCEs, Floor and Ceiling Effects; *Items represent those with skewness and kurtosis values above 







6.3.4 EFA findings 
The EFA sample size (n=366), of approximately six participants per item, met the 
minimum recommendations174,182 for analysing the 58-item preliminary pool. With a 
KMO value of 0.902 (acceptable values A? ? ? ?), the sample size was  ‘ŵĂƌǀĞůůŽƵƐ ?211 for 
EFA analyses. ĂƌƚůĞƚƚ ?ƐdĞƐt of Sphericity was significant (Chi-Square = 10585.7, 
df=1653; p< 0.001), suggesting that  data were factorable with adequate inter-variable 
correlations.211 Examining the WĞĂƌƐŽŶ ?ƐĐŽƌƌĞůĂƚŝŽŶŵĂƚƌŝǆƌĞǀĞĂůĞĚcorrelations in the 
range of 0.001 to 0.776, with only few correlations below 0.3. Inter-item correlations 
ĂďŽǀĞ ? ? ?ŝŶĚŝĐĂƚĞ ‘ĞŶŽƵŐŚcommonality to justify the presence of underlying 
ĨĂĐƚŽƌƐ ? ?211 On the other hand, there was no evidence of multi-collinearity (or 
redundancy) among items since all inter-variable correlations were below 0.8; very 
ŚŝŐŚůǇĐŽƌƌĞůĂƚĞĚŝƚĞŵƐĐĂŶƉŽƐĞĚŝĨĨŝĐƵůƚŝĞƐŝŶĂƐĐĞƌƚĂŝŶŝŶŐĞĂĐŚŝƚĞŵ ?ƐƵŶŝƋƵĞ
contribution to its corresponding factor.  
 
The initial EFA solution resulted into 13 factors with eigenvalues > 1, which explained 
63.4% of the total variance among all items. Inspection of the scree plot revealed a 
sudden break in the curve (inflexion point) between factors 7 and 9 suggesting 
retention of 8 factors (see Figure 6-3). 
 
Figure 6-3 Scree plot estimating the number of factors to retain in the LMQ-2.1 
 




To further ascertain the optimal number of factors, parallel analysis revealed seven 
factors meeting statistical inclusion criteria (See Table 6-4). With more iterations in 
EFA, factor solutions with 7 to 13 factors were further investigated. The eight-factor 







1 13.838 1.8815                Accept 
2 4.731 1.7979                Accept 
3 2.834 1.7380                Accept 
4 2.494 1.6846                Accept 
5 1.997 1.6382                Accept 
6 1.800 1.5950                Accept 
7 1.739 1.5553                Accept 
8 1.370 1.5172                Investigate 
9 1.317 1.4819                Investigate 
10 1.298 1.4478 Investigate 
11 1.218 1.4161   Investigate 
12 1.115 1.3842                Investigate 
13 1.048 1.3541                Investigate 
Table 6-4 Comparison of eigenvalues using parallel analysis (LMQ-2.1) 
 
Notes; * Predicted eigenvalues generated, randomly, in 1000 replications/ simulations for a dataset with 
58 variables, and sample size of 366 using Monte Carlo PCA for Parallel Analysis171 
















Item reduction  
Seventeen (n=17) items were deleted from the preliminary 58-item pool (See Table 6-
5), leaving a 41-item questionnaire. All item reduction was informed by the statistical 
inclusion criteria, and qualitative meanings of individual items discussed through 
professional judgement with the help of the supervision team, as described in the 
methods section. This meant that items were retained if they had adequate factor 
loadings  ?A? 0.3), and did not cross load highly on other factors (>0.4). In addition, every 
stable factor required at least 3 items.  
 
 
                   Item Reason for 
deletion 
1. I find the written instructions on  how to use my medicines easy to 
understand  
LC,PL 
2. Taking medicines is routine for me LC, PL,HCE 
3. If I forgot to take my medicines, it would worry me PL 
4. It is difficult to identify which medicine is which LC, PL 
5. I get enough information about my medicines from my pharmacist LC, PL 
6. I find opening the packaging of my medicines difficult  LC, PL 
7. I am concerned about experiencing side effects  CL*  
8. /ĚŽŶ ?ƚŵŝŶĚƉĂǇŝŶŐĨŽƌŵǇŵĞĚŝĐŝŶĞƐďĞĐĂƵƐĞ/ŶĞĞĚƚŚĞŵ LC, PL 
9. I can adapt using my medicines to fit my lifestyle PL 
10. I am not confident speaking to my doctor about my medicines  UF 
11. I am not confident speaking to my pharmacist about my medicines UF 
12. I am concerned that my medicines affect what I can eat or drink PL 
13. The medicines I use make it difficult to plan holidays PL, CL**      
14. Changes in daily routine causes problems with my medicines  PL 
15. I accept that I have to take medicines long term LC 
16. I understand what my doctors tell me about my medicines UF 
17. I understand what my pharmacists tell me about my medicines UF 
Table 6-5 Items deleted from the 58-item interim tool (LMQ-2.1) 
 
Notes; LC=Low communality; PL=Poor loadings; HCE=highest ceiling effect; CL=cross loading; UF= loaded 
on an unstable factor with only two items. *This item cross-loaded significantly on two factors:  ‘ƐŝĚĞ
ĞĨĨĞĐƚƐ ?ĂŶĚ ‘ĐŽŶĐĞƌŶƐ ? ? ? ?This item cross-loaded ƐŝŐŶŝĨŝĐĂŶƚůǇŽŶƚǁŽĨĂĐƚŽƌƐ P ‘ŝŶƚĞƌĨĞƌĞŶĐĞƐǁŝƚŚĚĂǇ-to-
ĚĂǇůŝĨĞ ?ĂŶĚ ‘ƉƌĂĐƚŝĐĂůĚŝĨĨŝĐƵůƚŝĞƐ ? 
 
EFA-derived factor solution 
The resultant 41-item eight-factor solution was conceptually interpretable. Factors 1 
to 8 were taken to mean: interferences with day-to-day life (6 items), patient-doctor 
relationships and communication about medicines (5 items); lack of effectiveness (6 
items); general concerns about medicines (7 items); side effects (4 items); practical 
difficulties (7 items); cost-related burden (3 items); and lack of autonomy/control of 
medicine use (3 items) (See Table 6-6).   
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My medicines interfere with my social relationships. 
.892 .060 .009 -.121 -.002 -.001 .062 .018 
My medicines interfere with my social or leisure activities. 
.779 .078 -.022 .139 -.015 -.052 -.079 .000 
Taking medicines affects my driving. 
.690 -.045 -.064 .030 -.034 -.039 -.002 -.023 
Taking medicines causes me problems with daily tasks (such as work, 
housework, hobbies). 
.644 .025 .052 -.112 .319 -.105 .066 .014 
My medicines interfere with my sexual life. 
.643 .036 .006 -.036 .056 .011 .088 -.023 
My life revolves around using my medicines. 
.480 .034 -.078 .089 .102 .066 .052 .023 
My doctor(s) listen to my opinions about my medicines. 
.032 .810 -.051 -.018 -.028 .048 -.042 .047 
My doctor(s) take my concerns about side effects seriously. 
.059 .794 .015 -.061 -.009 -.066 .042 -.002 
I get enough information about my medicines from my doctor(s). 
.049 .761 .000 .094 -.033 .025 -.014 .043 
The health professionals providing my care know enough about me and my 
medicines. 
-.001 .612 .133 .044 -.051 .085 -.048 -.033 
I trust the judgement of my doctor(s) in choosing medicines for me. 
.001 .556 .152 .027 .007 .137 -.031 -.085 
My medicines are working. 
-.142 -.026 .882 -.004 .072 -.007 .067 .083 
My medicines live up to my expectations. 
-.043 .062 .711 .084 .066 .057 .040 .064 
I am satisfied with the effectiveness of my medicines. 
-.026 .061 .719 .054 .078 .032 -.071 -.018 
The side effects are worth it for the benefits I get from my medicines. 
-.151 .173 .601 .046 -.077 -.225 .062 .040 
My medicines prevent my condition getting worse. 
.247 -.044 .523 -.144 -.142 .160 -.046 -.134 
My medicines allow me to live my life as I want to. 
.345 .106 .525 .017 -.084 .023 -.087 -.007 
I am concerned about possible damaging long term effects of taking medicines. 
-.086 .008 .020 .648 .270 -.035 -.067 -.076 
I worry that my medicines may interact with each other. 
-.004 -.073 .128 .639 .165 -.061 -.018 .003 
I am concerned that I am too reliant on my medicines. 
.167 .043 -.028 .635 -.173 -.099 .037 -.096 
I worry that I have to take several medicines at the same time. 
-.056 -.091 .061 .550 -.003 .135 .126 -.091 
    Table 6-6 The final 41-item, EFA-derived, 8-factor solution of the Living with Medicines Questionnaire version 3 (LMQ-3) 
  































   
 
    
I am concerned that my medicines interact with alcohol. 
.339 -.069 -.015 .505 -.171 -.169 .060 .158 
I feel I need more information about my medicines. 
-.014 .252 .036 .544 .058 -.010 .022 .016 
I would like more say in the brands of medicines I use. 
-.196 .200 -.081 .447 .134 .005 .076 -.009 
The side effects I get from my medicines are bothersome. 
.131 -.099 -.072 .054 .812 .063 -.027 .024 
The side effects I get from my medicines interfere with my day-to-day life 
(e.g. work, housework, sleep). 
.355 -.023 -.014 -.026 .687 -.072 .031 .009 
 The side effects I get are sometimes worse than the problem for which I 
take medicines. 
.051 .029 .078 .030 .647 .016 -.042 .007 
The side effects I get from my medicines adversely affect my well-being. 
.346 .019 .020 .016 .612 -.040 -.028 .013 
I find getting my prescriptions from the doctor difficult. 
-.093 .225 -.110 -.148 .089 .734 .060 .061 
It is easy to keep to my medicines routine. 
.044 -.079 .174 -.065 -.024 .631 -.009 -.018 
I find getting my medicines from the pharmacist difficult. 
-.017 .090 -.111 .033 -.041 .616 .090 .023 
I am comfortable with the times I should take my medicines. 
-.048 -.093 .323 .024 -.024 .398 .031 .010 
I have to put a lot of planning and thought into taking my medicines. 
.295 -.092 -.116 .169 .145 .464 -.036 .000 
I am concerned that I may forget to take my medicines. .170 -.139 -.056 .343 -.162   .421 -.139 .172 
I find using my medicines difficult.  
.311 -.020 .028 .102 .086 .410 -.021 -.102 
I have to pay more than I can afford for my medicines. 
.081 -.039 .029 .028 -.062 .004 .838 .032 
I sometimes have to choose between buying basic essentials or medicines. 
.130 .002 .109 -.057 .016 .013 .704 -.050 
I worry about paying for my medicines. 
-.071 -.021 -.102 .165 -.026 .132 .679 .004 
I can choose whether or not to take my medicines. 
.051 -.036 .005 .000 -.012 -.029 -.020 .732 
I can vary the dose of the medicines I take. 
-.102 .008 .086 -.179 .089 .035 .033 .668 
I can vary the times I take my medicines. 
.050 .058 .000 .051 -.021 .085 -.018 .628 
     Table 6-6 The final 41-item, EFA-derived, 8-factor solution of the Living with Medicines Questionnaire version 3 (LMQ-3)  
 
     Notes;  Int = interferences with day-to-day life; Doct = patient-doctor relationships and communication about medicines; Effec = lack of effectiveness; Conc =   
 general concerns about medicines.Prac= practical difficulties; SideE = Side Effects; Cost =Cost-related burden;  













6.3.5 CFA findings 
The CFA subset of data (n=363) was also adequate in size, and multivariate normality 
was judged acceptable ďǇDĂƌĚŝĂ ?ƐĐŽĞĨĨŝĐŝĞŶƚ ? ? ? ?.618, critical ratio= 27.532).  
 
6.3.5.1 Estimates for the first-order model  
The first-order model had 110 free parameters to be estimated: 33 factor loadings, 8 
factor variances, 28 factor correlations, 41 error variances. This model has 751 degrees 
of freedom, and was plausible or agreeable to estimation. 
 
Examination of standardised factor solutions revealed all factor loadings and 
correlations to be of reasonable sizes. As shown in Figure 6-4, first-order factor 
loadings were in the range of 0.396 to 0.891 and were statistically significant (p 
<0.001) for all items. CFA confirmed inter-correlations among factors underlying the 
LMQ- ? ?ĂůƚŚŽƵŐŚ ‘ lack of ĂƵƚŽŶŽŵǇ ?ǁĂƐůĞĂƐƚwell correlated with other factors. The 
ƐƚƌŽŶŐĞƐƚƌĞůĂƚŝŽŶƐŚŝƉǁĂƐďĞƚǁĞĞŶƚŚĞĨĂĐƚŽƌƐ ‘ƐŝĚĞĞĨĨĞĐƚƐ ?ĂŶĚ ‘ŝŶƚĞƌĨĞƌĞŶĐĞƐǁŝƚŚ
day-to-ĚĂǇůŝĨĞ ? (r=0.81). Domains relating to patient-doctor relationships, 
communication about medicines, and lack of effectiveness were also strongly 












Figure 6-4 First-order model estimates (Model 1) 
 
Notes; Standardised path estimates are shown. The numbers in blue(between curved arrows) represent 
correlations among the eight factors; the numbers in the left column (starting at 0.891) clarify item 






Item  loadings 
Q53 <--- .891 
Q22 <--- .808 
Q42 <--- .501 
Q54 <--- .753 
Q51 <--- .868 
Q58 <--- .489 
   
Q28 <--- .776 
Q19 <--- .769 
Q32 <--- .711 
Q50 <--- .767 
Q11 <--- .720 
   
Q56 <--- .774 
Q33 <--- .790 
Q5 <--- .843 
Q57 <--- .581 
Q23 <--- .558 
Q52 <--- .690 
   
Q25 <--- .674 
Q14 <--- .679 
Q21 <--- .484 
Q9 <--- .535 
Q24 <--- .430 
Q15 <--- .653 
Q10 <--- .396 
   
Q1 <--- .537 
Q40 <--- .737 
Q2 <--- .449 
Q6 <--- .601 
Q30 <--- .551 
Q16 <--- .508 
Q43 <--- .676 
Q46 <--- .816 
Q29 <--- .835 
Q26 <--- .699 
Q55 <--- .854 
Q49 <--- .864 
Q47 <--- .756 
Q7 <--- .698 
   
Q20 <--- .574 
Q17 <--- .717 




6.3.5.2 Estimates for the second-order model  
In the hypothesised second-order model, all factor loadings were in the range of 0.39 
ƚŽ ? ? ? ?ĂŶĚƐƚĂƚŝƐƚŝĐĂůůǇƐŝŐŶŝĨŝĐĂŶƚ ?ƉAM ? ? ? ? ? )ĞǆĐĞƉƚĨŽƌ  ‘ĂƵƚŽŶŽŵǇ ? ?ƚŚĂƚĚŝĚŶŽƚůŽĂĚ
significantly on medicine burden (- 0.09, p= 0.224). dŚĞ ‘ŝŶƚĞƌĨĞƌĞŶĐĞƐ ?ĚŽŵĂŝŶůŽĂĚĞĚ
most strongly on mediciŶĞďƵƌĚĞŶ ? ? ? ? ? ) ?ĨŽůůŽǁĞĚďǇ ‘ƐŝĚĞ-ĞĨĨĞĐƚƐ ? ? ? ? ? ? ) ?ĂŶĚ ‘ŐĞŶĞƌĂů 




Figure 6-5 Second-order model estimates (Model 2) 
Notes; Standardised path estimates are shown; Int = interferences with day-to-day life;  Relat = patient-
doctor relationships and communication about medicines; Effec = lack of effectiveness;  Conc = general 
concerns about medicines; Prac= practical difficulties; SideE = Side Effects; Cost =Cost-related burden; 
Auto =  Lack of autonomy/control over medicine use; e1 to e41 represent errors for each item;  eI to eA 




6.3.5.3 Comparison of model fit indices for the first- and second-order models 
In terms of model fit, the chi-square F2 probability value was significant (p <0.001) for 
both models 1 and 2, inferring that neither model fitted the data exactly. As previously 
described, chi-square F2 tests are sensitive to sample size and alternative fit indices 
were used to assess model fit. Although relative chi-square values (F2 /df <3) and 
RMSEA coefficients (< 0.06) depicted adequate model fit for both models, CFI/TLI 
values wĞƌĞƐůŝŐŚƚůǇďĞůŽǁƚŚĞƚĂƌŐĞƚŽĨA? ? ? ? ?. Therefore, statistically and strictly 
speaking, both the first- and second-order models, hypothesised a priori, did not attain 
 ‘ŐŽŽĚ ?Ĩit to the sample data. Table 6-7 compares model fit indices across all models 
tested.  
 
Model  F2 df p-value 
(target  
p>0.05) 





A? ? ? ? ? )
CFI 
(target
A? ? ? ? ? )
RMSEA (90% CI)     





1471.151 751  <0.001 1.959 0.881 0.891 0.051 
(0 .048 -0.055)  
1691.151 
Model 2  
(second-order)  






1288.357 765 <0.001 1.684 0.915 0.921 0.043  
(0.039- 0.048)  
1480.357 
Table 6-7 Comparison of fit indices for all models tested in CFA (LMQ-3) 
 
Notes; F2 = Chi square statistic, df= degrees of freedom, F2 /df= relative chi-square, TLI= Tucker Lewis 
Index; CFI= Comparative fit index; AIC- ŬĂŝŬĞ ?Ɛ/ŶĨŽƌŵĂƚŝŽŶƌŝƚĞƌŝĂ 
 
From Table 6-7, it is clear that Model 1 and Model 2 had close model fit to the data. 
However, the second-order model (Model 2) had fewer parameters (n=90) to estimate 
when compared to the first-order model (n=110). As previously described in the 
methods section, the principle of parsimony proposes that given two models with 
relatively similar fit, the simpler model (that is one with fewer parameters to estimate) 
is preferable, as long as it is conceptually plausible. Thus, the second-order factor 
model was adopted as the simpler model explaining inter-relationships among the 41 







6.3.5.4 Testing a revised second-order model ʹModel 3 
To improve fit of the simpler model, further modifications were made to the second-
order model, deriving Model 3. Model fit indices for the latter are included in Table 6-
8. This revised second-order model (Figure 6-6) revealed relatively better model fit 
indices with CFI and TLI values above 0.9, indicating acceptable fit for this somewhat 

























































Figure 6-6 Revised second-order model estimates (Model 3) 
 
Notes; Standardised path estimates are shown; Interferences = interferences with day-to-day life; HCPs= 
Healthcare professionals; Effectiveness = lack of effectiveness; Concerns = General concerns about 
medicines; Cost =Cost-related burden; Autonomy = Lack of autonomy/control over medicines. Curved 





6.3.5.5 Explaining modifications in Model 3 
Figure 6-6 shows that there were three modifications in Model 3 .i.e. three pairs of 
correlated error terms ĨŽƌŝƚĞŵƉĂŝƌƐůŽĂĚŝŶŐŝŶ ‘ĐŽŶĐĞƌŶƐ ? ? ‘ƉƌĂĐƚŝĐĂůŝƚŝĞƐ ?ĂŶĚ
 ‘ĐŽŵŵƵŶŝĐĂƚŝŽŶ ?ƌĞůĂƚŝŽŶƐŚŝƉ ?ĚŽŵĂŝŶƐ. As described in the methods section, these 
modifications were guided by their large modification indices (MI > 20) generated by 
the computer programme (see Table 6-8). Allowing correlations among error terms 
enabled understanding relationships among closely related items. For instance, the 
ĐŽƌƌĞůĂƚŝŽŶďĞƚǁĞĞŶĞƌƌŽƌƚĞƌŵƐĐŽƌƌĞƐƉŽŶĚŝŶŐƚŽƚǁŽŝƚĞŵƐŝŶƚŚĞ ‘ƉƌĂĐƚŝĐĂůŝƚŝĞƐ ?
domain (0.52),  ‘/ĨŝŶĚŐĞƚƚŝŶŐŵǇƉƌĞƐĐƌŝƉƚŝŽŶƐĨƌŽŵƚŚĞĚŽĐƚŽƌĚŝĨĨŝĐƵůƚ ? ĂŶĚ ‘/ĨŝŶĚ
ŐĞƚƚŝŶŐŵǇŵĞĚŝĐŝŶĞƐĨƌŽŵƚŚĞƉŚĂƌŵĂĐŝƐƚĚŝĨĨŝĐƵůƚ ? ?was strongest and reflects that the 
two items measure something in common besides that reflected by their respective 
domain. All model modifications were informed by empirical data, substantive 
reasoning, and professional judgement based on earlier qualitative work about the 
meaning of items (See Chapter 5). Table 6-8 details other modifications in Model 3. 
 
All but one item in Model 3 loaded adequately on their respective domains;  ‘I feel I 
need more information about my medicines ? cross-ůŽĂĚĞĚĂůŵŽƐƚĞƋƵĂůůǇŽŶ ‘ƉĂƚŝĞŶƚ-
doctor communication ?ƌĞůĂƚŝŽŶƐŚŝƉƐ ? ?ĨĂĐƚŽƌůŽĂĚŝŶŐA? ? ? ? ? ) ĂŶĚŽŶ ‘ŐĞŶĞƌĂůĐŽŶĐĞƌŶƐ
about medicines ? ?Ĩactor loading = 0.37). This item was initially hypothesised to relate 





















Q1 <--> Q2 Correlation between error terms associated with two items, 
ůŽĂĚŝŶŐŽŶ ‘ƉƌĂĐƚŝĐĂůĚŝĨĨŝĐƵůƚŝĞƐ ? ?
I find getting my prescriptions from the doctor difficult.  
I find getting my medicines from the pharmacist difficult.  
92.890 0.502 
Q14 <--> Q20 Correlation between error terms associated with two items 
loading on ƚŚĞ ‘ĚŽĐƚŽƌ/relationships ? domain. 
My doctor(s) take my concerns about side effects seriously. 
My doctor(s) listen to my opinions about my medicines. 
29.228 0.162 
Q12 <--> Q16 Correlation between error terms associated with two items 
loading ŽŶ ‘ĐŽŶĐĞƌŶƐ ? ?
 I am concerned about possible damaging long-term effects 
of taking medicines. 
I am concerned that I am too reliant on my medicines. 
22.042 0.204 
Table 6-8 Modifications in the revised second-order model (LMQ-3) 
 
6.3.6 Internal consistency   
ǆĐĞƉƚĨŽƌŽŶĞƐƵďƐĐĂůĞ ? ‘ĂƵƚŽŶŽŵǇ ? ?ĂůůLMQ-3 subscales had acceptable internal 
ĐŽŶƐŝƐƚĞŶĐǇ ?ƌŽŶďĂĐŚ ?ƐɲĐŽĞĨĨŝĐŝĞŶƚƐAN ? ? ? )ĂƐƐŚŽǁŶ ŝŶTable 6-9. 
 
Subscale (number of items) EFA subsample CFA subsample 
Doctor (n=5) 0.870 0.860 
Interferences (n=6) 0.865 0.863 
Practicalities (n=7) 0.738 0.769 
Effectiveness (n=6) 0.851 0.858 
Concerns (n=7) 0.796 0.757 
Cost (n=3) 0.801 0.806 
Side effects (n=4) 0.901 0.879 
Autonomy (n=3) 0.692 0.610 
Table 6-9 Internal consistency (Cronbach alpha) for LMQ-3 subscales 
 
Notes; Doctor = patient-doctor relationships and communication about medicines; Interferences = 
interferences with day-to-day life; Practicalities= practical difficulties; Effectiveness = Lack of 
effectiveness;  Auto = Lack of autonomy/control over medicine; Concerns = General concerns about 






6.4 Discussion  
This study aimed to formulate the LMQ-3 and ascertain its construct validity through 
exploratory and confirmatory factor analyses. The LMQ-3 is a multidimensional scale, 
as revealed by these standard, iterative, multi-step, analyses conducted using 
responses from the adult general public in the UK using at least one prescription 
medicine.   
 
The revised second-order model (Model 3) attained the best model fit (CFI/TLI > 0.9), 
when compared to all alternative models tested. Re-specified models tend to have 
improved model fit since they are products of modifications, such as allowing 
correlation of measurement error terms that reflected strong relationships among 
items measuring a common attribute. Revisions to models, aimed at addressing poorly 
fitting parameters, were data driven and conceptually justifiable. However, excessive 
model modification aimed at attaining near-perfect fit to sample data is not 
recommended to avoid model instability.180 In addition, some researchers, like Marsh 
et al (2004), warn ĂŐĂŝŶƐƚĚĞƉĞŶĚĞŶĐĞŽŶƌĞƐƚƌŝĐƚŝǀĞ ‘ŐŽůĚĞŶƐƚĂƚŝƐƚŝĐĂůƌƵůĞƐ ?ĨŽƌ
evaluating model fit.219 For complex measurement models with multiple domains, and 
items per subscale, such as that underlying the LMQ-3,  ‘ŝƚŝƐĂůŵŽƐƚŝŵƉŽƐƐŝble to get 
ĂŶ ?ĞǆĐĞůůĞŶƚ ?Ĩŝƚ ?defined by higher cut-ŽĨĨǀĂůƵĞƐĨŽƌ&/ĂŶĚd>/ ?A? ? ? ? ? ) ?219 There is a 
need to balance demands for optimising model fit and attaining standard cut-off 
values and ensuring adequate questionnaire content coverage, and interpretability of 
the model. Therefore to minimise further model complexity and enhance parsimony 
and model stability, Model 2 (Figure 6-5) was selected as the  ‘ƐŝŵƉůĞƐƚ ?ĂŶĚŵŽƐƚ
interpretable representation of concepts underlying the LMQ-3. 
 
The preferred LMQ-3 measurement model (Model 2) comprised 41 items, which were 
best represented as one overarching construct, medicine burden, measured indirectly 
by the eight inter-correlated, yet distinct, subscales: 1) interferences with day-to-day 
life; 2)side-effect-related burden; 3) general concerns about medicines; 4) practical 
difficulties; 5) lack of effectiveness;  6) patient-doctor relationships/ communication 
problems; 7) cost-related burden; and 8) lack of autonomy/control over medicines use. 
The first three subscales were the strongest measures/predictors of medicine burden, 
followed by subscales 4-6 in decreasing strength respectively. Cost-related burden 
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ŵŽĚĞƌĂƚĞůǇĞǆƉůĂŝŶĞĚŵĞĚŝĐŝŶĞďƵƌĚĞŶ ?dŚĞ ‘ĂƵƚŽŶŽŵǇ ?Ěomain was least associated 
with medicine burden. 
 
ƐĚĞƐĐƌŝďĞĚŝŶƚŚĞŝŶƚƌŽĚƵĐƚŽƌǇĐŚĂƉƚĞƌƐ ?ƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨůŝǀŝŶŐǁŝƚŚ
medicines are wide-ranging88 and as indicated previously,  ‘ŝŶƚĞƌĨĞƌĞŶĐĞƐǁŝƚŚĚĂǇ-to-
ĚĂǇůŝĨĞ ?ǁĂƐƚŚĞƉƌŝŵe indicator of medicine burden. It covered specific issues such as 
disruptions to daily tasks, social and leisure activities, social relationships, sexual life, 
and the need to carefully plan medicine regimens to fit lifestyle. For people with 
cognitive and or physical difficulties, exacerbated by aging and polypharmacy (or its 
side effects), planning ĂŶĚƉĞƌĨŽƌŵŝŶŐ ‘ĐŽŵƉůĞǆƚĂƐŬƐĚĞƉĞŶĚĞŶƚŽŶĐŽŐŶŝƚŝŽŶ ? can be 
especially difficult.220 Medicine use routines tend to be planned alongside usual 
activities of daily life (e.g. having meals, sleeping), and changes in daily routine could 
also be disruptive to medicine use experiences. Nevertheless, an item intended to 
measure the latter concept,  ‘ŚĂŶŐĞƐŝŶĚĂŝůǇƌŽƵƚŝŶĞĐĂƵƐĞƐƉƌŽďůĞŵƐǁŝƚŚŵǇ
medicines ? ?did not meet inclusion criteria and was excluded from the final item pool. 
 
The side-effect dimension strongly explained medicine burden, and was closely 
ĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞ ‘ŝŶƚĞƌĨĞƌĞŶĐĞƐ ?ĚŽŵĂŝŶĚĞƐĐƌŝďĞĚĂďŽǀĞ ?The burden of side 
effects, and their impact on physical, social, and emotional wellbeing, is well 
documented.92 Side effects were also strongly associated with concerns about 
medicines in this study. Medicines are often perceived by the general public to be 
damaging and harmful, and to have long-term effects.21,81 Concerns about harm from 
side effects are also related to perceived dependency from long-term use of 
medicines.81 
 
Practical difficulties were significantly related to the  ‘ŝŶƚĞƌĨĞƌĞŶĐĞ ?domain. The 
practical difficulties subscale covered issues around access to prescriptions, obtaining 
regular medicine supplies, identification of different medicines, and general use of 
medicines. The burden of self-care, including of managing medicine routines and self-
administration of medicines, has been documented as a demanding activity.48,50,85,89 
Managing medicine routines can be time- and resource-demanding, with respect to 
accessing medicines, learning how to use therapies, and/or monitoring regular use.50,89 
This may even be worsened by complex regimens (e.g. quantity and frequency of 
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use),83,98 varied formulations or their packaging, and switching between generics and 
brands.100 Regardless, some of these concepts were not adequately captured in the 
final LMQ-3 since three potentially relevant items were excluded due to poor 
performance in the psychometric analyses:  ‘I find the written instructions on  how to 
use my medicines easy to understand ?;  ‘It is difficult to identify which medicine is 
which ?; and  ‘I find opening the packaging of my medicines difficult ?. Regardless, the 
LMQ-3 has an item hinting on patient autonomy to choose which brands of medicines 
to use. ^ƵĐŚĂƐƚĂƚĞŵĞŶƚ ? ‘I would like more say in the brands of medicines I use ? ?
although ĐůƵƐƚĞƌĞĚŝŶƚŚĞ ‘ŐĞŶĞƌĂůĐŽŶĐĞƌŶƐ ?ĚŽŵĂŝŶ ?ŵĂǇŝŶĚŝƌĞĐƚůǇƌĞĨůĞĐƚŝƐƐƵĞƐ
around medicine formulations, packaging, or dosage regimen used by patients, and 
need for brands/generics that minimise practical difficulties while enhancing the 
medicine use experience.  
 
In this study, negative experiences with effectiveness were also related to medicine 
burden. Medicine-related benefits are often weighed against any associated burden 
among patients who may deliberately ignore any inconveniences of medicine 
use.195,198 Although many patients value the positive effects of medicines, including 
relief of symptoms, control/managing illnesses, and prevention of illness-associated 
morbidity or mortality as the prime rationale for using medicines, their expectations 
may not always be met.115 Perceived inadequacies in desired outcomes may impact 
ŶĞŐĂƚŝǀĞůǇŽŶŝŶĚŝǀŝĚƵĂůƐ ?ŽǀĞƌĂůůĞǆƉĞƌŝĞŶĐĞƐŽĨŵĞĚŝĐŝŶĞƵƐĞ ?ĂŶĚŝŶĨůƵĞŶĐĞŵĞĚŝĐŝŶĞ-
related behaviour including non-adherence.23,88   
 
Poor doctor-patient relationships and communication about medicines were also 
significantly correlated with medicine burden.  Interpersonal relationships and 
information sharing by healthcare providers influences factors such as patient-provider 
partnerships and increased commitment to use medicines,195,221 which in turn affects 
perceived effectiveness. SoŵĞŽĨƚŚĞŝƚĞŵƐŝŶƚŚĞ ‘ĚŽĐƚŽƌ ?domain related to trust and 
confidence in health professionals, as well as information sharing. Patient trust and 
confidence is also associated with positive attitudes and experience with medicine use, 
and attainment of treatment outcomes.23 Poor patient-provider relationships may 
deter information sharing and could be burdensome to some individuals. Medicine-
information-related burden may also be exacerbated by poor consultation styles, 
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conflicting information, patient understanding and the amount of information 
provided.196,197  
 
One of the differences between the 41-item final LMQ-3 and the LMQ-2 (reported in 
ŚĂƉƚĞƌ ? )ŝƐƚŚĞůĂĐŬŽĨĂĚŽŵĂŝŶŽŶ ‘ƉĂƚŝĞŶƚ-pharmacist communication about 
ŵĞĚŝĐŝŶĞƐ ? ?ƚŚĞŝƚĞŵƐĨŽƌǁŚŝĐŚĚŝĚŶŽƚ meet the inclusion criteria in the present study. 
This finding poses a specific challenge to pharmacists who have a professional 
responsibility to support patients with medicines use through existing or new 
ƉŚĂƌŵĂĐǇƐĞƌǀŝĐĞƐ ?,ŽǁĞǀĞƌĂƐƚŚĞ ‘ƉŚĂƌŵĂĐŝƐƚ ?Ěomain did not factorise  W it formed a 
psychometrically unstable factor with fewer than three items loading in the final 
measure, it was judged to be of low importance as a separate domain.  
 
One potential reason for this is that patient-communication experiences, in terms of 
medicine use, are explained mostly by doctor-communication and less by pharmacist-
communication. Many studies show that patients prefer to talk to doctors about 
medicines than to pharmacists,222 even though pharmacists are more accessible.  
Patienƚ ?ƉƵďůŝĐƉĞƌĐĞƉƚŝŽŶƐŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐƌŽůĞŵĂǇĐŽŵƉůŝĐĂƚĞƚŚŝƐŝƐƐƵĞ ?ĂƐ
pharmacists are often perceived as busy and pharmacies lacking in facilities for 
private/confidential consultations.223 Moreover, increasingly many patients have 
medicines delivered to their homes directly and have no interaction with a pharmacist. 
None of the additional comments provided in the studies cited pharmacist interaction 
as contributing to burden, or indeed other health professionals who may discuss 
medicines with them. It is important to recognise that the LMQ was not developed as a 
measure of satisfaction with pharmacists or their services.  
 
dŚĞƌĞĨŽƌĞ ?ŝƚĐŽƵůĚďĞĂƌŐƵĞĚƚŚĂƚƚŚĞůĂĐŬŽĨĂ ‘ƉŚĂƌŵĂĐŝƐƚĐŽŵŵƵŶŝĐĂƚŝŽŶ ?ĚŽŵĂŝŶŝŶ
the final LMQ-3 was not detrimental. This is especially the case if pharmacists are to 
take the lead in supporting patient evaluations of their own medicines. Patients are 
more likely to give an accurate reflection of challenges with doctor-communication, 
represented in the LMQ-3, than when reporting deficiencies with pharmacist-
communication to pharmacists themselves. Further work may establish the latter 
proposition, as well as the impact of pharmacist-communication on medicine burden 
levels among individual patients. 
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A new addition to the LMQ-3 structure ǁĂƐƚŚĞ ‘ĐŽƐƚ ?ƐƵďƐĐĂůĞ. Cost-related burden 
was found to be moderately correlated with medicine burden. As described previously, 
the financial burden associated with long-term prescription medicines can be a 
demanding aspect of the medicine use experience, for not only chronically-ill patients 
but also their family and social life.46,51,52,102,104,224 Although only approximately a third 
of patients paid for their prescription medicines in this study, the cost domain was 
clearly associated with medicine burden. According to the Prescription Charges 
Coalition, a group of patient-ŽƌŐĂŶŝƐĂƚŝŽŶƐĂĚǀŽĐĂƚŝŶŐƚŽ ‘end unfair prescription 
charges for people with long-term medical conditions ?ŝŶŶŐůĂŶĚ ?cost-related burden 
is real and impacts on non-adherence,  and other aspects of day-to-day life, 
particularly  affecting the younger population and those in lowest income 
brackets.47,102  
 
Perceived lack of autonomy over medicine use was a relatively weak indicator of 
medicine burden compared to other domains in LMQ-3. Statistical analyses indicated 
that decreasing autonomy to vary regimen dose or timing (or even stopping 
medicines) was not significantly associated with medicine burden. This may suggest 
that negative experiences with respect to the autonomy to change dosing schedules or 
time are not necessarily burdensome in this sample of the public. Paradoxically, 
experimental analyses to delete ƚŚĞ ‘ĂƵƚŽŶŽŵǇ ?ƐƵďƐĐĂůĞĨƌŽŵƚŚĞŚŝĞƌĂƌĐŚŝĐĂůŵŽĚĞů
(Model 3) did not improve model fit significantly, and thus this dimension was 
retained. Further studies are needed to cross-validate the relative importance of 
perceived lack of autonomy in explaining medicine burden, and overall medicine use 
experiences. 
 
Regardless, inconvenient regimes can negatively impact on the medicine use 
experience, and lead to perceived loss of control over medicines use.95,225 Moreover, 
qualitative studies indicate that ƉĂƚŝĞŶƚƐǁŚŽĞǆƉĞƌŝĞŶĐĞĚŝĨĨŝĐƵůƚŝĞƐŝŶ ‘ĞǆĞƌƚŝŶŐ
ĐŽŶƚƌŽůŽǀĞƌŵĞĚŝĐŝŶĞƌŽƵƚŝŶĞƐƐƉĞĐŝĨŝĞĚďǇŚĞĂůƚŚƉƌŽĨĞƐƐŝŽŶĂůƐ ?23 may perceive more 
medicine burden as inflexible schedules may interfere with day-to-day life. Practical 
difficulties and autonomy subscales were also slightly correlated in this study. Some 
patients may manipulate their medicine regimens, especially when they experience 
unbearable burden,88 while others unable to cope may feel negative emotions about 
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their medicines.78 For those able to adapt medicine regimes to fit in with their lifestyle, 
they may perceive little or no medicine burden. Coping strategies may draw on family 
and social support, health provider support, and personal strategies like information 
seeking, record keeping, adjusting regimes, use of reminders, and pill organisers.88,221  
 
Study strengths and limitations 
All data were utilised resourcefully to suit the analyses performed. All factor analyses 
were conducted on an adequate sample of survey responses from adults, using regular 
medicines, recruited via the general public in the UK, although limited to web-based 
survey methodology. Although the survey was accessed by a wider, geographically-
representative, population across the UK, it is likely that issues around prescription 
costs and charges, currently applicable to England only, were irrelevant to the few 
participants living elsewhere in the UK. The majority of respondents were females, and 
the results may be representative of those with higher education levels and access to 
the internet.  
Poorly performing items were eliminated using psychometrically sound criteria, and 
conceptual decisions guided by discussions with the supervisory team. Nevertheless, 
item deletion may have led to loss of potentially relevant items. A factorially complex 
item,  ‘/ĨĞĞů/ŶĞĞĚŵŽƌĞŝŶĨŽƌŵĂƚŝŽŶĂďŽƵƚŵǇŵĞĚŝĐŝŶĞƐ ?, was retained in the final 
LMQ-3. Streiner and Norman (2008) suggest that such an item cross loads comparably 
well on two or more factors, and may pose measurement problems as it appears to 
assess multiple constructs.127 Future work on the LMQ-3 may consider the specificity 
of this item, as a possible candidate for item reduction when devising a shorter version 
of the instrument. Nevertheless, further studies, described in Chapter 7 and 8, were 








6.5 Chapter summary 
This study set out to refine the LMQ-2.1 and assess the construct validity of a newer 
and shorter version of the questionnaire (LMQ-3). The 41-item, 8-factor, modified 
second-order measurement model (LMQ-3) revealed better model fit statistics, and 
was most interpretable. Of the eight LMQ-3 subscales (interferences with day-to-day 
life; side-effect-related burden;  general concerns about medicines; practical 
difficulties; lack of effectiveness; patient-doctor relationships/communication 
problems; cost-related burden; and  lack of autonomy/control over medicines use), the 
first seven were adequately and significantly correlated with medicine burden, as the 
hypothesised overarching construct purported to underlie the measure. All seven 
subscales had acceptable internal consistency ?ĂŶĚƚŚĞ ‘ĂƵƚŽŶŽŵǇ ?ƐƵďƐĐĂůĞǁĂƐĐůŽƐĞ
ƚŽĂƚƚĂŝŶŝŶŐƚŚĞƚĂƌŐĞƚƌŽŶďĂĐŚ ?ƐĂůƉŚĂ.  
 
This chapter extends knowledge on the LMQ as a measure of medicine burden and 
adds to the understanding of the best representation of its dimensions, and their 
internal consistency. The findings also contribute to evidence of ƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞ ?Ɛ
measurement properties, particularly construct validity. ^ŝŶĐĞƚŚĞƌĞĂƌĞŶŽ ‘ŐŽůĚ-
ƐƚĂŶĚĂƌĚ ? measures of prescription medicine burden, future studies could explore how 
the LMQ-3 and its subscales relate to other measures of medicine-related experiences. 
Such studies can help to further validate the LMQ-3 and double check construct 




Chapter 7 Criterion-related 
validation of the LMQ-3  
Acknowledgements 
Data used in Chapter 7 was collected by myself (BK), with assistance from five 
undergraduate students conducting their final-year research projects at the Medway 
School of Pharmacy. BK sought ethics approval and research governance for all study 
sites and co-ordinated all data collection. The students conducted part of the data 
entry. All datasets were double-checked, cleaned and merged by BK, who conducted 
the analysis and interpreted the results presented in this chapter. 
7.1 Introduction 
In the previous chapter, construct validity of the Living with Medicines Questionnaire 
(LMQ-3) was assessed, confirming the internal structure of the instrument. Although 
its overarching construct of medicine burden and eight subordinate domains were 
illuminated, the preceding chapter also revealed the need for further construct 
validation. Particularly, there was a need to cross-validate LMQ-3 concepts and how 
they relate to other medicine-related attributes (such as treatment satisfaction), so as 
to fully understand the constructs described in Chapter 6. It was necessary to conduct 
further testing of the instrumĞŶƚ ?ƐƉƐǇĐŚŽŵĞƚƌŝĐƉƌŽƉĞƌƚŝĞƐ (i.e. construct validity) to 
help substantiate the nature of concepts underlying the LMQ-3. 
 
^ƚĂŶĚĂƌĚŐƵŝĚĂŶĐĞĚĞĨŝŶĞƐĐƌŝƚĞƌŝŽŶǀĂůŝĚŝƚǇĂƐ ‘the extent to which the scores of [an] 
instrument are related to a known gold standaƌĚŵĞĂƐƵƌĞŽĨƚŚĞƐĂŵĞĐŽŶĐĞƉƚ ? ?124  
Criterion testing is a form of external validation, in which relationships with other 
measures of the same construct are verified.226 However, the same guidance 
ĂĐŬŶŽǁůĞĚŐĞƐƚŚĂƚ ‘ĨŽƌŵŽƐƚ ?ŝŶƐƚƌƵŵĞŶƚƐ ?, criterion validity cannot be measured 








/ŶƚŚĞĂďƐĞŶĐĞŽĨĂ ‘ŐŽůĚ-ƐƚĂŶĚĂƌĚ ?ŵĞĂƐƵƌĞŽĨŵĞĚŝĐŝŶĞďƵƌĚĞŶ ?Ăůternative measures 
provide an option. Criterion-related validation can help explore the degree to which a 
newly developed measure (e.g. the LMQ-3) relates to previously validated measures of  
similar or dissimilar constructs that are presumably related.227,228 In other words, 
 ‘ŵĞĂƐƵƌĞƐŽĨĐŽŶƐƚƌƵĐƚƐƚŚĂƚƚŚĞŽƌĞƚŝĐĂůůǇƐŚŽƵůĚŶŽƚďĞƌĞůĂƚĞĚƚŽĞĂĐŚŽƚŚĞƌ are, in 
fact, observed to not be related to each other (known as divergent or discriminant 
validity) ?or  ‘ŵĞĂƐƵƌĞƐ of constructs that theoretically should be related to each other 
are, in fact, observed to be related to each other (known as convergent validity) ?.228 
 
In Chapter 2, the Treatment Satisfaction Questionnaire for Medication (TSQM-II) was 
identified as a generic measure of satisfaction with prescription medicines for any 
disease/condition,109 and it has been widely used in other questionnaire validation 
studies.83,130,229 One such study involved validation of the Treatment Burden 
Questionnaire (TBQ), also identified in Chapter 2, where a negative relationship was 
established between treatment burden and treatment satisfaction.83 Although a 
similar negative relationship is expected between medicine burden and satisfaction 
with therapy, it has not yet been established, empirically, using TSQM-II dimensions of 
effectiveness, side effects, convenience, and general satisfaction.  
 
More so, health-related quality of life (HRQoL), which encompasses multiple 
dimensions including physical, mental and psychosocial components, is another widely 
researched concept128 whose association with medicine burden is unknown. However, 
it is well documented that using medicines impacts on different aspects of 
HRQoL.23,92,134,149 It was thus relevant to compare the LMQ-3 with a suitable measure 
of HRQoL. The EuroQol five-dimensional questionnaire, the EQ-5D-5L,230 was selected 
as an additional comparator tool to verify the medicine burden concept, and how its 










Aim and objective 
This chapter aimed to examine the criterion-related validity of the LMQ-3, against 
suitable measures administered to an adult patient population using regular 
prescription medicines in south-east England.  
The specific objective was to examine the divergent/discriminant validity of the LMQ-3 
by comparing patient scores on the LMQ-3 (and its subscales) with those obtained 
using the TSQM-II, and the EQ-5D-5L.  
 
7.2 Methods 
7.2.1 Study design 
This was a cross-sectional validation study, conducted between October and December 
2015, in which all three questionnaires (the LMQ-3, TSQM-II and EQ-5D-5L) were self-
completed at the same time. The National Research Ethics Service (NRES Committee 
South Central -Oxford C) approved this study (See Appendix 18). Separate research 
governance approvals were granted by participating organisations (Appendix 19). All 
participants had access to study information (Appendix 20), and consent was implied 
by return of complete questionnaires.  
 
7.2.2 Study participants and inclusion criteria 
Similar to previous studies (described in Chapters 4-6), participants were adults (18 
years or older), using at least one long-term prescription medicine for any 
disease/condition, and living in England.  
 
7.2.3 Study instruments 
The questionnaires employed in this validation study were the LMQ-3, the TSQM-II, 
and the EQ-5D-5L. All three questionnaires were combined and printed in form of a 
booklet to ease handling and completion. The ordering of questionnaires in the 
booklet prioritised the LMQ-3, then the TSQM-II as another medicine-related 
questionnaire, and the EQ-5D-5L came last. A brief overview of each instrument is 







7.2.3.1 The LMQ-3  
As described in Chapter 6, the LMQ-3 is a self-completion questionnaire with 41 Likert-
type statements rated on a 5-point rating scale (strongly agree to strongly disagree) 
(See Appendix 21). It also has visual analogue scales, including a global item assessing 
overall medicine burden (VAS-burden). The LMQ-3 also has a free-text question, and 
participant characteristics. In terms of scoring, Likert-item responses are coded from 1 
to 5, while the VAS-burden is rated using a 0-10 scale, with anchors indicating  ‘ŶŽ
burden at alů ?ƚŽ ‘ĞǆƚƌĞŵĞůǇďƵƌĚĞŶƐŽŵĞ ? ?
 
As described in previous chapters, negatively phrased items were reverse scored, such 
that higher scores reflect higher medicine burden. Subscale/domain scores were a sum 
of item scores per domain (relating to interferences with day-to-day life; side effects; 
general concerns about medicines; practical difficulties; lack of effectiveness; patient-
doctor relationships/communication problems; cost-related burden; and lack of 
autonomy/control over medicines use). The LMQ-3 total scale score (i.e. overall 













Figure 7-1 Scoring of LMQ-3 items and subscales/domains 
 
 
The LMQ-3 was the primary study instrument whose scores were hypothesised to 
relate to the TSQM-II and the EQ-5D-5L as described below. 
 
Subscale/domain scores 
[1] Interferences score=Q19 + Q28 + Q35 + Q36 + Q37 + Q41 
[2] Side-effect-burden score = Q21 + Q22 + Q30 + Q38 
[3] General concerns score=Q6 + Q8 +Q9 + Q12 + Q16 + Q17 + Q18 
[4] Practical difficulties score = Q1 + Q2 + Q4 + Q10 + Q23 + Q27 + Q29 
[5] Lack of effectiveness score =Q3 + Q15 + Q25 + Q32 + Q39 + Q40 
[6] Patient-doctor communication problem score=Q7 + Q14 + Q20 + Q24 + 
Q34 
[7] Cost-burden score = Q5 + Q31 + Q33 
[8] Lack of autonomy score=Q11 + Q13 + Q26 
Total scale score  





7.2.3.2 The TSQM-II 
Permission to use the TSQM Version II was granted by the Quintiles group Inc. (See 
Appendix 22). The TSQM-II is a short, 11-item, self-completion, generic questionnaire 
tested in patients with a range of long-term conditions, and assesses satisfaction with 
various prescription medicines.109 It has four internally consistent subscales 
 ?ƌŽŶďĂĐŚ ?ƐĂůƉŚĂrange, 0.85-0.87) including satisfaction with side effects, 
effectiveness, convenience, and global satisfaction. Items are scored on a 6 or 7-point 
Likert-type scale with descriptive anchors (e.g. extremely dissatisfied to extremely 
satisfied). The TSQM-II instrument also has a binary response option assessing whether 
(or not) patients experience side effects. All TSQM-II scores are transformed according 
to a standard scoring algorithm (See Appendix 22), and range from 0 to 100.  
 
The TSQM-II was selected for use in this study because of its face-, content-, and 
construct validity, and the fact that it has been tested for comprehension in the UK 
population. Moreover, as a popular measure of treatment satisfaction, this 
questionnaire has been widely used as a criterion-referenced tool to validate other 
instruments, including the Treatment Burden Questionnaire (TBQ).83 The latter 
questionnaire was not used as a criterion-reference in the present study since some of 
its items are not specific to prescription medicines.231 For instance, they relate to 
treatment burden associated with laboratory tests and self-monitoring, and difficulties 
associated with doctor appointments.83 Moreover, the original questionnaire was 
developed and tested in a French population, and the more recently validated English 
translation232 was not easily accessible at the time of the study.  
Hypotheses  
 A negative relationship between medicine burden and treatment satisfaction was 
hypothesised i.e. higher perceived medicine burden corresponding to lower 
satisfaction with medicines use. Composite scores on the LMQ-3, and its subscales, 
were predicted to show negative correlations with scores on the TSQM-II global 
satisfaction, side effects, effectiveness, and convenience subscales. Correlations 
between the latter three TSQM-II subscales and three LMQ-3 subscales (also relating 
to side effects, effectiveness (or lack of it) and practical difficulties) were expected to 





7.2.3.3 The EQ-5D-5L  
Permission to use the EQ-5D-5L (UK English version) was granted by the EuroQol 
Research Foundation (See Appendix 23). The EQ-5D-5L is the EuroQol ?Ɛ five-
dimensional, self-administered, questionnaire. It is a standardised, commonly used 
generic measure of HRQoL that has demonstrated validity and reliability in diverse 
settings. 230,233 It was selected for use in this study as a widely acceptable tool recently 
recommended for use within the English NHS.234 Unlike the relatively longer health 
status questionnaires (such as the 36-Item Short- Form Health Survey (SF-36),235,236 the 
EQ-5D-5L is short and consists of 5 questions assessing mobility, self-care, usual 
activities, pain or discomfort, and anxiety or depression. Its length was exploited to 
minimise response burden, an important factor to consider for participants having to 
complete three questionnaires overall.   
 
Designed to improve its sensitivity and discriminatory properties, the EQ-5D-5L has five 
answer options reflecting no problem, slight problems, moderate problems, severe 
problems and extreme problems, which are scored from 1 to 5 respectively.230,233 The 
EQ-5D-5L also has a 20- cm visual analogue scale, the EQ-VAS, ƌĂƚĞĚĨƌŽŵ ‘ƚŚĞǁŽƌƐƚ
ŚĞĂůƚŚǇŽƵĐĂŶŝŵĂŐŝŶĞ ? ?ƐĐŽƌĞĚĂƐ ? )ƚŽ ‘ƚŚĞďĞƐƚŚĞĂůƚ ǇŽƵ ĐĂŶŝŵĂŐŝŶĞ ?(scored as 
100).233  
Hypotheses 
It was hypothesised, a priori, that medicine burden would be negatively related to 
overall health status88,92 i.e. higher perceived medicine burden would be associated 
with the lower self-reported general health scores. It was also anticipated that 
negative correlations between LMQ-3 medicine burden and HRQoL domains of the EQ-
5D-5L would be of small to moderate magnitude, since the two instruments were 
hypothesised to measure distinct constructs. Generally, low correlations between 










7.2.4 Study settings and procedures 
Three recruitment settings were used in this study: community pharmacies, GP 
practices, and outpatient waiting areas of the Medway Maritime Hospital.  
Research governance to access the outpatient areas was granted by the Research and 
Development department at the Hospital (See Appendix 19), which also provided a 
letter of access for individual researchers. Permission to recruit via local community 
pharmacies and GP practices (in areas of Kent and Medway) was obtained for each 
study site. 
a) Community pharmacy recruitment 
Recruitment via community pharmacies, conducted over a 6-week period, was 
intended to capture medicine use experiences of users of pharmacy services. The 
justification for distributing surveys via pharmacies was described under general 
methodology in Chapter 3, and in Chapter 4 where similar methods were applied. A 
purposive sample of small-medium sized pharmacies (independents) was selected 
from the NHS choices website (http://www.nhs.uk/pages/home.aspx), and used to 
recruit potential participants. Multiple-chain community pharmacies (e.g. Boots) were 
excluded from survey distributions owing to time-demanding procedures for obtaining 
in-house governance. More so, it was assumed that there was no difference in patient 
characteristics across different pharmacy service providers. All pharmacies were 
located in Medway towns and areas of Kent, within close proximity to the Medway 
School of Pharmacy for easier access.  
 
Letters of invitation, study information, and copies of the questionnaires were sent to 
pharmacists in charge at selected community pharmacies, followed by a phone call 
after a week to verbally ask for permission and to arrange questionnaire distributions. 
Potential participants were people waiting in the pharmacy (e.g. those refill their 
prescriptions). Across all three recruitment settings, screening for pre-defined 
inclusion criteria was done verbally by asking patients if they used long-term 
medicines, checking they were 18 years or older and resident in England. Screened 
participants were provided with survey packs containing questionnaires, participant 






b) Recruitment via General Practices 
Similar to procedures used in pharmacy recruitment, GP practices were purposively 
selected from the NHS choices websites for their location in areas of Medway and 
Kent, near to the School of Pharmacy. Practices with more registered patients were 
selected to access a higher footfall of patients. Similar to pharmacy recruitment, letters 
of invitation (and study information) were sent to GP practice managers followed by a 
phone call, to recruit practices to the study.  
 
Once permission to distribute study packs to people waiting for appointments was 
obtained, practices were visited by researchers. Potential participants were those 
waiting for GP appointments; they were approached directly or with help from 
practice administrators to invite them to the study. Brief verbal information about the 
study was provided, and potential participants were verbally screened for eligibility to 
participate. If meeting all criteria, a study pack containing the questionnaire booklet 
was provided. Participants could choose to complete the questionnaires while waiting 
for their appointment with the GP or could take them away and return them using the 
prepaid envelope provided. Recruitment in practices was conducted over a three-week 
period. 
 
c) Recruitment via outpatient clinics 
A three-week questionnaire distribution exercise was conducted in outpatient clinics 
of the Medway Maritime hospital. As stated previously within the methodology 
section (Chapter 3), recruitment of participants via the local hospital was intended to 
capture medicine use experiences of patients in secondary care. The hospital has a 
diverse and high footfall of patients. Similar to other recruitment settings, a letter of 
invitation was sent to ƚŚĞŽƵƚƉĂƚŝĞŶƚƐ ?ĂƌĞĂŵĂŶĂŐĞƌ followed by a phone call, to 
recruit outpatient clinics to the study.  
 
Once permission was obtained, seven different outpatient areas were visited by 
researchers to distribute study packs to people waiting for appointments. These areas 
provide care under specialities, including dermatology, gynaecology, general surgery, 
rheumatology, urology, general medicine, neurology. Potential participants were 




Participants completed questionnaires while waiting for appointments or off-site; the 
former returned completed questionnaires in sealed envelopes to either researchers 
or dropped them in designated boxes in the outpatient areas (e.g. at the reception) 
where they were collected on the same day. Again, questionnaires completed outside 
the premises were returned by post using prepaid envelopes.  
 
7.2.5 Data analysis 
7.2.5.1 Data preparation 
All data were entered in SPSS (version 22). All data were double-checked, cleaned, and 
pooled from all sources. Quality checks were made to correct potential errors, visually 
and by descriptive statistics, to enhance accuracy of data. The extent of missing data 
was assessed for all items, and demographic questions. Subscale (domain) and total 
scale (composite) scores on all LMQ-3 were computed as per Figure 7-1. Computation 
of TSQM-II subscale and global scale scores was done in accordance with the 
ĚĞǀĞůŽƉĞƌ ?ƐĂůŐŽƌŝƚŚŵ ?^ĞĞƉƉĞndix 22).109 Raw item scores on the EQ-5D-5L, and its 
general health scale (the EQ-VAS) scores were used. The distribution of scores on all 
three instruments was assessed using descriptive statistics including medians, mean, 
and range of scores.   
 
7.2.5.2 Correlation analyses 
To address the primary study objective, correlations between scores on the LMQ-3, 
the TSQM-II, and the EQ-5D-5L were examined. ^ƉĞĂƌŵĂŶ ?Ɛ ?ƌĂŶŬ correlation 
coefficient (rs), a non-parametric test, was reported for the asymmetrical scores. The 
magnitude and direction (as positive or negative) of correlations were assessed.  
Correlations below 0.34, 0.35-0.50, and > 0.5 were interpreted as weak/small, 
moderate, and high (or strong) respectively, and p-values <0.05 were deemed 
statistically significant.83 Positive correlations denote that an increase in one variable 









7.3.1 Response rates 
Out of a purposive sample of 20 community pharmacies, and 20 GP practices 
contacted initially, six pharmacies (30%) and five GP practices (25%) granted 
permission to recruit participants from their premises. Seven of eight (87.5%) 
outpatient clinics were accessible for hospital recruitment. A total of 1306 
questionnaires were distributed across all study sites: 220 questionnaires in GP 
practices; 150 questionnaires in community pharmacies; and 936 questionnaires in 
outpatient clinics. Overall, 422 questionnaires were returned representing 32.3% 
response rate. Site-specific response rates were 44.7% (n=67), 36.4% (n=80), and 29.4 
% (n=275) for community pharmacies, GP practices and outpatient clinics respectively.  
 
Item-level response rates were excellent (95% to 100%) for all but two LMQ-3 Likert-
type items ( ‘Q33-I have to pay more than I can afford for my medicines ? and  ‘Q5-I 
worry about paying for my medicines ?) that had responses missing for 6.8% and 9.3% 
of all participants respectively. Pairwise deletion of missing data was used to include 
participants that provided responses necessary for each analysis.   
 
7.3.2 Patient population 
Half of all participants were female (52.8%, n= 208). The mean age was 56.1 (± 18.17), 
including those between 18-92 years, and the vast majority of participants were 65 
years or over (40.5%, n=170). Nearly half of the respondents were retirees (45.6%, 
n=187). The mean number of medicines used was 4.6 (±3.67), with some participants 
self-reporting to use up to 26 medicines (median= 4, range 1-26). Hyperpolypharmacy 
(10 or more medicines) was experienced by 13% (n=54) of all participants. All 









































































 Table 7-1 Characteristics of participants in the criterion-related validation study 
      
 
Notes; 
µincludes GP practice nurse; ** Different times of the day, week, or month  
 
 
Characteristic  Frequency 
(%) 
Gender Female 208(52.8) 
(n= 394) Male 186(47.2) 
Age 18-29 51(12.1) 
(n = 420) 30-49 81(19.3) 
 50-64 118(28.1) 
 65 or over 170(40.5) 
Education level School 158(40.3) 
(n=392) Technical college/Apprenticeship 117(29.9) 
 University 89(22.7) 
 Other 28(7.1) 
Employment status Employed 159(38.8) 
(n=410) Unemployed 44(10.7) 
 Retired 187(45.6) 
 Full-time student 20(4.9) 
Ethnicity White 353(86.5) 
(n= 408) Asian/Asian British 15(3.7) 
 Mixed 10(2.4) 
 Black/African/Caribbean 26(6.4) 
 Other 4(1.0) 
No. of medicines 1-4 236(56.7) 
(n=416) 5-9 126(30.3) 
 10 or more 54(13.0) 
Formulation used Tablets/capsules 284(70.3) 
(n = 404) Parenteral formulations 30 (7.4) 
 Mixed formulations 90 (22.3) 
Frequency of use Once per day 146(35.9) 
(n = 406) Twice per day 136(33.5) 
 Three times per day 49(12.1) 
 More than 3 times per day 47(11.6) 
 Other times** 28(6.9) 
Managing medicines No (Autonomous) 349(85.7) 
(n=407) Yes (Requires assistance) 58(14.3) 
Medicines carer  
(n=56) 
Spouse/ Partner 33(58.9) 
Relative 10(17.9) 











7.3.3 Distribution of scores on all instruments 
Compared to the LMQ-3 domain scores, TSQM-II scores were skewed towards the 
ƐĐĂůĞ ?ƐĐĞŝůŝŶŐ ?ŝŶĚŝĐĂƚŝŶŐŚŝŐŚĞƌƐĞůĨ-reported satisfaction with medicines). For 
instance, the satisfaction with side effects subscale had a median score of 100 
(observed and possible range of scores, 0-100), suggesting that the average participant 
was fully satisfied with their experience of side effects. Median scores on the EQ-5D-5L 
indicated no or slight problems with the five aspects of health for this sample 
population. Overall health status was good as indicated by a median score of 75 on the 
EQ-VAS, where 100 represents the best imaginable health. Table 7-2 illustrates score 
distribution across all questionnaires used in this study.  
 










LMQ-3    
Patient-doctor communication 5 (5-25) 12.0(5-25) 12.5(3.9)  
Practical difficulties  7(7-35) 15.0 (7 -28) 15.4 (4.1)  
Cost- burden  3(3-15) 6.0 (3-15) 6.6 (3.0) 
Side-effect-burden  4(4-20) 9.0 (4-20) 9.8(3.6) 
Lack of effectiveness  6(6-30) 14.0 (6-29) 13.9 (3.7) 
General concerns 7(7-35) 20.0(7-35) 20.2 (5.1) 
Interferences with daily life 6(6-30) 13.0 (6-29) 13.8(4.8)           
Lack of autonomy/control  3(3-15) 10.0 (3-15) 10.2(2.6) 
LMQ-3 total /composite score  41(41-205) 101.0 (50-172) 102.7(20.0) 
VAS-burden scale score 1(1-10) 1.5(0-10) 2.8(3.0)  
TSQM-II    
Satisfaction with effectiveness 2 (0-100) 66.7(0-100) 68.2(18.4 )    
Satisfaction with side-effects 3 (0-100) 100 (0-100) 83.5(22.7)           
Satisfaction with convenience 3 (0-100) 72.2(16.7-100) 72.6(17.0)  
Global satisfaction 2(0-100) 66.7(0-100) 70.9(18.8)       
EQ-5D-5L        
Mobility 1(1-5) 1.0 (1-5) 1.7(1.0) 
Self-care 1(1-5) 1.0(1-5) 1.3(0.7) 
Usual activities 1(1-5) 1.0(1-5) 1.7(1.0) 
Pain/discomfort 1(1-5) 2.0(1-5) 2.1(1.1) 
Anxiety / depression  1(1-5) 1.0(1-5) 1.7(0.9) 
EQ-VAS for general health state 1 (0-100) 75.0 (1-100) 69.4( 20.5)          
 Table 7-2 Distribution of scores obtained using the LMQ-3, TSQM-II and EQ-5D 
  
 Notes; the EQ-5D-5L is scored such that higher scores depict severe problems with a specific 
 aspect of HRQoL (1 indicates no problem, 5 indicates extreme problems).  
 All scores on the TSQM-II are measured so that higher scores depict greater satisfaction 








7.3.4 Criterion-related validity of the LMQ-3 
The magnitude of correlations between LMQ-3 scores and those on the TSQM-II were 
in the range of 0.010-0.628, suggesting weak to strong correlations among subscales 
(See Table 7-3). As predicted, correlations were strongest between thematically 
comparable subscales of the two instruments: LMQ-3 lack of effectiveness with TSQM-
II satisfaction with effectiveness (rs = - 0.628); LMQ-3 side-effect-burden with TSQM-II 
satisfaction with side effects (rs = -0.597); and LMQ-3 practical difficulties with TSQM-II 
satisfaction with convenience of medicine use (rs = -0.529). The correlations between 
treatment satisfaction and autonomy- and cost-related burden were generally weak (rs 
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Table 7-3 Correlations between LMQ-3 scores and TSQM-II scores 
 
Notes; ůůĐĞůůĞŶƚƌŝĞƐĂƌĞ^ƉĞĂƌŵĂŶ ?Ɛcorrelations. 
All correlations are significant at the p< 0.05 level (2-tailed), except those denoted by
¥ for non-significant.  
All scores on the TSQM-II (and its subscales) are measured so that higher scores depict higher satisfaction 







Overall, the correlation between scores on the LMQ-3 total scale and the global 
satisfaction scale was strong and negative (rs = -0.616) as hypothesised (see Figure 7-
2). This confirms the negative relationship between medicine burden and treatment 
satisfaction i.e. higher medicine burden was associated with lower satisfaction with 




















Correlations between LMQ-3 and EQ-5D-5L scores were in the range of 0.041-0.436, 
depicting weak to moderate relationships between dimensions of medicine burden 
and health-related quality of life (See Table 7-4). In terms of specific aspects of HRQoL, 
self-reported anxiety/depression was moderately and positively associated (rs = 0.436) 
with overall medicine burden assessed by the LMQ-3 total scale score. This finding 
demonstrates the psychological features of medicine burden. The pain/discomfort 
subscale was positively correlated with side-effect-burden (rs =0.304). Higher side-
effect-burden scores were weakly associated with lower general health scores (rs = - 
0.317). Perceptions of therapeutic ineffectiveness were weakly associated with 
increasing pain/discomfort (rs = 0.305) and anxiety/depression (rs =0.300), but lower 
general health (rs = -0.307). Lack of autonomy to vary regimes (rs = -0.081) and cost-
related burden (rs =0.022) did not show any significant correlations (p > 0.05) with 








LMQ-3                                            



















Patient-doctor communication 0.111* 0.104* 0.141** 0.169** 0.234** -0.192** 
Practical difficulties 0.177** 0.217** 0.215** 0.172** 0.237** -0.231** 
Cost-related burden - 0.043 0.033 -0.066 -0.041 0.025  0.022 
Side-effect-burden 0.208** 0.265** 0.248** 0.304** 0.323** -0.317** 
Lack of effectiveness 0.237** 0.232** 0.248** 0.305** 0.300** -0.307** 
General concerns 0.149** 0.145** 0.156** 0.259** 0.324** -0.237** 
Interference with day-to-day  life 0.264** 0.290** 0.312** 0.315** 0.352** -0.360** 
Lack of autonomy/control 0.150** 0.056 0.115* 0.083  0.022 -0.081 
LMQ-3 total scale/composite score  0.306** 0.284** 0.318** 0.382** 0.436** -0.383** 
Table 7-4 Correlations between LMQ-3 scores and EQ-5D-5L scores 
 
Notes; ůůĐĞůůĞŶƚƌŝĞƐĂƌĞ^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶƐ ? 
**Correlation is significant at the 0.01 level (2-tailed).            
*Correlation is significant at the 0.05 level (2-tailed).            
Each dimension of the EQ-5D-5L is scored such that higher scores depict severe problems with a specific aspect of HRQoL. 







Overall, higher medicine burden, as measured by the LMQ-3 total scale score, was 
associated with lower general health status reported on the EQ-VAS (rs = - 0.383), and 




Figure 7-3 Scatter plot showing a negative relationship between medicine burden and 




















This chapter aimed to test criterion-related validity of the LMQ-3 by comparing the 
instrument to generic measures of treatment satisfaction and health-related quality of 
life (HRQoL). Since medicine use experiences are often evaluated in terms of 
satisfaction,109,130,231,237 this study was designed to double check construct validity of 
the LMQ-3 by testing its correlation with a measure of treatment satisfaction. The 
burden construct was found to be related to treatment satisfaction and HRQoL, and all 
observed correlations were in the anticipated direction. 
 
A negative relationship between medicine burden and satisfaction with various aspects 
of medicine use was revealed. This finding is similar to that established by Tran et al 
(2012) who also revealed a negative relationship between treatment satisfaction and 
treatment burden, a broader concept relating to patient workload associated with all 
healthcare activities.83 In terms of specific aspects of medicine use, the LMQ-3 and 
TSQM-II have three subscales that correspond directly, relating to effectiveness, side-
effects and practicalities or ease of use of medicines, and their inter-correlation was 
strong (range, -0.529 to -0.628). This finding affirms criterion-related (and construct 
validity) of the LMQ-3. Although less strong, similar correlations were observed 
between treatment burden scores and those on the TSQM-II (range, -0.26 to -0.53), 
which also depicted negative relationships.83 
 
Other LMQ-3 subscales, particularly medicine-related interferences with day-to-day 
living were also negatively associated with all aspects of treatment satisfaction. Peyrot 
and colleagues (2012), in their validation study of a disease-specific measure of 
satisfaction with medicines among diabetic patients (known as the DSMRQ), found 
ŶĞŐĂƚŝǀĞƌĞůĂƚŝŽŶƐŚŝƉƐďĞƚǁĞĞŶ ‘ŝŶƚĞƌĨĞƌĞŶĐĞ ?ĂŶĚƐĂƚŝƐĨĂĐƚŝŽŶǁŝƚŚĞĨĨŝĐĂĐǇ ?-0.262), 
side effects (-0.273), ease of medicine use (-0.366) and global satisfaction (-0.292).229 
These correlations are generally lower than those reported between the LMQ-3 
interference domain and all TSQM-II domains in the present chapter (-0.360 to -0.560), 
suggesting that interferences are moderately-to-strongly associated with 





The DSMRQ also covers medicine-related social burden, negative events, and negative 
mood that were associated with dissatisfaction with medicine use.229 The former three 
concepts are akin to those assessed by LMQ-3 items related disruptions to social 
activities and/relationships, side-effect burden, and general concerns respectively, 
which were all negatively associated with treatment satisfaction.  
 
Patient-doctor communication problems about medicines were also related to 
dissatisfaction with effectiveness. This finding is similar to that reported in Chapter 6 
where moderately strong correlations between communication- and effectiveness-
related domains of the LMQ-3 were elucidated. Cost-related burden was also 
moderately associated with dissatisfaction with medicine use in the present study, a 
finding that is not surprising.  
 
In terms of HRQoL, a trend of weak to moderate correlations was observed between 
all LMQ-3 domains and health dimensions of mobility, self-care, and performance of 
usual activities, pain/discomfort, and anxiety/depression. This finding infers 
discriminant validity of the LMQ-3 and depicts conceptual differences between 
constructs underlying the LMQ-3 and the EQ-5D-5L. Although there is limited guidance 
on the standard cut-off values for correlations indicative of discriminant (or divergent) 
validity, all inter-correlations were below 0.8 suggesting that the three instruments 
used in this study assess different constructs.218 Overall, it is empirically reasonable to 
confirm discriminant validity of the LMQ-3 and its subscales. 
 
/ƌƌĞƐƉĞĐƚŝǀĞŽĨƚŚĞƚŽŽů ?ƐǀĂůŝĚŝƚǇ ?ƌĞƐĞĂƌĐŚŚĂƐƐŚŽǁŶƚŚĂƚĚŝĨĨĞƌĞŶƚƚƌĞĂƚŵĞŶƚƐ ?
including medicines, impact on HRQoL both positively and negatively.238 In the present 
study, medicine burden was negatively associated with general health status; higher 
burden scores corresponded to lower general health status. In other studies, the level 
of discomfort associated with life-ůŽŶŐƚŚĞƌĂƉŝĞƐĂĨĨĞĐƚƐƉĂƚŝĞŶƚƐ ?ƉĞƌĐĞƉƚŝŽŶƐŽĨƚŚĞŝƌ
own HRQoL,239 and is significantly associated with symptoms such as depression and 
fatigue, while some therapies may restrict usual activities.240 The impact of side effects 
ŽŶƉĂƚŝĞŶƚ ?ƐƐǇŵƉƚŽŵƐ ?ĨƵŶctional status, and general HRQoL has been widely 
documented.48,89,92 In this chapter, side-effect-burden was negatively related to 





influencing symptom status, physical and mental status, and general health 
perceptions.92 General concerns, including worries about drug-drug or drug-alcohol 
interactions and fears related to long-term effects, were moderately associated with 
anxiety/depression, and with general health. According to Murawski and Bentley 
(2001),  ‘ĂƉĂƚŝĞŶƚŵĂǇĞǆƉĞƌŝĞŶĐĞ QƐƵďĐŽŶƐĐŝŽƵƐĂŶǆŝĞƚǇŝŶƌĞƐƉŽŶƐĞƚŽĐŽŶĐĞƌŶƐĂďŽƵƚ
ŚŝƐ ?ŚĞƌŵĞĚŝĐĂƚŝŽŶƐ ? ? ?ůƚĞƌŶĂƚŝǀĞůǇ ?ƚŚĞƐĂŵĞƉĂƚŝĞŶƚ ?ƐĨƵŶĐƚŝŽŶĂůƐƚĂƚƵƐŵŝŐŚƚďĞ
impaired as a result of their conscious anxiety concerning their medicine use and its 
ĞĨĨĞĐƚƐ Q[moreover] patient anxiety...may be induced in response to [biological] 
ĐŚĂŶŐĞƐ QŽĐĐƵƌƌŝŶŐĂƐĂĐŽŶƐĞƋƵĞŶĐĞŽĨƉŚĂƌŵĂĐĞƵƚŝĐĂůƚŚĞƌĂƉǇ Q ?.92 Regardless, 
autonomy to vary regimes and cost-related burden were not significantly associated 
with general health status, implying that these aspects of medicine burden may not 
have affected HRQoL for this sample of participants.  
 
A standard generic measure of HRQoL, the EQ-5D-5L, was used in this study. This and 
ƌĞůĂƚĞĚŚĞĂůƚŚƐƚĂƚƵƐŵĞĂƐƵƌĞƐŚĂǀĞďĞĞŶƌĞĐĞŶƚůǇĐƌŝƚŝĐŝƐĞĚĨŽƌŚĂǀŝŶŐ ‘ŵŝŶŝŵĂůƚŽ
moderate sensitivity to pharmaceƵƚŝĐĂůĐĂƌĞŝŶƚĞƌǀĞŶƚŝŽŶƐ ?ĂŶĚunlikely to detect 
changes due ƚŽ ‘ƚŚĞďƵƌĚĞŶŽĨŵĞĚŝĐŝŶĞƐŽŶƋƵĂůŝƚǇŽĨůŝĨĞ ?.241 A similar finding was 
reported by Krska and Rowe in 2010.242 Although this study did not primarily set out to 
investigate the impact of medicine burden on quality of life, it is apparent that there 
was a dearth of suitable comparator instruments for validating a new measure of 
medicine burden. The SF-36,235,236 although recently cited as more sensitive in 
detecting changes in HRQoL due to pharmaceutical care interventions ůŝĨĞ ?,241 is 
relatively lengthy, thus was not employed as a criterion-reference questionnaire in this 
study. More recently, the Medication-Related Quality of Life Scale (MRQoLS-v1.0) 
ƐƉĞĐŝĨŝĐĂůůǇĐŽŶƐŝĚĞƌƐ ‘ƚŚĞŽǀĞƌĂůůĞĨĨĞĐƚŽĨpolypharmacy on quality of life.149 However, 
the MRQOLS-v1.0 was only tested in the Chinese population and a suitable adaptation 
for the English population was not available at the time of conducting this study, and 
was thus not used as a criterion-reference instrument. Moreover, the MRQOLS-v1.0  is 
largely focussed on subjective wellbeing, assessing the impact of medicines on role 
limitations (including interferences with work, social- or leisure activities), self-control, 
and vitality (relating to feelings of fatigue/being worn out),149 and no other aspects of 




Study strengths and limitations 
Multiple recruitment sites, across primary and secondary care, enabled a diverse 
patient population and adequate sample size for the study. Despite this, the vast 
majority of participants were outpatients, possibly due to the high footfall of patients 
at the local hospital clinics that had relatively longer waiting times, which enabled 
more on-site survey completion, compared to community pharmacies and GP 
practices. Self-reports indicated that the sample population, encountered during 
routine outpatient care, had relatively good health status scores. It is uncertain 
whether similar findings would be obtained with the frail, housebound, or inpatients 
that were excluded from this study, by virtue of the method employed.  
 
Standard criterion-reference tools were used in this validation study. The lack of a 
gold-standard measure of prescription medicine burden implies that concepts 
underlying the LMQ-3 may not be fully cross-validated. As previously discussed, the 
TBQ,83,232 a broader generic measure of treatment burden, was not used as a possible 
comparator tool despite having a few items on medicine-related burden. Future cross-
validation studies would benefit from checking associations between LMQ-3 items and 
those of the recent English adaptation of the TBQ. Irrespective, validated criterion-
related measures of treatment satisfaction and HRQoL were exploited to test 
hypothesised relations with medicine burden. Though not an objective of this study, 
causal associations among medicine burden, treatment satisfaction, and/or HRQoL 
were not established and further analyses may attempt to model their interrelations.  
 
All new questionnaires should not only be valid but also demonstrate adequate 
reliability to enable future use in research and/or clinical settings. Up to this phase of 
research, all studies on the LMQ-3, and its interim versions, have focussed on 
validation of the tool to understand whether it measures what it purports to measure. 
All studies have confirmed that, on the whole, the LMQ-3 measures medicine burden 







Additional studies should examine test-retest reliability of the LMQ-3, to check the 
stability of scores, as another key psychometric property. This is relevant if the 
instrument is to be adapted in future clinical research or practice, including 
pharmaceutical interventions which may result in changes in medicines over time. This 
is the subject of Chapter 8. In addition, predictive validity of the LMQ-3, as well as 
gaining a further understanding of risk factors associated with medicine burden is 
necessary to target interventions to those most affected by medicine burden; this will 
be explored in Chapter 9. 
 
7.5 Chapter summary  
This chapter provides evidence for criterion-related validity of the LMQ-3. It confirms 
that the Living with Medicines Questionnaire (LMQ-3) assesses a distinct concept, 
medicine burden, which is negatively related to treatment satisfaction and HRQoL as 
measured by the TSQM-II and EuroQol five-dimensional questionnaire respectively. 
This finding sheds more light on understanding the concept of medicine burden, and 




















Chapter 8 Test-retest reliability 
of the LMQ-3 
8.1 Introduction 
In the previous chapters, extensive work demonstrated validation of the Living with 
Medicines Questionnaire (LMQ-3) as an instrument designed to assess medicine 
burden among patients using regular medicines in England. All studies leading up to 
this chapter have focussed mainly on questionnaire validity, especially to understand 
which concepts underlie the LMQ-3, and to confirm if it measures what it was intended 
to measure (construct validity). However, standard guidance on development and 
validation of new patient-reported measures demands testing both validity and 
reliability.124  
 
Among investigations on questionnaire reliability, both internal consistency and test-
retest reliability are widely recommended.118,127 Chapter 6 reported acceptable 
ŝŶƚĞƌŶĂůĐŽŶƐŝƐƚĞŶĐǇ ?ƌŽŶďĂĐŚ ?ƐɲA? ? ? ? )ĨŽƌĂůůďƵƚŽŶĞƐƵďƐĐĂůĞŽĨƚŚĞ>DY-3, and 
further tests were necessary. Test-retest reliability of the revised instrument (LMQ-3), 
and how it performs when administered at different time points, had not been fully 
established.   
 
Test-retest reliability reflects stability of the measure and its ability to obtain 
consistent scores in a stable group of patients.243 According to Rust and Golombok 
(2015) ?ĂƋƵĞƐƚŝŽŶŶĂŝƌĞŝƐĚĞĞŵĞĚƌĞůŝĂďůĞŝĨ ‘Ărespondent obtains similar scores on 
different occasions, providing the respondent has not changed in a way which affects 
ŚŝƐŽƌŚĞƌƌĞƐƉŽŶƐĞƚŽƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞ ? ?244 A test-retest study involves administering 
the same questionnaire twice to the same group of respondents, usually two weeks 
apart. The test-ƌĞƚĞƐƚŝŶƚĞƌǀĂůŝƐƐĞůĞĐƚĞĚƚŽĞŶƐƵƌĞƚŚĂƚĂƉĂƌƚŝĐŝƉĂŶƚ ?ƐƐƚĂƚƵƐŚĂƐŶŽƚ
changed (or is unlikely to change) and to minimise recall of the first set of 
responses.244,245 Assessing test-retest reliability is relevant if the instrument is to be 
used in longitudinal research or practice involving follow-up interventions planned 
over different times. 
Aim  
The aim of this study was to examine the test-retest reliability of the LMQ-3 in a 





8.2.1 Study design 
A repeated cross-sectional survey, in which the same questionnaire was completed on 
two separate occasions by the same participants, was conducted between June and 
August 2016.  
8.2.2 Study setting & participant inclusion criteria  
Ethics approval was granted by the Medway School of Pharmacy (See Appendix 24).  
The Kent Adult Research Unit (KARU), a public engagement group managed by the 
School of Psychology at the University of Kent, was used to recruit potential 
participants. About 300 members of the general public living in England, mostly 
resident in Kent or neighbouring counties, are signed up with the KARU database. The 
ĚĂƚĂďĂƐĞŚŽůĚƐƉĂƌƚŝĐŝƉĂŶƚƐ ?ĚĞƚails including email addresses. In this study, permission 
to recruit via the KARU database was granted by the database co-ordinator.  
Participants were included in the study if 18 years or older, using at least one regular 
prescription medicine, and willing to complete the same questionnaire twice. 
Screening questions were administered at the start of every survey to ensure that only 
participants who fulfilled the aforementioned inclusion criteria had access to the 
study.  
8.2.3 Study instrument 
The LMQ-3 the final instrument derived from Chapter 6 and tested in Chapter 7, which 
comprises 41 Likert-type statements clustered in eight domains, was used in this study.  
Statements are rated on a 5-point scale (i.e. strongly agree to strongly disagree). The 
LMQ-3 also has a global item, a 10-cm visual analogue scale to self-report medicine 
burden. In addition, the LMQ-3 has a free-text question and a section on participant 
characteristics. Similar to other study tools used in this doctoral programme, the LMQ-
3 was designed and administered in English. The questionnaire was formatted for on-
line use in Qualtrics© software. The study invitation and participant information 
(including a statement of implied consent) were embedded alongside the electronic 
questionnaire, and a unique url link 
(https://msp.eu.qualtrics.com/SE/?SID=SV_ekEVUe3u9O4LpKB) generated.  






8.2.4 Recruitment procedures  
All KARU members were invited to the study, via email, by the database co-ordinator. 
The first link to the questionnaire was promoted in the invitation email and on the 
University of Kent website (See Figure 8-1). Email recruitment was used to access and 




























Participants who accessed the first questionnaire were invited to take the second 
survey (retest). Consenting participants provided their email addresses, which were 
used to send the link to the retest questionnaire. About two weeks after the date the 
baseline survey link was sent to potential participants, the researcher sent them 
another survey link via Qualtrics Mailer©. As noted previously, the test-retest interval 
was  selected to minimise recall of answers from the first questionnaire.244  
Two reminder e-mails, including a notification prior to closing the surveys, were sent to 
follow-up participants who had not completed the retest questionnaire to maximise 
response rates. A small incentive, entry in a prize draw to win an Amazon shopping 
voucher (worth £30) for a randomly selected participant, was used to encourage 
completion of the repeat survey. During the retest surveys, the instructions cautioned 
participants against trying to deliberately remember answers from the first survey. 
 
8.2.5 Data cleaning and matching of test-retest responses 
All data were downloaded from Qualtrics©, directly into SPSS version 23, and screened 
for errors, outliers, and missing data. All test responses were matched to retest 
responses so that each eligible participant had two scores: a test score and the 
corresponding retest score on every item. The two sets of responses were matched 
using participant characteristics and demographic data. Postcodes were particularly 
useful in matching test-retest responses, since they served as a unique identification 
code for each participant. Where participants shared the same postcode, other 
characteristics such as gender, age, level of education, and number of medicines, were 
used to match responses. Participants missing retest scores were excluded, and only 













8.2.6 Statistical analysis  
Stability of scores was assessed for individual items, subscales (domains), and the 
LMQ-3 total/composite scale. 
For item-by-item analysis, agreement, ǁŚŝĐŚ ‘quantifies how close two measurements 
made on the same subject are ?, between test and retest scores was examined by 
different methods.246 The percentage of exact score agreement, where test-retest 
score differences equalled zero, was calculated to reflect the fraction of participants 
who selected exactly the same answer on test and retest questionnaires. For each 
item, the test-retest score differences were calculated as test score  W retest score. The 
percentage of participants with test-retest score differences of ± 1 point or lower, 
ǁŚŝĐŚƌĞĨůĞĐƚ ‘ŶĞĂƌŵŝƐƐĞƐ ? ?e.g. the difference between endorsing strongly agree on 
test and agree on retest), was also examined.247   
 
 Intraclass correlation coefficients (ICCs) and their 95% confidence intervals were also 
used to assess agreement between item scores.118 ICCs were also calculated for 
subscale scores and the LMQ-3 composite score (total scale score). The average ICC 
value, estimated by the two-way mixed effects method available in the statistical 
package, was reported to account for multiple ratings at test and retest occasions. ICC 
valueƐŽĨA? ? ? ?ĂƌĞƌĞĐŽŵŵĞŶĚĞĚĂƐĂŵŝŶŝŵƵŵƐƚĂŶĚĂƌĚĨŽƌƌĞůŝĂďŝůŝƚǇ ?122 Bland-
Altman plots were used to present some of the data visually, by displaying the limits of 
agreement122 between LMQ-3 composite scores at test-retest time points. ^ƉĞĂƌŵĂŶ ?Ɛ
correlations were also examined across all subscales and for the composite score; 
coefficients range from 0 to 1 reflecting worst possible to perfect relationships 


















8.3.1 Response rate 
Of the 45 participants who accessed the study invitation, 35 (77.8%) completed the 
baseline questionnaire. All 35 consented to answer the retest questionnaire, 30 
(85.7%) of whom completed it fully.  
8.3.2 Test-retest duration 
The median and mode test-retest duration was 15 days (~2.1 weeks). One participant 
completed the questionnaires within one week while another completed them just 




  Figure 8-2 Bar chart showing the test-retest intervals for the LMQ-3 
 
8.3.3 Participant characteristics 
Across both test and retest samples, participants were of median age 68 years (range 
29 to 86). The vast majority (77%, n=23) were retirees of 65 years or older. Two-thirds 
(67%, n=20) were female. Just over half had University level of education (57%, n=17).  
The median (range) of medicines used was four (1-9), in mostly tablet/capsule 
formulation (93%, n=28). Most participants managed medicine use independently 

















































                  Table 8-1 Characteristics of participants in the test-retest study 
  
       Notes; *includes professional qualifications, and other courses (e.g. PGCE); 
  ^includes full time carer, part-time self-employed; 











Characteristic  n % 
Gender Female 20  67 
 Male 10  33 
Age (years) 18-29 1  3 
 30-49 1  3 
 50-64 5  17 
 65 or over 23  77 
Education level School 5  17 
 Technical college/ 
Apprenticeship 
5 17 
 University 17 57 
 Other* 3 10 
Employment status Employed 5 17 
 Retired 23 77 
 Other^ 2  7 
Ethnicity White 29 97 
 Mixed 1 3 
Number of medicines 1-4 16 53 
 5-9 14 47 
Type of medicines Tablets/Capsules 28 93 
 Parenteral formulations 16 53 
Frequency of medicine 
use 
Once per day 18    60       
Twice per day 10  33 
Three times per day 6 20 
More than 3 times per 
day 
1 3 
Other times** 2  7 
Help with using 
medicines 
Manages independently 29  97 
Assisted by 
spouse/partner 
1  3 
Paying for prescriptions No 27  90 




8.3.4 Item-level stability  
To assess item-level stability, the percentage agreement between test-retest scores 
was examined as described in the methods section (8.2.6). The third column of Table 
8-2, which considers the percentage of exact agreement between test-retest scores, 
indicates that 40% to 80% of participants obtained the same score at test-retest times 
across all Likert-type items; only five of the 41 items had percentage of exact 
agreement below 50%.  
Stability of item scores was also examined by the percentage of participants with test-
retest score difference of ± 1 point or lower on the rating scale (See Column 4 in Table 
8-2 under % (n) with test-retest difference in scores within ±1 point). A greater 
percentage of participants (76.7% to 100%) scored within ± 1 point of the Likert-type 
rating scale between test-retest time points. The VAS-burden, 10-cm rating scale, had 
the least percentage (30%) of participants with the same scores at test and retest time 
points. However, 70% of participants scored within ± 1 point for both measurements 
over the study period. Figure 8-3 illustrates that two participants ?VAS-burden scores 
changed by more than 2 points, in absolute value across test-retest assessments (i.e. 
test-retest difference of 3.0 and 8.7). This finding suggests that scores obtained using 
the global item were reasonably stable over the retest interval.  
  
Figure 8-3 Bar chart showing relative stability of VAS ratings over the test-retest period 
 
Note; The chart shows that most participants had scores within ± 1 point on the 10-cm visual analogue 






Intraclass correlation coefficients (ICCs) were also assessed at item level, as shown in  
the last column of Table 8-2. The vast majority (37/41) of Likert-type items had ICC 
values ĂďŽǀĞƚŚĞƌĞĐŽŵŵĞŶĚĞĚǀĂůƵĞ ?A? ? ? ? ? ?-0.947). Only four items had ICC values 
below 0.7, as the target cut-off for test-retest reliability:122 ( ‘Q37-My medicines 
interfere with my sexual life ?;  ‘Q28- Taking medicines affects my driving ?;  ‘Q40-The side 
effects are worth it for the benefits I get from my medicines ?; ĂŶĚ ‘Q21-My doctor takes 
my concerns about side effects seriously ?). Overall, these findings indicate that most 


















% (n) with test-
retest difference in 
scores  within ±1 
point  
ICC [95% CI] 
 Interference to day-to-day life    
Q19 My medicines interfere with my social or leisure activities 60.0%(18) 90.0%(27) 0.802 [0.585-0.906] 
Q28 Taking medicines affects my driving 66.7%(20) 93.3%(28) 0.623[0.208-0.821] 
Q36 My medicines interfere with my social relationships 56.7%(17) 86.7%(26) 0.733[0.439-0.873] 
Q34 Taking medicines causes problems with daily tasks 70.0%(21) 86.7%(26) 0.768 [0.499-0.893] 
Q37 My medicines interfere with my sexual life 53.3%(16) 83.3%(25) 0.674[0.307-0.847] 
Q41 My life revolves around using medicines 60.0%(18) 86.7%(26) 0.772[0.521-0.891] 
 Patient-doctor communication/relationships     
Q10 I trust the judgement of my doctor(s) in choosing medicines for me.  70.0% (21) 90.0%(27) 0.857[0.687-0.935] 
Q14 My doctor(s) listen to my opinions about my medicines  50% (15) 90.0%(27) 0.866 [0.719-0.936] 
Q21 My doctor takes my concerns about side effects seriously. 63.3%(19) 90.0%(27) 0.561 [0.065-0.794] 
Q24 I get enough information about my medicines from my doctor(s) 56.7%(17) 93.3%(28) 0.761[0.491-0.888] 
Q33 The health professionals providing my care know enough about me and my 
medicines 
46.7%(14) 90.0%(27) 0.771[0.519-0.891] 
 Side effects    
Q20 The side effects I get are sometimes worse than the problems for which I 
take my  medicines 
53.3%(16) 86.7%(26) 0.764[0.504-0.888] 
Q22 The side effects that I get from my medicines interfere with my day to day 
life 
73.3%(22) 93.3%(28) 0.917[0.825-0.960] 
Q30 The side effects I get from my medicines are bothersome 73.3%(22) 100%(30) 0.947[0.888-0.975] 
Q38 The side effects I get from my medicines adversely affect my wellbeing 53.3%(16) 86.7%(26) 0.797[0.568-0.905] 
 General concerns    
Q8 I worry that I have to take several medicines at the same time 63.3% (19) 90.0%(27) 0.845[0.674-0.926] 
Q9 I would like more say in the brands of medicines I use 50.0%(15) 93.3(28) 0.786[0.550-0.898] 
Q7 I feel I need more information about my medicines 56.7%(17) 90.0%(27) 0.707 [0.384-0.860] 
Q13 I am concerned about possible damaging long-term effects of taking 
medicines 
60%(18) 96.7%(29) 0.895[0.780-0.950] 
Q16 I am concerned that I am too reliant on my medicines 50% (15) 90.0%(27) 0.720[0.411-0.867] 
Q18 I am concerned that my medicines interact with alcohol 46.7%(14) 86.7%(26) 0.830[0.643-0.919] 
Q17 I worry that my medicines may interact with each other 53.3%(16) 90.0%(27) 0.835[0.653-0.921] 
 Table 8-2 Test and retest stability of the LMQ-3 at item level 
 
 











% (n) with test-
retest difference 
score  within ±1 
point 
ICC [95% CI] 
 Practical difficulties    
Q1 I find getting my prescriptions from the doctor difficult. 63.0% (19) 100%(30) 0.908 [0.808-0.956] 
Q2 I find getting my medicines from the pharmacist difficult 66.7% (20) 93.3%(28) 0.869[0.724-0.937] 
Q4 I am comfortable with the times i should take my medicines 60% (18) 86.7%(26) 0.840[0.644-0.928] 
Q6 I am concerned that I may forget to take my medicines 40% (12) 83.3%(25) 0.788[0.554-0.899] 
Q23 I have to put a lot of planning and thought into taking my medicines. 46.7%(14) 86.7%(26) 0.823[0.628-0.916] 
Q26 It is easy to keep my medicines routine 46.7%(14) 86.7%(26) 0.743[0.460-0.878] 
Q29 I find using my medicines difficult 70%(21)  0.884[0.749-0.946] 
 Perceived effectiveness    
Q3 I am satisfied with the effectiveness of my medicines  56.7%(17)  86.7%(26) 0.787 [0.525-0.905] 
Q15 My medicines prevent my condition getting worse 76.7% (23) 100%(30) 0.866[0.719-0.936] 
Q25 My medicines live up to my expectations 73.3% (22)  100%(30) 0.866[0.719-936] 
Q35 My medicines allow me to live my life as I want to 66.7%(20) 90.0%(27) 0.730[0.432-0.871] 
Q39 My medicines are working 66.7%(20) 96.7%(29) 0.824[0.631-0.916] 
Q40 The side effects are worth it for the benefits I get from my medicines 53.3%(16) 86.7%(26) 0.569[0.055-0.804] 
 Patient-doctor communication/relationships     
Q10 I trust the judgement of my doctor(s) in choosing medicines for me.  70.0% (21) 90.0%(27) 0.857[0.687-0.935] 
Q14 My doctor(s) listen to my opinions about my medicines  50% (15) 90.0%(27) 0.866 [0.719-0.936] 
Q21 My doctor takes my concerns about side effects seriously. 63.3%(19) 90.0%(27) 0.561 [0.065-0.794] 
Q24 I get enough information about my medicines from my doctor(s) 56.7%(17) 93.3%(28) 0.761[0.491-0.888] 
Q33 The health professionals providing my care know enough about me and my 
medicines 
46.7%(14) 90.0%(27) 0.771[0.519-0.891] 
 Cost-related burden    
Q5 I worry about paying for my medicines 66.7%(20) 80.0%(24) 0.848[0.671-0.930] 
Q31 I sometimes have to choose between buying basic essentials or medicines  80.0%(24) 90.0%(27) 0.892[0.763-0.951] 
Q32 I have to pay more than I can afford for my medicines. 76.7%(23) 93.3%(28) 0.850[0.685-0.929] 
 Lack of autonomy    
Q11 I can vary the dose of the medicines I take 56.7% (17) 86.7%(26) 0.862[0.710-0.934] 
Q12 I can choose whether or not to take my medicines 43.3%(13) 76.7%(23) 0.712[0.391-0.865] 
Q27 I can vary the times I take my medicines 60.0% (18) 90.0%(27) 0.825[0.633-0.917] 
              VAS-burden score 30.0%(9) 70.0%(21) 0.789[0.556-0.899] 
Table 8-2 Test and retest stability of the LMQ-3 at item level 




8.3.5 Stability of subscales and composite score 
Stability of all eight subscales of the LMQ-3, and its total scale (composite score), was 
also assessed by similar methods (See Table 8-3). All subscales had satisfactory ICC 
values ranging from 0.733-0.929 between test-retest measurements. The ICC values 
for the LMQ-3 composite score was excellent (0.954) between test-retest 
administrations. ^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶƐ ?ƉƌĞƐĞŶƚĞĚŝŶdĂďůĞ ?-3, revealed mixed 
findings across subscale scores between test-retest assessments, four of which were 
below the target correlations of 0.7.  
 





Patient-doctor communication  0.52 (p=0.003) 0.733[0.439-0.873] 
Practical difficulties 0.71 (p<.001) 0.896[0.782-0.951] 
Cost-burden 0.56 (p=0.001) 0.759 [0.494-0.885] 
Side-effect-burden 0.84 (p<0.001) 0.929[0.849-0.967] 
Lack of effectiveness 0.64 (p<0.001) 0.872[0.733-0.939] 
Concerns  0.80 (p<0.001) 0.909[0.809-0.957] 
Interferences 0.64 (p<0.001) 0.774 [0.525-0.893] 
Lack of autonomy 0.70 (p<0.001) 0.843[0.671-0.925] 
LMQ-3 total scale (composite score) 0.90 (p<0.001) 0.954 [0.902-0.978] 
Table 8-3 Test-retest stability of LMQ-3 subscales and total scale 
 








A Bland-Altman plot was used to visualise agreement between LMQ-3 composite 
scores over the test-retest period (See Figure 8-4). The upper and lower limits of 
agreement, represented by the two broken lines, were 16.87 and -14.73 respectively.   
ůůĞǆĐĞƉƚŽŶĞƉĂƌƚŝĐŝƉĂŶƚƐĐŽƌĞĚďĞƚǁĞĞŶƚŚĞƐĞůŝŵŝƚƐƐƵŐŐĞƐƚŝŶŐ ‘ƌĞĂƐŽŶĂďůĞ ?
agreement of composite scores across the study duration. In Figure 8-4, the 
continuous horizontal line across the chart portrays the mean of the differences 
between test-retest composite scores, which was close to zero over the retest interval. 
Looking at the spread of composite scores shows a generally horizontal distribution, 
depicting no systematic increase or decreases of test-retest score differences. These 
findings complement the presented evidence for stability of the LMQ-3 total scale. 
 
 
Figure 8-4 Bland-Altman plot showing agreement between LMQ-3 composite scores 










This chapter presented an evaluation of the test-retest reliability of the LMQ-3. Overall, 
the LMQ-3 has excellent stability of scores when administered at different time points.  
Item-level analyses indicated that the vast majority of item scores were reasonably 
consistent over the test-retest interval. Overall, the data presented contributes to 
evidence of the reliability of the LMQ-3.  
 
However, these findings ought to be interpreted in light of the methods used in this 
study. The choice of methods to estimate reliability coefficients in test-retest studies is 
debatable. Multiple techniques were used to assess consistency and agreement of item-, 
subscale- and composite- scores over the study period. A combination of methods was 
adopted to minimise the limitations of reporting single estimates of reliability.248  
Spearman ?ƐŽƌWĞĂƌƐŽŶ ?Ɛcorrelations between test-retest scores are commonly reported 
in questionnaire validation studies.  
 
Although correlational techniques are cited to overestimate the true reliability,118 in this 
chapter their estimates were generally lower than expected for certain subscales. 
Regardless,  ‘ƌĞůĂƚŝǀĞůǇƐŵĂůů ?ĐŽƌƌĞůĂƚŝŽŶƐĂƌĞĂƐƐŽĐŝĂƚĞĚǁŝƚŚŚŽŵŽŐĞŶĞŽƵƐƐĂŵƉůĞƐ,249 
such as those involved in the study. In particular, the present study was largely comprised 
of elderly retirees signed up to research studies at a single setting. Correlational 
techniques, though predominant in psychometric literature, are criticised for measuring 
linear relationships between scores instead of their agreement.118,250 Correlational 
methods are criticised as  ‘ĂŶŝŶĂƉƉƌŽƉƌŝĂƚĞĂŶĚůŝďĞƌĂůŵĞĂƐƵƌĞŽĨƌĞůŝĂďŝůŝƚǇ ?118 citing 
inability to detect systematic bias associated with learning/practice effects251 following 
exposure to the first survey.  
 
Intraclass correlation coefficients (ICCs) are increasingly preferred over 
WĞĂƌƐŽŶ ?Ɛ ?^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶƐǁŚĞŶĞǆĂŵŝŶŝŶŐĂŐƌĞĞŵĞŶƚďĞƚǁĞĞŶƚĞƐƚ-retest 
scores on a continuous scale.118,248 Therefore ICCs were also tested for items, subscales, 
and the LMQ-3 total scale. The desired magnitude of reliability coefficients depends on 





/ƐǀĂůƵĞƐŽĨA? ? ? ? ?ĂŶĚA? ? ? ? ?ĂƌĞƌĞĐŽŵŵĞŶĚĞĚĨŽƌƚŽŽůƐƵƐĞĚŝŶŚĞĂůƚŚƌĞƐĞĂƌĐŚ- and 
clinical  settings respectively.118  Values above 0.9 are often ambitious, while values close 
to 1 suggest higher reliability.118 In this study, the LMQ-3 composite score had an 
excellent ICC value (0.954) at test-retest assessment. Only four items in the LMQ-3 had 
ICCs below 0.7, which is the bare minimum value for reliability of research-intended 
tools.127,252 However, the finding suggests adequate stability for most items.  
 
All eight subscales of the LMQ-3 also had acceptable ICC values above 0.7. However, the 
 ‘ƉĂƚŝĞŶƚ-doctor communicĂƚŝŽŶ ?ƐƵďƐĐĂůĞ ?ǁŚŝĐŚĂůƐŽŚĂƐŝƚĞŵƐŽŶƉĂƚŝĞŶƚŝŶƚĞƌĂĐƚŝŽŶƐ
and relationships with providers, had the least reliability coefficient (an ICC value of 
0.733) when compared to other subscales. KŶƚŚĞŽƚŚĞƌŚĂŶĚ ?ƚŚĞ ‘ƐŝĚĞ-effect-ďƵƌĚĞŶ ?
subscale showed the highest stability (an ICC value of 0.929). Relatively longstanding 
concepts may show higher consistency when measured over time than those that may 
vary with day-to-day experiences. The present study did not assess whether participants 
had new medicine-related appointments with their doctors or health providers over the 
test-ƌĞƚĞƐƚƉĞƌŝŽĚ ?ǁŚŝĐŚŵĂǇŚĂǀĞĂĨĨĞĐƚĞĚƌĞůŝĂďŝůŝƚǇǀĂůƵĞƐŽĨƚŚĞ ‘ƉĂƚŝĞŶƚ-doctor 
ĐŽŵŵƵŶŝĐĂƚŝŽŶ ?ƐƵďƐĐĂůĞ ? Nevertheless, data revealed consistency in self-reports of 
medicine use characteristics over the study period (such as the number, frequency, and 
formulation of medicines) that may indirectly infer stability of medicine use experiences. 
It is also ƉŽƐƐŝďůĞƚŚĂƚƚŚĞƌĞůĂƚŝǀĞůǇŚŝŐŚƐƚĂďŝůŝƚǇŽĨƚŚĞ ‘ƐŝĚe-effect-burden ?ƐƵďƐĐĂůĞŝƐ
related to minimal changes in the experience or impact of side effects over the short 
study duration.  
 
Although most measures of medicine-related experiences are not assessed for test-retest 
reliability,231 test-retest assessments of the Treatment Burden Questionnaire (TBQ), a 
convenient comparison for reliability coefficients, revealed ICC values relatively lower 
than those of the LMQ-3 i.e. 0.77 (95% CI, 0.70-0.82) versus 0.954 (95% CI, 0.902-0.978) 
respectively.83,232 Regardless, caution needs to be exercised when comparing LMQ-3 
reliability coefficients with those reported for a distinct measure of overall treatment 
burden, as different study conditions (e.g. patient populations, sample size) involved in 






The time interval to retest is a factor to consider in test-retest reliability studies. In the 
present study, the median test-retest interval was two weeks, but the range was one 
week to just after five weeks from the baseline survey. There is no consensus regarding 
test-retest intervals, but 1-2 weeks is usual.122,127 Median retest intervals as short as 1-7 
days have also been reported.243 A retest period of two weeks to one month was used 
while validating the TBQ83 and it is likely that the LMQ-3 retest intervals were appropriate 
and balanced. Regardless, selection of an optimal test-retest interval is a delicate balance 
between minimising recall of initial test responses and preventing change of participants ? 
circumstances.118,122,245 Broadly, shorter retest intervals are associated with improved 
reliability coefficients, but may be affected by recall bias.251 In the present study, the 
instructions to the retest survey cautioned participants against trying to deliberately 
remember answers from the first survey. 
 
In test-retest studies, it is worth considering the nature of the construct under 
investigation, and how likely it is to change over a given time. For instance, certain 
psychological traits (e.g. mood) are liable to rapid changes118 similar to clinical states of 
ƉĂƚŝĞŶƚƐǁŝƚŚĂĚǀĂŶĐĞĚĐĂŶĐĞƌĂƌĞ ‘ƉƌŽŶĞƚŽĂĨĂƐƚĞƌƌĂƚĞŽĨĐůŝŶŝĐĂůĚĞƚĞƌŝŽƌĂƚŝŽŶ ? ?243    
However, medicine burden is a multifaceted attribute with physical, psychosocial, and 
clinical aspects and, as a relatively new concept,88 its long-term stability is not well 
understood. Medicine burden, and how it affects individual patients over time, is not well 
ƐƚƵĚŝĞĚ ?ĨĞǁƌĞƐĞĂƌĐŚĞƌƐƉƵƌƉŽƌƚƚŚĂƚ ‘ŝŶƚŚĞĂďƐĞŶĐĞŽĨĂŶǇŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐĞůĨ-
ŵĂŶĂŐĞŵĞŶƚĂƚƚŝƚƵĚĞƐĂŶĚďĞŚĂǀŝŽƵƌƐĂƌĞƌĞůĂƚŝǀĞůǇƐƚĂďůĞĐŽŶĐĞƉƚƐ ?.253 Nevertheless, 
medicine use experiences may vary over time and are unique to individuals; some people 
accept and persist with regimens despite any difficulties, others are unable to cope and 
reject their treatment regimens.21 For those who continue to juggle medicine use,  they 
may manipulate dosing or timing of regimens, stop medicines completely or even switch 
to alternative treatment options.88 This is especially true if the interferences, associated 









Implications for research and practice 
Whether intended for use in research or clinical practice, patient-reported measures are 
often selected based on their psychometric properties, including test-retest reliability.  
Data from this chapter contributes to evidence for the LMQ-3 measurement properties, 
most of which have been demonstrated in studies described in previous chapters. It is 
now evident that the LMQ-3 is stable and can obtain consistent scores over time. A 
questionnaire that demonstrates stability of responses over a short period may predict 
long-term stability. Moreover, the higher the reliability of a questionnaire, the better its 
discriminative capability;118 this feature can be exploited to identify patients most at risk 
of medicine burden. 
 
With a stable instrument, the LMQ-3 may be used in future longitudinal/prospective 
research and/or practice to monitor levels of medicine burden in at-risk populations, 
which are defined and tested in Chapter 9. Keeping track of inĚŝǀŝĚƵĂůƐ ?ĂĐĐŽƵŶƚƐŽĨ
medicine burden over time may help inform future targeted interventions. Follow-up of 
patients with the greatest burden could be done at appropriate time points determined 
by the patient (say at quarterly, bi-annually, or annually).  
 
Upon ascertaining long-term stability of scores, the LMQ-3 could be used as a screening 
tool for recruiting patients in interventional studies designed to improve ƉĂƚŝĞŶƚƐ ?
experience of care. Further research could use the LMQ-3 as an outcome measure in trials 
evaluating new medicines or pharmaceutical care interventions. All the aforementioned 
applications of the LMQ-3 would only be plausible if its sensitivity to change and 
responsiveness are determined in future validation studies. Sensitivity to change is the 
 ‘ĂďŝůŝƚǇƚŽŵĞĂƐƵƌĞĂŶǇĚĞŐƌĞĞŽĨĐŚĂŶŐĞ ?following an intervention,118  and 
ƌĞƐƉŽŶƐŝǀĞŶĞƐƐƌĞůĂƚĞĚƚŽƚŚĞ ‘ĂďŝůŝƚǇŽĨĂƋƵĞƐƚŝŽŶŶĂŝƌĞƚŽĚĞƚĞĐƚĐůŝŶŝĐĂůůǇŝŵƉŽƌƚĂŶƚ
ĐŚĂŶŐĞƐŽǀĞƌƚŝŵĞ ?ĞǀĞŶŝĨƚŚĞƐĞĐŚĂŶŐĞƐĂƌĞƐŵĂůů ? ?122 
 
Study limitations and strengths 
^ƚĂďŝůŝƚǇŽĨƉĂƌƚŝĐŝƉĂŶƚƐ ?ĐŝƌĐƵŵƐƚĂŶĐĞƐŝƐĂƉƌĞƌĞƋƵŝƐŝƚĞŝŶƚĞƐƚ-retest study designs.243 In 
fact, guidelines ƐƵŐŐĞƐƚƚŚĂƚĂŶŝŶƐƚƌƵŵĞŶƚ ?s reproducibility relates to the extent to which 
 ‘ƌĞƉĞĂƚĞĚŵĞĂƐƵƌĞŵĞŶƚƐŝŶƐƚĂďůĞƉĞƌƐŽŶƐƉƌŽǀŝĚĞƐŝŵŝůĂƌĂŶƐǁĞƌƐ ? ?122 This study 




experiences over the study period. Data revealed consistency in self-reports of prescribed 
regimens (number of medicines, frequency and formulations) over the study period; 
these may indirectly infer stability of medicine use experiences. 
 
WĂƌĂĚŽǆŝĐĂůůǇ ? ‘ƌĞůŝĂďŝůŝƚǇĐĂŶŶŽƚďĞĐŽŶĐĞŝǀĞĚ of as a property that a particular 
instrument does or does not possess; rather, any measure will have a certain degree of 
ƌĞůŝĂďŝůŝƚǇǁŚĞŶĂƉƉůŝĞĚƚŽĐĞƌƚĂŝŶƉŽƉƵůĂƚŝŽŶƐƵŶĚĞƌĐĞƌƚĂŝŶĐŽŶĚŝƚŝŽŶƐ ? ?118 and reliability 
estimates reflect the performance of a measure in a given population. The present study 
was limited to a self-selected, small purposive sample of the public, living mostly in south-
east England and signed up to an on-line database as volunteers for research studies. The 
sample participant group is, thus, not geographically representative of users of long-term 
medicines in England, and LMQ-3 test-retest reliability may differ with diverse patient 
cohorts. ůƚŚŽƵŐŚƉĂƌƚŝĐŝƉĂŶƚƐǁĞƌĞŵŽƐƚůǇŽůĚĞƌƉĞŽƉůĞ ?ĂŐĞA?  ? ) ?ƌĞĨůĞĐƚŝŶŐ
characteristics of people likely to use long-term medicines - to whom the LMQ-3 may be 
applied in practice, the relatively homogenous study population may have led to 
miscalculates of reliability coefficients.248 
 
Although the sample size in this chapter (n=30) was lower than that recommended for 
test-ƌĞƚĞƐƚƐƚƵĚŝĞƐ ?ŶA? ? ? ) ?122 the reliability coefficients were mostly adequate across 
items, subscales, and for the LMQ-3 composite score. It is unlikely that a bigger sample 
size may change the present findings, as indicated by other researchers assessing  test-
retest reliability of patient questionnaires.254 Regardless, 95% confidence intervals (CI) 
around some reliability coefficients showed wide variations (See the last columns of Table 
8-2 and Table 8-3 respectively). 
 
For item-level stability, the percentages of absolute and relative agreement between test 
retest score were ĂƐƐĞƐƐĞĚďĂƐĞĚŽŶEĞǀŝůů ?ƐƐƚƵĚǇ.247 The percentage of absolute 
agreement reflects the extent to which respondents provide the same answer on the two 
assessments ?ǁŚŝůĞƌĞůĂƚŝǀĞĂŐƌĞĞŵĞŶƚŵĂǇĂĐĐŽŵŵŽĚĂƚĞ ‘ŶĞĂƌŵŝƐƐĞ ?ŽƌƐŵĂůů
differences between test-retest scores e.g. a participant who strongly agrees with an item 
on test- but agrees on retest assessment. Nevill and colleagues (2001) stipulated that, for 
relative stability, at least 90% of participants should have test-retest score differences 




ĚŝƐĂŐƌĞĞŵĞŶƚƐ ?ĂŵŽŶŐƚĞƐƚ-retest scores.247  Although, this  chapter revealed that some 
LMQ- ?ŝƚĞŵƐŵĞƚEĞǀŝůů ?ƐĐƌŝƚĞƌŝŽŶ ?these indices of item-score stability are somewhat 
arbitrary,249 and restricted to 5-point scales- it is possible that it was not suitable for  
assessing stability of responses on the 10-cm visual analogue scale which showed wider 
disagreements in scores. Nonetheless, additional reliability analyses were conducted for 
the latter scale.  
 
Methods based on the proportion of exact score agreement are prone to obtaining the 
same answer bǇĐŚĂŶĐĞĂŶĚŵĂǇ ‘ŽǀĞƌůŽŽŬƚŚĞŶĂƚƵƌĞŽĨĚŝƐĂŐƌĞĞŵĞŶƚ ?ďĞƚǁĞĞŶƚĞƐƚ-
retest scores.247 It is important, however, to recognise that few  medicine-related 
questionnaires  have assessed  test-reliability by percentage of exact agreement between 
scores, for example, ƚŚĞƉĂƚŝĞŶƚƐ ?ĂƚƚŝƚƵĚĞƐƚŽǁĂƌĚƐĚĞƉƌĞƐĐƌŝďŝŶŐ ?Wd )ƋƵĞƐƚŝŽŶŶĂŝƌĞ,64 
which assesses constructs different from the LMQ- ? ?Ɛ ?  
 
Finally yet importantly, this test-retest study may have imposed response burden, as 
participants had to retake a relatively lengthy survey in a short space of time. Thus, the 
present sample size represents decent efforts among participants who were offered the 
chance to be entered into a draw for £30 to complete both test and retest surveys. 
However, it is unlikely that this very small incentive may have affected the response 
rates.118  
 
8.5 Chapter summary 
This chapter set out to determine the test-retest reliability of the LMQ-3, as assessment 
of the extent to which the instrument obtains consistent scores over time. The findings 
are promising and suggest that the LMQ-3 has excellent test-retest reliability and obtains 
relatively consistent scores in the same group of participants over a short period of time 
(1-5 weeks); this was assessed through multiple methods. The findings presented in this 
chapter are a first step towards determining longitudinal validity (i.e. responsiveness) of 
the LMQ-3, which could be used in future research and/or practice to monitor those most 
at risk of medicine burden. The next chapter will explore patient attributes and treatment 
characteristics associated with medicine burden, in addition to interpreting LMQ-3 




Chapter 9 Interpretation of scores, 
prevalence of medicine-related 
difficulties, and predictors of 
medicine burden   
9.1 Introduction 
Chapters 4 to 8 have focussed on measurement properties of the Living with Medicines 
YƵĞƐƚŝŽŶŶĂŝƌĞ ?>DY ) ?ƉĂƌƚŝĐƵůĂƌůǇƚĞƐƚŝŶŐǀĂƌŝŽƵƐĂƐƉĞĐƚƐŽĨƚŚĞŝŶƐƚƌƵŵĞŶƚ ?ƐǀĂůŝĚŝƚǇĂŶĚ
reliability. Despite being the mainstay of this doctoral thesis, the work reported in these 
Chapters has paid little or no attention to the prevalence of medicine-related problems 
uncovered by this measure. It is, thus, important to consider what proportion of the 
population experience or perceive difficulties with their long-term prescription 
medicine(s). A recent systematic review and metasynthesis of qualitative studies 
ŝŶĚŝĐĂƚĞĚƚŚĞŶĞĞĚĨŽƌĨƵƌƚŚĞƌƌĞƐĞĂƌĐŚĂŶĚ ‘ ?ƋƵĂŶƚŝƚĂƚŝǀĞ ?sub-group analysis to 
determine the common types of [medicine] burden in ĂƐƉĞĐŝĨŝĐ QŚĞĂůƚŚĐĂƌĞƐĞƚƚŝŶŐ ?.88 
Thus, further investigations were necessary to understand aspects of medicine-related 
burden that are challenging to most individuals. 
 
As a new concept, the level(s) of medicine burden have also not yet been established 
empirically and yet preceding chapters indicated the need to target future interventions 
ƚŽƚŚŽƐĞǁŝƚŚ ‘ŚŝŐŚ ?Žƌ ‘ĞǆĐĞƐƐŝǀĞ ?ŵĞĚŝĐŝŶĞďƵƌĚĞŶ ?Like many psychological and clinical 
screening tools, the LMQ ŝƐƐĐŽƌĞĚĂůŽŶŐĂ ‘ƋƵĂŶƚŝƚĂƚŝǀĞĐŽŶƚŝŶƵƵŵ ?.255 The LMQ collects 
self-reported scores using multiple items assessing various aspects of the medicine 
burden construct. Item scores are summed up to produce a total scale score (or 
composite score), which depicts the overall experience of prescription medicine use. 
Chapter 7 revealed that higher LMQ composite scores reflected worse experiences of 
prescription medicine use (higher medicine burden). It is relevant to classify levels of 
medicine burden, based on this composite score, to estimate the proportion of the 
general population that is most affected. 
 
Discriminative capability, in distinguishing groups of people with certain characteristics, is 
also a desirable property for new measurement tools.118 From the previous chapter, the 
ƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ƐƌĞůŝĂďŝůŝƚǇƉƌŽƉĞƌƚŝĞƐǁĞƌĞŚǇƉŽƚŚĞƐŝƐĞĚƚŽĐŽŶĨĞƌĚŝƐĐƌŝŵŝŶĂƚŝǀĞĂďŝůŝƚǇƚŽ




Ideally, an instrument should be able to show  ‘ĚŝĨĨĞƌĞŶƚůĞǀĞůƐŽĨƚŚĞĐŽŶƐƚƌƵĐƚ ?ŝŶĐŽŚŽƌƚƐ
that are known to be different or logically should be different (i.e. known-groups 
validity).256 Earlier work using the original LMQ found that the instrument could 
differentiate between people using different a number of medicines,193 but this version of 
the questionnaire was subsequently modified. Following questionnaire revisions reported 
in Chapter 5, the revised LMQ (versions 2.1 and 3) incorporated additional medicine-
related questions (e.g. about frequency of administration, or formulation) and 
demographic-related questions, including postcodes to estimate levels of relative 
deprivation in ƚŚĞƌĞƐƉŽŶĚĞŶƚ ?Ɛ area of residence. Further analyses were needed to check 
if the revised questionnaires could distinguish people using different formulations (e.g. 
oral solid dose versus other dosage forms), or those administering medicines at different 
time intervals.  
To confirm significant predictors of prescription medicine burden, additional work was 
also necessary. It was relevant to investigate whether and to what extent the 
aforementioned medicine-related attributes and other socio-demographic characteristics 
(e.g. age, employment status) were associated with medicine burden. This is especially 
relevant if the LMQ is to be used as a screening tool for identifying patients most at risk of 
medicine burden or in guiding decisions related to assigning patients to clinical and/or 
research interventions that are based on individual assessments.   
Aim and research questions  
To determine the prevalence and levels of medicine burden, and to explore factors 
associated with negative experiences of medicine use in the sample populations used in 
the development of the instrument. 
Research questions posed were: 
1) What proportion of people experience difficulties with medicine use? What are the 
cutoffs or levels of medicine burden as measured by the LMQ? What percentage of 
the sample population experiences high medicine burden? 
2) Is the LMQ able to show different levels of medicine burden in groups of people 
that have different treatments characteristics? 
3) What socio-demographic- and treatment-related characteristics are associated 
with negative experiences of medicine use, and to what extent do they predict 





9.2.1 Datasets, recruitment, and study instruments  
Two existing datasets gathered via a national and a regional survey, used in Chapter 6 and 
Chapter 7 respectively, were reanalysed. National-level data were gathered using an on-
line survey accessible to the general public via social media, health websites, electronic 
health magazines and newsletters, and via direct email invitation by participating patient 
organisations or fora. Regional-level data were gathered through face-to-face recruitment 
(using paper-based questionnaires) of patients in primary and secondary care settings (GP 
practices, community pharmacies and outpatient clinics of Medway Maritime Hospital) in 
south-east England. Ethics approval and research governance were obtained for each 
phase of data collection from relevant committees.   
 
With ready access to the two datasets, secondary data analysis provided an expedient 
and cost-effective means of answering new research questions using existing variables.257 
As described in Chapter 6, an interim version of the LMQ (the 58-item LMQ-2.1) was used 
to gather national-level data. Chapter 7 reported a survey dataset gathered using the 
LMQ-3, which comprised 41 Likert-type items (derived from the LMQ-2.1) covering 
different views and experiences of medicine use. Both datasets were reconciled to ensure 
that only common variables were retained for the secondary data analysis for this 
chapter. The survey dataset obtained using the original questionnaire (LMQ-1), in Chapter 
4, was not used in this secondary data analysis owing to substantial differences in the 
items and demographic questions when compared to the other two datasets. 
 
Total scale scores were calculated based on the 41 Likert-type items present in the final 
questionnaire (ie LMQ-3) that were common to the two datasets to enable comparison of 
findings. Total-scale scores and subscale/domain scores were calculated as described in 
Chapter 7 and possible composite scores ranged from 41 to 205. Both datasets had a 10-
cm visual analogue scale assessing perceptions of medicine burden, based on the 
ƋƵĞƐƚŝŽŶ ? ‘ŽǀĞƌĂůů ?ŚŽǁŵƵĐŚŽĨĂďƵƌĚĞŶĚŽǇŽƵĨĞĞůǇŽƵƌŵĞĚŝĐŝŶĞƐƚŽǇŽƵ ? ?(rated from 
0 for no burden at all to 10 for extremely burdensome). This visual analogue scale was 





Both datasets included demographic information, including age, gender, education levels, 
employment status, ethnicity, and postcodes. Postcodes were used to calculate indices of 
multiple deprivation (IMD ranks) using the English indices of deprivation 2015 on-line 
tool258 available at http://imd-by-postcode.opendatacommunities.org/. Additionally, 
datasets contained medicine-related variables including the number of medicines, 
formulations used, frequency of use, ability to manage medicines independently or need 
for social support, and paying for prescriptions. Both datasets included free-text 
comments, which elaborated on experiences of medicine use for some participants. 
 
9.2.2 Participants 
 All participants were at least 18 years of age and used at least one long-term prescription 
medicine. Participants in the national survey resided anywhere in the UK, whereas 
participants in the regional survey were mostly residents of south-east England. 
 
9.2.3 Data preparation  
All datasets were managed using SPSS version 24.   
9.2.3.1 Missing data and outliers 
For this secondary data analysis, the two datasets were examined for missing data. It was 
observed that although most participants completed all Likert-type items, some 
demographic questions or those asking about treatment-related characteristics were not 
fully completed. Participants with incomplete answers on the 41 Likert-type items were 
eliminated from the analyses. For analyses involving demographic- or treatment-related 
characteristics, all statistical analyses were based on pairwise deletion of missing data 
where respondents with data on variables involved in a specific analysis were retained. 
Although pairwise deletion of missing data led to variations of sample sizes across this 
chapter, listwise deletion would have significantly reduced the sample sizes across both 
datasets. Scatter plots and box plots assessed outliers, visually. 
 
9.2.3.2 Dummy coding and recoding of variables 
To facilitate regression analyses, all categorical variables with more than two levels were 
recoded to create dummy variables- these are dichotomous variables that are recoded as 
0 or 1.174 For instance, age categories (18-29, 30-49, 50- ? ? ?ĂŶĚA? ? ? )ĂŶĚĐĂƚĞŐŽƌŝĞƐŽĨ




variables respectively, using the first group as a reference. Reference categories were 
coded based on logic, theory, or were based on category with the majority of 
participants.250 For instance, when coding dosage forms, tablets/capsule were used as the 
reference variable that was assumed to be more convenient ƚŚĂŶ ‘ĂŶǇ other ĨŽƌŵƵůĂƚŝŽŶ ?
or a  ‘ĐŽŵďŝŶĂƚŝŽŶof tablets/capsulĞƐĂŶĚ ‘ĂŶǇŽƚŚĞƌĨŽƌŵƵůĂƚŝŽŶ ? ?Similarly, using 
ŵĞĚŝĐŝŶĞƐ ‘ŽŶĐĞĚĂŝůǇ ?ǁĂƐƚĂŬĞŶĂs the simplest dosing frequency and used as the 
reference category when comparing other frequencies of administration in the regression 
analyses.98 Ethnicity was recoded to a binary variable (white and other) as the other 
subcategories had very few participants. 
 
9.2.3.3 Sample size requirements 
Sample size requirements were variable across the different statistical analyses. For 
regression analyses, Tabachnick and Fidell (2013) recommend the sample size to be 
greater than 50 + 8m; where m represents the number of independent variables.182 Using 
this criterion, the minimum sample size for regression analysis was exceeded. 
 
9.2.4 Analyses 
9.2.4.1. Descriptive statistics  
To answer the first research question, descriptive statistics, including percentages and 
frequencies, were used to describe self-reported experiences with medicine use and the 
prevalence of medicine burden, which was derived from the distribution of LMQ 
composite scores. Five categories of medicine burden were hypothesised to exist, 
determined by dividing LMQ composite scores into quintiles and the proportion of 
respondents in each determined. The categories were: 41- ? ?ƚŽƌĞĨůĞĐƚ ‘ŶŽďƵƌĚĞŶĂƚĂůů ? ?
74- ? ? ?ƚŽƌĞĨůĞĐƚ ‘ŵŝŶŝŵĂůďƵƌĚĞŶ ? ? ? ? ?- ? ? ?ƚŽŝŶĚŝĐĂƚĞ ‘ŵŽĚĞƌĂƚĞĚĞŐƌĞĞŽĨďƵƌĚĞŶ ? ?
140- ? ? ?ƚŽƌĞĨůĞĐƚ ‘ŚŝŐŚďƵƌĚĞŶ ? ?and those with scores in the range of 173-205 were 
categorisĞĚĂƐ ‘ĞǆƚƌĞŵĞůǇŚŝŐŚďƵƌĚĞŶ ? ?dŽǀĞƌŝĨǇƚŚŝƐĐůĂƐƐŝĨŝĐĂƚŝŽŶ of medicine burden, 
further analyses were conducted.  Correlations between LMQ composite scores were run 
against scores ďĂƐĞĚŽŶƚŚĞǀŝƐƵĂůĂŶĂůŽŐƵĞƐĐĂůĞ ‘ŽǀĞƌĂůů ?ŚŽǁŵƵĐŚŽĨĂďƵƌĚĞŶĚŽǇŽƵ
ĨĞĞůǇŽƵƌŵĞĚŝĐŝŶĞƐĂƌĞƚŽǇŽƵ ? ? ?ůƐŽ ?ĐƌŽƐƐ-tabulations (contingency tables) compared 
proportions of participants in the five categories of burden with similar categories of self-




Participants in the  ‘high ? or  ‘ĞǆƚƌĞŵĞůǇŚŝŐŚ ? medicine burden categories based on the 
ƚǁŽĂƐƐĞƐƐŵĞŶƚƐǁĞƌĞĚĞĞŵĞĚƚŽ ‘ĐĞƌƚĂŝŶůǇ ?ŚĂǀĞƚŚĞse levels of medicine burden.  
 
9.2.4.2. Free-text comments 
The two survey datasets also included an open-ended question,  ‘If you have any other 
views about how your medicines affect your day-to-day life, please describe them here ? ? 
This open question served as a qualitative data collection tool that enabled elaboration of 
lived experiences covered in the tick-box type questions in the two surveys, thus allowed 
ƉĂƌƚŝĐŝƉĂŶƚƐƚŽĂĚĚĂ ‘ǀŽŝĐĞ ?ƚŽƚŚĞŝƌǀŝĞǁƐĂŶĚĞǆƉĞƌŝ ŶĐĞƐŽĨ medicine use. These were 
analysed thematically based on the eight domains underlying the revised questionnaires 
that were revealed and tested in Chapter 6; this was thought to give a holistic picture of 
challenging medicine-related experiences. 
 
9.2.4.3. Between-group differences 
To answer the second research question, checking if there were significant differences in 
medicine use experiences between groups of participants predicted to experience 
different degrees of burden, such as those with different treatment characteristics, 
composite mean scores were compared; this constituted the known-groups validation. 
Statistical tests used included: independent-samples t-tests for dichotomous variables, 
and one-way ANOVAs where variables had three or more categories. These parametric 
tests were used since the data were normally distributed. Post hoc comparisons were 
assessed using Tukey HSD test or the Gabriel test depending on whether or not 
assumptions for homogeneity of variance were met; the latter were assessed using 













9.2.4.4. Regression analysis 
9.2.4.4.1. Simple and multiple linear regressions 
To address the third research question, socio-demographic and treatment-related factors 
associated with LMQ composite scores were examined. Preliminary bivariate analyses 
(simple linear regressions) were used to test each candidate independent variable against 
the dependent variable. The variables which achieved p-values <0.05 and/or those with p-
values < 0.2 in either dataset were considered for inclusion in the multivariable regression 
models.250 To estimate the explanatory power of the combination of independent 
variables, standard multiple linear regressions (forced entry method),175 were conducted 
using LMQ composite scores as the dependent variable.  
 
A priori hypotheses 
Decisions about which variables were included in the regression analyses were based on 
previous research or logic. Experiences of medicine use were hypothesised to relate to 
demographic characteristics, particularly age, and socioeconomic status.48,88,259 The latter 
was thought to relate to financial-burden of paying for long-term prescriptions medicines, 
particularly for the unemployed. Living in areas of higher level of relative deprivation, 
measured using the English IMD 2015, was hypothesised to impact negatively on the 
medicine use experience, as was thought to relate to access to healthcare e.g. GP 
appointments, pharmacist consultation or even access to prescription medicines. 
Medicine use experiences were hypothesised to also relate to regimen complexity, 
particularly the number of medicines, frequency of administration and the formulation 
used.98,260 The need for social support with managing medicines was also predicted to 













9.2.4.4.2. Testing regression assumptions  
To accurately estimate the regression models, a number of assumptions needed to be 
met. Firstly, the dependent variable, the LMQ composite score, needed to be continuous, 
which is the case.    
a) Assessing normality 
 Normality of residuals, another prerequisite in multiple regression analyses, was 
assessed using histograms and the normal probability plots (P-P plots).250 
b) Assessing multicollinearity 
 Other regression assumptions relate to absence of multicollinearity, ensuring that 
independent variables are not too strongly correlated with each other. Collinearity 
diagnostic tests were used to assess this assumption. One such test, known as the 
variance inflation factor (VIF), was used to assess if a predictor variable had a strong 
relationship with other hypothesised predictors. Although it is not clear-cut, as a rule of 
thumb, Field (2013) indicates that VIF values above 10 are undesirable.174 Tolerance is 
another diagnostic for test for multicollinearity, calculated as 1/VIF; values below 0.1 
suggest serious problems with multicollinearity.174  
c) Testing for homoscedasticity and independence of errors 
 Homoscedasticity, also known as homogeneity of variance, and independence of errors 
(residuals) are also prerequisite assumptions for multiple regression. They relate to 
residuals in the model that should be independent of the fitted values (i.e. do not 
increase or decrease with fitted values)250 and how well the model fits the data. A scatter 
plot of residual values against values of the dependent variable predicted by the model, 
the zpred vs. zresid plot (standardised predicted value against standardised residual), was 
used to assess these assumptions.174 If the ĂƐƐƵŵƉƚŝŽŶƐĂƌĞŵĞƚ ? ‘ƚŚĞƌĞƐŚŽƵůĚďĞŶŽ
systematic relationship between the errorƐŝŶƚŚĞŵŽĚĞůĂŶĚǁŚĂƚƚŚĞŵŽĚĞůƉƌĞĚŝĐƚƐ ? ?











9.2.4.4.3. Regression model evaluation 
Overall model fit was evaluated using R-squared (R2) and adjusted R-squared (adj R2) as 
ĂŶ ‘ĂŵĞĂƐƵƌĞŽĨŚŽǁŵƵĐŚŽĨƚŚĞǀĂƌŝĂďŝůŝƚǇŝŶƚŚĞŽƵƚĐŽŵĞŝƐ accounted for by the 
predictor  ?ǀĂƌŝĂďůĞƐ ? ? ?ǁŚŝůĞits adjusted value reflects generalisability of the model to the 
population.174 Regression coefficients, including B-values that are unstandardised and 
ďĞƚĂ ?ɴ )ǀĂůƵĞƐƚŚĂƚĂƌĞƐƚĂŶĚĂƌĚŝƐĞĚ ?ǁĞƌĞƵƐĞĚƚŽĞƐƚŝŵĂƚĞƚŚĞŵĂŐŶŝƚƵĚĞĂŶĚĚŝƌĞĐƚŝŽŶ
of the relationship (as positive or negative) between each predictor variable and the 
outcome variable. Standardised values are easier to interpret and are directly 
comparable. Beta values  ?ɴ )ĂƌĞĐŝƚĞĚƚŽƉƌŽǀŝĚĞďĞƚƚĞƌŝŶƐŝŐŚƚŝŶƚŽƚŚĞ ‘ŝŵƉŽƌƚĂŶĐĞ ?ŽĨĂ
variable in the model.174 B-ǀĂůƵĞƐĂƌĞĂůƐŽŝŶĚŝĐĂƚŝǀĞŽĨƚŚĞĞǆƚĞŶƚƚŽǁŚŝĐŚ ‘ĞĂĐŚ
ƉƌĞĚŝĐƚŽƌĂĨĨĞĐƚƐƚŚĞŽƵƚĐŽŵĞŝĨƚŚĞĞĨĨĞĐƚƐŽĨĂůůŽƚŚĞƌƉƌĞĚŝĐƚŽƌƐĂƌĞŚĞůĚĐŽŶƐƚĂŶƚ ? ?174 
The t-test associated with each B-value was used to assess whether or not the predictor 
variable made a significant contribution to the model (p < 0.05). Predictor variables with 
smaller p-values (<0.05) of the t-test statistic indicated greater and significant 
contribution to the regression model. 
 
9.3 Results 
9.3.1 Sample characteristics  
The characteristics of participants in the national-level dataset (from here on, referred to 
as Sample 1), recruited via the LMQ-2.1 survey, were described in Chapter 6 (see Table 6-
2). Repeated here for clarity purposes, 729 participants had fully completed all 41 Likert-
type items of the LMQ-2.1. However, some participants did not provide responses to 
some of the demographic questions, or to some questions relating to their medicine 
regimens. Participants in Sample 1 were of mean age 48.7 (SD±11.6). Most participants in 
this sample were female (83.9%, n= 612) and the mean number of medicines used was 
4.6 (SD±3.7).  
 
In Sample 2, which is the region-level dataset completed using the LMQ-3, 336 completed 
all 41 Likert-type items. Similar to Sample 1, some participants had missing data on 
demographic- and treatment-related questions. Over half of participants were female      
(61.9%, n= 208). The mean age was slightly higher (56.1 ± 18.17) compared to Sample 1, 
but the mean number of medicines used was similar (4.6 ± 3.7). WĂƌƚŝĐŝƉĂŶƚƐ ?




9.3.2 Prevalence and narratives of medicine-related problems  
To estimate the percentage of people experiencing different medicine-related problems 
assessed by the LMQ, item-level analyses were conducted for each dataset. Table 9-1 
shows the percentage of participants endorsing specific Likert-type statements. Sample 
quotations from the free-text comments, which relate to each of the eight domains 
underlying the LMQ, have been included to illustrate the statistical findings. 
 
Practical difficulties  
About 1 in 6 reported difficulties getting their prescriptions across the national (17.2%, 
n=125) and the regional samples (16.1%, n=54). Similar findings were revealed for 
difficulties relating to accessing medicines from the pharmacist: 16.6% (n=121) versus 
11.6% (n=39) of the national and regional sample, respectively, agreed/strongly agreed 
that they found getting their medicines from the pharmacist difficult. Up to a third 
(33.7%, n=246) of the national sample admitted to putting a lot of planning and thought 
into using their medicines, though a lower proportion of the regional sample (18.8%, 
n=63) had the same challenge. Practical difficulties relating to access to prescription 
medicines are illustrated in the quotes below; 
  ‘My GP will not allow me to get a prescription unless I have less than 2 weeks of 
 tablets left. This makes planning for holidays difficult at times. ?    
     Female, 48 years, uses one prescription medicine 
 
  ‘I run out of meds because I cannot see the doctor, I run out of meds because I 
 cannot get to the chemist. When I change to a different doctor (i.e. I move home) it 
 takes me a long time to get my GP prescribing medicines that my consultant wants 
 ŵĞƚŽƚĂŬĞ ?/ŚĂǀĞƚŽďƵǇŵĞĚŝĐŝŶĞƐŽŶƚŚĞŝŶƚĞƌŶĞƚ ?I can't get medicines 
 prescribed long term for my medical conditions that last for years but come and 
 ŐŽ ? ? ?     Female, 54 years, six prescription medicines 
 
  ‘GP management insist all prescriptions are requested in person at the surgery, 
 the opening times are incompatible with my work hours. Fortunately  ?
 pharmacist has a collection service, so is able to request, collect and dispense on 
 ŵǇďĞŚĂůĨ ? ? Female , 47 years, uses one prescription medicine 
 
A few participants reported difficulty with using their medicines in general: 8.0% (n= 58) 







Cost-related burden  
About 30.3% (n=221) of the national sample paid for their prescription medicines. 
Although the cost of prescription medicines did not appear to be worrisome for the vast 
majority, about 1 in 5 participants worried about paying for their medicines across the 
national (22.8%, n=166) and regional samples (24.1%, n=81) respectively.  
A few participants echoed their concerns about costs of long-term medicines through 
additional comments: 
  ‘Paying for them [prescription medicines] is my biggest problem/worry. I am long 
 term sick and unable to work. Yet don't qualify for free prescriptions. Long-term 
 illness should qualify iŶŶŐůĂŶĚ ? ?               Female, 39 years, uses three medicines 
 
  ‘/ƌĞůǇŽŶŵǇŵĞĚŝĐŝŶĞƐ ?All these prescriptions are of a high cost to my budget as 
 i may have eight items on one prescription. I was forced to take ill health 
 retirement and my ƉĞŶƐŝŽŶŽĨƐĞƌǀŝĐĞŝƐǀĞƌǇůŽǁ ? ?  
       Female, 54 years, uses five medicines 
 
  ‘ ?it is a nightmare having to pay out ridiculous amounts for drugs that are 




Across the national and regional samples respectively, the vast majority of participants 
felt that their medicines were working (63.9 %( n=466) to 75% (n=252)), and prevented 
their condition getting worse (64.2 %( n=468) to 77.4 %( n=260)).  
  ‘As my AED's [medicines] help control my seizures I am very grateful they exist. ? ?   
     Female, 37 years, uses five prescription medicines 
 
However, a smaller proportion (12.5 %( n=42) to 25.0 %( n=182)) were dissatisfied with 
the effectiveness of their medicines across both datasets.  
    ‘Have no effect on the amount of pain i am in, which makes my life revolve 
  around pain & depression ?        Female, 63 years, uses sixteen medicines 
 
   ‘Find them ineffective, but nothing else iƐĂǀĂŝůĂďůĞĨŽƌŵǇĐŽŶĚŝƚŝŽŶ ? ? 
     Female, 53 years, uses three prescription medicines 
 
   ‘Not very effective at helping but have been told I cannot try others as the 
  alternaƚŝǀĞƐĂƌĞŶŽƚŽŶƚŚĞE/ůŝƐƚ ? ?   








Communication about medicines with healthcare professionals  
Most participants reported good communication and relationships with health providers, 
in terms of their medicine use experiences. For instance, about a half (52.7% (n=177) to 
55.6% (n=405)) felt that doctor(s) listened to their opinions about their medicines for 
regional- and national-level data respectively. However, about a third (33.8%, n=246) of 
participants in the national survey dataset did not feel that they got enough information 
about their medicines (see Table 9-1). For instance, while some participants expressed 
concerns about lacking information about risks of using medicines, others mistrusted 
health professionals. 
  ‘I was given no information about the long-term side effects on the other systems 
 of my body. ../ĨĞĞůŵŽƌĞ ? information needs to be  given into the long term side 
 ĞĨĨĞĐƚƐĂŶĚƉĂƚŝĞŶƚƐŝŶĨŽƌŵĞĚ ?Female, 25 years, uses two prescription medicines 
 
  ‘I feel that my doctor does not review or explain why he has prescribed the 
 particulaƌĚƌƵŐƐƚŚĂƚŚĞŚĂƐĨŽƌŵĞ ? ? Female, 71 years, uses two medicines 
 
  ‘I don't feel that I have a GP that I can talk to or who believes or supports me. I 
 have no faith in them now. ?Female, 54 years, uses nine prescription medicines 
             
 Concerns about using medicines 
Over half of participants were concerned about long-term effects of using medicines 
among regional (58.3%, n=196) and national-level samples (73.9%, n=539) respectively.  
Other concerns related to potential drug-drug interactions, and worries relating to 
switching between branded/originator medicines to generic versions. 
  ‘My only concern is long term effects, which no one knows. ?  
       Female, 61 years, uses four medicines 
  
  ‘I take many medications for several conditions and I am not sure they always 
 take interactions into account and have had a ĨĞǁƌĞĂĐƚŝŽŶƐƚŽŵĞĚŝĐĂƚŝŽŶƐ ? ? 
       Female, 46 years, uses ten medicines 
 
  ‘I had  been stable on a branded medication for over 10 years, but they have just 
 discontinued it. So now I feel anxious that this latest generic will put me back to 









Side effects experience 
About half of the national sample agreed or strongly agreed that the experience of side 
effects was bothersome (51.1%, n=372) and that side effects interfered with day-to-day 
life (45.8%, n=334).  About 20.2% (n= 68) and 20.8% (n=70) of the regional sample were 
bothered by side effects and acknowledged their interferences/impact on life. 
  ‘Side effects aƌĞƚŚĞƉƌŽďůĞŵŽĨŵŽƐƚĐŽŶĐĞƌŶ ? ? 
       Male, 70 years, uses seven medicines 
 
  ‘Exhaustion, nausea, dizziness, cold getting better- the immunosuppressants and 
 [ulcerative colitis] UC medications. ..really awful side effects they have on me- low 
 white blood cell rate & low red blood cell rate & coming down consiƐƚĞŶƚůǇ ? 
       Female , 55 years, uses ten medicines 
 
  ‘My medication causes horrible side effects ƚŚĂƚĂĨĨĞĐƚŵǇƋƵĂůŝƚǇŽĨůŝĨĞ ? ?  
      Female , Age 27, uses three medicines 
 
In addition to general concerns about side effects, one participant hinted at the burden 
resulting from prescribing cascades associated with having more medicines prescribed to 
counteract the side effects of existing medicines. 
  ‘I worry on a daily basis about the strong side-effects of Prednisolone; the 
 personality changes also affect everyone around me. It is annoying because of one 
 medicine I have to take several others to counteract those side-ĞĨĨĞĐƚƐ ? ?  
       Female, Age 54, uses five medicines  
 
 
Interference to day-to-day life  
About 3 in 10 participants (30.6%, n=223) in the national dataset agreed or strongly 
agreed that using medicines interfered with their social or leisure activities; a slightly 
higher prevalence when compared to that reported in the regional-survey dataset (20.2%, 
n=68). Medicines were perceived to affect social relationships (13.1% versus 24.5% and 
sexual lives (14.9% versus 29.4%) among the national- and regional- samples respectively.   
Interferences to daily tasks were also reported by some participants. 
 
  ‘[Medicines] they make me tired, meaning that I can't get out a lot, have a social 
 life or do a lot of activities. They also make me dizzy, so I often find it hard to be 
 fully focused and present during conversations, making social interaction 
 sometimes challenging... I find it hard to remember to take them and to fit this in 
 to whatever activity I am doing, but this isn't really something I can avoid so I 






  ‘it is hell!! I have very little social life, virtually no sex ůŝĨĞ ? ? 
       Female, 21 years, uses seven medicines  
 
  ‘After only taking my medication for a short time I feel the tablets have affected 
 me socially. Mainly by giving me ďůŽĂƚĞĚƐƚŽŵĂĐŚĂŶĚĨůĂƚƵůĞŶĐĞ ? ? 
       Female, 49 years, uses one medicine 
 
  ‘Also, sometimes it is difficult to say whether my medication is adversely affecting 
 my daily life/hobbies/socialising, or if it's my condition (as in, I have a choice - I can 
 be unable to go out because I'm in too much pain, or I can be unable to go out 
 ďĞĐĂƵƐĞ/ ?ǀĞƚĂŬĞŶŽƉŝĂƚĞƐ ? ? ? Female, 28 years, uses eight medicines 
 
 
A few others hinted at the social stigma associated with using certain formulations.  
  ‘My medicine is prescribed as patches and I have not been offered tablets (though 
 I know they exist) and the patches and dirty mĂƌŬƚŚĞǇůĞĂǀĞŝƐĞŵďĂƌƌĂƐƐŝŶŐ ? ? 
       Female, 47 years, uses one medicine 
  
  ‘I have to carry a glucose test kit, insulin pen, needles and sugar for hypos. It's 
 often hard to carry the supplies discreetly thus advertising my condition which 
 ƵŶĚĞƌŵŝŶĞƐĐŽŶĨŝĚĞŶĐĞĂƚƚŝŵĞƐ ? ?                   Male, 34 years, uses two medicines 
 
  ‘Possibly the largest burden is the social effect of sometimes having to take them 
 in public (feelings ŽĨƐŚĂŵĞ ?ŐƵŝůƚ ?ĨƵƌƚŝǀĞŶĞƐƐĂƚďĞŝŶŐŽďǀŝŽƵƐůǇ ‘ŽŶƉĂŝŶŬ ůůĞƌƐ ? ?
 and having to answer questioŶƐĂďŽƵƚǁŚĂƚ/ ?ǀĞũƵƐƚƚĂŬĞŶ ? ? ? 
                  Female, 28 years, uses eight medicines 
 
 
Patient autonomy/control over their regimens 
Most participants reported limited empowerment to alter their medicine regimes to suit 
their lifestyle. For instance, over a half (57.5% to 64.5%) reported that they could neither 
change the dose nor the times (45.8% to 53.9%) they use their medicines, if they wanted 
to.   
  ‘If consultant at hospital has prescribed medication, and then you are discharged, 
 it is often very difficult to get GP to alter dose or change medication. Should be 
 given indicator when starting new meds ŽƌĚŝĨĨĞƌĞŶƚĚŽƐĞ ? ? ? ? 
       Female, 64 years, uses five medicines 
 
  ‘I am not given choices on medicines and treatments available to treat my  





Statements in their respective domains National-level dataset 
Sample 1 (LMQ-2.1) (N=729)
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 Regional-level dataset 
























Practical difficulties (7 items)       
I find getting my prescriptions from the doctor difficult. 17.2(125) 70.5(514) 12.3(90) 16.1(54) 68.7(231) 15.2(51) 
I find getting my medicines from the pharmacist difficult 16.6(121) 70.2(512) 13.2(96) 11.6(39) 76.5(257) 11.9(40) 
I am comfortable with the times i should take my medicines 86.8(633) 5.2(38) 8.0(58) 81.8(275) 8.1(27) 10.1(34) 
I am concerned that I may forget to take my medicines 41.7(304) 42.1(307) 16.2(118) 26.8(90) 54.5(183) 18.8(63) 
I have to put a lot of planning and thought into taking my medicines. 33.7(246) 45.3(330) 21.0(153) 18.8(63) 59.0(198) 22.3(75) 
It is easy to keep my medicines routine 75.0(547)  11.7(85) 13.3(97) 74.7(251) 8.9(30) 16.4(55) 
I find using my medicines difficult 8.0(58) 77.4(564) 14.7(107) 6.3(21) 85.2(286) 8.6(29) 
Perceived effectiveness (6 items)       
I am satisfied with the effectiveness of my medicines. 52.8(385) 25.0(182) 22.2(162) 70.8(238) 12.5(42) 16.7(56) 
My medicines prevent my condition getting worse 64.2(468) 17.0(124) 18.8(137) 77.4(260) 8.4(28) 14.3(48) 
My medicines live up to my expectations 40.9(298) 26.8(195) 32.4(236) 62.5%(210) 9.5%(32) 28.0(94) 
My medicines allow me to live my life as I want to 43.3(316) 33.8(246) 22.9(167) 67.3(226) 11.9(40) 20.8(70) 
My medicines are working 63.9(466) 12.6(92) 23.5(171) 75.0(252) 6.3(21) 18.8(63) 
The side effects are worth it for the benefits I get from my medicines 41.3(301) 12.6(92) 41.3(301) 35.7(120) 17.6(59) 46.7(157) 
Communication/relationships with HCPs (5 items)       
I trust the judgement of my doctor(s) in choosing medicines for me. 56.8(414) 20.7(151) 22.5(164) 70.2(236) 11.6(39) 18.2(61) 
My doctor(s) listen to my opinions about my medicines 55.6(405) 22.1(161) 22.3(163) 52.7(177) 19.6(66) 27.7(93) 
My doctor takes my concerns about side effects seriously. 45.4(331) 22.8(166) 31.8(232) 51.2(172) 14.3(48) 34.5(116) 
I get enough information about my medicines from my doctor(s) 44.0(321) 33.8(246) 22.2(162) 53.6(180) 22.3(75) 24.1(81) 
The health professionals providing my care know enough about me 
and my medicines 
44.0(321) 36.5(266) 19.5(142) 59.2(199) 18.8(63) 22.0(74) 
Cost-related burden (3 items)       
I worry about paying for my medicines 22.8(166) 49.2(359) 28.0(204) 24.1(81) 51.5(173) 24.4(82) 
I sometimes have to choose between buying basic essentials or 
medicines 
8.9(65) 68.9(502) 22.2(162) 9.5(32) 77.1(259) 13.4(45) 
I have to pay more than I can afford for my medicines. 13.7(100) 49.1(358) 37.2(271) 15.5(52) 64(215) 20.5(69) 
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National-level dataset 
 



























Concerns about medicine use (7 items)       
I worry that I have to take several medicines at the same time 32.1(234) 41.6(303) 26.3(192) 22.3(75) 55.4(186) 22.3(75) 
I would like more say in the brands of medicines I use 49.2(359) 21.3(155) 29.5(215) 26.8(90) 35.4(119) 37.8(127) 
I feel I need more information about my medicines 42.7(311) 33.6(245) 23.7(173) 33.9(114) 44.6(150) 21.4(72) 
I am concerned about possible damaging long-term effects of taking 
medicines 
73.9(539) 13.9(101) 12.2(89) 58.3(196) 26.4(89) 15.2(51) 
I am concerned that I am too reliant on my medicines 41.3(301) 33.7(246) 25.0(182) 36.0(121) 39.9(134) 24.1(81) 
I am concerned that my medicines interact with alcohol 23.6(172) 45.8(334) 30.6(223 19.6(66) 48.5(163) 31.8(107) 
I worry that my medicines may interact with each other 44.1(322) 30.5(222) 25.4(185) 35.7(120) 35.7(120) 35.7(120) 
Side-effect-burden (4 items)       
The side effects I get are sometimes worse than the problems for 
which I take my  medicines 
36.8(268) 40.5(295) 22.8(166) 
 
21.1(71) 51.8(222) 27.1(91) 
The side effects that I get from my medicines interfere with my day 
to day life 
45.8(334) 33.1(241) 21.1(154) 20.8(70) 58.1(195) 21.1(71) 
The side effects I get from my medicines are bothersome 51.1(372) 25.9(189) 23.0(168) 20.2(68) 63.7(214) 16.1(54) 
The side effects I get from my medicines adversely affect my 
wellbeing 
36.5(266) 40.5(295) 23.0(168) 14.3(48) 67.8(228) 17.9(60) 
Interference to day-to-day life (6 items)       
My medicines interfere with my social or leisure activities 30.6(223) 53.1(387) 16.3(119) 20.2(68) 64.9(218) 14.9(50) 
Taking medicines affects my driving 17.3(126) 54.9(400) 27.8(203) 11.3(38) 72.3(243) 16.4(55) 
My medicines interfere with my social relationships 24.5(179) 59.1(431) 16.3(119) 13.1(44) 71.1(239) 15.8(53) 
Taking medicines causes problems with daily tasks 28.7(209) 50.2(366) 21.1(154) 14.6(49) 74.4(250) 11.0(37) 
My medicines interfere with my sexual life 29.4(214) 46.6(340) 24.0(175) 14.9(50) 65.8(221) 19.3(65) 
My life revolves around using medicines 29.5(215) 51.2(373) 19.3(141) 27.1(91) 54.1(182) 18.8(63) 
Autonomy/control (3 items)       
I can vary the dose of the medicines I take 32.6(238) 57.5(419) 9.9(72) 18.8(63) 64.5(217) 16.7(56) 
I can choose whether or not to take my medicines 25.4(185) 64.1(467) 10.6(77) 27.4(92) 55.0(185) 17.6(59) 
I can vary the times I take my medicines 30.2(220) 53.9(393) 15.9(116) 34.8(117) 45.8(154) 19.3(65) 
Table 9-1 Percentage of participants endorsing (agreeing or disagreeing) with the 41 Likert-type statements common to the two datasets 
 




9.3.3 What proportion of people experience high medicine burden? 
Figure 9-1 illustrates the distribution of LMQ composite scores for the two samples, 
which were used to classify levels of medicine burden. 
 
 
LMQ total scale score 
 
Figure 9-1 Histograms showing distribution of LMQ composite scores  
 
For the national-level sample, data showed that the majority had minimal (34.3%, n= 
250) or moderate (47.7%, n=348) burden. Just over 1 in 10 (13.3%, n=97) participants 
had scores reflecting high burden, while five participants (0.7%) had scores reflecting 
 ‘ĞǆƚƌĞŵĞůǇŚŝŐŚďƵƌĚĞŶ ? ?&Žƌ^ĂŵƉůĞ ? ?ĂŶĂůǇƐĞƐƌĞǀĞĂů ĚĨĞǁĞƌƉĂƌƚŝĐŝƉĂŶƚƐǁŝƚŚŚŝŐŚ
medicine burden (4.8%, n=16) and whŝůĞŶŽŶĞŽĨƚŚĞŵƐŚŽǁĞĚ ‘ĞǆƚƌĞŵĞůǇŚŝŐŚ
ďƵƌĚĞŶ ? ?^ĞĞ&ŝŐƵƌĞ ?-2).  
 
Mean (SD) =102.8(20) 
Sample 2 (LMQ-3) 
Mean (SD) =114.1(23) 












National-level sample (N=729) 
Sample 1 
 





Verifying medicine burden categories against self-perceptions of burden 
Further descriptive analyses, in the form of correlations and cross-tabulations with 
scores on the 10-cm visual analogue scale assessing perceptions of burden (VAS 
burden), were conducted to verify the five categories of medicine burden based on 
overall composite scores. A positive, moderately strong, correlation between VAS 
burden scores and composite scores was obtained for both national- (r=0.542, 
p<0.001) and regional samples (r= 0.571, p<0.001), suggesting that perceptions of 
medicine burden were related to experiences of burden in the appropriate direction.  
  
For cross-tabulations, the VAS burden scores were divided into five groups: 0.0- 2.0; 
2.1-4.0; 4.1-5.9; 6.0-7.9; 8.0-  ? ? ? ? ?ƐĐŽƌĞƐƌĂŶŐĞĨƌŽŵ ?ƚŽ ? ?ĚĞƉŝĐƚŝŶŐ ‘ŶŽďƵƌĚĞŶĂƚ
aůů ?ƚŽ ‘ĞǆƚƌĞŵĞůǇďƵƌĚĞŶƐŽŵĞ ? ?Of the 29 national-survey participants assessed to have 
 ‘ŶŽďƵƌĚĞŶ ?ďĂƐĞĚŽŶĐŽŵƉŽƐŝƚĞƐĐŽƌĞƐ ?ƚŚĞǀĂƐƚŵĂũŽƌŝƚǇ ? ? ? ? ?A? ?ŶA? ? ? )ŚĂĚ
perception ratings in the lowest category (0.0-2.0) of the VAS scale. Similar findings 
were found in the second sample, where all but one participant (95.7%, n=22) assessed 
ƚŽŚĂǀĞ ‘ŶŽďƵƌĚĞŶ ?ďĂƐĞĚŽŶĐŽŵƉosite scores had perceptions ratings in the lowest 
category of the VAS scale (0.0-2.0). These findings may suggest that, on the whole, 
LMQ composite scores in the range 41-73 closely reflect absence of medicine burden.   
 
 Of the five national-ƐƵƌǀĞǇƉĂƌƚŝĐŝƉĂŶƚƐĂƐƐĞƐƐĞĚĂƐŚĂǀŝŶŐ ‘ĞǆƚƌĞŵĞůǇŚŝŐŚďƵƌĚĞŶ ?
based on composite scores, 80% (n=4) had perception ratings in the topmost category 
(8.0-10.0) of the VAS scale. None of the participants in the second sample (Sample 2) 
ŚĂĚĐŽŵƉŽƐŝƚĞƐĐŽƌĞƐĂŶĚs^ƌĂƚŝŶŐƐƌĞĨůĞĐƚŝŶŐ ‘ĞǆƚƌĞŵĞůǇŚŝŐŚďƵƌĚĞŶ ? Žƌ ‘Ğǆƚƌemely 
ďƵƌĚĞŶƐŽŵĞ ?ƌĞƐƉĞĐƚŝǀĞůǇ ?In Sample 2 ?ĂďŽƵƚ ? ? ? ?A? ?ŶA? ? ? )ŽĨƚŚŽƐĞǁŝƚŚ ‘ŚŝŐŚďƵƌĚĞŶ ?
based on composite scores had perception ratings in the topmost category (8.0-10.0) 
of the VAS scale. dŚŝƐĨŝŶĚŝŶŐŝŶĚŝĐĂƚĞƐƚŚĂƚ>DYĐŽŵƉŽƐŝƚĞƐĐŽƌĞƐŽĨA? ? ? ?ƌĞĨůĞĐƚ ?ĨŽƌ








The data showed that the middle categories of medicine burden (i.e.  ‘ŵŝŶŝŵĂůďƵƌĚĞŶ ?
ĂŶĚ ‘moderate burdeŶ ? ) ?ďĂƐĞĚŽŶĐŽŵƉŽƐŝƚĞƐĐŽƌĞƐ ?were less discriminative (See 




Table 9-2 Cross-validation of medicine burden categories derived using LMQ-3 
composite scores 
 
Notes; *Reflects the sample size for participants that had complete data on both the LMQ composite 
scores and VAS burden scores. Colour codes green = minimal/no burden; yellow = some degree of 
burden; orange =  ‘certainly ? high/extremely high degree of burden 
 
 
Table 9-2 shows that for national-level sample, a total of 70 participants (~ 9.6% of the 
ŽƌŝŐŝŶĂůƐĂŵƉůĞ ) ‘ĐĞƌƚĂŝŶůǇ ?ŚĂĚŚŝŐŚ ?ĞǆƚƌĞŵĞůǇŚŝŐŚŵĞĚŝĐŝŶĞďƵƌĚĞŶĨŽůůŽǁŝŶŐƚǁŽ
assessments using compŽƐŝƚĞƐĐŽƌĞƐ ?A? ? ? ? )ĂŶĚs^ƌĂƚŝŶŐƐ ?A? ?.0); only 14 (~ 4.2%) of 
the regional sample participants  ‘ĐĞƌƚĂŝŶůǇ ?ĞǆƉĞƌŝĞŶĐĞĚŚŝŐŚ ?ĞǆƚƌĞŵĞůǇ high burden. 
Table 9-3 summarises the characteristics of the latter subgroups. Appendix 25 
illustrates free-text comments from participants with scores reflecting  ‘ĐĞƌƚĂŝŶůǇ ?
































Sample 1  
(N=704)* 
0.0- 2.0 79.3% (23) 44.5%(106) 11.0%(37) 5.2%(5) 0.0%(0) 
2.1 -4.0 3.4%(1) 22.7%(54) 21.4%(72) 9.4%(9) 0.0%(0) 
4.1-5.9 6.9%(2) 14.3%(34) 31.0%(104) 16.7%(16) 20.0%(1) 
6.0-7.9 6.9%(2) 12.2%(29) 20.2%(68) 28.1%(27) 0.0%(0) 




0.0- 2.0  95.7% (22) 68.2%(118) 30.3%(37) 6.3%(1) 0.0%(0) 
2.1-4.0 4.3%(1) 12.1%(21) 15.6%(19) 0.0%(0) 0.0%(0) 
4.1-5.9 0.0%(0) 11.0%(19) 23.8%(29) 6.3%(1) 0.0%(0) 
6.0-7.9 0.0%(0) 1.7%(3) 18.9%(23) 18.8%(3) 0.0%(0) 










Gender Female 79(55) 64(9) 
 Male 21(15) 36(5) 
Age 18-29 10(7) 0(0) 
 30-49 36(25) 57(8) 
 50-64 47(33) 36(5) 
 65 or over 7(5) 7(1) 
Ethnicity White 96(67) 79(11) 
 Other 4(3) 21(3) 
Employment Employed 36(25) 43(6) 
 Unemployed 40(28) 36(5) 
 Retired 11(8) 21(3) 
 Full time student 7(5) 0(0) 

























 10 or more 17(12) 29(4) 
Formulation Tablets/capsules 59(41) 50(7) 
 Mixed*  41(29) 50(7) 
 
Table 9-3 Characteristics of participants with  ‘ĐĞƌƚĂŝŶůǇ ?ŚŝŐŚŽƌextremely high 
medicine burden based on their LMQ-3 composite scores and global VAS ratings  
 

















9.3.4 Subgroup differences  
 
Differences in medicine burden (measured by LMQ composite scores) were examined 
ǁŝƚŚƌĞƐƉĞĐƚƚŽƉĂƌƚŝĐŝƉĂŶƚƐ ?ƐŽĐŝŽ-demographic and treatment characteristics for both 






Characteristics  National-level data 
Sample 1 (LMQ-2.1) 
(N=729) 
   Regional-level data 
    Sample 2 (LMQ-3) 
   (N=336) 
  Mean(SD) p-value Mean (SD) p-value 
Gender Female 113.8(25.2)  103.6 (19.4)  
 Male 114.6(22.5) .784 101.2 (20.5) .289 
Age (years) 18-29 119.9(20.3)  104.6(18.4)  
 30-49 114.3(22.4)  108.4(22.4)  
 50-64 113.7(24.1)  102.8(20.5)  
 A? ? ? 107.8(23.1) .055 98.4(17.5) .007* 
Education  School 114.5(23.3)  103.4(21.5)  
              College/App$    115.9(23.3)  100.5(20.1)  
 University 112.0(22.6)  103.4(20.0)  
 Other 124.8(22.3) .073 107.7(15.2) .439 
Employment  Employed 111. 1(21.6)  103.2(20.1)  
 Unemployed 122.2(24.2)  118.0(21.5)  
 Retired 109.1(21.84) <.00* 98.3(17.3) <.001* 
Ethnicity White 113.6(23.2)  101.9(19.4)  
 Other  122.5(17.5) .070 106.8(22.6) .153 
No. of 
medicines 
1-4 111.1(23.2)  100.3(17.7)  
5-9 117.2(21.6)  107.8(23.8)  
 A? ? ? 121.4(24.2) <.001* 104.4(20.3) .010* 
Formulation  Tablet/capsule 113.3(23.7)  102.4(18.7)  
 Any other   96.8(17.6)  103.4(17.6)  
 Combinations# 116.0(22.1) .001* 103.1(24.8) .954 
Frequency of 
use 
Once daily 106.3(22.5)  97.8(16.0)  
Twice daily 117.7(24.9)  101.7(20.0)  
 Thrice daily 111.9(21.3)  111.4(23.8)  
 A? ?ƚŝŵĞƐĚĂŝůǇ 121.3(21.1) <.001* 112.7(22.1) <.001* 
Managing 
medicines 
Independent 112.1(22.8)  100. 8(19.5)  
Requires help 124.6(22.1) <.001* 116.4(17.8)       <.001* 
Paying for 
prescriptions 
No 114.0(23.8)  100.6(19.5)  
Yes 113.6(21.5) .844 106.2(20.3)        .014* 
Table 9-4 Differences in medicine burden by demographic and treatment characteristics 
 
Notes;






9.3.4.1 Socio-demographic characteristics 
Gender; Gender did not seem to affect medicine use experiences in the sample 
populations. Across both samples, there were no statistically significant differences 
(p>0.05) in mean composite scores between males and females based on findings of 
the independent-samples t-tests. The qualitative analyses revealed most free-text 
comments were from females, most of which described negative experiences. 
 
Age; One-way ANOVAs indicated that medicine use experiences significantly differed 
with age. For instance, post-hoc Tukey HSD tests on the regional-level data revealed 
significantly lower mean composite scores (98.4±17.5) among those 65 years and over 
when compared to the 18-29-year-olds (104.6±18.4). The same finding was observed 
in the national dataset, except that it was marginally significant. This finding may 
suggest that increasing age is associated with lower self-reported medicine burden, 
while younger participants seem to report relatively worse experiences with medicine 
use. 
 
Employment status; One-way ANOVAs revealed statistically significant differences in 
medicine uses experiences in terms of employment status. Across both samples, 
unemployed participants, including those self-reporting to be homebound, disabled, or 
those unable to work due to illness or other reasons, had the highest mean composite 
scores (reflecting relatively higher medicine burden) when compared to employed or 
retired participants (p < 0.001) (See Table 9-4). 
 
Education and ethnicity; Across both samples, there were no statistically significant 












Deprivation levels and medicine burden 
As shown in Table 9-5, significant differences were found between deprivation levels 
and medicine burden levels (LMQ composite scores); higher relative deprivation levels 
(lower IMD ranks) were associated with increasing medicine burden (higher LMQ-3 
composites). 
 










No burden at all 21 24850  18 18459  
Minimal/very little burden 188 18725  149 17415  
Some/moderate burden 263 17152  100 15755  
High burden 74 15768  12 9841  
Extremely high burden 4 10022 < 0.001    0.025 





9.3.4.2 Medicine-related characteristics 
Number of medicines; One-way ANOVAs revealed statistically significant differences in 
mean composite scores across number of medicines categories. Post-hoc tests for 
multiple comparisons (Tukey HSD) showed significantly higher scores (higher burden) 
among those using 5-9 medicines when compared to those using 1-4 medicines across 
both subsamples (p <0.05). Further subgroup analyses showed variations in levels of 








Figure 9-3 Comparison of medicine burden categories with number of medicines used 
across the two sample populations. 
 
Note; The figure shows that the number of prescription medicines used varies across different levels of 
medicine burden. The first bar chart (for national-level data) shows that people with extremely high 
medicines were mostly using 5-9 medicines. The regional-level data shows that people with high 














































Formulation; There were variations in medicine use experiences with regards to the 
formulation of medicine used. Based on national-level data, one-way ANOVAs (and 
post-hoc Games-Howell tests) showed significantly (p < 0.001) higher mean scores 
(higher burden) ĨŽƌƉĞŽƉůĞƵƐŝŶŐĂĐŽŵďŝŶĂƚŝŽŶŽĨƚĂďůĞƚƐ ?ĐĂƉƐƵůĞƐĂŶĚ ‘ĂŶǇŽƚŚĞƌ ?
formulations (116.0±22.1) compared to those using a non-oral solid dose formulation 
(96.8± 17.6). Data from the second subsample revealed mixed findings, with no 
statistically significant differences across formulation types (p =0.954).  
 
Frequency of medicine use; For both samples, one-way ANOVAs showed significant 
differences in medicine use experiences with respect to the frequency of medicine use. 
Mean composite scores generally increased with more frequent medicine use per day. 
Across the national sample, post hoc (Tukey) tests showed significantly higher mean 
composite scores among participants using medicines four or more times daily 
(121.3±21.1) when compared to those using medicines once daily (106.3±22.5) (p 
<0.001). 
 
Ability to manage medicine use; Across both datasets, independent samples t-tests 
revealed significantly lower mean composite (less burden) scores among participants 
managing medicines independently when compared to those needing social support 
with managing their medicines use (p<0.001) (See Table 9-4). 
 
Paying for prescriptions; Mixed findings were observed with regards to paying for 
prescriptions. In the regional sample, participants who paid for their prescriptions had 
relatively higher burden (composite mean scores =106.2±20.3) than those who did not 
pay for their prescriptions (composite mean scores =100.6±19.5) (p=0.014), but the 
national-level sample showed no statistically significant differences (p=0.781). 
 
Cost-burden mean scores were significantly higher among the unemployed (7.7(±3.1) 
to 8.8(±3.2)) and compared to those employed (6.9 (±2.9) to 7.3(±3.2)) across Samples 
1 and 2 respectively; one-way ANOVAs followed by post-hoc Tukey-HSD tests revealed 
significant findings (p-values, <0.001 to 0.022). Cost burden scores did not vary 





9.3.5. Findings of regression analyses  
To address the third research question, predictors of medicine burden were 
investigated through simple- and multiple linear regression analyses.   
 
9.3.5.1. Assumptions for regressions 
To ensure suitability of both datasets for regression analyses, specific statistical 
assumptions were tested, as previously described in the methods section. 
 
Multicollinearity; All intervariable correlations between independent variables were 
below 0.9, and thus the multicollinearity assumption was met.174 For both datasets, 
tolerance values were above 0.1 (range of 0.136 to 0.952), reflecting absence of 
multicollinearity.174,175 VIF values were all below 10 (range, 1.05-7.345) confirming that 
there were no serious problems with multicollinearity among predictor variables.174,175  
 
Normality; As shown in Figure 9-1, both datasets had relatively normal distributions of 
LMQ composite scores as the dependent variable. For both samples, histograms of 
standardised residuals also ĂƉƉĞĂƌĞĚ ‘ďĞůů-ƐŚĂƉĞĚ ?ĂŶĚW-P plots revealed most data 



























































 Homoscedasticity & independence of errors; For both samples, the scatterplots 
showed that most residuals were distributed haphazardly and no systematic pattern 
was immediately visible, thus the assumptions for homoscedasticity and independence 





Figure 9-5 Scatter plots of standardised residuals against standardised predicted values  
 
Note; The Graph from National-level data (Sample 1) is at the top and that for Regional-level data 
(Sample 2) is at the bottom 
 
Outliers, data points whose standardised residual values are greater than 3 in absolute 
value,175 were assessed using scatter plots shown in Figure 9-5. Only a few outliers 
were present in Sample 1, but were retained in subsequent analyses owing to the large 




















9.3.5.2. Findings from simple linear regression  
Simple linear regression was used to estimate the relative contribution of each 
independent variable to the prediction of LMQ composite scores as the dependent 
variable (See Table 9-6). Independent variables tested were those identified to show 
significant differences in composite scores in the preceding subgroup analyses (i.e. 
age, employment status, number of medicines, formulation, frequency of 
administration, managing medicines independently or need for social support and 
paying for prescriptions). In addition, deprivation level and perceptions of burden were 
tested as independent variables. 
 
The findings revealed that nearly a third of the total variation in LMQ composite scores 
was predicted by self-perceptions of medicine burden across both sample populations 
(R2=29.4% to 32.6%). Other statistically significant predictors of negative experiences 





Table 9-6 Simple linear regression analyses of predictors of medicine burden 
 
Notes;; a reference variable; B- Unstandardised coefficients; ɴ- Standardised beta coefficients;  
§Area deprivation levels based on IMD ranks for England 2015; 
 ܶ  ‘KǀĞƌĂůů ?ŚŽǁŵƵĐŚŽĨĂďƵƌĚĞŶĚŽǇŽƵĨĞĞůǇŽƵƌŵĞĚŝĐŝŶĞƐare to you?;  
 ? ‘dĂŬŝŶŐĞǀĞƌǇƚŚŝŶŐŝŶƚŽĂĐĐŽƵŶƚ ?ŚŽǁƐĂƚŝƐĨŝĞĚĂƌĞǇŽƵǁŝƚŚǇŽƵƌŵĞĚŝĐŝŶĞƐ ? ? ? 
§Index of Multiple Deprivation Rank 2015;  
~ R-squared range reported for both samples;  
# Combinations of tabletƐ ?ĐĂƉƐƵůĞƐĂŶĚ ‘ĂŶǇŽƚŚĞƌĨŽƌŵƵůĂƚŝŽŶ 








Sample 1 (LMQ-2.1)  Sample 2 (LMQ-3) 
 B SE ɴ p B SE ɴ p R2 (%)~ 
Age (years) -0.21 0.07 -0.11 .004* -0.17 0.1 -0.16 . 005* 1.2-2.4 
Employment           
Employed a           
Unemployed 10.5 2.1 0.19 .000* 14.6 3.4 0.23 .000* 4.8-9.1 
Retired  -2.6 2.2 -0.04 .242 -5.14 2.3 -0.13 .026*  
Deprivation 
level§ 
0.00 0.00 -0.19 .000* 0.00 0.00 -0.18 .003* 3.2-3.5 
Number of 
medicines 
         
1-4 a          
5-9  5.7 1.9 0.11 .002* 7.44 2.47 .167 .003*  
A? ? ? 9.9 3.1 0.12 .001* 4.02 3.53 .063 .256 2.2-2.7 
Formulation          
Tablets/capa          
Any other form  -16.8 5.1 -0.124 .001* 0.69 4.1 0.009 .868  
Combinations# 2.4 1.7 0.051 .177 0.40 2.7 0.008 .882 0.0-2.0 
Frequency          
Once daily a            
Twice daily  7.3 1.76 0.16 .000* 3.2 2.6 0.074 .209  
Thrice daily   6.3 2.12 0.11 .003* 13.0 3.5 0.208 .000  
A? ?ƚŝŵĞƐĚĂŝůǇ 11.9 2.29 0.20 .000* 14.2 3.5 0.234 .000  
Other times -4.31 2.48 -0.06 .083 2.5 4.4 0.032 .568 6.1-7.2 
Managing 
medicines 
Independent a  
         
Requires help 12.52 2.48 0.188 .000* 15.56 3.2 0.259 .000* 3.5-6.7 
Paying for 
prescriptions 
         
Noa          
Yes -3.73 1.89 -0.007 .844 5.57 2.26 0.135 .014* 0.0-1.8 
Perceptions of 
burdenܶ 




9.3.5.3. Results from multiple regressions 
To investigate the combined effect on LMQ composite scores and the explanatory 
power of all independent variables, standard multiple linear regressions (forced entry 
method) were conducted based on the regional-level sample (Sample 2) which used 
the final version of the questionnaire (LMQ-3). Analyses showed statistically (or 
marginally) significant predictors of negative experiences: a) being unemployed (ɴ 
=0.10 , p=0.053); b) relative level of deprivation in a partiĐŝƉĂŶƚ ?Ɛ ĂƌĞĂŽĨƌĞƐŝĚĞŶĐĞ ?ɴ
=-0.11, p =.023); c) needing assistance/social suppŽƌƚǁŝƚŚŵĞĚŝĐŝŶĞƵƐĞ ?ɴA?0.13, p= 
0.008); d) paying for prescription mĞĚŝĐŝŶĞƐ ?ɴA?0.09, p= .068);  and e) perceptions of 
ŵĞĚŝĐŝŶĞďƵƌĚĞŶ ?ɴA? ? ? ?8,p <.001). This model explained 36% of the variance in LMQ 
composite scores (See Table 9-7). 
 
Independent variable B SE B ɴ p-value 
Constant 94.0 2.38  .000 
Unemployed  5.86 3.01 0.10 .053 
Deprivation level§ 0.00 0.00 -0.11 .023 
Help/support with 
managing medicines 
8.25 3.09 0.13 .008 
Paying for prescriptions 3.63 1.98 0.09 .068 
Perceptions of burden  3.10 0.33 0.48 .000 
Table 9-7 Multiple regression analyses of predictors of medicine burden  
 






















Using secondary data obtained from earlier studies, this chapter interpreted 
questionnaire scores of the LMQ-3. Particularly, this chapter investigated the 
prevalence of medicine use issues covered in the questionnaire. The results indicated 
variations in medicine use experiences across the sample populations.  
 
Although the vast majority reported positive experiences with various aspects of 
medicine use, a fair proportion also reported practical difficulties (including problems 
accessing prescriptions and medicines), ineffective therapies, and impacts of side 
effects. A few indicated gaps in communication and relationships with healthcare 
professionals, citing a genuine lack of information about their medicines. Cost-related 
burden appeared to affect a smaller proportion of the sample population, particularly 
the unemployed. General concerns about medicine use often related to possible long-
term harm and risks associated with medicine use. For others, planning and using 
ĚŝĨĨĞƌĞŶƚƌĞŐŝŵĞŶƐ ?ĂƌŽƵŶĚƵƐƵĂůůŝĨĞ ?ƐĚĞŵĂŶĚƐ ?e.g. work, meals, sleep), hindered 
performance of tasks, social and/or leisure activities, and restricted social life. These 
findings support medicine-related issues reported in the literature (as discussed in 
Chapter 1 and 2), and some have been discussed in Chapter 6 and 7.  
 
The findings are supported by recent reviews of qualitative studies, exploring patient 
perspectives of treatment and medicine burden.85,86,88,89 IŶĚŝǀŝĚƵĂůƐ ?ǀŝĞǁƐŽĨƚŚĞŝƌ
regimen, within tŚĞĐŽŶƚĞǆƚŽĨůŝĨĞ ?ƐĚĞŵĂŶĚƐĂŶĚƌĞƐƉŽŶƐŝďŝůŝƚŝĞƐ ?e.g. family, work, 
school), may also affect perceived or actual treatment burden.260 For instance, Demain 
et al reported biographical disruption (including restriction of activities and social 
stigma), relational disruptions (e.g. strain to family and social relationships), and 
biological disruptions associated with side effects from using different therapies.95  
 
Autonomy/flexibility to vary regimens appeared to be limited in the sample 
population, and most participants reported minimal or no control over their regimen 
dosing or timing. Flexibility in regimes, where clinically beneficial, may reduce 
perceived medicine burden and encourage persistence with long-term medicine 
use.221,241,260 On the hand, loss of independence, freedom, and/or spontaneity 




individuals.95 Moreover, demands in time and effort to organise and use certain 
therapies (such as nebulised medicines, or prolonged, inpatient, iron chelation 
therapies238,240) may infringe on individual freedom and arouse negative emotions and 
ĨĞĞůŝŶŐƐ ‘ŝŶƚŚĞƐĞŶƐĞŽĨŶŽƚďĞŝŶŐ ‘ĐĂƌĞĨƌĞĞ ? ?.95 
 
This study also attempted to define and verify levels of medicine burden, as measured 
by the LMQ-3 instrument. It was found that about 1 in 10 of the national sample 
population experienced and self-reported high medicine burden. The findings suggest 
that, although broadly the LMQ-3 may be able to categorise the degree of medicines 
burden, allocating individuals to the category which they perceive themselves to be 
 ‘ƌŝŐŚƚ ?ŵĂǇďĞŵŽƌĞƉƌŽďůĞŵĂƚŝĐ ? KŶĞŽĨƚŚĞƉĞĐƵůŝĂƌĨŝŶĚŝŶŐƐŝƐƚŚĂƚƉĞŽƉůĞ ?Ɛ
perceptions of medicine burden may not necessarily align well with their experiences 
of medicine burden, when different aspects of medicine use are taken into 
consideration using the LMQ-3 composite score. For instance, a few participants ? 
composite scores reĨůĞĐƚĞĚ ‘ŚŝŐŚ ?ŵĞĚŝĐŝŶĞďƵƌĚĞŶ ?ĂŶĚǇĞƚƚŚĞǇdid not perceive their 
medicines as burdensome (as indicated by low VAS rating) when asked directly using 
one question  ‘ŽǀĞƌĂůůŚŽǁŵƵĐŚŽĨĂďƵƌĚĞŶĚŽǇŽƵĨĞĞůǇŽƵƌŵĞĚŝĐŝŶĞƐĂƌĞƚŽǇŽƵ ? ?
The latter finding may reflect a range of issues, including necessity beliefs about 
medicines.110,112 In addition, evaluation or appraisal of medicines often involves 
weighing risks against benefits of using medicines,17,108,109 and many participants may 
appreciate the prevention of disease, symptom control, and reduction in mortality, 
which they set against actual burden. Thus, medicines are not necessarily viewed as a 
 ‘ďƵƌĚĞŶ ?ĂŵŽŶŐsome participants on long-term prescription medicines, but rather a 
 ‘ŶĞĐĞƐƐŝƚǇ ?ƚŽŐĞƚƚŚƌŽƵgh life.  
 
The findings also indicate that one general question may not accurately assess the 
overall experience of medicine use and thus confirms the advantage of using the LMQ-
3 composite score that uses multiple item scores when quantifying the level of 
medicine burden. However, the study also showed that perceptions of medicine 






To examine the questiŽŶŶĂŝƌĞ ?ƐŬŶŽǁŶ-groups validity, sub-group analyses were tested 
for different treatment-related characteristics. The LMQ-3 questionnaire was able to 
discriminate between participants using different formulations, number of medicines, 
and frequency of administrations. Particularly, higher burden scores were obtained 
among those using combination of formulations (both oral and non-oral types), five or 
more medicines, and among those using medicines more frequently (i.e. four or more 
times daily). These findings are related to regimen complexity, which affects 
adherence.261,262  
 
There is limited literature investigating treatment characteristics associated with 
medicine burden. Sawicki et al suggests that burden relates to  ‘ŶƵŵďĞƌŽĨƚŚĞƌĂƉŝĞƐ
required on a daily basis, the frequency of such therapies, the complexity of 
administering therapieƐ ?ĂŶĚƚŚĞĂŵŽƵŶƚŽĨƚŝŵĞŶĞĞĚĞĚƚŽĐŽŵƉůĞƚĞĂƚŚĞƌĂƉǇ ? ?260  
The latter was not investigated in this study, and future studies using the LMQ-3 may 
incorporate patient estimates of the time needed to use or plan medicines on a regular 
basis as a possible indicator of medicine burden.  
 
 In the US, Vijan et al found higher perceived burden among diabetic patients using a 
combination of parenteral (e.g. insulin injections) and oral  medicines when compared 
to those using oral agents alone.259 Similar finding were reported by Sawicki et al who 
also found that using more types of nebulized, inhaled, and oral medications were all 
associated with higher treatment burden.260 Vijan also reported treatment burden 
ƌĂƚŝŶŐƐƚŽŝŶĐƌĞĂƐĞŝŶĂ ‘ĨĂŝƌůǇůŝŶĞĂƌƉĂƚƚĞƌŶďĂƐĞĚŽŶŝŶĐƌĞĂƐŝŶŐĨƌĞƋƵĞŶĐǇŽĨ
ĂĚŵŝŶŝƐƚƌĂƚŝŽŶ ? ?259 The present study found that medicine burden scores generally 
increased with frequent use of medicines per day. 
 
The number of medicines was associated with higher medicine burden scores, 
although this finding was inconclusive when examining the combined effects of 
multiple explanatory variables in the regression analyses; the number of medicines 
used was a not a statistically significant predictor of negative experiences when all 
other factors were included in the multiple regression model. In a recent 
conceptualisation of medicine-related burden, Mohammed and colleagues also 




number of medicines used.88 The authors suggest that people using the same number 
of medicines may have different levels of medicine burden, as they could struggle with 
different aspects of medicine burden; a finding clarified by the qualitative data. 
Illustratively, Zarowitz (2011) ŶŽƚĞĚƚŚĂƚ ‘Ĩor some patients, one medication may be 
too much, and for others, 15 medications may be too fĞǁ ?,8  while Cadogan and 
colleagues questioŶ ‘ǁŚĞŶŵĂŶǇŝƐŶŽƚƚŽŽŵany ?ŝŶƚŚĞŝƌƌĞĐĞŶƚŽƉŝŶŝŽŶƉĂƉĞƌŽŶ
polypharmacy.16 
 
In terms of demographic characteristics, medicine burden was not statistically related 
to gender, education levels, or ethnicity, although qualitative data indicated more 
females reporting negative experiences. One study investigating treatment burden 
among adult patients with cystic fibrosis in the US reported statistically significant 
gender differences whereby females had higher treatment burden scores than males; 
however, no significant differences were found in terms of age.260 The present study, 
on the contrary, found that, compared to younger participants (<65 years), those aged 
65 years or older tended to report lower medicine burden. This may be explained by a 
tendency to report positive experiences (higher satisfaction) in this age group, possibly 
due to lower expectations of care in this group,106 and greater acceptance of need for 
and gratitude for medicines in older people. 
 Unemployed participants, including those self-reporting to be homebound and unable 
to work due to illness or other reasons, had worse medicine use experiences when 
compared to those employed or retired, and this may be due to cost-related burden. 
In addition, living in an area of higher level of relative deprivation was significantly 
associated with poor experiences of medicine use. People of low socioeconomic status 
may experience challenges with medicine use, as it affects access to healthcare, 
including obtaining prescription medicines.    
Those in need of social support to manage their medicines were also found to report 
higher medicine burden compared to those managing independently. In fact, needing 
help/support with managing medicines was a statistically significant predictor of 






Implications for research and practice 
Now that we know the prevalence and levels of medicine burden, as well as 
treatment-related or demographic characteristics associated with higher medicine 
burden, future research or practice may target those affected. Individuals identified as 
 ‘ŚŝŐŚďƵƌĚĞŶ ?could be targeted for medicine use reviews or other medicine-related 
intervention/services to plan ways of reducing the burden among of those using long-
term medicines. 
 
Prescribers and suppliers of long-term medicines should consider medicine-related 
burden, and further studies may engage providers to investigate their understanding 
and perception of medicine burden, as a step towards engaging in meaningful 
conversations with patients about their medicines. Providers should be made aware of 
the potential burden of treatments for long-term conditions, as this may be an initial 
step to discussing issues affecting some people.  
 
Communication gaps between people on long-term medicines and HCPs may also be 
addressed. Huang (2008) suggests that ´actively acknowledging the burden of life with 
treatments early on in the disease; and anticipating the psychological distress that 
pĞŽƉůĞŵĂǇĞǆƉĞƌŝĞŶĐĞŽǀĞƌƚŝŵĞ ?could prove beneficial for patient-centred 
communication.263 Again, patient education not only about the effects of disease but 
also about the effects and demands of treatments may be beneficial in managing 
expectations, reducing psychological burden,263 and improving experiences of long-
term use of medicines.  
 
Where possible, and clinically justifiable, simplifying/modifying medicine regimens 
could reduce the burden.263 Pharmaceutical companies and related research could 
develop and test formulations that are less burdensome e.g. those with lower 
frequency of administration. Evaluation of medicine burden as an outcome when 
developing new medicine agents may be incorporated in medicines development 
guidance, particularly for long-term medicines.263  
 
 For patient populations that are particularly at risk of adverse effects of medicines, 




reviewing clinical targets to less intense treatments, may be beneficial.263 If warranted, 
and if part of patient preferences, wants or wishes, medicine use review to uncover 
unnecessary medicines may help in discontinuing/deprescribing as this could 
potentially reduce medicine burden. As recommended by Vijan et al (2005),  ‘ƚreatment 
burden [and medicine burden may] be explicitly considered when making clinical and 
ƉŽůŝĐǇĚĞĐŝƐŝŽŶƐĂďŽƵƚƚŚĞŵĂŶĂŐĞŵĞŶƚŽĨĐŚƌŽŶŝĐĚŝƐĞĂƐĞƐ ? ?259 
 
Where modifications to regimens or cessation is not possible, reassuring individuals 
ƚŚĂƚƚŚĞǇĐĂŶĂĚĂƉƚƚŽůŝǀŝŶŐǁŝƚŚŵĞĚŝĐŝŶĞƐĂŶĚ ?ŽƌĚŝƐĐŽƵƌĂŐŝŶŐ ‘ĨĞĂƌƐ ?ŽĨŵĞĚŝĐŝŶĞƐ
may prove useful.259 Coping strategies could include focussing on the positive effects 
of using medicines (e.g. having control over their disease/condition and preventing 
long-term complications),263 and seeking social support.221  
 
Study strengths & limitations 
This study employed secondary data to address new research questions, and further 
studies may be needed to attempt to cross-validate the current findings using primary 
data.  
While the two datasets used were adequate, in terms of sample size and content 
coverage of variables used in all analyses, it is worth noting that the two questionnaire 
versions employed in this study (LMQ-2.1 and LMQ-3) were administered through 
different methods (on-line versus face-to-face recruitment respectively). Although 
they shared a vast proportion of items and demographic questions, on which all 
analyses were based, it is uncertain that the differing number of items in the data 
collection instruments did not affect the results. The use of combined datasets is 
increasingly popular in clinical research. This is evident in studies such as meta-
analyses where information from individual studies is pooled from several sources to 
derive findings that are more conclusive. Nevertheless, challenges such as missing 
data, between-practice variations, and other methodological differences in the way 
data are collected may affect the results. Efforts were made to examine and minimise 
potential heterogeneity across the two datasets, including reconciling items across the 





It was difficult to assess the impact of using multiple recruitment sites (general 
practices, hospital outpatient areas, community pharmacies, and the general public) 
on the response patterns, but it is likely that using multiple sources of data enhances 
generalisability and reliability of findings reported in Chapter 9. Moreover, using the 
LMQ across various settings also serves as a preliminary test of acceptability of the 
instrument in these settings, and employing paper- and electronic distribution of the 
measure considered alternative methods by which patients may report medicine use 
issues. Nonetheless, the sample populations comprised mostly females partly because 
relatively more women than men use prescription medicines in England.31  
 
Also, multiple linear regressions were conducted using one sample dataset, (the final 
LMQ-3 or regional sample), despite relatively larger sample for National-level data 
(gathered using an interim questionnaire) that covered the views of those in wider 
geographical area. The national survey was accessed across the UK, and it is likely that 
cost-related items were irrelevant to people living in Scotland owing to different 
schemes for paying (or not) for prescriptions.  
 
Methods for determining optimal cut-off scores, reflecting appropriate classifications 
of individual levels of an attribute (e.g. level of burden), for clinical and psychological 
scales, are wide ranging.118,255 Future studies may use the Receiver Operating 
Characteristic (ROC) analysis to confirm the sensitivity and specificity of LMQ-3 cut-off 
scores for the categories of medicine burden, ŽŶĐĞĂ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?ĐŽŵƉĂƌĂƚŽƌ












9.5 Chapter summary 
This study determined the prevalence of medicine-related difficulties, defined levels of 
medicine burden based on LMQ composite scores, as well as examined potential 
predictors of medicine burden. Using secondary survey data, the findings showed that 
medicine-related issues assessed using the LMQ are wide ranging, and affect users of 
long-term medicines differently. Although the vast majority report positive 
experiences with different aspects of medicine use, this study found that about 10% of 
the national-level sample population reported high medicine burden. Burden levels 
differed with multiple factors such as employment status, the relative level of 
deprivation in area of residence, needing support with managing medicines, and 
paying for prescriptions. Perceptions of burden significantly influenced the actual 
























Chapter 10 General discussion 
10.1 General introduction 
/ŶƚŽĚĂǇ ?ƐŚĞĂůƚŚƐǇƐƚĞŵƐ ?ŝŶĐůƵĚŝŶŐƚŚĞŶŐůŝƐŚEĂƚŝŽŶĂů,ĞĂůƚŚ^ĞƌǀŝĐĞ ?E,^ ) ?ŝƚŝƐ
ŝŶĐƌĞĂƐŝŶŐůǇĚĞƐŝƌĂďůĞƚŽƵŶĚĞƌƐƚĂŶĚĂŶĚŵŽŶŝƚŽƌƉĂƚŝĞŶƚƐ ?experiences, in order to 
enhance the quality of their care.75,234 Monitoring experiences of medicines use is a 
priority since prescription medicines are the most common healthcare intervention.1 
Given the growing numbers of people using long-term medicines for multiple chronic 
conditions, thus having to deal with the additional burden of polypharmacy, the need 
to not only understand but also to measure this burden is urgent. This is evidenced by 
recent policy and research funding initiatives by the National Institute for Health 
Research (NIHR) to establish useful ways of measuring and addressing the problem of 
inappropriate polypharmacy in the UK.4,264  
Patient reported experience measures (PREMs), and patient-reported outcome 
measures (PROMs), provide a means for exploring, understanding and reporting 
personal experiences and outcomes of healthcare interventions respectively.234 As 
described in Chapters 1 and 2, the medicine use experience is multifactorial including 
patient-related factors (e.g. type and severity of disease condition(s)), medicine-
related factors (e.g. formulation, cost, regimen complexity, effectiveness) and health-
system-related factors (e.g. access to medicines and health-provider communication).  
ƐĚŝƌĞĐƚĂƐƐĞƐƐŵĞŶƚƐ ?WZDƐĂŶĚWZKDƐĐĂŶ ‘ŚĞůƉƉĂƚŝĞŶƚƐ ŽũƵĚŐĞŚŽǁƚŚĞǇĨĞĞů
about their own experiences and outcomes of care, including the benefits and risks of 
ƚƌĞĂƚŵĞŶƚ ? ?231 when compared to clinician-driven measures that tend to focus on 
 ‘ƉƌĞƐĐƌŝďĞƌ-ĚĞĨŝŶĞĚŽƵƚĐŽŵĞƐ ?231 (e.g. inappropriate prescribing and drug-related 
problems,19 and adherence265). The literature review revealed the dominance of 
measures of satisfaction with treatments.108,109,129,130 In addition, there are tools to 
assess patient satisfaction with pharmacy services,266 including the Community 
Pharmacy Patient Questionnaire (CPPQ) that is mandatory across England and 
Wales.267 Measures such as the CPPQ, currently used to gather patient feedback, are 
designed to improve organisational efficiency and enable compliance with clinical 
governance requirements, therefore focus on process and structural indicators (such 




It is well documented that satisfaction measures are prone to acquiescence bias 
(tendency to give positive responses),268 and patients are unlikely to be open about 
negative medicine use experiences through satisfaction tools.  
Other tools to obtain information on actual use of medicines have neither been 
standardised nor validated.269 Tools to assess medicines management ability,270,271 as 
one aspect of the medicine use experience, are also common, but most require health 
professional assistance to assess issues such identification of medicines, or ability to 
read and follow written instructions, and thus are not direct assessments from 
patients. Moreover, no gold-standard measure of medicine management ability exists 
to date.271 Existing tools assessing treatment burden or medicine use experiences 
consist of disease-specific measures, mainly in diabetes,120 but also specific medicines, 
such as inhalers for asthma,272 parenteral iron-chelation used for managing blood 
disorders,240 and antipsychotics.273 As already noted in Chapter 1, the increasing 
prevalence of multimorbidity and polypharmacy implies that more patients have to 
cope with multiple, complex treatment regimens and generic measures are potentially 
more relevant and applicable to assessing broader experiences.  
 
The overall aim of this research programme was to identify, develop, and test a generic 
measure of negative experiences (burden) of long-term prescription medicine among 
the adult English population. The Living with Medicines Questionnaire (LMQ) was 
developed and validated as a multifaceted outcome measure for this purpose. This 
thesis presents the LMQ (version 3) as the only available, in-depth, generic measure of 
the burden associated with using medicine-only therapies long-term.  
As already described in previous chapters, a mixed methods approach was used to 
ŝĚĞŶƚŝĨǇ ?ĚĞǀĞůŽƉĂŶĚƚĞƐƚƚŚĞ>DY ?ƐŵĞĂƐƵƌĞŵĞŶƚƉƌŽƉĞƌƚŝĞƐ ?ŝ ?Ğ ?different forms of 
validity and reliability) and its potential applications. Face and content validity, 
ascertaining the meaning and relevance of questionnaire content, was tested in a 
qualitative, cognitive interview study. A series of iterative, cross-sectional, surveys of 
the target sample population (users of long-term prescription medicines for any 
disease/condition) enabled item reduction, from a 60-item originator tool (LMQ-1) to a 
more manageable, 41-item, tool (See Appendix 26 for item tracking). Survey data 




that established the eight domains of medicine burden. Criterion-related validation 
revealed relationships among medicines burden, and other relevant concepts (i.e. 
treatment satisfaction and health-related quality of life measured by the TSQM-II and 
EQ-5D-5L respectively). Forms of reliability (internal consistency and test-retest) were 
also assessed for the LMQ-3, and interpretation of questionnaire scores allowed 
qualitative meanings that clarified levels of medicine burden (as none, minimal, 
moderate, high or extremely high). The next section discusses the overall key findings 
of this research programme. 
 
10.2 Discussion of key findings  
The key finding established from this research programme was that the Living with 
Medicines Questionnaire (LMQ-3) is a generic, comprehensive, valid, reliable, and 
interpretable measure of medicines burden suitable for use among adults using long-
term medicines for any disease/condition (s) in England. As a multidimensional tool, 
the LMQ-3 covers different medicine use issues: interferences with day-to-day life; 
patient-doctor relationships and communication about medicines; lack of 
effectiveness; general concerns; side effects; practical difficulties; cost-related burden, 
and lack of autonomy/control over medicines use. All eight domains were confirmed to 
contribute to prescription medicine burden, an overarching construct underlying the 
LMQ-3. These findings addressed the primary research question of this thesis. 
 
Having proposed a suitable measure, it was worth considering the extent of the 
burden problem in the sampled population and likely causal factors as a secondary, yet 
indispensable, research objective. The present thesis established that about 1 in 10 
patients in England are at risk of high-level medicine burden, a finding that is not 
surprising. This finding indicates that the vast majority of patients do not perceive 
medicines use experiences as burdensome. Qualitative findings (in Chapters 5) 
indicated that some patients do not view their prescription medicines (or their effects) 
ĂƐĂ ‘ďƵƌĚĞŶ ? ?/ŶĂĚĚŝƚŝŽŶ ?ƐƵďŐƌŽƵƉĂŶĂůǇƐĞƐŝŶŚĂƉƚĞƌ ?ĐŽŶĨŝƌŵĞĚƚŚĂƚƉĞŽƉůĞ ?Ɛ
perceptions of medicine burden might not necessarily align well with their experiences 
of medicine burden, self-reported through the LMQ-3 composite score; this may 




There is limited data on actual medicines usage in England. The 2013 Health Survey for 
England estimated that approximately 50% (n= 4398) of all adults used at least one 
prescription medicine based on a sample of 8,795, and 22%-24% had used three or 
more medicines in the week before the survey. Growing polypharmacy, as highlighted 
in Chapter 1, remains a cause for concern. Data from NHS digital, formerly the Health 
and Social Care Information Centre (HSCIC), shows that the average number of 
prescription items dispensed in the community (by community pharmacists, dispensing 
doctors in rural areas, and in general practices) in England per head of the population 
was 19.6 in 2014 compared to 13.7 in 2004.32 Data from prescribing records of 1,777 
patients in general practices in England, in 2012, suggested that 17% were prescribed 
5-9 medicines, and about 10% used ten or more medicines.274 In the present thesis, 
21.6% and 24.2% of participants taking part in a nationwide survey used 5-9 and 10 or 
more medicines, suggesting an upward trend in polypharmacy. Extrapolating these 
data to predict the numbers affected by high levels of prescription medicine burden at 
a population level is not that straightforward. What is clear, however, is that a number 
of people using long-term medicine(s) are overwhelmed by a range of medicine-
related challenges beyond the number of medicines used. 
This thesis confirms that prescription medicine burden is multifactorial, similar to the 
findings of earlier researchers.88,92 Empirical findings depicted multiple factors that 
significantly influence self-reported levels of medicine burden among users of long-
term medicines in the study samples, including socio-demographic characteristics. 
Relatively higher self-reported medicine burden was found among younger adults (age 
< 65 years), the unemployed, and among those living in areas with a higher relative 
level of deprivation.  
Socioeconomic factors are cited to influence medicines use experiences, 48,88,259 thus 
these findings are not surprising. Younger patients (< 65 years) may have higher 
expectations of healthcare,106and less acceptance of the need for medicines when 
compared to older patients (> 65 years), which may translate into higher perceived 
burden. The financial-burden of paying for long-term prescriptions medicines may 
affect some patients, particularly the unemployed or those with lower disposable 
incomes.46,52,224 Residents of areas with a higher level of relative deprivation, 




experience challenges with access to healthcare (e.g. difficulties getting prescriptions, 
GP appointments, and/or pharmacist consultations). This in turn may affect the overall 
medicine use experiences.  
A number of medicine-related factors were significantly associated with higher self-
reported medicine burden. Managing medicines independently was associated with 
lower burden. On the other hand, higher medicine burden was reported among those 
acknowledging assistance or social support with day-to-day practicalities of using 
medicines. Qualitative data revealed spouses/partners or relatives, paid carers, or 
healthcare professionals (e.g. district nurses) as a common source of support. The 
literature review in Chapter 1 highlighted multiple factors that affect patient capacity 
(ability to handle workload demands imposed by healthcare), including social 
support.84 Coping strategies for managing medicine-related demands tend to draw on 
family and health provider networks, aŶĚ ‘ůĂĐŬŽĨor inadequate [social] support can 
ůŝŵŝƚƚŚĞƉĂƚŝĞŶƚƐ ?ĐĂƉĂĐŝƚǇƚŽŵĂŶĂŐĞ ?ĨƵƌƚŚĞƌĞǆĂĐĞƌďĂƚŝŶŐƚŚĞŝƌďƵƌĚĞŶ ? ?88 It is likely 
that excessive medicine burden on the patient, if transferred to carers (e.g. family or 
friends), may cause relational disruptions.95 
Mixed findings were revealed in terms of the number of medicines used versus the 
level of medicine burden reported by individuals. This thesis revealed a unique, albeit 
unexpected, finding that higher medicine burden is not necessarily associated with a 
larger number of medicines used. Some studies have reported positive associations 
between treatment burden and the number of medicines,83,232 and quantitative data in 
this thesis found a similar, but inconclusive, trend. Qualitative data showed that some 
patients using one prescription medicine reported higher levels of medicine burden 
associated with different aspects of medicine use (e.g. impact on social life or 
interferences with day-to-day life), while others using five or more medicines reported 
no or minimal burden. The present thesis confirms that medicine burden goes beyond 
the number of prescription medicines used. This finding is in agreement with a recent 
ƋƵĂůŝƚĂƚŝǀĞƐǇŶƚŚĞƐŝƐĞǆƉůŽƌŝŶŐŵĞĚŝĐŝŶĞďƵƌĚĞŶ ?ǁŚŝĐŚĐŝƚĞĚƚŚĂƚ ‘ƉĂƚŝĞŶƚƐŽŶƚŚĞ
same number of medicines may experience different levels and aspects of MRB 
[medicine-related burden];88 this was established in the subgroup analyses illustrated 
in Chapter 9 (See Figure 9-3). The finding also aligns well with views that polypharmacy 




Higher medicine burden was also associated with more frequent medicine use (e.g. 
four times daily versus once daily) and using a combination of formulations 
(tablets/capsules and non-oral types). Complex medicine regimens can be difficult to 
manage alongside day-to-day life and may aggravate burden. 
Although polypharmacy is mostly defined in terms of the number of medicines 
prescribed and/or their appropriateness, the findings indicate that evaluations of 
medicines use should consider other factors. This is especially important since views of 
appropriateness of medicines differ between patients and health professionals. 
Appropriateness of medicine use in practice is mostly evaluated from the biomedical 
perspective by health professionals who often consider medicine benefits and risks 
stipulated in evidence-based guidelines, and pay little or no attention to the subjective 
experiences discussed in this thesis. Clearly, there is a need to prioritise the patient 
perspective and guidelines or tools that solely rely on the number of medicines as the 
only indicator to screen patients in need of medicines support or review may need to 
be revised. 
Individual beliefs and perceptions towards medicines may also influence the level of 
medicine burden reported, as hypothesised in the theoretical framework in Chapter 1 
(See Figure 1-7). ůƚŚŽƵŐŚƚŚŝƐƚŚĞƐŝƐĚŝĚŶŽƚĞǀĂůƵĂƚĞƉĂƚŝĞŶƚƐ ? beliefs (and concerns) 
about their specific medicines and illness perceptions, it is well documented that they 
influence medicine use.110,112,114 Minimal-to-moderate medicine burden, reported by 
the vast majority of participants, may be associated with stronger beliefs about the 
necessity (and effectiveness), fewer concerns about harms of medicines, and stronger 
perceptions of disease/symptom severity; further work is needed to confirm this. It is 
likely that most patients perceived greater benefits of their regimens (such as 
prevention of mortality) than medicine-related issues evaluated by the LMQ (e.g. 
interferences to day-to-day life, practical difficulties, and communication problems 
with health professionals). Treatment-related decisions by individuals ( e.g. adherence 
or persistence) are influenced by weighted evaluations of benefits versus risks, harms 
and/or inconvenience of medicines use.108,109 If effectiveness is not achieved, 
tolerating side effects or medicine-related discomforts/inconveniences becomes more 




For those that experience significant levels of medication burden, the consequences 
can be wide-ranging. Medicine burden is likely to cause non-adherence, an undesirable 
ďĞŚĂǀŝŽƵƌĨƌŽŵƚŚĞƉƌŽǀŝĚĞƌ ?ƐƉĞƌƐƉĞĐƚŝǀĞ ?&ƌŽŵƚŚĞƉĂƚŝĞŶƚƉĞƌƐƉĞĐƚŝǀĞ ? ‘rationalised 
non-ĂĚŚĞƌĞŶĐĞ ?ŝƐan undisclosed coping strategy and may be a manifestation of 
workload-capacity imbalances among those with intolerable treatment burden.95 Sub-
optimal clinical outcomes (e.g. poor symptom control, disease progression or relapse, 
deterioration of health and quality of life), may arise from any form of non-adherence. 
Besides decreasing health-related quality of life, medicine-related burden may directly 
or indirectly affect other aspects of an individual, including decreased productivity 
associated with time and energy invested in performing healthcare tasks (e.g. in 
seeking doctor appointments, repeat prescriptions and refills ).48  
10.3 Summary of key contributions to knowledge 
The findings presented in this thesis contribute to new knowledge by identifying, 
developing and validating a novel outcome measure of medicine-related burden, the 
LMQ-3. To my knowledge, this is the first research programme to develop and test an 
instrument for this purpose. The tool presented offers a practical and timely means of 
evaluating medicine use challenges, including psychosocial disruptions, which are 
encountered in the day-to-day lives of some users of long-term regimens and yet 
rarely considered in health settings. The need to evaluate medicine burden among 
patients, clearly identified as the rationale for this multiphase research programme, is 
crucial in lieu of the growing polypharmacy, multimorbidity, and subsequent patient 
ĐŽŵƉůĞǆŝƚǇŝŶŶŐůĂŶĚ ?'ŝǀĞŶƚŚĞŝŶĐƌĞĂƐŝŶŐŶĞĞĚƚŽĂƐĞƐƐƉĂƚŝĞŶƚƐ ?ĞǆƉeriences and 
outcomes of healthcare interventions, it was considered worthwhile to develop and 
validate a multidimensional scale for assessing the effects of medicine-only 
interventions.  
Through in-depth review of the literature and critical analyses of existing theories of 
treatment- and medicine-related burden, most of which required further development 
and empirical testing, a collated conceptual framework of prescription medicine 
burden was formulated (See Figure 1-7) and some constituent factors investigated. 
The framework provides insight into likely causative factors and potential 




This research programme confirmed that healthcare system factors, particularly 
patient-provider communication and relationships impact significantly on the 
medication burden reported by an individual.  
Prescription costs also affect access and use of medicines and Chapter 9 showed that 
30% of the on-line national sample population who paid prescription charges had 
concerns about the financial burden of using medicines long-term, which most 
affected unemployed patients that were not exempt from prescription charges. 
According to the 2015 report by NHS digital (formerly HSCIC), 9.4% of prescriptions 
were 'charged at the ƉŽŝŶƚŽĨĚŝƐƉĞŶƐŝŶŐ ?ŝŶ ? ? ? ? ?32 although this finding was based on 
prescription records and the proportion of people who self-report paying prescription 
charges may vary. In this research programme, 10% of the test-retest sample (n=30), 
recruited via an on-line public panel in Kent, paid the prescription charge while 33% of 
the criterion validation sample (n=408), recruited face-to-face in community 
pharmacies, GP practices and outpatient clinics in Kent, made the co-payment. The 
figures reported may reflect, partly, the sample demographics and methods of data 
collection, and further studies are needed to ascertain the actual number of people 
who pay to obtain their long-term prescription medicines in England as a step towards 
identifying those affected by medicine costs. 
In terms of medicine characteristics, regimen complexity was established as a 
predictor of medicine burden especially among those using medicines four or more 
times daily. The LMQ-3 instrument can identify patients with practical difficulties, 
including those related to administering medicines, as well as patients concerned 
about formulations (and brands). Issues around lack of effectiveness are also covered 
in the measure as hypothesised in the conceptual framework (Figure 1-7).  
Psychological concerns about long-term harm (and dependency) are covered in the 
final measure, and perceptions of burden were found to predict negative experiences 
of long-term medicines use. Satisfaction with treatments was negatively associated 
with medicine burden as hypothesised in the conceptual framework. Future work may 
test the impact of resilience or use of different coping strategies to manage burden, 
perceived locus of control and self-efficacy beliefs on individual levels of burden. These 
factors were hypothesised in the initial framework to affect medicine burden but 




Individual characteristics established to significantly predict medicine burden levels 
were age, employment status, and residence in areas with higher deprivation levels, 
suggesting that people who are under 65 years of age, unemployed or residents in 
more deprived areas may be at risk of higher medicine burden and could be included 
in future targeted interventions. Needing social support, in the form of help with 
managing medicine use, was established as a predictor of medicine burden as 
hypothesised a priori. Future work may empirically test the hypothesised 
consequences of medicine burden, particularly non-adherence and how burden 
impacts on other patient outcomes. The present research programme established a 
negative association between medicine burden and HRQOL and targeted interventions 
may minimise the impact of medicine burden on physical, emotional and social 
functioning. 
Incorporating the first reported systematic review of generic, patient-reported, 
measures of different aspects of the medicine use experience (see Chapter 2), which 
was published in the journal of Patient Related Outcome Measures,231 this thesis 
provides a starting point for researchers and/or clinicians who need to select suitable 
outcome measures for use in designing, planning and implementing other healthcare 
interventions. The systematic review also confirmed that medicine use experiences are 
wide-ranging and complex, and that no single instrument, to-date,  covers all issues 
affecting users of long-term prescription medicines.231   
Although the original 60-item Living with Medicines Questionnaire, developed by Krska 
and colleagues,119 was initially reported as a suitable measure of medicine burden, 
further investigations and empirical tests revealed that it required extensive 
modifications (including additions to content coverage) and further testing. These 
modifications were reported in Chapter 5 and the resulting interim questionnaire, the 
LMQ-2, is also published in the journal of Patient Preference and Adherence.193 As a 
novel contribution, the proposed final instrument, the LMQ-3, encompasses more 
diverse and relevant patient-generated domains presented in the form of 41 
comprehensible and psychometrically sound statements/items.  
The proposed tool (LMQ-3), unlike most instruments encountered in the literature, is 
patient-focused both in content and intended purpose. The LMQ-3 is grounded in 




item generation, modification, and testing. It also includes a free-text response box to 
enable clarifications of challenging experiences. 
The burden of medicines on individual patients and at population level has not been 
previously quantified, and this thesis presents an initial attempt to do so. Earlier 
discussions of key findings (see section 10.2) revealed that about 10% of adults using 
long-term prescription medicines in England are prone to high-level medicine burden. 
This preliminary estimate of the prevalence of medicine burden, though it demands 
further cross-validation studies, provides new evidence that may inform planning and 
designing of national-level, targeted, interventions to identify and support those most 
affected.  
The next sections discuss potential implications for future research, clinical practice, 
and policy before acknowledging potential strengths and limitations of the present 
thesis.  
10.4 Implications for research  
As a generic tool, the LMQ-3 was designed to evaluate user experiences for different 
medicine classes used in variable chronic conditions. Further comparative research 
may test suitability of the tool in assessing treatment-specific experiences in particular 
patient cohorts (e.g. those with diabetes, asthma, epilepsy). For researchers wishing to 
develop a disease-specific version of the LMQ-3, it would enable further understanding 
of unique medicine-related challenges faced by patients with similar long-term 
conditions. Such studies would enable an understanding of the contextual relevance 
and sensitivity of the LMQ-3 in assessing issues specific to certain patient groups and 
determine if some of the items (questions) are more relevant (or not) to those using 
certain classes of medicines. 
The LMQ-3 was designed as a self-reported tool for completion by patients. Collecting 
patient-reported data from all patients may not always be feasible, as some conditions 
(e.g. cognitive difficulties like in ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ?ĚĞǆƚĞƌŝƚǇƉƌŽďůĞŵƐŝŶWĂƌŬŝŶƐŽŶ ?Ɛ
disease) may affect reliability and accuracy of self-reports.275,276 Data collection by 
ƉƌŽǆǇ ?ŽŶƚŚĞƉĂƚŝĞŶƚ ?s behalf) may enhance wider application of the LMQ-3, and 
support evaluation of challenging medicine-related experiences of those unable to 




of patients who do not manage their own medicines. As healthcare proxies,276 carers 
would enable identification of unique issues and ƉĂƚŝĞŶƚƐ ?ĚŝĨĨŝĐƵůƚŝĞƐamong, for 
instance the disabled or housebound, and allow them to identify areas of support. 
Nonetheless, the use of proxy measures may under or overestimate the experienced 
burden, as only the patient knows how he or she actually feels;276,277 assistance in 
completion of the questionnaire could offer an alternative means to proxy 
administration.277  
The LMQ-3 could be tested for completion via different modes (e.g. telephone) beyond 
the existing written (text) format. Such an application would support capturing of 
medicine use experiences for people with reading/writing difficulties.  
Increasingly, more people have access to the Internet and portable devices (e.g. 
tablets, iPads, and smart phones). Technological adaptations of the LMQ-3, for 
instance through user-ĨƌŝĞŶĚůǇ ‘ĂƉƉƐ ?ƚŽŚŽƵƐĞ and access the tool may offer an 
additional means of reporting to those who prefer electronic/digital media over paper-
based administration. Such electronic data may not only enhance self-monitoring of 
challenging experiences in everyday settings but could also be easily shared with 
authorised health professionals to offer targeted support.  
The predominant cross-sectional study designs (surveys) may not have allowed for 
accurate modelling of causative relationships among concepts of medicine burden 
explored in this thesis. Future research may investigate longitudinal validity of the 
LMQ-3 to confirm sensitivity to change and/or responsiveness (i.e. ability to detect any 
amount of change after an intervention118), as a relevant measurement property. A 
recent systematic review and meta-analysis establŝƐŚĞĚƚŚĂƚ ‘ĞǆŝƐƚŝng measures [of 
health-related quality of life] may have minimal to moderate sensitivity to 
pharmaceutical care ŝŶƚĞƌǀĞŶƚŝŽŶƐ ? ?ĂŶĚ ‘ŵĂǇŶŽƚďĞƐĞŶƐŝƚŝǀĞĞŶŽƵŐŚƚŽĞǀĂůƵĂƚĞƚŚĞ
ďƵƌĚĞŶŽĨŵĞĚŝĐŝŶĞƐ ? ?241 Ascertaining sensitivity properties of the LMQ-3 would enable 
assessments of reductions (or increments) in medicine burden following targeted 
pharmaceutical care interventions. With such data, the LMQ-3 may be used in 
monitoring patients affected by high medicine burden over time or support its use as 
an outcome measure in clinical trials evaluating the impacts of new medicines or 
formulations. The LMQ-3 could also be trialled to assess the effects of medicine 




Cross-cultural adaptations of the LMQ-3, for instance the recent translation for Arabic-
speaking countries,278 ŵĂǇƐƵƉƉŽƌƚƚŚĞƚŽŽů ?ƐƵƐĂďŝůŝƚǇŝŶĚŝĨĨĞƌĞŶƚƌĞƐĞĂƌĐŚŽƌĐůŝŶŝĐĂů
practice settings.  At the time of writing this thesis, the LMQ-3 was being used in 
different medicine-related interventions internationally (in Belgium, Slovenia and 
Qatar) and such data may aid further improvements in the tool. Further validation 
work on the LMQ-3 may also obtain views, particularly from healthcare professionals, 
on how best to use it in practice.  
As a relatively comprehensive tool encompassing a wide-range of relevant issues, 
shortening the LMQ-3 instrument, without greatly losing its content, presents another 
challenge. Classical test theory (CTT) was adopted in this research programme as a 
predominant measurement framework recommended in health services research,179 
and alternative analytical frameworks, particularly item response theory or  
Rasch analysis could be employed in future studies to formulate a shorter, more 
precise instrument. This analytical approach alongside new qualitative data from 
different users of long-term medicines may help in selecting the  ‘ďĞƐƚ ?ĂŶĚ ‘ŵŽƐƚ
ƌĞůĞǀĂŶƚ ?ŝƚĞŵƐ ?,ŽǁĞǀĞƌ ?Ĩuture item-reduction may attempt to balance adequate 
content coverage with practical usability/feasibility in clinical practice, while 
minimising respondent burden. 
10.5 Implications for clinical practice 
ǀĂůƵĂƚŝŽŶŽĨƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨĐĂƌĞŝƐŝŶĐƌĞĂƐŝŶŐůǇƉƌŽŵŽƚĞĚǁŝƚŚŝŶƚŚĞE,^ŝŶ
England,234,275 and suitable tools are desirable. With an estimated 10%  prevalence pf 
high-level medicine burden in the English population, and more people likely to be at 
risk owing to a growing population, health systems need to be aware that medicine 
use can present challenging experiences for many individuals. As already reported, 
insufficient up-to-date data on actual medicine usage in England may not allow 
accurate projections of the magnitude of the burden problem. However, it is clear that 
a substantial proportion of patients have real, day-to-day, medicine-related challenges.  
With demographic variations in patient reporting (e.g. with age), and likely fears of 
reporting negative experiences to prevent any consequences (such as changes to 
medications, including cessation), health professionals need to take a proactive 




need to be encouraged to share their day-to-day experiences of medicine-use during 
consultations with health professionals, but this may be constrained in busy practice 
settings. This will be discussed further in Section 10.6 under policy implications. 
A key implication for clinical practice relates to health professional awareness of the 
challenges of long-term prescription medicine use for individuals beyond side effects 
and efficacy-related problems. Not all health professionals may appreciate that 
prescription medicines use can be burdensome to some individuals with long-term 
conditions. It is well-known that patienƚƐ ?ĞǀĂůƵĂƚŝŽŶƐof prescription medicines use 
experiences differ from those of health professionals.17,18 Several studies show that 
patients are more concerned about their experiences of medicines, long-term impact, 
and juggling medicine use with day-to-day life than health professionals.18,23,81  
dŚĞůĂƚƚĞƌĂƌĞƌĞƉŽƌƚĞĚĂƐŵŽƌĞĐŽŶĐĞƌŶĞĚĂďŽƵƚ ‘ƉƌĞƐĐƌŝďŝŶŐƉƌŽďůĞŵƐ ?ĞǀŝĚĞŶĐĞ-
based gƵŝĚĞůŝŶĞƐ ?ĂŶĚ QĐŚĂůůĞŶŐĞ ?Ɛ ?ŽĨĐŽŵƉůĞǆĚĞĐŝƐŝŽŶ-ŵĂŬŝŶŐ ? ?ŝŶĐůƵĚŝŶŐ
deprescribing.18,279 Moreover the literature shows that health professionals tend to 
focus on biomedical problems and strict adherence to therapies, while giving less 
consideration to psychosocial and everyday issues that may affect patients.37,78,101 This 
ŝŵƉůŝĞƐƚŚĂƚĞǀĂůƵĂƚŝŽŶƐŽĨƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐ ?ĂŶĚŵĞdicine burden) in clinical 
practice presents a new challenge; what may be viewed as a problem for the patient 
may not be perceived as a problem to the health professional. Subsequently, it is 
extremely important that health professionals are made aware of the potential burden 
of long-ƚĞƌŵŵĞĚŝĐŝŶĞƐŽŶƉĂƚŝĞŶƚƐ ?ůŝǀĞƐďĞǇŽŶĚǁŚĂƚƚŚĞǇŚĞĂƌin brief patient-
consultations. Increased awareness may be an initial step to having meaningful 
discussions with affected patients or those at risk of high medicine burden.  
For prescribers and/or pharmacists, knowledge of correlates and consequences of 
medicine burden may also enable selection of medicine regimes (and convenient 
formulations) that are least burdensome to patients, for instance by prescribing 
regimes with manageable dosing frequencies and dosage units per day. Such changes 
in prescribing patterns may not only minimise patient workload of using complex 
medicine regimes, but may also, in the long-term, trigger pharmaceutical companies to 




Where changes in formulations are not possible, providing information (and 
reassurance) about how patients can adapt medicine regimes to their day-to-day 
schedules could empower them to cope with potential disruptions associated with 
regular medicine use, for instance by building confidence, resilience, and/or acquiring 
practical skills and resources to minimise medicine-related challenges.  
The LMQ-3 could be adapted for use before or during medicine use reviews in 
community pharmacies in England or other medicine-related support services. Patients 
could, for instance, complete the questionnaire prior to appointments for reviews with 
pharmacists, and self-reports used to kick-start conversations and/or aid in-depth 
discussions about different challenges with medicine use and means to alleviate these. 
Pharmacists could keep track of burden levels reported by individuals, and monitor any 
fluctuations as a result of changes to prescriptions or to individual circumstances 
including physical/mental health, social/family life and social economic status. Such 
data may not only support person-centred pharmacy practice, but also could help in 
the development of health interventions to support long-term medicine use. A shorter 
form of the LMQ-3 may support such evaluations of the medicine use experiences in 
busy pharmacy settings. Further work involving pharmacists may be required to 
inform/support the uptake of the LMQ-3 in community pharmacy practice. 
 
For patients, most importantly, the LMQ-3 tool could help them in pinpointing 
potentially problematic areas, and in seeking individualised support to address specific 
medicine-related challenges. For instance, those experiencing problems with access to 
prescriptions or medicines could ask for repeat dispensing via electronic prescriptions 
sent directly to community pharmacies and/or home delivery of their medicines. 
Patients with practical difficulties could ask for pre-packaged pill organisers, and those 
with psychosocial concerns may seek reassurance from skilled health providers or 
other social support (from family, friends, or peer support groups).  
The LMQ- ?ĐŽƵůĚďĞƵƐĞĚ ?ŝŶƉƌĂĐƚŝĐĞ ?ƚŽŬĞĞƉƚƌĂĐŬŽĨŝŶĚŝǀŝĚƵĂůƐ ?ĂĐĐŽƵŶƚƐŽĨ
medicine burden as this may help inform future targeted interventions. Follow-up of 
patients at risk or those experiencing high medicine burden could be done at 





ďƵƌĚĞŶ ?ĐŽƵůĚďĞƚĂƌŐĞƚĞĚĨŽƌĂĚĚŝƚŝŽŶĂůŵĞĚŝĐŝŶĞ-related support in suitable 
interventions/services designed to reduce medication burden. 
10.6 Implications for policy 
Although health policies and NHS England are increasingly emphasising patient-
centred care and improving outcomes and quality of life for people with long-term 
conditions,57,74,75,79 they offer limited guidance on appropriate tools to evaluate service 
user experiences of healthcare interventions. The routine use of patient-reported 
measures has been recommended since 2009, but only to assess outcomes of elective 
surgical procedures.234 Recent evidence suggests challenges of using PROMS to 
monitor outcomes of managing long-term conditions in primary care practices in 
England, owing to complexity and diversity of interventions, and limited patient 
engagement manifesting in low response rates.275  
The medicines optimisation agenda in England, which is also supported by NHS 
ŶŐůĂŶĚ ?ĞŵƉŚĂƐŝƐĞƐĂŶƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞƉĂƚŝĞŶƚ ?ƐĞǆƉĞƌŝĞŶĐĞƐ ?ĂƐƚŚĞƉƌŝŵĂƌǇ
tenet, but does not clarify how to measure or monitor these in practice. NICE policy 
guidelines, on the other hand, encourage discussions with patients and consideration 
of their values and preferences in health professional decision-making, but a 
biomedical evidence-based approach to prescribing is still dominant in practice with 
little or no consideration of psychosocial or day-to-day aspects of medicine use in 
prescribing decisions.  
National inclusion criteria for patients targeted for medicine use reviews and support 
are mostly disease-oriented, for instance cover respiratory conditions and patients 
with or at risk of cardiovascular disease.280 Other criteria consider quantitative cut-offs 
(e.g.  prescription of at least four medicines),280 ĂŶĚǇĞƚĂĐŬŶŽǁůĞĚŐŝŶŐƚŚĂƚ ‘ ? ?ƚŚĞ
ŶƵŵďĞƌŽĨŵĞĚŝĐŝŶĞƐ QŵĂǇŶŽƚďĞƚŚĞŽŶůǇĨĂĐƚŽƌƚŽĐŽŶƐŝĚĞƌǁŚĞŶƌĞǀŝĞǁŝŶŐ ?ƚŚĞ
ŝŵƉĂĐƚŽĨ ?ƉŽůǇƉŚĂƌŵĂĐǇ ? ?57 The latter is emphasised and supported by the findings of 
this thesis, and points to the need for a holistic approach in evaluating and monitoring 
ƉĂƚŝĞŶƚƐ ?ĞǆƉeriences of medicine therapies. Nonetheless, the lack of suitable patient-
centred tools to support these evaluations is also a challenge. Again, the NICE 
guidelines57 recommend tools such as the START/ STOPP, but these are mostly 




inappropriate medicines, drug interactions, ADRs) and offer guidance on deprescribing. 
There is a need to consider patiĞŶƚƐ ?ƐƵďũĞĐƚŝǀĞĞǆƉĞƌŝĞŶĐĞƐŝŶƐĐƌĞĞŶŝŶŐĂůŐŽƌŝƚŚŵƐĨŽƌ
medicine-related support services (such as the targeted MURs), and to trial patient-
reported tools (such as the LMQ-3) in this process. This may support the person-
centred agendas set out in the aforementioned policy documents, and contribute to 
improvements in patientƐ ?ŽǀĞƌĂůůĞǆƉĞƌŝĞŶĐĞƐŽĨĐĂƌĞ ? 
Patient-provider communication about medicines emerged as a significant factor 
associated with medicine burden. With an increasing drive to provide more self-
management services (e.g. smoking cessation, diet and exercise) to a growing 
population, time constraints, more so to discuss medicine-only issues, are a real 
ĐŚĂůůĞŶŐĞŝŶƚŽĚĂǇ ?ƐĐůŝŶŝĐĂůƐĞƚƚŝŶŐƐ ?WŽůŝĐǇŵĂŬĞƌƐĂŶĚ ?ŽƌƉƌĂĐƚŝĐĞŵĂŶĂŐĞƌƐŵĂǇ
review consultation times and allocate resources to enable in-depth patient-provider 
discussions of medicine use experiences to minimise medicine burden. There is some 
evidence that lengthening patient consultation time may indirectly contribute to 
better clinical outcomes and cost-savings for the health system.281,282 Potential long-
term benefits of curbing medicine burden (e.g. better adherence, fewer drug-related 
problems and hospitalisation) could counteract the costs associated with longer 
consultations; further empirical work, however, needs to confirm these potential 
benefits. 
The burden associated with accessing regular prescriptions from the doctor, organising 
refills from community pharmacies, amidst usual day-to-day responsibilities (such as 
work, school), usually every 28 days, can affect some individuals. For patients on 
stable, life-time, medicines, this burden may be lessened through longer prescribing 
intervals and repeat dispensing in community pharmacies, which allows patients to 
ŽďƚĂŝŶƌĞŐƵůĂƌƉƌĞƐĐƌŝƉƚŝŽŶŵĞĚŝĐŝŶĞƐ ‘without a face-to-face consultation with the 
prescriber ĂƚĞĂĐŚŝƐƐƵĞ ‘ ?283 Although this may be convenient, minimising time and 
travel demands and financial burden for patients who pay for their prescriptions, 
ƌĞƉĞĂƚĚŝƐƉĞŶƐŝŶŐĐŽƵůĚůĞĂĚƚŽ ‘ ? ?ĂŵŝƐƐĞĚŽƉƉŽƌƚƵŶŝƚǇfor identifying medicines-
related issueƐďĞĨŽƌĞƚŚĞǇďĞĐŽŵĞƉƌŽďůĞŵƐ ? ?283 Regular medicine reviews or 
communication may help to follow up patients with repeat prescriptions, particularly 




Reviewing of policies for prescription charges in England, for instance to include 
exemptions for people with all life-threatening, long-term, conditions (such as asthma) 
and those living in areas with high deprivation levels, may enhance access to medicines 
and prevent cost-related burden on individual patients. 
10.7 Overall strengths and limitations  
The standard methodological approach used in this complex, iterative, multi-phase 
research programme of instrument development and validation, discussed in-depth in 
Chapter 3, is a key strength. The literature review (in Chapter 2) highlighted 
inconsistencies in methods of development (and minimal or no patient involvement) 
among some tools purporting to measure medicine-related experiences of patients.  
This thesis adhered to standard guidance on the development of patient-reported 
outcome measures122,124,154 It achieved this, firstly, by involving the target population 
using long-term prescription medicines (for any disease/condition) at all stages of 
instrument development and validation of the LMQ-3. The concepts underlying 
medicine burden were generated and tested by patients, thus supporting the LMQ-3 
as a patient-centred tool.  
Secondly, the LMQ-3 underwent rigorous validation processes using a mixture of 
qualitative and quantitative methodology. Different recruitment techniques (face-to-
face and on-line) were used to reach out to varying cohorts of patients in different 
settings and the general public in England, generating adequate responses to 
investigate psychometric properties of the LMQ-3 (i.e. face/content validity, construct 
validity, criterion-related validity, and reliability). The use of multiple data collection 
methods was underpinned by the pragmatic mixed-methodological approach chosen 
for this research programme. By triangulating multiple research techniques (including 
a systematic review, cross-sectional surveys, and qualitative interviews), the resulting 
data enabled comprehensive revisions, validation and interpretation of the LMQ 
measure and its underlying concepts. Nonetheless, multiple statistical testing 
employed in the various studies has its limitations - it is possible that some of the 
results reported as statistically significant occurred by chance (giving a false positive), 
particularly the simple linear regression results reported in Chapter 9. A combined 




overcome this possible effect. Future work may address challenges of multiple 
statistical testing a priori, for instance by setting more stringent probability values (e.g. 
using Bonferroni correction). 
Nevertheless, the sample populations enrolled in this research programme may not be 
representative of the entire English population using long-term medicines, and further 
studies are necessary to cross-validate the reported findings. The questionnaire 
distribution methods used may not have adequately captured experiences of 
housebound patients, especially those with no internet access. Regardless, nearly half 
of all qualitative cognitive interviews, though primarily aimed to evaluate the LMQ, 
were coŶĚƵĐƚĞĚŝŶƉĂƌƚŝĐŝƉĂŶƚƐ ?ŚŽŵĞƐ ?
Across most studies reported in this thesis, participants had relatively higher education 
levels, with up to 48% and 57% reporting University-level education among 
participants in the construct validation (chapter 6) and test-retest (chapter 8) samples 
respectively. However, 23% of the criterion-validation sample (Chapter 7) reported the 
same level of education. This may reflect the methods used for participant recruitment 
in the respective studies; on-line recruitment, used in Chapter 6 and 8 tends to include 
those with higher level of education compared to face-to-face distribution that was 
used in the study reported in Chapter 7. Chapter 9, however, established no significant 
association between education status and medicine burden.  
As a self-completed questionnaire, which allows direct assessment of individual 
experiences, the LMQ-3 is, also, prone to different forms of response bias. The mixture 
of positively- and negatively-phrased items in the LMQ-3 and the intermixed order of 
items across different content domains in the questionnaire, may have minimised 
 ‘ĂƵƚŽŵĂƚŝĐƌĞƐƉŽŶƐĞƐ ? and increased the reliability of the tool in supporting subjective 
patient evaluations of medicine use experiences.  
Across all studies, survey response rates were reasonable (32% to 60%). Caution needs 
to be exercised when comparing these response rates with those reported in other 
studies, due to different study conditions (e.g. varying patient populations, settings, 
study duration, or instruments used and their mode of distribution). However, the  
response rates obtained across this research programme were slightly higher than 




in an English-speaking sample.232 In a multinational study, including the UK, 20% of all 
patients invited to  complete the TBQ measure on-line, via a patient website,  
responded over a 2-month period, 9% of whom were from the UK.232 As discussed in 
Chapter 3, questionnaire response rates are affected by multiple factors including the 
modes of questionnaire distribution. Electronic formatting of on-line surveys, although 
minimising missing data at item-level, means that overall response rates are hard to 
compute.118 On-line surveys, which attracted a higher number of responses in this 
research programme, tend to reach out to a geographically wider sample and are less 
laborious or time demanding to distribute or promote. Self-completed paper surveys 
achieved the lowest response rates possibly  due to issues such as willingness to 
complete and return questionnaires (by post or by hand).161 Across all studies, it was 
difficult to interview non-respondents and reasons for non-completion may not be 
fully understood, but lack of time or interest in the study was observed in some 
potential participants during paper distribution. 
As already noted, the length of the LMQ-3 is a potential limitation that may have 
affected response rates. CTT methodology, as a more liberal approach118 to item 
reduction, may have led to retention of more items (n=41) and domains (n=8) in the 
final tool presented, thus leading to a relatively lengthy questionnaire. Nevertheless, 
the number of items in the LMQ-3 is comparable to other broad measures of 
medicine-related experiences, particularly the PROMPT-QoL that has 43 items in ten 
domains.134 As already proposed, further item reduction may facilitate uptake of the 
LMQ-3 in practice settings. 
The scoring system and levels/cut-off scores for overall medicine burden (e.g. none, 
minimal, moderate, high) were based on grouping composite scores. Although it is 
ĐŽŵŵŽŶƉƌĂĐƚŝĐĞƚŽƐƚƌĂƚŝĨǇƉĂƚŝĞŶƚƐ ?ƐĐŽƌĞƐŝŶƚŽĚŝƐƚŝŶĐƚŐroups to aid clinical decision 
making (for example, in determining eligibility for interventions and/or treatment 
allocation),255,284 LMQ-3 cut-off values and burden categories, obtained by inspecting 
the distribution of scores for one sample population, require further investigation. 
Assumptions of linearity of the 5-point Likert-type scale used for LMQ-3 items, similar 
to most CTT-derived measures, may have underestimated measurement error118 and 




sense. Nevertheless, professional judgement of the researcher and supervision team 
were used to double-check data used to defined levels of burden.  
The language used in describing the hypothesised concepts underlying the LMQ-3 (i.e. 
medicine burden) is a particular challenge and potential limitation to the findings 
reported here-in. Although empirical qualitative work, described in Chapter 5, revealed 
minimal language problems, as most patients understood the meanings of different 
items in the LMQ-3 instrument, a few indicated potential problems with the word 
 ‘ďƵƌĚĞŶ ? ?dŚĞǁŽƌĚǁĂƐƵƐĞĚŝŶƚŚĞŐůŽďĂůŝƚĞŵ ? ‘overall, how much of a burden do you 
feel your medicines are ƚŽǇŽƵ ? ?The findings and literature show that medicines use 
ŵĂǇŶŽƚďĞƉĞƌĐĞŝǀĞĚĂƐĂ ‘ďƵƌĚĞŶ ?ĂŵŽŶŐƐŽŵĞƉĂƚŝĞŶƚƐƵƐŝŶŐůŽŶŐ-term medicines, 
ďƵƚƌĂƚŚĞƌĂƐĂ ‘ŶĞĐĞƐƐŝƚǇ ? ?ĚŝĨĨĞƌĞŶƚŝŶƚĞƌƉƌĞƚĂƚŝŽŶƐŽĨ ‘ďƵƌĚĞŶ ?ĂƌĞůŝŬĞůǇƚŽĂĨĨĞĐƚ
accurate assessments based on this item. Additional qualitative research may be 
needed to explore, in-ĚĞƉƚŚ ?ƚŚĞĐŽŶŶŽƚĂƚŝŽŶƐŽĨ ‘ďƵƌĚĞŶ ?ŝŶƚĞƌŵs of prescription 
medicine use. 
10.8 Thesis summary 
Long-term use of prescription medicines (and polypharmacy) can be a double-edged 
sword; with clinical benefits (such as prevention of disease and/or mortality) in 
contexts of chronic illness and multimorbidity, but also wide-ranging challenges for 
individuals who have to cope with different practical, psychosocial and sometimes 
financial issues surrounding the use of medicines. The findings presented in this thesis 
indicate that although most people using prescription medicines report positive 
experiences (low medicine burden), a significant proportion report problems and 
negative impacts and thus may need more support. 
Prescription medicine burden is a relatively new concept, but increasingly recognised 
as a challenging and multifactorial problem. Nevertheless, there is no clear evidence 
on the most appropriate way to address or evaluate medicine burden and its impact 
on individuals. A systematic review of measures of medicine-related experiences 
identified a potential measure of burden (the 60-item LMQ-1), but which required 
extensive development and validation. This research programme further developed 
and validated the Living with Medicines Questionnaire, and a final version (the LMQ-3) 




burden, applicable to any long-term condition (or disease), suitable for use in the adult 
English population.  
dŚĞƚŽŽůǁĂƐĨŽƵŶĚĞĚŽŶƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨŵĞĚŝĐŝŶĞƵƐĞĨŽƌĂŶǇůŽŶŐ-term 
condition. Questionnaire content and measurement properties were tested iteratively 
through a series of qualitative and quantitative studies involving users of long-term 
prescription medicines in England. A wide range of domains are covered in the LMQ-3: 
interferences with day-to-day life, patient-provider relationships and communication 
about medicines, practical difficulties, lack of effectiveness, side effects, general 
concerns, cost-related burden, and lack of autonomy/control over medicines.  
The LMQ-3 is a 41-item novel measure of medicine-related burden with adequate 
construct validity and reliability. The LMQ-3 is recommended for use in future research 
studies and/or clinical settings to not only quantify medicine burden but also as an 
outcome measure in pharmaceutical or clinical interventions that attempt to alleviate 
burden. Ultimately, the identification, prevention, and/or reduction of medicine 
burden, through patient-led interventions may improve patient outcomes, particularly 
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Appendix 1 Full search strategy for systematic review 
 
Search title: Instruments measuring medicine-related experiences 
 Ovid Embase (1995 t0 2015 week 16) 
1. medicine.mp. or exp medicine/ 
2. medication.mp. or exp drug therapy/ 
3. medication.mp. or exp drug therapy/ 
4. exp patient/ or exp inappropriate prescribing/ or exp prescription/ or prescri$.mp. or exp treatment 
planning/ 
5. drug.mp. or exp drug administration/ or exp drug/ or exp drug self administration/ or  ‘drug toxicity 
and intoxication ?/ or adverse drug reaction/ or drug interaction/ or exp repeated drug dose/ or exp 
 ‘drug use ?/ or new drug/ or drug administration route/ or drug underdose/ or topical drug 
administration/ or generic drug/ or exp drug dosage form/ or exp drug effect/ or multiple drug dose/ or 
 ‘food and drug administration ?/ or food drug interaction/ or exp drug labeling/ or auricular drug 
administration/ or herb drug interaction/ or low drug dose/ or exp prescription drug/ or long acting 
drug/ or acute drug administration/ or exp drug efficacy/ or exp drug dose/ or drug choice/ or exp 
chronic drug administration/ or exp  ‘drug cost ?/ or drug quality/ or exp recommended drug dose/ or 
drug potency/ 
6. therapy/ or drugs/ or polypharmacy/ or treatment/ or prescription drugs/ 
7. (therapy adj3 (drug$ or medic$)).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
8. pharmaceutical therapy.mp. 
9. (pharmaceutical adj3 therapy).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
10. polypharmacy/ or exp drug therapy/ 
11. *treatment outcome/ or treatment duration/ or *treatment failure/ or exp time to treatment/ or 
*treatment planning/ or *treatment indication/ or *treatment refusal/ or treatment.mp. or exp 
treatment contraindication/ or topical treatment/ 
12. (prescription adj3 medicine$).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
13. drug seeking behavior/ or exp drug self administration/ 
14. exp patient/ or *attitude/ or *attitude to health/ or Drug Us$ Attitude$.mp. or exp prescription/ 
15. ((Drug or medicine) adj3 dos$).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
16. side effect/ or side effect assessment/ 
17. exp Choice Behavior/ or exp Drug Therapy/ or exp Health Care Costs/ or prescription drug*.mp. or 
exp Consumer Attitudes/ or exp Consumer Behavior/ or exp Prescription Drugs/ or Physicians/ or Health 
Promotion/ or exp Drug Usage/ 
18. exp  ‘Medical Treatment (General) ?/ or exp Drug Therapy/ or regular medicine*.mp. 
19. exp Treatment Compliance/ or exp Drug Therapy/ or regimen.mp. or exp Drug Dosages/ 
20. exp Polypharmacy/ or exp Prescription Drugs/ or exp Drug Therapy/ or exp Coping Behavior/ or exp 
Treatment Compliance/ or multiple medicine$.mp. 
21. (excessive adj3 medicine$).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
22. exp Drug Therapy/ or unnecessary medicine$.mp. 
23. (tak$ adj3 medicine$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
24. (Medicine adj3 us$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 








25. (taking adj3 medicine$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
26. (administ$ adj3 medicine$).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
27. (self adj3 medic$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
28. (medicine$ adj manag$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
29. or/1-28 
30. (instrument$ or tool$ or scale* or indicator$ or technique or method$ or form$ or survey* or 
questionnaire$ or self report or measure or (patient adj3 report$) or outcome measure or PROM or PRO 
or quantif$ or rate or rating or assess$ or evaluat$ or estimat$ or develop$ or valid$ or reliab$ or 
psychometr$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] 
31. (patient experience$ or experienc$ or view$ or perception$ or attitude$ or belief$ or concern$ or 
worr$ or burden$ or (medic$ adj5 burden$) or pill burden or problem or distress or (medicin$ adj3 
problem) or (drug adj3 problem) or financial burden or (cost adj3 burden) or psycholog$ or social 
activit$ or family or friend$ or time or travel or emotion$ or satisf$ or dissatisf$ or happ$ or unhapp$ or 
(cop$ adj5 medic$) or (cop$ adj3 drug$) or behav$ or lifestyle or routine or life or activities of daily 
living).mp. or (*day/ adj3 lif$.mp.) or life.mp. or live$.mp. or health$.mp. or fitness.mp. or wellbeing.mp. 
or quality of life.mp. or self care.mp. or impact.mp. 
32. *doctor patient relation/ or *patient care/ or exp patient attitude/ or *health care quality/ or exp 
questionnaire/ or patient/ or exp *patient satisfaction/ or patient experience$.mp. or *psychological 
aspect/ 
33. (patient adj3 view$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
34. (patient adj3 perception$).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
35. (patient adj3 attitude$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
36. (patient adj3 belief$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
37. (patient adj3 concern$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
38. (patient adj3 worr$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
39. (patient adj3 burden$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
40. (patient adj5 satisf$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
41. (patients$ adj3 dissatisf$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
42. ((patient$ adj3 happ$) or (patient$ adj3 unhapp$)).mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
43. ((cop$ adj5 medic$) or (cop$ adj5 drug$) or (medic$ adj5 behav$) or (medic$ adj5 lifestyle) or 
(medic$ adj5 routin$) or (medicine adj5 lif$) or (medicine$ adj10 activities of daily living)).mp. or 
(medicine.mp. adj5 *day/) or (drug adj5 health$).mp. or (drug therapy adj10 fitness).mp. or 








44. ((cop$ adj5 medic$) or (cop$ adj5 drug$) or (medic$ adj5 behav$) or (medic$ adj5 lifestyle) or 
(medic$ adj5 routin$) or (medicine adj5 lif$) or (medicine$ adj10 activities of daily living)).mp. or 
(medicine.mp. adj5 *day/) or (drug adj5 health$).mp. or (drug therapy adj10 fitness).mp. or 
(pharmaceutical therapy adj5 quality of life).mp. or (drug adj5 self care).mp. or (drug$ adj5 impact).mp. 
45. ((cop$ adj5 medic$) or (cop$ adj5 drug$) or (medic$ adj5 behav$) or (medic$ adj5 lifestyle) or 
(medic$ adj5 routin$) or (medicine adj5 lif$) or (medicine$ adj5 activities of daily living) or (drug adj5 
health$) or (drug therapy adj5 fit$) or (pharmaceutical therapy adj3 quality of life) or (drug adj5 self 
care) or (drug$ adj5 impact)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
46. or/31-45 
47. 29 and 46 
48. 30 and 47 
49. develop$.mp. 
50. 48 and 49 
51. psychometr$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
52. 50 and 51 
53. limit 52 to (human and english language and embase and (adult <18 to 64 years> or aged <65+ 
years>)) 
54. limit 53 to yr= ‘1995 -Current ? 
   
PsycINFO and PSych articles 
1. medicine.af. 
2. medication.mp. or exp Drug Therapy/ 
3.  ‘prescribing (drugs) ?/ or drug therapy/ or drugs/ or polypharmacy/ or treatment/ or prescription 
drugs/ 
4. exp Drug Usage Screening/ or exp Drug Therapy/ or exp Drug Seeking/ or exp Drug Usage Attitudes/ 
or drug*.mp. or exp Drug Usage/ or exp Drug Self Administration/ or exp Drug Dosages/ or exp  ‘Side 
Effects (Drug) ?/ 
5. exp Prescription Privileges/ or exp Prescription Drugs/ or prescription*.mp. 
6. exp Choice Behavior/ or exp Drug Therapy/ or exp Health Care Costs/ or prescription drug*.mp. or 
exp Consumer Attitudes/ or exp Consumer Behavior/ or exp Prescription Drugs/ or Physicians/ or Health 
Promotion/ or exp Drug Usage/ 
7. (prescription adj3 medicine).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
8. exp  ‘Medical Treatment (General) ?/ or exp Drug Therapy/ or regular medicine*.mp. 
9. exp Treatment Compliance/ or exp Drug Therapy/ or regimen.mp. or exp Drug Dosages/ 
10. polypharmacy.mp. or exp Polypharmacy/ 
11. exp Polypharmacy/ or exp Prescription Drugs/ or exp Drug Therapy/ or exp Coping Behavior/ or exp 
Treatment Compliance/ or multiple medicine$.mp. 
12. (excessive adj3 medicine$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
13. exp Drug Therapy/ or unnecessary medicine$.mp. 
14. drug therapy.mp. or exp Drug Therapy/ 
15. therapy.mp. or exp Treatment/ 
16. overprescrib$.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, 








17. (tak$ adj3 medicine$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
18. (tak$ adj3 medicine$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
19. Medicine us$.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, 
tests & measures] 
20. taking medicine.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, 
tests & measures] 
21. (administ$ adj3 medicine$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
22. (self adj3 medic*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] 
23. (medicine$ adj manag$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
24. or/1-23 
25. (instrument$ or tool$ or scale* or indicator$ or technique or method$ or form$ or survey* or 
questionnaire$ or self report or measure or (patient adj3 report$) or outcome measure or PROM or PRO 
or quantif$ or rate or rating or assess$ or evaluat$ or estimat$ or develop$ or valid$ or reliab$ or 
psychometr$).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests 
& measures] 
26. (patient experience$ or experienc$ or view$ or perception$ or attitude$ or belief$ or concern$ or 
worr$ or burden$ or (medic$ adj5 burden$) or pill burden or problem or distress or (medicin$ adj3 
problem) or (drug adj3 problem) or financial burden or (cost adj3 burden) or psycholog$ or social 
activit$ or family or friend$ or time or travel or emotion$ or satisf$ or dissatisf$ or happ$ or unhapp$ or 
(cop$ adj5 medic$) or (cop$ adj3 drug$) or behav$ or lifestyle or routine or life or activities of daily 
living).mp. or (*day/ adj3 lif$.mp.) or life.mp. or live$.mp. or health$.mp. or fitness.mp. or wellbeing.mp. 
or quality of life.mp. or self care.mp. or impact.mp. [mp=title, abstract, heading word, table of contents, 
key concepts, original title, tests & measures] 
27. patient experience$.mp. [mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] 
28. (patient adj3 view$).mp. [mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] 
29. (patient adj3 perception$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
30. (patient adj3 attitude$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
31. (patient adj5 belief$).mp. [mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] 
32. (patient adj5 concern$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
33. (patient adj5 worr$).mp. [mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] 
34. (patient adj5 burden$).mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] 
35. (patient adj5 satisf$).mp. [mp=title, abstract, heading word, table of contents, key concepts, original 
title, tests & measures] 
36. ((patients$ adj3 dissatisf$) or (patient$ adj5 happ$) or patient$ unhapp$).mp. [mp=title, abstract, 








37. ((cop$ adj5 medic$) or (cop$ adj5 drug$) or (medic$ adj5 behav$) or (medic$ adj5 lifestyle) or 
(medic$ adj5 routin$) or (medicine adj5 lif$) or (medicine$ adj10 activities of daily living)).mp. or 
(medicine.mp. adj5 *day/) or (drug adj5 health$).mp. or (drug therapy adj10 fitness).mp. or 
(pharmaceutical therapy adj5 quality of life).mp. or (drug adj5 self care).mp. or (drug$ adj5 impact).mp. 
[mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 
38. or/27-37 
39. 24 and 38 
40. 25 and 39 
41. limit 40 to (psycarticles journals and adulthood <18+ years> and english and human and yr= ‘1995 -
Current ?) 
42. limit 40 to (all journals and 2220 tests & testing and  ‘300 adulthood  ? and english) 
43. limit 40 to (all journals and (2200 psychometrics & statistics & methodology or 2220 tests & testing 
or 2222 developmental scales & schedules or 2223 personality scales & inventories or 2224 clinical 
psychological testing or 2225 neuropsychological assessment or 2226 health psychology testing or 2260 
research methods & experimental design or 2300 human experimental psychology or 2500 physiological 
psychology & neuroscience or 2580 psychopharmacology or 2600 psychology & the humanities or 2800 
developmental psychology or 3300 health & mental health treatment & prevention or 3310 
psychotherapy & psychotherapeutic counseling or 3311 cognitive therapy or 3312 behavior therapy & 
behavior modification or 3315 psychoanalytic therapy or 3360 health psychology & medicine or  ‘3361 
behavioral & psychological treatment of physical illness ? or  ‘3363 medical treatment of physical illness ? 
or  ‘3365 promotion & maintenance of health & wellness ? or 3370 health & mental health services or 
3371 outpatient services or 3373 community & social services or 3900 consumer psychology or 3920 
consumer attitudes & behavior) and adulthood <18+ years> and  ‘300 adulthood  ? and english and 
human) 
44. from 43 keep 31,57 
45. limit 43 to (( ‘0400 empirical study ? or  ‘0410 experimental replication ? or  ‘0430 followup study ? or 
 ‘0450 longitudinal study ? or  ‘0451 prospective study ? or  ‘0453 retrospective study ? or  ‘0600 field study ? 
or  ‘0700 interview ? or  ‘0750 focus group ? or 1600 qualitative study or 1800 quantitative study) and 
( ‘0100 journal ? or  ‘0110 peer-reviewed journal ? or  ‘0120 non-peer-reviewed journal ? or  ‘0130 peer-
reviewed status unknown ?)) 
46. limit 45 to ( ‘0400 empirical study ? or  ‘0430 followup study ? or  ‘0450 longitudinal study ? or 1800 
quantitative study) 









CINAHL Plus and MEDLINE, 1995-2015 week 16 (accessed via EBSCOHOST) 
 
# Query Limiters/Expanders Last Run Via Results 
S53 S50 AND S51 Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
895 
S52 S50 AND S51 Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
1,645 
S51 S2 OR S5 OR S7 OR S13 
OR S14 
Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
9,379,820 
S50 S46 AND S47 Limiters - Published 
Date: 19950101-
20151231  
Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
5,011 
S49 S46 AND S47 Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
5,331 
S48 S46 AND S47 Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
13,240 
S47 psychometric Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
89,259 
S46 S44 AND S45 Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
1,855,365 
S45 develop* Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  







Search modes - Find 
all my search terms 
Plus;MEDLINE 
S44 S42 AND S43 Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
8,527,673 
S43 (instrument$ or tool$ or 
scale* or indicator$ or 
technique or method$ or 
form$ or survey* or 
questionnaire$ or self 
report or measure or 
(patient adj3 report$) or 
outcome measure or 
PROM or PRO or quantif$ 
or rate or rating or 
assess$ or evaluat$ or 
estimat$ or develop$ or 
valid$ or reliab$ or 
psychometr$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
16,198,585 
S42 S27 AND S41 Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
2,888,057 
S41 S28 OR S29 OR S30 OR 
S31 OR S32 OR S33 OR 
S34 OR S35 OR S36 OR 
S37 OR S38 OR S39 OR 
S40 
Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
18,831,167 
S40 ((cop$ adj5 medic$) or 
(cop$ adj5 drug$) or 
(medic$ adj5 behav$) or 
(medic$ adj5 lifestyle) or 
(medic$ adj5 routin$) or 
(medicine adj5 lif$) or 
(medicine$ adj10 
activities of daily 
living)).mp. or 
(medicine.mp. adj5 *day/) 
or (drug adj5 health$).mp. 
or (drug therapy adj10 
fitness).mp. or 
(pharmaceutical therapy 
adj5 quality of life).mp. or 
(drug adj5 self care).mp. 
or (drug$ adj5 
impact).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
18,550,078 
S39 ((patient$ adj3 happ$) or 
(patient$ adj3 
unhapp$)).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  








any of my search 
terms 
S38 (patients$ adj3 
dissatisf$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
5,009,958 
S37 (patient adj5 satisf$).mp. Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,353,411 
S36 (patient adj3 
burden$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,439,824 
S35 patient adj3 worr$).mp. Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,211,145 
S34 (patient adj3 
concern$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,510,950 
S33 (patient adj3 belief$).mp. Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,407,809 
S32 (patient adj3 
attitude$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  








S31 (patient adj3 
perception$).mp 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,657,219 
S30 (patient adj3 view$).mp. Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,576,537 
S29 *doctor patient relation/ 
or *patient care/ or exp 
patient attitude/ or 
*health care quality/ or 
exp questionnaire/ or 
patient/ or exp *patient 
satisfaction/ or patient 
experience$.mp. or 
*psychological aspect/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
13,078,605 
S28 (patient experience$ or 
experienc$ or view$ or 
perception$ or attitude$ 
or belief$ or concern$ or 
worr$ or burden$ or 
(medic$ adj5 burden$) or 
pill burden or problem or 
distress or (medicin$ adj3 
problem) or (drug adj3 
problem) or financial 
burden or (cost adj3 
burden) or psycholog$ or 
social activit$ or family or 
friend$ or time or travel 
or emotion$ or satisf$ or 
dissatisf$ or happ$ or 
unhapp$ or (cop$ adj5 
medic$) or (cop$ adj3 
drug$) or behav$ or 
lifestyle or routine or life 
or activities of daily 
living).mp. or (*day/ adj3 
lif$.mp.) or life.mp. or 
live$.mp. or health$.mp. 
or fitness.mp. or 
wellbeing.mp. or quality 
of life.mp. or self care.mp. 
or impact.mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
17,029,596 
S27 S1 OR S2 OR S3 OR S4 OR 
S5 OR S6 OR S7 OR S8 OR 
S9 OR S10 OR S11 OR S12 
OR S13 OR S14 OR S15 OR 
S16 OR S17 OR S18 OR 
Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  







S19 OR S20 OR S21 OR 
S22 OR S23 OR S24 OR 
S25 OR S26 
Plus;MEDLINE 
S26 (medicine$ adj 
manag$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,311,939 
S25 (self adj3 medic$).mp. Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
949,167 
S24 (administ$ adj3 
medicine$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,251,710 
S23 (taking adj3 
medicine$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,436,866 
S22 . (Medicine adj3 us$).mp. Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,532,075 
S21 (tak$ adj3 medicine$).mp. Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,255,372 
S20 exp Drug Therapy/ or 
unnecessary 
medicine$.mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  









S19 (excessive adj3 
medicine$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
6,318,996 
S18 exp Polypharmacy/ or exp 
Prescription Drugs/ or exp 
Drug Therapy/ or exp 




Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
11,814,728 
S17 exp  ‘Medical Treatment 
(General) ?/ or exp Drug 
Therapy/ or regular 
medicine*.mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
8,909,446 
S16 . exp Choice Behavior/ or 
exp Drug Therapy/ or exp 
Health Care Costs/ or 
prescription drug*.mp. or 
exp Consumer Attitudes/ 
or exp Consumer 
Behavior/ or exp 
Prescription Drugs/ or 
Physicians/ or Health 
Promotion/ or exp Drug 
Usage/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
14,685,952 
S15 side effect/ or side effect 
assessment/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
8,236,212 
S14 (Drug or medicine) adj3 
dos$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - 
SmartText 
Searching 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
855 
S13 (Drug or medicine) adj3 
dos$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  








all my search terms 
S12 exp patient/ or *attitude/ 
or *attitude to health/ or 
Drug Us$ Attitude$.mp. 
or exp prescription/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
676,248 
S11 drug seeking behavior/ or 
exp drug self 
administration/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
all my search terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
8,990 
S10 . *treatment outcome/ or 
treatment duration/ or 
*treatment failure/ or exp 
time to treatment/ or 
*treatment planning/ or 
*treatment indication/ or 
*treatment refusal/ or 
treatment.mp. or exp 
treatment 
contraindication/ or 
topical treatment/ 12. 
(prescription adj3 
medicine$).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
20,568,797 
S9 polypharmacy/ or exp 
drug therapy/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
8,824,202 
S8 (pharmaceutical adj3 
therapy). 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
5,574,272 
S7 . pharmaceutical 
therapy.mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
457,846 
S6 . (therapy adj3 (drug$ or 
medic$)).mp. 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  








any of my search 
terms 




Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
7,659,230 
S4 drug.mp. or exp drug 
administration/ or exp 
drug/ or exp drug self 
administration/ or  ‘drug 
toxicity and intoxication ?/ 
or adverse drug reaction/ 
or drug interaction/ or 
exp repeated drug dose/ 
or exp  ‘drug use ?/ or new 
drug/ or drug 
administration route/ or 
drug underdose/ or 
topical drug 
administration/ or generic 
drug/ or exp drug dosage 
form/ or exp drug effect/ 
or multiple drug dose/ or 
 ‘food and drug 
administration ?/ or food 
drug interaction/ or exp 
drug labeling/ or auricular 
drug administration/ or 
herb drug interaction/ or 
low drug dose/ or exp 
prescription drug/ or long 
acting drug/ or acute drug 
administration/ or exp 
drug efficacy/ or exp drug 
dose/ or drug choice/ or 
exp chronic drug 
administration/ or exp 
 ‘drug cost ?/ or drug 
quality/ or exp 
recommended drug dose/ 
or drug potency/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
17,932,905 
S3 exp patient/ or exp 
inappropriate prescribing/ 
or exp prescription/ or 
prescri$.mp. or exp 
treatment planning/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Search modes - Find 
any of my search 
terms 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  
Database - CINAHL 
Plus;MEDLINE 
9,417,571 
S2 medication.mp. or exp 
drug therapy/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles  
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  







Search modes - Find 
any of my search 
terms 
Plus;MEDLINE 
S1 medicine.mp. or exp 
medicine/ 
Expanders - Apply 
related words; Also 
search within the 
full text of the 
articles. 
Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced 
Search  










Appendix 2 Cognitive interview probing guide 
 
Project title. Revising the Living with Medicines Questionnaire 
 
[ I will first explain to the participant that he/she is supposed to think (and talk out) 
aloud when filling in the questionnaire, and that he/she should be prepared to answer 
questions as he/she completes the questionnaire. I will also emphasise that the purpose 
of the interview is to help us in revising the questionnaire, and not to gauge the 
ƉĂƌƚŝĐŝƉĂŶƚƐ ?beliefs, attitudes, or adherence to their medicines. I will remind them to 
first read the instructions (stipulated on the cover page). I will then remind them to 
read each statement aloud and then comment on what they think about the text and 
how they expect to arrive at the response. ] 
 
General probes 
 What were you thinking when you answered that question? 
 I noticed that you hesitated while responding to that statement, please tell me 
what you were thinking then. 
 tŚĂƚĚŽĞƐƚŚĞƚĞƌŵ ?Ğ ?Ő ? ‘ǁƌŝƚƚĞŶŝŶƐƚƌƵĐƚŝŽŶƐ ? )ŵĞĂŶƚŽǇŽƵ ? 
 tŚǇĚŽǇŽƵƚŚŝŶŬƚŚĂƚ Q ? 
 ĂŶǇŽƵƌĞƉĞĂƚƚŚĞƋƵĞƐƚŝŽŶ/ũƵƐƚĂƐŬĞĚŝŶǇŽƵƌŽǁŶǁŽƌĚƐ ? ? 
 tŚĂƚĚŽǇŽƵƚŚŝŶŬŽĨƚŚĞƚĞƌŵ ‘ ?ǆǆ ? ? 
 How did you arrŝǀĞĂƚƚŚĂƚĂŶƐǁĞƌ ? ? ‘/ŶŽƚŝĐĞĚǇŽƵŚĞƐŝƚĂƚĞĚ 
 Was this question hard or easy to answer? 
Examples of specific probes for new and revised items  
/ƚĞŵ ‘/ĨŝŶĚƚŚĞǁƌŝƚƚĞŶŝŶƐƚƌƵĐƚŝŽŶƐŽŶŚŽǁƚŽƵƐĞŵǇŵĞĚŝĐŝŶĞƐĞĂƐǇƚŽƵŶĚĞƌƐƚĂŶĚ ? ? 
 What do you think about when reading the words  ‘written instructions on how 
to use my medicines ? 
/ƚĞŵ ‘/ǁŽƵůĚďĞǁŽƌƌŝĞĚŝĨ/ĨŽƌŐŽƚƚŽƚĂŬĞŵǇŵĞĚŝĐŝŶĞƐ ? ? 
 If you should rephrase this item, what words would you use? 
/ƚĞŵ ‘DǇƉŚĂƌŵĂĐŝƐƚƚĞůůƐŵĞĞŶŽƵŐŚĂďŽƵƚŵǇŵĞĚŝĐŝŶĞƐ ? ? 
 What do you  understand by this statement?  
/ƚĞŵ ‘DǇĚŽĐƚŽƌƚĞůůƐŵĞĞŶŽƵŐŚĂďŽƵƚŵǇŵĞĚŝĐŝŶĞƐ ? ?
 What does this statement mean to you? 
/ƚĞŵ ‘DǇŵĞĚŝĐŝŶĞƐŝŶƚĞƌĨĞƌĞǁŝƚŚŵǇƐŽĐŝĂůĂĐƚŝǀŝƚŝĞƐ ? 
/ƚĞŵ ‘DǇŵĞĚŝĐŝŶĞƐŝŶƚĞƌĨĞƌĞǁŝƚŚŵǇƐŽĐŝĂůƌĞůĂƚŝŽŶƐŚŝƉƐ ? 
 Do you think there is any difference between these two statements 
/ƚĞŵ ‘/ŚĂǀĞƚŽƉĂǇŵŽƌĞƚŚĂŶ/ĐĂŶĂĨĨŽƌĚĨŽƌŵǇŵĞĚŝĐŝŶĞƐ ? 
 If you were to rephrase this statement, what words would you use? 
/ƚĞŵ ‘dŚĞƐŝĚĞĞĨĨĞĐƚƐ/ŐĞƚĨƌŽŵŵǇŵĞĚŝĐŝŶĞƐĂƌĞďŽƚŚĞƌƐŽŵĞ ? 
 What doeƐƚĞƌŵ ‘ďŽƚŚĞƌƐŽŵĞ ?ŵĞĂŶƚŽǇŽƵ ? 
/ƚĞŵ ‘dŚĞƐŝĚĞĞĨĨĞĐƚƐ/ŐĞƚĨƌŽŵŵǇŵĞĚŝĐŝŶĞƐŝŶƚĞƌĨĞƌĞǁŝƚŚŵǇĚĂǇ-to-day life (e.g. 
ǁŽƌŬ ?ƐůĞĞƉ ?ǁŽƌŬ ?ŚŽƵƐĞǁŽƌŬ ?ƐůĞĞƉ ?ǁĞůůďĞŝŶŐ ) ? ? 
 What does the phrase  ‘interfere with my day-to-day life ? mean to you? 
/ƚĞŵ ‘dŚĞƐŝĚĞ ĞĨĨĞĐƚƐ/ŐĞƚĂƌĞǁŽƌƐĞƚŚĂŶƚŚĞƉƌŽďůĞŵĨŽƌǁŚŝĐŚ/ƚĂŬĞŵĞĚŝĐŝŶĞƐ ? 
 If you were to rephrase this statement, what words would you use? 
/ƚĞŵ ‘dŚĞƐŝĚĞĞĨĨĞĐƚƐĂƌĞǁŽƌƚŚŝƚĨŽƌƚŚĞďĞŶĞĨŝƚƐ/ŐĞƚĨƌŽŵŵǇŵĞĚŝĐŝŶĞƐ ? 







 What do you think of the instructions on the cover page of the questionnaire?  
(To probe for clarity)? 
 What did you think about the response options (i.e. strongly agree, agree, 
neutral opinion, disagree, and strongly disagree? 
 Was there anything that you perceived as difficult or uncomfortable when you 
filled in the questionnaire? Which one was that? Why is that? 
 Overall, what did you think about this questionnaire? Do you feel it covers most 
of the issues that concern people using medicines on a regular basis? 
How did you feel about the interview? Is there anything you would like to add? 
 






















































































































































































































































































































































































WŚƉƌŽũĞĐƚ PWĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨƵƐŝŶŐŵĞĚŝĐŝŶĞƐ ?ƌĞǀŝƐŝŶŐƚŚĞ>ŝǀŝŶŐǁŝƚŚ
Medicines Questionnaire
© 
/ǁŽƵůĚůŝŬĞƚŽŝŶǀŝƚĞǇŽƵƚŽŚĞůƉƵƐǁŝƚŚĂƌĞƐĞĂƌĐŚƐƚƵĚǇůŽŽŬŝŶŐĂƚƉĂƚŝĞŶƚƐ ? experiences 
of using medicines, being conducted at Medway School of Pharmacy, in Kent, as part of 
my PhD studies. My name is Barbra Katusiime, a postgraduate student, and I am kindly 
asking you to support our study in a small way.  
 
As you may be aware, many patients have to cope with using medicines long-term, 
balancing the risk of potential adverse effects against the perceived benefits, plus coping 
generally with the challenges of managing these on a day- to day basis. Our study is 
seeking the views of patients  belonging  to your patient organisation or forum. It will 
employ a specially designed Living with Medicines Questionnaire© (LMQ) that people can 
use to share their experiences of what it is like to use medicines on a regular basis.  
WĂƚŝĞŶƚƐ ?ƌĞƐponses will be used to revise this questionnaire (LMQ). If you are willing, we 
would like you to help us distribute a link to our on-line questionnaire through your 
website, for up to three months. The inclusion criteria for the study are those over 18, 
living in England  and who use regular prescription medicines. We envisage that the 
findings will support the Medicines Optimisation agenda developed by the Royal 
WŚĂƌŵĂĐĞƵƚŝĐĂů^ŽĐŝĞƚǇ ?ǁŚŽƐĞŽďũĞĐƚŝǀĞŝƐƚŽĞŶŚĂŶĐĞƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨĐĂƌĞ ?ĂŶĚ
medicine use). 
 
If you would like more information around the study you can contact my project 
supervisor Professor Janet Krska either by telephone (01634202950) or email 
(j.krska@kent.ac.uk). 
 
Many thanks and regards,  
Barbra Katusiime 














































































































































































List of study sites for criterion validation study 
 
List of GP Practices 
The College Practice  
50/52 College Road, Maidstone, 
Kent 
Kent, ME15 6SB 
Dr. Mara HK and Partners 
The Elms Medical Centre 
Tilley Close Main Road 
Hoo, Rochester, Kent, ME3 9AE 
The Sunlight Centre  
105 Richmond Road 
Gillingham, Kent, ME7 1LX 
Dr. Patel JRA & Partners 
Shorne village Surgery 
Shorne, Gravesend, DA12 3DY 
The Kings Family Practice 
30-34 Magpie Hall Road 
Chatham, Kent, ME4 5JY 
 
 
List of community pharmacies  
*Karsons Pharmacy, Pattens Lane, Chatham 
 
Paydens Pharmacy, Week Street, 
Maidstone 
 
Paydens Pharmacy, New Road, Chatham 
 
Williams Chemist, Frindsbury Road, Strood 
 
 






































































































































































Scoring method for the final LMQ-3  
 
Scoring method for  
LMQ© Version 3 2015 
 
Composition: 41 Likert-type statements (strongly agree to strongly disagree), one visual 
analogue scale, free-text open question, and participant characteristics. 
 
Domain 1 ʹ Relationships with HCPs /Communication with HCPs about medicines 
Statement numbers: 7, 14, 20, 24, 34 (total = 5; scoring range 5 - 25) 
Number Statement  Direction Scoring 
7  I trust the judgement of my doctor(s) in 
choosing medicines for me. 
+ 1 = Strongly 
disagree 
5 = Strongly agree 
14 My doctor(s) listen to my opinions about my 
medicines. 
+ 1 = Strongly 
disagree 
5 = Strongly agree 
20 My doctor(s) take my concerns about side 
effects seriously 
+ 1 = Strongly 
disagree 
5 = Strongly agree 
24 I get enough information about my 
medicines from my doctor(s). 
+ 1 = Strongly 
disagree 
5 = Strongly agree 
34 The health professionals providing my care 
know enough about me and my medicines.  
+ 1 = Strongly 
disagree 
5 = Strongly agree 
 
Domain 2 ʹ Practicalities/ Practical difficulties 
Statement numbers: 1, 2, 4, 10, 23, 27, 29 (total = 7; scoring range 7 W 35) 
Number Statement Direction Scoring 
1 I find getting prescriptions from the doctor 
difficult 
- 1 = Strongly agree 
5 = Strongly 
disagree 
2 I find getting medicines from the pharmacist 
difficult 
- 1 = Strongly agree 
5 = Strongly 
disagree 
4 I am comfortable with the times I should 
take my medicines. 
+ 1 = Strongly 
disagree 
5 = Strongly agree 
10 I am concerned that I may forget to take my 
medicines. 
- 1 = Strongly agree 
5 = Strongly 
disagree 







into taking medicines 5 = Strongly 
disagree 
27 It is easy to keep my medicines routine + 1 = Strongly 
disagree 
5 = Strongly agree 
29 I find using my medicines difficult - 1 = Strongly agree 
5 = Strongly 
disagree 
 
Domain 3 ʹ Cost-related burden 
Statement numbers: 5, 31, 33 (total = 3; scoring range 3 - 15) 
Number Statement Direction Scoring 
5 I worry about paying for my medicines. - 1 = Strongly agree 
5 = Strongly 
disagree 
31 I sometimes have to choose between buying 
basic essentials or medicines. 
- 1 = Strongly agree 
5 = Strongly 
disagree 
33 I have to pay more than I can afford for my 
medicines. 
- 1 = Strongly agree 
5 = Strongly 
disagree 
 
Domain 4 ʹ Side effects  
Statement numbers: 21, 22, 30, 38 (total = 4; scoring range 4 - 20) 
Number Statement Direction Scoring 
21 The side effects I get are sometimes worse 
than the problem for which I take medicines. 
- 1 = Strongly agree 
5 = Strongly 
disagree 
22 The side effects I get from my medicines 
interfere with my day-to-day life (e.g. work, 
housework, sleep). 
- 1 = Strongly agree 
5 = Strongly 
disagree 
30 The side effects I get from my medicines are 
bothersome. 
- 1 = Strongly agree 
5 = Strongly 
disagree 
38 The side effects I get from my medicines 
adversely affect my well-being. 
- 1 = Strongly agree 
5 = Strongly 
disagree 
 
Domain 5 ʹ Effectiveness 
Statement numbers: 3, 15, 25, 32, 39, 40 (total = 6; scoring range 6 - 30) 
Number Statement Direction Scoring 
3 I am satisfied with the effectiveness of my 
medicines  
+ 1 = Strongly 
disagree 
5 = Strongly agree 
15 My medicines prevent my condition getting 
worse 
+ 1 = Strongly 
disagree 
5 = Strongly agree 







5 = Strongly agree 
32 My medicines allow me to live my life as I 
want to. 
+ 1 = Strongly 
disagree 
5 = Strongly agree 
39 My medicines are working  + 1 = Strongly 
disagree 
5 = Strongly agree 
40 The side effects are worth it for the benefits I 
get from my medicines. 
+ 1 = Strongly 
disagree 
5 = Strongly agree 
 
 
Domain 6 ʹ Attitudes/ Concerns about medicine use 
Statement numbers: 6, 8, 9, 12, 16, 17, 18 (total = 7; scoring range 7 - 35) 
Number Statement Direction Scoring 
6 I worry that I have to take several medicines 
at the same time 
- 1 = Strongly agree 
5 = Strongly disagree 
8 I would like more say in the brands of 
medicines I use. 
- 1 = Strongly agree 
5 = Strongly disagree 
9 I feel I need more information about my 
medicines. 
- 1 = Strongly agree 
5 = Strongly disagree 
12 I am concerned about possible damaging 
long term effects of taking medicines. 
- 1 = Strongly agree 
5 = Strongly disagree 
16 I am concerned that I am too reliant on my 
medicines. 
- 1 = Strongly agree 
5 = Strongly disagree 
17 I am concerned that my medicines interact 
with alcohol. 
- 1 = Strongly agree 
5 = Strongly disagree 
18 I worry that my medicines may interact with 
each other. 
- 1 = Strongly agree 
5 = Strongly disagree 
 
Domain 7 ʹ Impact / Interference to day-to-day life 
Statement numbers: 19, 28, 35, 36, 37, 41 (total = 6; scoring range 6 - 30) 
Number Statement Direction Scoring 
19 My medicines interfere with my social or 
leisure activities. 
- 1 = Strongly agree 
5 = Strongly disagree 
28 Taking medicines affects my driving. - 1 = Strongly agree 
5 = Strongly disagree 
35 My medicines interfere with my social 
relationships. 
- 1 = Strongly agree 
5 = Strongly disagree 
36 Taking medicines causes me problems with 
daily tasks (such as work, housework, 
hobbies) 
- 1 = Strongly agree 
5 = Strongly disagree 
37 My medicines interfere with my sexual life. - 1 = Strongly agree 
5 = Strongly disagree 
41 My life revolves around using my medicines  - 1 = Strongly agree 








Domain 8 ʹ Control/ Autonomy to vary regimen 
Statement numbers: 11, 13, 26 (total = 3, scoring range 3 - 15) 
Number Statement Direction Scoring 
11 I can vary the dose of the medicines I take. + 1 = Strongly 
disagree 
5 = Strongly agree 
13 I can choose whether or not to take my 
medicines  
+ 1 = Strongly 
disagree 
5 = Strongly agree 
26 I can vary the times I take my medicines. + 1 = Strongly 
disagree 
5 = Strongly agree 
 
Total/composite score for Likert-type statements range 41  W 205; higher scores indicate 
worse experiences of medicine use (higher medicine burden). 
 
Visual Analog Scale (VAS) item, score range 0  W 10. 
 Statement Scoring 
VAS item Overall, how much of a burden do you 
feel your medicines are to you? 
0= No burden at all                          
10= Extremely burdensome           
 
 
All negatively phrased items are reverse scored to compute composite scores.  
 
Based on English sample data, burden categories using LMQ-3 composite scores:  
No burden at all (41-73); Minimal burden (74-106); Moderate burden(107-139);High 
burden(140-172); and Extremely high burden (173-205). 
 
Burden categories based on VAS scores are: no burden at all (0.0- 2.0); minimal burden 
(2.1 -4.0); moderate (4.1-5.9); high burden (6.0-7.9); extremely high burden (8.0-10.0). 
 
Participants with high or extremely high burden on both assessments can be categorised 




















Appendix 22 The Treatment Satisfaction Questionnaire for Medication 
TSQM (Version II) 
 
Treatment Satisfaction Questionnaire for Medication 
 
Instructions:  Please take some time to think about your level of satisfaction or 
dissatisfaction with the medication you are taking in this clinical trial.  We are 
interested in what you think about the effectiveness, side effects, and convenience 
experienced when using the medication over the last two to three weeks, or since you 
last used it.  For each question, please place one tick next to the response that most 
closely corresponds to your own experiences. 
 
1. How satisfied or dissatisfied are you with the ability of the medication to prevent or 
treat the condition?  
 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Dissatisfied ප4   Somewhat Satisfied ප5   Satisfied ප6   Very Satisfied ප7   Extremely Satisfied 
 
2. How satisfied or dissatisfied are you with the way the medication relieves symptoms? 
 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Dissatisfied ප4   Somewhat Satisfied ප5   Satisfied ප6   Very Satisfied ප7   Extremely Satisfied 
 
3.  As a result of taking this medication, do you experience any side effects at all? 
 ප1   Yes ප0   No 
 
4. How dissatisfied are you by side effects that interfere with your physical health and 
ability to function (e.g. strength, energy levels)? 






ප5   Not at all Dissatisfied ප(5) Not Applicable 
 
5. How dissatisfied are you by side effects that interfere with your mental function (e.g. 
ability to think clearly, stay awake)? 
 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Somewhat Dissatisfied ප4   Slightly Dissatisfied ප5   Not at all Dissatisfied ප(5) Not Applicable 
 
6. How dissatisfied are you by side effects that interfere with your mood or emotions (e.g. 
anxiety/fear, sadness, irritation/anger)? 
 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Somewhat Dissatisfied ප4   Slightly Dissatisfied ප5   Not at all Dissatisfied ප(5) Not Applicable 
 
7. How satisfied or dissatisfied are you with how easy the medication is to use? 
 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Dissatisfied ප4   Somewhat Satisfied ප5   Satisfied ප6   Very Satisfied ප7   Extremely Satisfied 
 
8. How satisfied or dissatisfied are you with how easy it is to plan when you will use the 
medication each time? 
 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Dissatisfied ප4   Somewhat Satisfied ප5   Satisfied ප6   Very Satisfied ප7   Extremely Satisfied 
 







 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Dissatisfied ප4   Somewhat Satisfied ප5   Satisfied ප6   Very Satisfied ප7   Extremely Satisfied 
 
10. How satisfied are you that the good things about this medication outweigh the bad 
things? 
 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Dissatisfied ප4   Somewhat Satisfied ප5   Satisfied ප6   Very Satisfied ප7   Extremely Satisfied 
 
11. Taking all things into account, how satisfied or dissatisfied are you with this 
medication? 
 ප1   Extremely Dissatisfied ප2   Very Dissatisfied ප3   Dissatisfied ප4   Somewhat Satisfied ප5   Satisfied ප6   Very Satisfied ප7   Extremely Satisfied 
 
 





























4820 Emperor Boulevard 
Durham, North Carolina 27703 
 
 
Treatment Satisfaction Questionnaire for Medication (version II format b)  
 
Scoring Algorithm:  TSQM Scale scores range from 0 to 100 and no score should be lower 
or higher than these limits.  This is computed by adding the items loading on each factor.  
The lowest possible score is subtracted from this composite score and divided by the 
greatest possible score minus the lowest possible score. This provided a transformed 
score between 0 and 1 that should be multiplied by 100.  (see below) [Note that only one 
item may be missing from each scale before the subscale should be considered invalid for 
that respondent] 
 
EFFECTIVENESS:  ([(Item 1 + Item 2)  W 2] divide by 12) * 100 
            If one item is missing: ([(Use the completed item))  W 1] divide by 6) * 100 
 
SIDE-EFFECTS:   
 ?ůů ?E ?ƌĞƐƉŽŶƐĞƐĂƌĞĐŽĚĞĚĂƐ ? ? ?ŝŶĚŝĐĂƚŝŶŐ ?EŽƚĂƚĂůůŝƐƐĂƚŝƐĨŝĞĚ ? ? 
 
([Sum(Item 4 to Item 6)  W 3] divide by 12) * 100 
 
            If one item is missing: ([(Sum(the two completed items))  W 2] divide by 8) * 100 
 
CONVENIENCE:  ([Sum(Item 7 to Item 9)  W 3] divided by 18) * 100 
If one item is missing: ([(Sum(the two completed items))  W 2] divided by 12) * 100 
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June 26th, 2015 
 
Medway School of Pharmacy, Universities of Kent & Greenwich, UK 
Barbra Katusiime, Ms 
Central Avenue, Chatham Maritime 
Kent, ME4 4TB, UK 




Re:   Treatment Satisfaction Questionnaire for Medication Version II ( ‘TSQM ?) and TSQM 
Scoring Algorithm 
 
Dear Barbra Katusiime (Ms), 
 
With this letter, we are providing Barbra Katusiime with the TSQM and TSQM Scoring 
Algorithm, and the following translations specified in Attachment A (collectively, the 
 ‘Licensed Materials ?), solely for use in connection with protocol  01/2015, titled 
ǀĂůƵĂƚŝŽŶŽĨƉŽƚĞŶƚŝĂůŵĞƚŚŽĚƐĨŽƌŵĞĂƐƵƌŝŶŐƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨƵƐŝŶŐŵĞĚŝĐŝŶĞƐʡ
Validation of the Living with Medicines Questionnaire (LMQ©). 
  
All rights, title and interest in and to the Licensed Materials are owned by Quintiles 
dƌĂŶƐŶĂƚŝŽŶĂůŽƌƉ ? ?YƵŝŶƚŝůĞƐ ?/ŶĐ ? ?ƐĐŽƌƉŽƌĂƚĞĂĨĨŝůŝĂƚĞĂŶĚůŝĐĞŶƐŽƌ ?dŚĞ>ŝĐĞŶƐĞĚ
Materials are protected by copyright, trade secret and other laws.  The TSQM may only 
be administered by you in connection with patients participating in the Project.  The 
TSQM Scoring Algorithms may only be provided to your Personnel (defined below) 







In the event that you need a translation of the Licensed Materials which Quintiles 
Transnational Corp. and Quintiles, Inc. (individually and collectively,  ‘Quintiles ?) do not 
already have in their possession, you may, following receipt of the written consent of 
Quintiles, translate the Licensed Materials into the requested language; provided that the 
translation (a) is carried out in accordance with applicable standards for linguistic 
adaptation, and (b) is carried out in accoƌĚĂŶĐĞǁŝƚŚYƵŝŶƚŝůĞƐ ?ŝŶƐƚƌƵĐƚŝŽŶƐĂŶĚƐƵďũĞĐƚƚŽ
YƵŝŶƚŝůĞƐ ?ĨŝŶĂůĂƉƉƌŽǀĂů ?hƉŽŶĐŽŵƉůĞƚŝŽŶŽĨƚŚĞƚƌĂŶƐůĂƚŝŽŶŽĨƚŚĞ>ŝĐĞŶƐĞĚDĂƚĞƌŝĂůƐ
pursuant to this procedure, you will promptly provide Quintiles, Inc. with a copy of the 
translated Licensed Materials together with a copy of the translation certificate executed 
by the official translator.  While you will not be charged a license fee for a translation 
conducted under this process, any such translation will be deemed Licensed Materials 
under this agreement and all rights that you and any party acting on your behalf may 
have therein shall be assigned to Quintiles Transnational Corp. 
 
All Licensed Materials are provided by Quintiles subject to terms regarding confidentiality 
as set forth in this paragraph and in the following paragraph.  You will receive, maintain, 
and hold the Licensed Materials in strict confidence and will use at least the same level of 
care in safeguarding them that you use with your own confidential material.  You will not 
reveal the Licensed Material to your employees, directors, or staff (collectively, 
 ‘Personnel ?) except to the extent required to administer the Project, and you will ensure 
that all Personnel treat the Licensed Material as strictly confidential and abide by the 
terms of this letter.  You will not disclose the Licensed Materials to any third party or 
utilize Licensed Materials, except as provided herein, without first having obtained 
Quintiles' written consent to such disclosure or utilization. 
 
The obligations of confidentiality set forth herein shall not apply to the Licensed Materials 
to the extent the Licensed Materials are required by law to be disclosed by you, provided 
that you notify Quintiles prior to such disclosure and offer Quintiles an opportunity to 
contest such disclosure. 
 
You agree to indemnify and hold harmless Quintiles and its affiliates, and its and their 
directors, officers, employees and agents from and against all liabilities, losses, claims, 
demands, damages, costs and expenses (including but not limited to reasonable legal fees 
and disbursements) suffered or incurred by Quintiles and arising as a direct or indirect 
result of (a) any claim, proceeding, civil, criminal or administrative action, inquiry, suit or 
legal action instituted against Quintiles and in respect of your use of the Licensed 
Materials, or (b) your negligence or willful misconduct or that of any of your directors, 
officers, employees or agents. 
 
Quintiles shall not be responsible for any special, incidental, consequential, exemplary or 
punitive damages relating to this letter or the License Materials even if Quintiles has 
knowledge of the possibility of such potential damages.   
You will ensure that any paper, article or other publication reporting results obtained 
using the Licensed Materials will include the following reference: 
 
Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment 
satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), 






2004;2:12.  Those seeking information regarding or permission to use the TSQM 
are directed to Quintiles, Inc. at www.quintiles.com/TSQM or 
TSQM@quintiles.com 
 
You agree to inform Quintiles upon the completion of the Project.  Following completion 
of your use of the Licensed Materials as contemplated by this letter, or upon termination 
of your rights to such materials hereunder, you agree to provide to Quintiles all data from 
the Project that could be used to build the psychometric properties of the Licensed 
Materials.  Any data provided will be used by Quintiles only to improve the psychometric 
properties of the Licensed Materials. 
 
The rights granted to you hereunder are subject to your acceptance of the terms of this 
letter as shown below.  The nonrefundable license fee is waived for your institution.   
 
Upon completion of your use of the Licensed Materials as contemplated by this letter, or 
upon termination of your rights to such materials hereunder, you shall destroy all copies 
of the Licensed Materials and have an officer of your institution certify in writing that all 
Licensed Materials have been destroyed, however you may retain one copy of the 
Licensed Materials under seal for regulatory purposes. 
 
The terms of this letter shall be considered effective as of the date signed by you below 
( ‘Effective Date ?). 
This letter agreement may be executed in any number of counterparts, each of which 
when executed and delivered, shall constitute an original, but all of which together shall 
constitute one agreement binding on all parties, notwithstanding that all parties are not 
signatories to the same counterpart.  Transmission by fax or by electronic mail of an 
executed counterpart of this letter agreement shall be deemed to constitute due and 
sufficient delivery of such counterpart.  This letter agreement and any amendment or 
modification may not be denied legal effect or enforceability solely because it is in 
electronic form, or because an electronic signature or electronic record was used in its 
formation. 
 
Should you have any questions, please contact us immediately.  To confirm your 
acceptance of these terms and conditions, please sign below and return this letter 














Appendix 23 The EQ-5D-5L Questionnaire 
 
 Under each heading, please tick the ONE box that best describes your health TODAY. 
MOBILITY  
I have no problems in walking about  
I have slight problems in walking about  
I have moderate problems in walking about  
I have severe problems in walking about  
I am unable to walk about  
SELF-CARE  
I have no problems washing or dressing myself  
I have slight problems washing or dressing myself  
I have moderate problems washing or dressing myself  
I have severe problems washing or dressing myself  
I am unable to wash or dress myself  
USUAL ACTIVITIES (e.g. work, study, housework, family or 
leisure activities)  
I have no problems doing my usual activities  
I have slight problems doing my usual activities  
I have moderate problems doing my usual activities  
I have severe problems doing my usual activities  
I am unable to do my usual activities  
PAIN / DISCOMFORT  
I have no pain or discomfort  
I have slight pain or discomfort  
I have moderate pain or discomfort  
I have severe pain or discomfort  
I have extreme pain or discomfort  
ANXIETY / DEPRESSION  
I am not anxious or depressed  
I am slightly anxious or depressed  
I am moderately anxious or depressed  
I am severely anxious or depressed  








The worst health 
you can imagine 
We would like to know how good or bad your health is TODAY. 
This scale is numbered from 0 to 100. 
100 means the best health you can imagine. 
0 means the worst health you can imagine. 
Mark an X on the scale to indicate how your health is TODAY. 












































The best health 
you can imagine 
 



























Permission to use the EQ-5D-5L 
26 June 2015  
Dear Ms. / Mr. Barbra Katusiime,  
EQ-5D registration 
Thank you for registering your research at the EuroQol Research Foundation's website.  
As the study  ‘Evaluation of potential methods for measuring patients' experiences of 
using medicines; Validation of the Living with Medicines Questionnaire (LMQ) ? you 
registered involves low patient numbers (600) you may use the EQ-5D-5L instrument 
(Paper version) free of charge.  
Please note that separate permission is required if any of the following is applicable:  
- Funded by a pharmaceutical company, medical device manufacturer or other profit-
making stakeholder;  
- Number of respondents over 5000  
- Routine Outcome Measurement;  
- Developing or maintaining a Registry;  
- Digital representations (e.g. PDA, Tablet or Web)  
 
Please find attached the English (United Kingdom) EQ-5D-5L version (word format). A 
brief user guide is downloadable from the EuroQol website (www.euroqol.org).  
Please note that over the next months the first value sets associated with the EQ-5D-5L 
system will be published. It will take time before 5L value sets will be available for most 
countries. Please check our website to see which 5L value sets are currently available. In 
the meantime, the EuroQol Research Foundation has developed a  ‘crosswalk ? between 
the EQ-5D-3L value sets and the new EQ-5D-5L descriptive system, resulting in interim 
value sets for the new EQ-5D-5L descriptive system. Please find all information about the 
crosswalk from EQ-5D-5L data to the EQ-5D-3L value sets on-line at the EuroQol website 
(http://www.euroqol.org/about-eq-5d/valuation-of-eq-5d/eq-5d-5l-value-sets.html).  
 
Kind regards,  
Mandy van Reenen  
Communications Officer  
EuroQol Research Foundation  
T: +31 88 4400190  






























































Appendix 25 Comments for participants with high/extremely high medicine burden 
 
 National-level sample  for those completing  the LMQ 2.1 (N=34)        
Domain Comment Gender Age No. 
of 
Meds 








 ‘they make me tired, meaning that I can't get out a lot, have a social life or do 
a lot of activities. They also make me dizzy, so I often find it hard to be fully 
focused and present during conversations, making social interaction 
sometimes challenging. But they are mostly effective for what they were 
prescribed for. I find it hard to remember to take them and to fit this in to 
whatever activity I am doing, but this isn't really something I can avoid so I 
just have to get used to it. ? 
F 18 1 Tablets/ 
capsules 





 ‘They make me feel tired, I should not drink alcohol and my latest one I have 
been put on makes me constipated. Above all my epilepsy still isn't controlled. ? 
F 38 3 Tablets/ 
capsules 




 ‘The doctors do not take into account how the patient actually feels, they go 
on blood results, with hypothyroidism they go on the TSH level, which does 
not reflect the true level, without taking into account the Free T4 and Free T3 
and reverse T3.  I have proved them wrong with my blood tests, I am not 
converting T4 to T3, I need T3, but they won't give it.  I am now self-
medicating with T3 together with T4, and feel much better.  So much for the 
medical profession, they are criminal, ruining our lives. ?  
F 60 2 Tablets/ 
capsules 





 ‘started sodium valproate age 37.  Menstruation stopped witout the 
menopause, age45.  I had many serious health issues, nystagmus, tremors, 
spelling and mental ability, lost power in my legs, my doc. wouldn't believe me 
through it all but they all finishe when I was taken off it 2014.  I tried 3 other 
drugs which all had bad effects + I''m also on Lamictal and Diazepam(I've drug 
resistant epilepsy and Diaz is the only med that controls them on bad days) 
which I suspect very much ? P3 
F 60 3 Tablets/ 
capsules 




 ‘Sometimes I feel they're not worth taking due to the tiredness side effects I 
get. Sometimes I struggle to do anything and sometimes I worry that at work 





F 23 1 Tablets/ 
capsules 







Table  continued  
Comment 
Gender Age No. 
of 
Meds 






 ‘Some of the medicines are short term, others long term and one is for life.  
Liiothyronine treats my thyroid, and is for life - this is taken 4 - 5 times a day, 
is supposed to be 30 mins clear either side of eating and drinking, 4 hrs clear 
of anything wih iron in it - impossible; so it gets ignored.  Diclofenac helps with 
joint and back pain which comes with fibromyalgia and Sjogrens syndrome - 
long term, but I can stop easily if I wish to take a break. Very unhappy this 
week to discover that I should hae had my kidney function tested on it, but 
never have in 10 years. No one ever discussed heart problems either.  
Gabapentin is for nerve pain due to a broken ankle, it makes me feel suicidal. I 
am withdrawing, but it is hard - sleeping far too much, dopey struggling to 
form sentences, etc. Chlorpromazin is the least used, it's for managing 
hypomania: it renders me unconscious quickly and takes several days to get 
over. ? 
F 64 4 Tablets/ 
capsules 





 ‘severe side effects, need to be near a loo, cant do  housework, having 
frightening experiences cant breath, make me feel worse, weight gain, 
cramps, exhaustion ? 
F 51 3 Mixed  tid 8.0 -10 High burden 
(140-172) 
?  ‘Ruin it ? F 42 1 Tablets/ 
capsules 
od 8.0 -10 High burden 
(140-172) 
SE  ‘One medicine in particular (a statin) has such bad side effects that it 
completely wrecks my quality of life. ? 
F 55 2 Tablets/ 
capsules 
bd 6.0 -7.9 High burden 
(140-172) 
Eff  ‘My medication is not totally addressing my health issue! F 71 1 Tablets/ 
capsules 




 ‘More of a hindrance than a help but this medication apparently is 'cheap as 
chips' (my doctor's comment not mine). So is the only  ‘recognised and 
accepted/licenced in the UK ? so there is nothing other than this on offer. The 
UK is well behind USA, Canada, and Germany for example, so other patients 
lucky enough to live in these countries have more choice than in  the UK and 
their health  flourishes...why is this so, it's just not right??? 
F 60 1 Tablets/ 
capsules 





 ‘Medicines heavily dictate my eating patterns which increase a lot of difficulty 
planning my day around work, classes and any social engagements.  Thus, my 
long-term medication use leads to social exclusion - it's easier to refuse and 














Table continued  
Comment 
Gender Age No. 
of 
Meds 
Form Freq VAS score LMQ 
composite 
score 
SE, HCP  ‘Medication affects my weight and has an impact on my physical activity and 
state of mind. Diet is very difficult and Drs are not helpful. ? 




 ‘Make me feel older than I am, suppress my already low energy levels re MS, 
not sure about their effectiveness. Although this is probably more about my 
condition and how best to manage it than the drugs I'm given to lessen the 
impact of my MS. ? 
F 49 6 Mixed  A?ƋŝĚ 6.0 -7.9 High burden 
(140-172) 
SE,  ‘Make me drowsy so I tend to sleep alot. I feel that I am wasting my life away 
sleeping the side effects off! ? 




 ‘it is hell!! I have very little social life, virtually no sex life, and it is a nightmare 
having to pay out ridiculous amounts for drugs that are essential to me being 
able to function! ? 





 ‘I no longer take my medication because the side effects were making my 
illness worse. I was on strong pain medication for ME and FM over 20yrs and 
found that I was not only addicted but they were also making me sicker. I 
went through dreadful with drawl ad my Dr just offered me stronger 
medication instead. I am not on any of the medication my Dr prescribed for 
my illness which now makes my Dr think I'm cured. Because I won't take any 
more strong medication my illness is still bad but I don't have the side effects 
that I have lived with for so long. ? 
F 52 7 Mixed  A?ƋŝĚ 8.0 -10 High burden 
(140-172) 
Concr  ‘I haven't a choice about taking them but no investigations have been carried 
out about why ? 
F 44 2 Tablets/ 
capsules 
bd 8.0 -10 High burden 
(140-172) 
Prac  ‘I have to leave considerable time after food before I take my meds, so I take 
them in the middle of the night. ? 
F 60 2 Tablets/ 
capsules 
bd 6.0 -7.9 High burden 
(140-172) 
Concr  ‘I have to choose between taking medication and being able to function. 
Either the medication or the pain/sleep problems rule my days & nights. ? 
F 51 8 Tablets/ 
capsules 





 ‘I have put weight on my sex life is suffering as I have lost all feelings for it and 
ƚŚĞĚŽƐĂŐĞŽĨƉĂŝŶŬŝůůĞƌŝƐůŽǁĂƐ/ĐĂŶ ?ƚĐŽƉĞǁŝƚŚƐŝĚĞĞĨĨĞĐƚƐĂŶĚƐŽƚŚĞƉĂŝŶ
never goes it just gets bearable ? 




 ‘I have ongoing dizziness as a side effect, which increases my existing 
tendency to accidents. My most recent long-term prescription drug is causing 
weight gain - an issue as I am already 'obese'. I have gone up one dress size in 
spite of my efforts to los weight before this started. ? 





 ‘I get fed up with having to take meds that rarely solve my problems, and 
often create more, and having to put up with side effects. But I have no 
choice. ? 
 





























 ‘I feel that I'm the person that has to search for appropriate medication; last 
year Drs kept saying there was nothing they could do; took ME Association 
book with me and asked if I could try duloxetine ; said they'd ask psychiatrist: I 
asked if they could ask ME consultant. Drs reduced painkillers in March; 
means that I have to choose when I can cope with pain; stops activity. The 
nausea from duloxetine is bad, Drs told me not to take domperidone daily as 
it's now been shown to thicken arteries in long ter use; I've been on it for 15 
years. Drs won't prescribe paracetamol or buccastem; have to buy them. After 
8 yrs diagnosis finally Drs have agreed to let me have free prescriptions on the 
unable to get there on my own. I don't feel that I have a GP that I an talk to or 
who believes or supports me. I have no faith in them now. ? 
F 54 9 Tablets/capsules A?ƋŝĚ 6.0 -7.9 High burden 
(140-172) 
Concr,  ‘I do well on branded medication, some of the generics are not very good. I 
had been stable on a branded medication for over 10 years, but they have just 
discontinued it. So now I feel anxious that this latest generic will put me back 
to square one.! ? 




 ‘I constantly feel tired, and spaced out I struggle to sometimes do basic tasks 
because I feel so tired and drained yet I am a complete insomniac.  I am a 
totally different person since been diagnosed with epilepsy and wish it would 
just go away I am so depressed ? 
F 38 6 Tablets/ 
capsules 
A?ƋŝĚ 6.0 -7.9 High burden 
(140-172) 
SE,   
Concr 
 ‘I am on Seroxat 15 years get severe withdrawal when try to come off now I 
have ME my life is ruined my nervous system is shot and there is no help ? 
F 57 5 Mixed  
 
bd 8.0 -10 Extremely 
high burden 
(173-205) 
Concer  ‘Have no quality of life ? F 43 26 Mixed  
 
A?ƋŝĚ 8.0 -10 Extremely 
high burden 
(173-205) 
Eff  ‘Find them ineffective , but nothing else is available for my condition ? F 53 3 Mixed  
 
tid 6.0 -7.9 High burden 
(140-172) 
SE  ‘Depression, anxiety, tiredness, suicidal thoughts, insomnia, nausea & 

















Table continued  
 
Comment 
Gender Age No. 
of 
Meds 







 ‘Constantly feeling tired, I have no energy. They have removed my libido. I can 
no longer legally drive under the new laws. I cannot enjoy a glass of wine any 
longer. There are food interactions that the GP does not inform you of and 
they can change your life. Avoiding food when I go out or people cook for me 
etc. ? 




Concr  ‘Change to generic Levothyroxine approximately 5  years ago has very badly 
adversely affected my health. ? 
F 69 2 Tablets/ 
capsules 
bd 8.0 -10 High burden 
(140-172) 
SE  ‘Breathing difficulties.   Attitude. ? F 18 14 Tablets/capsules bd 6.0 -7.9 High burden 
(140-172) 
Concr  ‘A constant reference to being ill ? M 60 8 Mixed  bd 6.0 -7.9 High burden 
(140-172) 
 Sample 1 completing paper questionnaires (LMQ-2.1)         
HCP  ‘ƐŽŵĞĚŽĐƚŽƌƐĚŽŶ ?ƚŬŶŽǁůŽŶŐƚĞƌŵĚĂŵĂŐĞ ? M 49 5 Tablets/Capsules tid 8.0-10.0 High burden 
(140-172) 
Eff  ‘My life is often controlled by pain which means it is therefore controlled by 
my pain medication (opiates) ? 
F 51 6 Tablets/Capsules tid 6.0-7.9 High burden 
(140-172) 
HCP, Eff  ‘My GP never reviews my medication, however i do depend on them/ need 
them for some quality of life and staying out of hospital. ? 
F 38 12 Any other type tid 6.0-7.9 High burden 
(140-172) 
HCP  ‘I feel like my doctors are trying to kill me! ? F 61 7 Both types tid 8.0-10.0 High burden 
(140-172) 
HCP  ‘ŽĐƚŽƌĚŽĞƐŶ ?ƚůŝƐƚĞŶƚŽŵĞ ? F 49 6 Both types tid 8.0-10.0 High burden 
(140-172) 
Note. HCP- patient-doctor relationships and communication about medicines; Eff- Effectiveness or lack of it; Concr- General concerns about medicines; SE- Side Effects; 





Appendix 26 Item tracking matrix 
 
 




























The instructions on 
my medicines are 







Retain Reword I find the 
written 
instructions 










I find getting my 
prescriptions from the 
doctor  difficult 
Retain Retain Leave as is   Leave as is Same as original 
 
3 
I find getting my 
medicines from the 
pharmacist  difficult 
Retain Retain Leave as is   Leave as is; 
To define 
pharmacist/chemist 
on cover page  
Same as original 
4 
My medicines are 











  Item dropped  
5 
I find  opening the  
packaging of my 
medicines difficult 
Retain Retain Leave as is   Leave as is Item dropped 
6 
I am concerned about 





None   Item dropped 
7 
It is difficult to 
identify which 
medicine is which 









It is easy to keep my 
medicines routine 




medicine is routine ?. 
To be left in, and 
wait for EFA after 
on-line survey 




I would be concerned 
if I forgot to take my 
medicines 
Retain Retain Reword; 
replace 
 ‘ĐŽŶĐĞƌŶĞĚ ?
ǁŝƚŚ ‘ǁŽƌƌŝĞĚ ? 
I would be 










If i forgot to take my 




I am concerned that I 
may forget to take my 
medicines 
Retain Retain Leave as is   Leave as is  Same as original item 
11 
I am concerned about 
experiencing  side 
effects 
Retain Retain  ‘  ൱To review 
later when 




Leave  as is  Item dropped 
12 
I am concerned about 
possible damaging 
long term effects of 
taking medicines 
Retain Retain Leave as is   Leave as is  Same as original  item. 
13 
Taking medicines is 
routine for me 
Retain Retain Leave as is   Leave  as is; 
Potential for 
removal after EFA 
as it is perceived 
repetitious with  ‘it 
is easy to keep my 
medicines routine ? 
Item dropped 
14 
I am comfortable 
taking medicines I 




 To include a 
global 
satisfaction 
item at a later 
stage. 
 Item dropped 
15 
I am comfortable with 
the times I should 




take my  medicines 
16 
I find  the patient  






   Item dropped 
17 
I find using my 
medicines  difficult 
Retain Retain Leave as is   Leave as is Same as original 
 
18 
I am satisfied with 
effectiveness of  my 
medicines 
Retain Retain 
Leave as is 
  Leave as is Same as original 
 
19 
I am concerned that I 
am too dependent on 
my medicines 
Retain Retain 
Leave as is 




I am concerned that 
I am too reliant on 
medicines. 
 I am concerned that I am too 
reliant on my medicines 
20 
I am confident 
speaking to my doctor 
(s) about my 
medicines 
Retain Retain 




I am not  confident 
speaking to my 




I understand what my 
doctor(s) tell me 




 Moderate  
ceiling effect 
Leave as is Item dropped 
22 
The information my 
doctor(s) give me 
















I get enough information about my 
medicines from my doctor(s). 
23 
I am confident 
speaking to my 
pharmacist about my 
medicine 
Retain Retain Leave as is   
Rephrase to 
negative wording: 
I am not  confident 









I understand what my 
pharmacist tells me 
about my medicines. 
Retain Retain Leave as is   Leave as is Item dropped 
25 
The information my 
pharmacist gives me 
about my medicines is 
useful 






 Reworded to: 
 I  get enough 
information about 










 Item dropped 
27 
I accept that I have to 






Retain Leave as is   Leave as is Item dropped 
28 
My medicines allow 
me to live my life as I 
want to 
Retain Retain Leave as is   Leave as is Same item 
29 
My life revolves 
around using my 
medicines 
Retain Retain Leave as is   Leave as is Same as original item 
30 
My medicines live up 
to  my expectations 
Retain Retain Leave as is   Leave as is Same item 
31 
My medicines prevent 
my condition getting 
worse 
Retain Retain Leave as is   Leave as is Same item 
32 
Taking medicines 
interferes with my 
social life 















interfere with my 
social  or leisure 
activities. 
My medicines interfere with my 
social  or leisure activities. 
33 
I trust the judgement 
of my doctor(s) in  
choosing medicines 
for me 
Retain Retain Leave as is   Leave as is Same as original item 
34 
I have to put a lot of 




planning and thought 




causes me problems 
with daily tasks (such 
as work, housework, 
hobbies). 
Retain Retain Leave as is   Leave as is : 
thought to be 
repetitious and as a 
potential side effect 
question 
 
Same as original item 
36 
I am unhappy with the 





Retain Leave as is;   Item removed 
by both EFA 
& CFA; but 
discussion 
suggested 
that we leave 









Replaced the word 
unhappy with 
concerned; deleted 
with the extent to 
which: 
 






 I am concerned that my medicines 
interact with alcohol. 
37 
Taking medicines 
affects my driving 
ability 
Retain Retain Reword; to 
delete the word 









 ‘ĚƌŝǀŝŶŐ ? ?
Leave as is Reworded:  
Taking medicines affects my 
driving. 
38 
I worry that I have to 
take several 
medicines at the same 
time of day. 
Retain 
 
Retain Leave as is   Leave as is Reworded to: 
 
 I worry that I have to take several 
medicines at the same time. 
39 
The side effects I get 
are worse than the 
problem for which I 
take medicines 




that we leave 










 ?ƐŽŵĞƚŝŵĞƐ ? 
 
The side effects I 
get are  sometimes 
worse than the 
problem for which I 
take medicines 
The side effects I get are 
sometimes worse than the problem 




items on side 
effects. 
40 
I worry that my 
medicines may 
interact with each 
other 
Retain Retain Leave as is   Leave as is Same as original item 
41 
I can choose whether 
or not to take my 
medicines 
Retain Retain Leave as is   Leave as is Same as original item 
42 
My doctor(s) spend 
enough time 
discussing my 
medicines with me. 
Retain Retain Deletion-
confirmed 
Delete Item deleted 
& thought to 
be redundant 









Retain Reword item; 
ĞůĞƚĞ ‘/ŬŶŽǁ ?
ƚŽ ‘ŵǇĚŽĐƚŽƌ











  Item dropped 
44 
I am able to balance 
my day to day life 
with taking medicines 
Remove Remove Deletion-
confirmed 
Delete   Item dropped 
45 
There is enough 
sharing of information 
about my medicines 
between the different 
health professionals 
providing my care 
Remove Remove Deletion-
confirmed 
Delete   Item dropped 
46 
I have a say in the 
brands of medicines I 
use 
Remove Remove Reword  I would like 















Leave as is Item reworded:  
 
I would like more say in the brands 
of medicines I use. 
47 
I always follow  my 
doctor (s) advice 
Retain Remove Deletion-
confirmed 
Delete Removed as it 
appeared to 
measure 




about my medicines adherence  
48 
I sometimes feel I 
need to get 
information from 
other sources(such as 
books, friends, 
internet) about my 
medicines. 
Remove Remove Reword; 
Delete the 
word 
 ‘ƐŽŵĞƚŝŵĞƐ ? ?




ŝŶƚĞƌŶĞƚ ) ? 









thought to be 
lacking in 
LMQ 
Leave as is  Item reworded:  
 
I feel I need more information 
about my medicines. 
49 
I can change the times 
I take my medicines if 
I want to 
Retain Retain Leave as is Same  Item reworded: 
 
Replaced  ‘ change ? 
with vary: 
I  can vary  the 
times I take my 
medicines . 





providing my care 
know enough about 
me and my medicines. 
Retain Retain Leave as is Same  Leave as is Same as original 
 
51 
My medicines are 
working 




I can adapt my 




Removed Leave as is Same  Reworded to: 
I can adapt using 
my medicine(s) to 
fit my lifestyle. 
Item dropped 
53 
My doctor listens to 
my opinions  and 
concerns about my 
medicines 







medicines.   




My doctor(s) listen to my opinions 
about my medicines.  
54 
I can vary the dose of 
the medicines  I take 
Retain Retain Leave as is Same  Leave as is Same as original item 
55 
I get too much 




Delete   Item dropped 
56 
Changes in daily 
Retain Retain Leave as is Same  Add an  ?s ? to cause: 






problems with  my 
medicines 
routine causes 
problems with  my 
medicines. 
57 
My doctor (s) take my 
concerns about side 
effects seriously 
Retain Retain Leave as is Same  Leave as is Same as original 
58 
My medicines have an 



















Leave as is Reworded:  
 
My medicines interfere with my 
sexual life. 
59 
The side effects are 
worth it for the 
benefits I get from my 
medicines 




that we leave 









items on side 
effects. 
Leave as is Same 
60 
The medicines I use 
have an adverse  
effect on the holidays 
I can take 
Retain Retain    Reword: 
The medicine (s) i 
use make it difficult 




My medicines can  
interfere with my 
ƐŽĐŝĂůƌĞůĂƚŝŽŶƐŚŝƉƐ ? 
   Rewording: 
ĚĞůĞƚĞĚ ‘ĐĂŶ ? 
   My medicines interfere with my 
social relationships. 
 
I am concerned that 
my medicine(s) affect 
what i can eat or 
drink. 
     Item dropped Item dropped 
 
I have to pay more 
than I can afford for 
my medicines. 










      Reained 
 
I worry about paying 
for my medicines. 
ƌŽƉƉĞĚ P/ĚŽŶ ?ƚŵŝŶĚ
paying for my 
medicines because I 
need them dropped: 
      Same item 
 
The side effects I get 
from my medicines 
adversely affect my 
well-being. 
      Retained 
 
The side effects I get 
from my medicines 
are bothersome. 
     Leave it as but look 
Look in Thesaurus 
for alternative word 






annoying). Leave as 




The side effects I get 
from my medicines 
interfere with my day-
to-day life (e.g. work, 
housework, sleep). 
 
       
 
My medicines 
interfere with my 
social or leisure 
activities. 
       
 
Taking everything into 




account, how satisfied 
are you with your 
medicines? 
 
How optimal do you 
feel your medicines 
are for you? 
     Reworded 
On balance, do you 
feel your medicines 
are right for you? 
Deleted from the final measure 
 
Overall, how much of 
a burden do you feel 
your medicines are to 
you? 
      Item retained and 10-cm visual 
analogue scale modified to include 
1cm marks and smiley faces at 
anchors 
 
Amendments/addition to instructions on cover page:  





Changes to last page on participant characteristics 
No 
Original question 
Proposed amendments/rationale Agreed question 
1 
How many medicines do you take regularly? 
<4          4-8                    >8 
(Medicines include tablets, capsules, creams, inhalers, liquids, eye drops, 
and so on-count each different prescription as one medicine) 
To amend response option to a numeric 
figure rather than a category? 
 
To amend stem ƚŽŝŶĐůƵĚĞƚŚĞǁŽƌĚ ‘ƵƐĞ ?
medicine rather than to take medicine? 
How many prescription medicines do you use 
regularly? (please write the total number of 
medicines here) 





Which type of medicines do you use? (You may tick one or more) 
Tablets in bottles               Capsules in bottles          Inhalers     Injections       
Tablets in  foil strip           Capsules in strips             Oral liquid      
ǇĞĚƌŽƉƐ ?ĂƌĚƌŽƉƐKƚŚĞƌ ?WůĞĂƐĞƐƉĞĐŝĨǇ ) Q Q Q Q Q Q Q Q Q Q Q Q ? ?
Can we ask the dosage form(s) of 
medicines used?  
 
Hypothesis: 
Non-oral dosage forms may be more 
burdensome than oral dosage forms 
Which type of medicines do you use? Partially 
accepted: Suggested options  
Tablets/Capsules                      Any other type 
New 
3  
How often do you use your medicine(s)? 
Once daily,            Twice daily       Thrice daily        
More than three times daily 
KƚŚĞƌ ?ƉůĞĂƐĞƐƉĞĐŝĨǇ ) Q Q Q Q Q Q Q Q 
Can we ask the frequency of using 
medicines? 
  
Hypothesis: Frequency of administration is 
associated with medication burden 
How often do you use your medicine(s)? 
Once per day Twice per day etc. 
4 




The categories of full or part-time 
employment are being proposed to assess 
the income (indirectly), and predict cost-
related medication burden. 
What is your current employment status?  
Added : Full-time student 
add  
Other (please specify 
5 
Does someone help you with your medicines? 
Yes                                 No 
 
Same question as In LMQ version 1 
 
 
If you answered yes, who helps you? 
Spouse/partner             Relative                            Other 
 
 
Propose to amend response items to 
include carer (or support worker), and  
friend  
 
If you answered yes, who helps you? 
Spouse/partner       Friend 
Relative                     Carer /support worker 
KƚŚĞƌ Q Q Q Q Q Q Q ? ?




WůĞĂƐĞƉƌŽǀŝĚĞƵƐǁŝƚŚǇŽƵƌĨƵůůƉŽƐƚĐŽĚĞ Q Q Q Q Q Q Q Q Q
Note:  We will NOT pass on your details to anyone else, we will not 
contact you or send you junk mail. We want to study if people living in 
different areas have different experiences of using medicines 
  
 
Proposed item to predict deprivation 
levels 
 Q 
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